當(dāng)前位置:首頁 > 產(chǎn)品中心 > 試劑/標(biāo)準(zhǔn)品/對照品 > EP標(biāo)準(zhǔn)品 > EP歐洲藥典標(biāo)準(zhǔn)品
簡要描述:EP歐洲藥典標(biāo)準(zhǔn)品
相關(guān)文章
Related Articles詳細(xì)介紹
Order Code | Reference Standard | Batch n° | Quantity per vial | Sale Unit | Information | Monograph | Leaflet | Storage | |
Y0001561 | Abacavir sulfate | 1 | 20 mg | 1 | 2589 | Yes | +5°C ± 3°C | ||
Y0001552 | Abacavir for peak identification | 1 | 10 mg | 1 | 2589 | Yes | +5°C ± 3°C | ||
Y0001551 | Abacavir for system suitability | 1 | 10 mg | 1 | 2589 | Yes | +5°C ± 3°C | ||
Y0000055 | Acamprosate calcium - reference spectrum | 1 | n/a | 1 | 1585 | ||||
Y0000116 | Acamprosate impurity A | 2 | 110 mg | 1 | 3-aminopropane-1-sulfonic acid (homotaurine) ; Batch 1 is valid until 31 January 2017 | 1585 | Yes | +5°C ± 3°C | |
Y0000500 | Acarbose | 3 | 100 mg | 1 | See leaflet | 2089 | Yes | +5°C ± 3°C | |
Y0000354 | Acarbose for identification | 1 | 10 mg | 1 | 2089 | Yes | +5°C ± 3°C | ||
Y0000427 | Acarbose for peak identification | 4 | 20 mg | 1 | Batch 3 is valid until 31 May 2017 | 2089 | Yes | +5°C ± 3°C | |
A0040000 | Acebutolol hydrochloride | 1 | 50 mg | 1 | 0871 | Yes | +5°C ± 3°C | ||
Y0000359 | Acebutolol impurity B | 2 | 10 mg | 1 | N-[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy] phenyl]acetamide (diacetolol) | 0871 | Yes | +5°C ± 3°C | |
Y0000127 | Acebutolol impurity C | 1 | 20 mg | 1 | N-(3-acetyl-4-hydroxyphenyl)but* | 0871 | Yes | +5°C ± 3°C | |
Y0000128 | Acebutolol impurity I | 2 | 0.004 mg | 1 | N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl]but* | 0871 | Yes | +5°C ± 3°C | |
Y0000056 | Aceclofenac - reference spectrum | 1 | n/a | 1 | 1281 | ||||
Y0000085 | Aceclofenac impurity F | 2 | 15 mg | 1 | benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate (benzyl ester of aceclofenac) | 1281 | Yes | +5°C ± 3°C | |
Y0000086 | Aceclofenac impurity H | 1 | 10 mg | 1 | [[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl] oxy]acetyl]oxy] acetic acid (diacetic aceclofenac) | 1281 | Yes | +5°C ± 3°C | |
Y0001094 | Aceclofenac for peak identification | 1 | 10 mg | 1 | 1281 | Yes | +5°C ± 3°C | ||
New | Y0001915 | Aceclofenac impurity I | 1 | 15 mg | 1 | 1281 | Yes | +5°C ± 3°C | |
Y0000810 | Acemetacin | 1 | 100 mg | 1 | 1686 | Yes | +5°C ± 3°C | ||
Y0000811 | Acemetacin impurity A | 1 | 10 mg | 1 | 4-chlorobenzoic acid | 1686 | Yes | +5°C ± 3°C | |
Y0000842 | Acemetacin impurity mixture | 1 | 0.06 mg | 1 | 1686 | Yes | +5°C ± 3°C | ||
A0070000 | Acesulfame potassium | 2 | 50 mg | 1 | 1282 | Yes | +5°C ± 3°C | ||
A0070020 | Acesulfame potassium impurity B | 4 | 15 mg | 1 | see leaflet; 5-chloro-6-methyl-1,2,3-oxathiazin-4(3§)-one 2,2-dioxide | 1282 | Yes | +5°C ± 3°C | |
A0100000 | Acetazolamide | 1 | 100 mg | 1 | 0454 | Yes | +5°C ± 3°C | ||
Y0001084 | Acetazolamide for system suitability | 2 | 0.0068 mg | 1 | 0454 | Yes | +5°C ± 3°C | ||
Y0000002 | Acetylcholine chloride | 1 | 50 mg | 1 | 1485.1971 | Yes | -20°C ± 5°C | ||
A0150000 | Acetylcysteine | 3 | 50 mg | 1 | 0967 | Yes | +5°C ± 3°C | ||
A0152000 | Acetylcysteine impurity C | 11 | 10 mg | 1 | (2R,2'R)-3,3'-disulfanediylbis[2-(acetylamino)propanoic acid] (N,N'-diacetyl- L-cystine) ; Batch 9 is valid until 31 July 2016 | 0967 | Yes | +5°C ± 3°C | |
A0153000 | Acetylcysteine impurity D | 7 | 10 mg | 1 | (2R)-2-(acetylamino)-3-(acetylsulfanyl)propanoic acid (N,S-diacetyl-L- cysteine) ; Batch 6 is valid until 31 May 2017 | 0967 | Yes | +5°C ± 3°C | |
Y0000565 | ß-Acetyldigoxin | 2 | 50 mg | 1 | See leaflet C÷–HÿÿOŒ— | 2168 | Yes | +5°C ± 3°C | |
Y0000642 | ß-Acetyldigoxin for peak identification | 1 | 10 mg | 1 | 2168 | Yes | +5°C ± 3°C | ||
A0200000 | Acetylsalicylic acid | 5 | 10 mg | 1 | Batch 4 is valid until 31 December 2016 | 0309 | Yes | +5°C ± 3°C | |
Y0001460 | Acetylsalicylic acid for peak identification | 3 | 10.3 mg | 1 | Batch 2 is valid until 31 December 2016 | 0309 | Yes | +5°C ± 3°C | |
Y0001462 | Acetylsulfadiazine | 1 | 0.002 mg | 1 | 0294 | Yes | +5°C ± 3°C | ||
A0208000 | N-Acetyltryptophan | 2 | 125 mg | 1 | 1383 | Yes | +5°C ± 3°C | ||
A0202000 | N-Acetyltyrosine | 1 | 200 mg | 1 | 1384 | Yes | +5°C ± 3°C | ||
Y0000693 | Acholeplasma laidlawii BRP | 1 | 1 ml | 1 | 20607 | Yes | -80°C ± 10°C | ||
A0220000 | Aciclovir | 3 | 75 mg | 1 | 0968 | Yes | +5°C ± 3°C | ||
Y0001271 | Aciclovir for peak identification 1 | 4 | 0.3 mg | 1 | Batch 3 is valid until 31 July 2016 | 0968 | Yes | +5°C ± 3°C | |
Y0001269 | Aciclovir for peak identification 2 | 4 | 0.004 mg | 1 | Batch 3 is valid until 31 August 2016 | 0968 | Yes | +5°C ± 3°C | |
Y0001264 | Aciclovir for system suitability | 1 | 10 mg | 1 | 0968 | Yes | +5°C ± 3°C | ||
A0225000 | Acitretin | 2 | 100 mg | 1 | See leaflet CœŒHœÿO– | 1385 | Yes | +5°C ± 3°C | |
Y0001463 | Actaea racemosa HRS | 1 | 1200 mg | 1 | 2069 | Yes | +5°C ± 3°C | ||
Y0001543 | Actaea racemosa for assay CRS | 1 | 300 mg | 1 | See leaflet C÷œHÿ—NOŒÿ; Monoammonium glycyrrhizate | 2069 | Yes | +5°C ± 3°C | |
Y0001464 | Actaea racemosa dry extract for system suitability HRS | 1 | 1200 mg | 1 | 2069 | Yes | -20°C ± 5°C | ||
Y0001121 | Adapalene | 1 | 100 mg | 1 | See leaflet Cœ‡Hœ‡O– | 2445 | Yes | +5°C ± 3°C | |
Y0001120 | Adapalene impurity C | 3 | 6 mg | 1 | 1-(2-methoxyphenyl)tricyclo[3.3.1.1]decane | 2445 | Yes | +5°C ± 3°C | |
Y0001119 | Adapalene for peak identification | 2 | 2.02 mg | 1 | 2445 | Yes | +5°C ± 3°C | ||
A0230000 | Adenine | 2 | 50 mg | 1 | 0800 | Yes | +5°C ± 3°C | ||
A0230200 | Adenosine | 1 | 50 mg | 1 | 1486 | Yes | +5°C ± 3°C | ||
Y0000110 | Adipic acid | 1 | 50 mg | 1 | 1586 | Yes | +5°C ± 3°C | ||
Y0000882 | Adrenaline | 1 | 5 mg | 1 | 2303 | Yes | +5°C ± 3°C | ||
Y0000740 | Adrenaline impurity mixture | 3 | 0.005 mg | 1 | 0254.2303 | Yes | +5°C ± 3°C | ||
Y0000883 | Adrenaline with impurity F | 1 | 10 mg | 1 | 2303 | Yes | +5°C ± 3°C | ||
A0300000 | Adrenaline tartrate | 6 | 100 mg | 1 | Batch 5 is valid until 31 October 2016 | 0254 | Yes | +5°C ± 3°C | |
Y0000707 | Adrenaline tartrate with impurity A | 1 | 15 mg | 1 | 0254 | Yes | +5°C ± 3°C | ||
Y0001527 | Aescin for LC assay HRS | 1 | 150 mg | 1 | see leaflet C—÷H‡÷Oœ– | 1830.1829 | Yes | +5°C ± 3°C | |
Y0001724 | Agnus castus fruit dry extract | 1 | 350 mg | 1 | see leaflet | 2309, 2147 | Yes | -20°C ± 5°C | |
A0325000 | Alanine | 3 | 60 mg | 1 | 0752 | Yes | +5°C ± 3°C | ||
A0325100 | Albendazole | 2 | 50 mg | 1 | 1386 | Yes | +5°C ± 3°C | ||
A0325200 | Alcuronium chloride | 2 | 50 mg | 1 | 1285 | Yes | -20°C ± 5°C | ||
A0325450 | Alfacalcidol | 9 | 5 mg | 1 | See leaflet | 1286 | Yes | -20°C ± 5°C | |
Y0001601 | Alfacalcidol for system suitability | 1 | 2.5 mg | 1 | 1286 | Yes | -20°C ± 5°C | ||
A0325451 | Alfacalcidol - reference spectrum | 1 | n/a | 1 | 1286 | ||||
A1225000 | Alfadex | 3 | 150 mg | 1 | See leaflet [CÿHŒÐ0—]ÿ | 1070.1487 | Yes | +5°C ± 3°C | |
A0325500 | * hydrochloride - reference spectrum | 1 | n/a | 1 | 1062 | ||||
Y0001883 | Alfuzosin for peak identification | 1 | 10 mg | 1 | 1287 | Yes | +5°C ± 3°C | ||
Y0001906 | Alfuzosin for system suitability A | 1 | 10 mg | 1 | 1287 | Yes | +5°C ± 3°C | ||
A0325800 | Alfuzosin hydrochloride | 2 | 10 mg | 1 | 1287 | Yes | +5°C ± 3°C | ||
Y0001583 | Alimemazine hemitartrate | 1 | 15 mg | 1 | 2650 | Yes | +5°C ± 3°C | ||
Y0001581 | Alimemazine for system suitability | 1 | 5 mg | 1 | 2650 | Yes | +5°C ± 3°C | ||
A0349000 | Allantoin | 1 | 60 mg | 1 | 1288 | Yes | +5°C ± 3°C | ||
A0350000 | Allopurinol | 3 | 100 mg | 1 | See leaflet | 0576 | Yes | +5°C ± 3°C | |
A0350010 | Allopurinol impurity A | 2 | 10 mg | 1 | 5-amiH-pyrazole-4-carboxamide | 0576 | Yes | +5°C ± 3°C | |
A0350020 | Allopurinol impurity B | 3 | 10 mg | 1 | 5-formylamiH-pyrazole-4-carboxamide | 0576 | Yes | +5°C ± 3°C | |
A0350030 | Allopurinol impurity C | 3 | 10 mg | 1 | 5-(4H-1,2,4-triazol-4-yl)-1H-pyrazole-4-carboxamide | 0576 | Yes | +5°C ± 3°C | |
A0350040 | Allopurinol impurity D | 4 | 15 mg | 1 | ethyl 5-amiH-pyrazole-4-carboxylate | 0576 | Yes | +5°C ± 3°C | |
A0350050 | Allopurinol impurity E | 1 | 20 mg | 1 | ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate | 0576 | Yes | +5°C ± 3°C | |
A0351000 | Allylstrychnine bromide | 1 | 10 mg | 1 | 1285 | Yes | -20°C ± 5°C | ||
Y0000235 | Almagate | 2 | 50 mg | 1 | See leaflet | 2010 | Yes | +5°C ± 3°C | |
Y0000255 | Almagate - reference spectrum | 1 | n/a | 1 | 2010 | ||||
A0357000 | Alprazolam - * psy | 2 | 100 mg | 1 | 1065 | Yes | +5°C ± 3°C | ||
A0360000 | Alprenolol hydrochloride | 1 | 100 mg | 1 | 0628.0876 | Yes | +5°C ± 3°C | ||
Y0000054 | Alprostadil | 3 | 25 mg | 1 | See leaflet ; Batch 2 is valid until 31 July 2016 | 1488 | Yes | -20°C ± 5°C | |
Y0000606 | Altizide | 2 | 150 mg | 1 | See leaflet CŒŒHŒ÷ClN–O÷S– | 0370.2185 | Yes | +5°C ± 3°C | |
Y0000843 | Altizide impurity B | 1 | 15 mg | 1 | 3-[(2,2-dimethoxyethyl)sulphanyl]prop-1-ene | 2185 | Yes | +5°C ± 3°C | |
Y0000687 | Alverine citrate | 1 | 5 mg | 1 | 2156 | Yes | +5°C ± 3°C | ||
Y0001819 | Alverine impurity C | 2 | 40 mg | 1 | N-ethyl-3-phenylpropan-1-amine ; Batch 1 is valid until 4 February 2017 | 2156 | Yes | -20°C ± 5°C | |
Y0000607 | Alverine impurity D | 1 | 10 mg | 1 | N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine | 2156 | Yes | +5°C ± 3°C | |
A0363000 | Amantadine hydrochloride | 1 | 100 mg | 1 | 0463 | Yes | +5°C ± 3°C | ||
A0363700 | Ambroxol hydrochloride | 3 | 125 mg | 1 | 1489 | Yes | +5°C ± 3°C | ||
A0900000 | Amfetamine sulfate - reference spectrum | 1 | n/a | 1 | 0368 | ||||
A0365000 | Amidotrizoic acid dihydrate | 1 | 100 mg | 1 | 0873 | Yes | +5°C ± 3°C | ||
Y0001461 | Amidotrizoic acid for system suitability | 1 | 0.08 mg | 1 | 0873 | Yes | +5°C ± 3°C | ||
A0368000 | Amikacin | 3 | 200 mg | 1 | See leaflet | 1289.1290 | Yes | +5°C ± 3°C | |
Y0001467 | Amikacin impurity I | 1 | 20 mg | 1 | (2S)-4-amino-2-hydroxybutanoic acid | 1289, 1290 | Yes | +5°C ± 3°C | |
Y0001117 | Amikacin for system suitability | 3 | 10 mg | 1 | Batch 2 is valid until 30 June 2016 | 1289.1290 | Yes | +5°C ± 3°C | |
A0365900 | Amikacin sulfate | 3 | 200 mg | 1 | The batch 3 is not suitable for use in the assay in monograph 1290:07/2014. Amikacin CRS A0368000 is also needed. See leaflet. | 1290 | Yes | +5°C ± 3°C | |
Y0001902 | Amiloride for peak identification | 1 | 10 mg | 1 | 0651 | Yes | +5°C ± 3°C | ||
A0370000 | Amiloride hydrochloride | 2 | 100 mg | 1 | 0651 | Yes | +5°C ± 3°C | ||
Y0000020 | Amiloride impurity A | 3 | 20 mg | 1 | methyl-3,5-diamino-6-chloropyrazine-2-carboxylate | 0651 | Yes | +5°C ± 3°C | |
Y0000173 | 4-Aminobenzoic acid | 2 | 60 mg | 1 | 1687 | Yes | +5°C ± 3°C | ||
A0420000 | Aminocaproic acid | 1 | 50 mg | 1 | 0874 | Yes | +5°C ± 3°C | ||
A0460000 | 7-Aminodesacetoxycephalosporanic acid | 2 | 20 mg | 1 | Cefadroxyl impurity B | 0708.0813 | Yes | +5°C ± 3°C | |
A0496000 | Aminoglutethimide | 1 | 125 mg | 1 | 1291 | Yes | +5°C ± 3°C | ||
A0496005 | Aminoglutethimide impurity A | 1 | 20 mg | 1 | (3¢£)-3-(3-aminophenyl)-3-ethylpiperidine-2,6-dione (3-aminoglutethimide) | 1291 | Yes | +5°C ± 3°C | |
A0496020 | Aminoglutethimide impurity D | 1 | 10 mg | 1 | 3,3'-[diazenediylbis(4,1-phenylene)]bis(3-ethylpiperidine-2,6-dione) (azoglutethimide) | 1291 | Yes | +5°C ± 3°C | |
A0575000 | Amiodarone hydrochloride | 3 | 100 mg | 1 | 0803 | Yes | +5°C ± 3°C | ||
Y0000129 | Amiodarone impurity D | 3 | 20 mg | 1 | (2-butylbenzofuran-3-yl)(4-hydroxy-3,5-diiodophenyl)methanone | 0803 | Yes | +5°C ± 3°C | |
Y0000130 | Amiodarone impurity E | 3 | 20 mg | 1 | (2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone | 0803 | Yes | +5°C ± 3°C | |
A0590000 | Amisulpride | 2 | 10 mg | 1 | 1490 | Yes | +5°C ± 3°C | ||
Y0001534 | Amisulpride for system suitability | 1 | 1.0015 mg | 1 | 1490 | Yes | +5°C ± 3°C | ||
Y0000563 | Amitriptyline hydrochloride | 1 | 10 mg | 1 | 0464 | Yes | +5°C ± 3°C | ||
Y0000049 | Amlodipine besilate | 4 | 150 mg | 1 | See leaflet | 1491 | Yes | +5°C ± 3°C | |
Y0001068 | Amlodipine impurity A | 3 | 15 mg | 1 | 3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-2-[[2-(1,3-dioxo-1,3-dihydro-2H- isoindol-2-yl)ethoxy]methyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate | 1491 | Yes | +5°C ± 3°C | |
Y0001069 | Amlodipine impurity B | 3 | 15 mg | 1 | 3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-6-methyl-2-[[2-[[2- (methylcarbamoyl)benzoyl]amino]ethoxy]methyl]-1,4-dihydropyridine-3,5- dicarboxylate ; Batch 2 is valid until 31 December 2016 | 1491 | Yes | +5°C ± 3°C | |
Y0001070 | Amlodipine impurity G | 3 | 10 mg | 1 | dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5- dicarboxylate | 1491 | Yes | +5°C ± 3°C | |
Y0001067 | Amlodipine for peak identification | 3 | 15 mg | 1 | Batch 2 is valid until 30 November 2016 | 1491 | Yes | +5°C ± 3°C | |
Y0000302 | Ammonio methacrylate copolymer(type A) - reference spectrum | 1 | n/a | 1 | 2081 | ||||
Y0000303 | Ammonio methacrylate copolymer(type B) - reference spectrum | 1 | n/a | 1 | 2082 | ||||
A0650000 | Amobarbital - * psy | 1 | 500 mg | 1 | 0594 | Yes | +5°C ± 3°C | ||
A0700000 | Amobarbital sodium - * psy | 1 | 500 mg | 1 | 0166 | Yes | +5°C ± 3°C | ||
Y0001794 | Amorolfine Hydrochloride | 1 | 10 mg | 1 | 2756 | Yes | +5°C ± 3°C | ||
Y0001795 | Amorolfine for system suitability | 1 | 10 mg | 1 | 2756 | Yes | +5°C ± 3°C | ||
A0800000 | Amoxicillin trihydrate | 5 | 200 mg | 1 | See leaflet CŒÿHŒ„N–O—S | 0167,0168,0 260, 0577,0578,0 813, 1140,1653 | Yes | +5°C ± 3°C | |
Y0001521 | Amoxicillin trihydrate for performance verification | 2 | 5000 mg | 1 | See leaflet ; Batch 1 is valid until 30 April 2017 | 20232, 20512, | Yes | +5°C ± 3°C | |
Y0000005 | Amphotericin B | 5 | 100 mg | 1 | See leaflet | 1292 | Yes | -20°C ± 5°C | |
New | Y0001361 | Amphotericin B for microbiological assay | 2 | 100 mg | 1 | See leaflet ; Batch 1 is valid until 30 November 2017 | 20702 | Yes | -20°C ± 5°C |
Y0001014 | Amphotericin B for peak identification | 2 | 10 mg | 1 | 1292 | Yes | -20°C ± 5°C | ||
A1000000 | Ampicillin (anhydrous) | 5 | 220 mg | 1 | See leaflet CŒÿHŒ„N–O÷S | 0167,0168,0 578, 1168,1169 | Yes | +5°C ± 3°C | |
A1100000 | Ampicillin trihydrate | 2 | 150 mg | 1 | 0168,0260,0 577, 0578,0808,2 211, 2212 | Yes | +5°C ± 3°C | ||
Y0001244 | Amylmetacresol | 1 | 285 mg | 1 | See leaflet CŒœHŒ‡O | 2405 | Yes | +5°C ± 3°C | |
Y0001245 | Amylmetacresol for peak identification | 1 | 10 mg | 1 | 2405 | Yes | +5°C ± 3°C | ||
Y0001522 | Anastrozole | 1 | 100 mg | 1 | See leaflet CŒŸHŒ„N— | 2406 | Yes | +5°C ± 3°C | |
Y0001531 | Anastrozole impurity E | 1 | 10 mg | 1 | 2,2'-[5-(hydroxymethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile) | 2406 | Yes | +5°C ± 3°C | |
Y0001870 | Andrographis herb HRS | 1 | 2050 mg | 1 | 2712 | Yes | +5°C ± 3°C | ||
Y0001866 | Andrographolide | 1 | 15 mg | 1 | see leaflet CœÐH–ÐO— | 2712 | Yes | +5°C ± 3°C | |
Y0001753 | Anemarrhena rhizome for system suitability HRS | 1 | 150 mg | 1 | 2661 | Yes | +5°C ± 3°C | ||
Y0001386 | Angelica dahurica root HRS | 1 | 160 mg | 1 | 2556 | Yes | +5°C ± 3°C | ||
Y0001385 | Angelica pubescens root | 1 | 500 mg | 1 | 2557 | Yes | +5°C ± 3°C | ||
A1200000 | Anhydrotetracycline hydrochloride | 5 | 25 mg | 1 | See leaflet ; Batch 4 is valid until 28 February 2017 | 0210,0211,1 654 | Yes | +5°C ± 3°C | |
Y0001466 | Anhydrous Docetaxel | 1 | 15 mg | 1 | 2593 | Yes | +5°C ± 3°C | ||
A1210000 | Antazoline hydrochloride | 1 | 50 mg | 1 | 0972 | Yes | +5°C ± 3°C | ||
Y0001777 | Apigenin 7-glucoside | 1 | 25 mg | 1 | see leaflet CœŒHœÐOŒÐ | 0404 | Yes | +5°C ± 3°C | |
Y0001465 | Apomorphine hydrochloride hemihydrate | 1 | 15 mg | 1 | 0136 | Yes | +5°C ± 3°C | ||
Y0001471 | Apomorphine impurity B (morphine sulfate) -* narc | 1 | 40 mg | 1 | See leaflet; 7,8-didehydro-4,5α-epoxy-17-methylmorphinan-3,6α-diol (morphine) | 0136 | Yes | +5°C ± 3°C | |
Y0001825 | Aprepitant | 1 | 150 mg | 1 | see leaflet Cœ–HœŒFŸN÷O– | 2757 | Yes | +5°C ± 3°C | |
Y0001826 | Aprepitant for system suitability | 1 | 15 mg | 1 | 2757 | Yes | +5°C ± 3°C | ||
Y0001154 | Aprotinin for system suitability | 1 | 2.7 mg | 1 | 0580, 0579 | Yes | +5°C ± 3°C | ||
A1250000 | Aprotinin solution BRP | 4 | 0.5 mL | 1 | See leaflet | 0579.0580 | Yes | +5°C ± 3°C | |
A1269000 | L-Arabinitol | 2 | 10 mg | 1 | 1381 | Yes | +5°C ± 3°C | ||
Y0000806 | Arbutin | 2 | 110 mg | 1 | See leaflet CŒœHŒÿOŸ ; Batch 1 is valid until 30 September 2016 | 1054 | Yes | +5°C ± 3°C | |
A1270000 | Arginine | 4 | 60 mg | 1 | See leaflet | 0806, 1654, 2114, 2566 | Yes | +5°C ± 3°C | |
Y0000304 | Arginine aspartate | 1 | 20 mg | 1 | 2096 | Yes | +5°C ± 3°C | ||
A1271000 | Arginine hydrochloride | 3 | 60 mg | 1 | 0805.0885 | Yes | +5°C ± 3°C | ||
Y0001649 | Aripiprazole | 2 | 170 mg | 1 | See leaflet ; Batch 1 is valid until 31 March 2017 | 2617 | Yes | +5°C ± 3°C | |
Y0001650 | Aripiprazole impurity F | 2 | 15 mg | 1 | 7-[4-[4-(2,3-dichlorophenyl)-1-oxidopiperazin-1-yl]butoxy]-3,4- dihydroquinolin-2(1H)-one | 2617 | Yes | +5°C ± 3°C | |
Y0001323 | Aristolochia | 1 | 140 mg | 1 | See leaflet | 20821 | Yes | +5°C ± 3°C | |
Y0001185 | Aristolochic acid I | 1 | 11 mg | 1 | See leaflet | 20821 | Yes | +5°C ± 3°C | |
Y0001175 | Aristolochic acid for system suitability | 1 | 1 mg | 1 | 20821 | Yes | +5°C ± 3°C | ||
Y0000079 | Articaine hydrochloride | 3 | 200 mg | 1 | 1688 | Yes | +5°C ± 3°C | ||
Y0000080 | Articaine impurity A | 3 | 25 mg | 1 | methyl 4-methyl-3-[[2-(propylamino)acetyl]amino]thiophene-2-carboxylate (acetamidoarticaine) | 1688 | Yes | +5°C ± 3°C | |
Y0000081 | Articaine impurity E | 2 | 10 mg | 1 | methyl 4-methyl-3-[[(2RS)-2-[(1-methylethyl)amino]propanoyl]amino] thiophene-2-carboxylate (isopropylarticaine) | 1688 | Yes | +5°C ± 3°C | |
Y0001091 | Artichoke leaf dry extract HRS | 1 | 60 mg | 1 | 2389 | Yes | -20°C ± 5°C | ||
A1300000 | Ascorbic acid | 4 | 100 mg | 1 | Vitamin C | 0253,0958,1 791 | Yes | +5°C ± 3°C | |
Y0001024 | Ascorbic acid impurity C | 3 | 20 mg | 1 | see leaflet CÿHŒÐOŸ; L-xylo-hex-2-ulosonic acid (L-sorbosonic acid) | 0253.1791 | Yes | +5°C ± 3°C | |
Y0001170 | Ascorbic acid impurity D | 2 | 10 mg | 1 | methyl L-xylo-hex-2-ulosonate (methyl L-sorbosonate) | 0253.1791 | Yes | +5°C ± 3°C | |
Y0000800 | Ascorbyl palmitate | 1 | 10 mg | 1 | 0807 | Yes | +5°C ± 3°C | ||
Y0001206 | Asiaticoside | 1 | 40 mg | 1 | see leaflet C÷‡HŸ‡OŒ„ | 1498 | Yes | +5°C ± 3°C | |
Y0000305 | Asparagine monohydrate | 2 | 60 mg | 1 | Batch 1 is valid until 31 January 2017 | 2086 | Yes | +5°C ± 3°C | |
A1320000 | Aspartame | 2 | 40 mg | 1 | 0973 | Yes | +5°C ± 3°C | ||
A1321000 | Aspartame impurity A | 5 | 10 mg | 1 | 2-[(2S,5S)-5-benzyl-3,6-dioxopiperazin-2-yl]acetic acid ; Batch 4 is valid until 30 June 2017 | 0973 | Yes | +5°C ± 3°C | |
A1330000 | Aspartic acid | 2 | 50 mg | 1 | 0750.0797 | Yes | +5°C ± 3°C | ||
New | Y0001171 | Astragaloside IV | 2 | 40 mg | 1 | See leaflet C÷ŒHÿ‡OŒ÷ ; Batch 1 is valid until 19 July 2017 | 2435 | Yes | -20°C ± 5°C |
A1340000 | Atenolol | 3 | 100 mg | 1 | 0703 | Yes | +5°C ± 3°C | ||
Y0001089 | Atenolol for system suitability | 2 | 5 mg | 1 | Batch 1 is valid until 31 October 2016 | 0703 | Yes | +5°C ± 3°C | |
Y0001586 | Atomoxetine hydrochloride | 1 | 110 mg | 1 | See leaflet CŒŸHœœClNO | 2640 | Yes | +5°C ± 3°C | |
Y0001588 | Atomoxetine impurity B | 1 | 10 mg | 1 | (3S)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1- amine | 2640 | Yes | +5°C ± 3°C | |
Y0001589 | Atomoxetine impurity D | 1 | 5 mg | 1 | (3R)-N-methyl-3-(3-methylphenoxy)-3-phenylpropan-1- amine | 2640 | Yes | +5°C ± 3°C | |
Y0001587 | Atomoxetine for impurity A identification | 1 | 10 mg | 1 | N-methyl-3-phenoxy-3-phenylpropan-1-amine | 2640 | Yes | +5°C ± 3°C | |
Y0001327 | Atorvastatin calcium trihydrate | 3 | 150 mg | 1 | See leaflet CÿÿHÿ‡CaFœN÷OŒÐ ; Batch 2 is valid until 31 August 2016 | 2191 | Yes | +5°C ± 3°C | |
Y0001328 | Atorvastatin impurity A | 3 | 5 mg | 1 | (3R,5R)-3,5-dihydroxy-7-[5-(1-methylethyl)-2,3-diphenyl-4- (phenylcarbamoyl)-1H-pyrrol-1-yl]heptanoic acid (desfluoroatorvastatin) ; Batch 2 is valid until 31 July 2017 | 2191 | Yes | +5°C ± 3°C | |
Y0001329 | Atorvastatin impurity B | 4 | 10 mg | 1 | (3RS,5SR)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4- (phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid ; Batch 2 is valid until 31 October 2016 Batch 3 is valid until 30 June 2017 | 2191 | Yes | +5°C ± 3°C | |
Y0001330 | Atorvastatin impurity C | 2 | 10 mg | 1 | (3R,5R)-7-[2,3-bis(4-fluorophenyl)-5-(1-methylethyl)-4- (phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid (fluoroatorvastatin) | 2191 | Yes | +5°C ± 3°C | |
Y0001331 | Atorvastatin impurity D | 4 | 5 mg | 1 | 3-[(4-fluorophenyl)carbonyl]-2-(2-methylpropanoyl)-N,3-diphenyloxirane-2- carboxamide ; Batch 2 is valid until 31 October 2016 Batch 3 is valid until 30 April 2017 | 2191 | Yes | +5°C ± 3°C | |
Y0001332 | Atorvastatin impurity E | 4 | 5 mg | 1 | (3S,5S)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4- (phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid (ent- atorvastatin) ; Batch 2 is valid until 31 August 2016 Batch 3 is valid until 4 May 2017 | 2191 | Yes | +5°C ± 3°C | |
Y0001572 | Atovaquone | 1 | 270 mg | 1 | See leaflet CœœHŒ„ClO– | 2192 | Yes | +5°C ± 3°C | |
Y0001573 | Atovaquone for system suitability | 1 | 10 mg | 1 | 2192 | Yes | +5°C ± 3°C | ||
Y0000424 | Atracurium besilate | 3 | 120 mg | 1 | see leaflet Cÿ—H‡œNœOŒ‡Sœ ; Batch 2 is valid until 30 September 2017 | 1970 | Yes | +5°C ± 3°C | |
Y0000503 | Atracurium for impurity F identification | 1 | 5 mg | 1 | 1970 | Yes | +5°C ± 3°C | ||
Y0000504 | Atracurium for peak identification | 1 | 5 mg | 1 | 1970 | Yes | +5°C ± 3°C | ||
Y0000878 | Atropine | 1 | 30 mg | 1 | 2056 | Yes | +5°C ± 3°C | ||
Y0000816 | Atropine impurity B | 2 | 10 mg | 1 | (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl (2RS)-3-hydroxy-2-phenylpropanoate (noratropine) ; Batch 1 is valid until 31 December 2016 | 0068.2056 | Yes | +5°C ± 3°C | |
Y0000845 | Atropine for peak identification | 2 | 0.25 mg | 1 | 0068.2056 | Yes | +5°C ± 3°C | ||
A1400000 | Atropine sulfate | 4 | 20 mg | 1 | 0068 | Yes | +5°C ± 3°C | ||
Y0000029 | Azaperone | 1 | 50 mg | 1 | 1708 | Yes | +5°C ± 3°C | ||
A1500000 | Azathioprine | 1 | 100 mg | 1 | 0369 | Yes | +5°C ± 3°C | ||
Y0001240 | Azathioprine impurity A | 1 | 10 mg | 1 | 1-methyl-4-nitro-1H-imidazol-5-amine | 0369 | Yes | +5°C ± 3°C | |
Y0001246 | Azathioprine impurity G | 2 | 5 mg | 1 | 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purin-2-amine (thiamiprine) | 0369 | Yes | +5°C ± 3°C | |
Y0000326 | Azelastine hydrochloride | 1 | 25 mg | 1 | 1633 | Yes | +5°C ± 3°C | ||
Y0000327 | Azelastine impurity B | 1 | 5 mg | 1 | N'-[(4RS)-1-methylhexahydro-1H-azepin-4-yl]benzohydrazide | 1633 | Yes | +5°C ± 3°C | |
Y0000328 | Azelastine impurity D | 1 | 5 mg | 1 | 4-[(4-chlorophenyl)methyl]phthalazin-1(2H)-one | 1633 | Yes | +5°C ± 3°C | |
Y0000329 | Azelastine impurity E | 1 | 5 mg | 1 | (3E)-3-[(4-chlorophenyl)methylidene]-2-benzofuran-1(3H)-one | 1633 | Yes | +5°C ± 3°C | |
Y0000306 | Azithromycin | 4 | 200 mg | 1 | See leaflet C–‡HŸœNœOŒœ | 1649 | Yes | +5°C ± 3°C | |
New | Y0000307 | Azithromycin impurity A | 3 | 10 mg | 1 | 6-demethylazithromycin ; Batch 2 is valid until 30 November 2017 | 1649 | Yes | +5°C ± 3°C |
Y0000637 | Azithromycin for peak identification | 3 | 15 mg | 1 | 1649 | Yes | +5°C ± 3°C | ||
Y0000641 | Azithromycin for system suitability | 9 | 0.05 mg | 1 | Batch 8 is valid until 30 June 2017 | 1649 | Yes | +5°C ± 3°C | |
Y0000285 | B19 virus DNA for NAT testing BRP | 1 | 150 mg | 5 | See leaflet | 0557, 1527,1646 | Yes | -20°C ± 5°C | |
B0070000 | Bacampicillin hydrochloride | 3 | 120 mg | 1 | See leaflet CœŒHœ‡ClN–OŸS | 0808.0852 | Yes | +5°C ± 3°C | |
Y0001867 | Bacitracin for system suitability | 1 | 40 mg | 1 | 0465.0466 | Yes | -20°C ± 5°C | ||
B0100000 | Bacitracin zinc | 3 | 150 mg | 1 | See leaflet | 20702 | Yes | -20°C ± 5°C | |
B0200000 | Baclofen | 2 | 130 mg | 1 | Batch 1 is valid until 30 September 2016 | 0653 | Yes | +5°C ± 3°C | |
B0200050 | Baclofen impurity A | 4 | 60 mg | 1 | (4RS)-4-(4-chlorophenyl)pyrrolidin-2-one | 0653 | Yes | +5°C ± 3°C | |
Y0001273 | Baicalin | 1 | 10 mg | 1 | See leaflet CœŒHŒ‡OŒŒ | 2438 | Yes | +5°C ± 3°C | |
B0250000 | Bambuterol hydrochloride | 1 | 100 mg | 1 | 1293 | Yes | +5°C ± 3°C | ||
B0300000 | Barbital - * psy | 1 | 500 mg | 1 | 0170 | Yes | +5°C ± 3°C | ||
Y0001525 | Basic butylated methacrylate copolymer | 1 | 20 mg | 1 | 1975 | Yes | +5°C ± 3°C | ||
B0305000 | Beclometasone dipropionate anhydrous | 4 | 150 mg | 1 | See leaflet Cœ‡H–ŸClOŸ | 0654,1449, 1709 | Yes | +5°C ± 3°C | |
Y0000469 | Beclometasone dipropionate for peak identification | 2 | 10 mg | 1 | Batch 1 is valid until 30 November 2016 | 0654.1709 | Yes | +5°C ± 3°C | |
Y0001916 | Teriparatide | 1 | 1 mg | 1 | see leaflet | 2829 | Yes | -20°C ± 5°C | |
Y0000352 | Beclometasone dipropionate for system suitability | 3 | 15 mg | 1 | 0654.1709 | Yes | +5°C ± 3°C | ||
Y0001073 | Beclometasone dipropionate impurities F and N | 2 | 0.052 mg | 1 | 0654.1709 | Yes | +5°C ± 3°C | ||
Y0000351 | Beclometasone dipropionate monohydrate | 1 | 10 mg | 1 | 1709 | Yes | +5°C ± 3°C | ||
Y0001607 | Belamcanda chinensis rhizome HRS | 1 | 110 mg | 1 | 2561 | Yes | +5°C ± 3°C | ||
Y0001025 | Benazepril hydrochloride | 1 | 160 mg | 1 | See leaflet Cœ÷Hœ„ClNœO— | 2388 | Yes | +5°C ± 3°C | |
Y0001026 | Benazepril impurity A | 2 | 10 mg | 1 | [(3R)-3-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2-oxo-2,3,4,5- tetrahydro-1H-1-benzazepin-1-yl]acetic acid | 2388 | Yes | +5°C ± 3°C | |
Y0001038 | Benazepril for system suitability | 2 | 0.016 mg | 1 | Batch 1 is valid until 30 April 2017 | 2388 | Yes | +5°C ± 3°C | |
B0400000 | Bendroflumethiazide | 1 | 100 mg | 1 | 0370 | Yes | +5°C ± 3°C | ||
Y0000564 | Bendroflumethiazide impurity A | 1 | 5 mg | 1 | 4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide | 0370 | Yes | +5°C ± 3°C | |
B0470000 | Benperidol | 1 | 100 mg | 1 | 1010,1172,1 254, 1708 | Yes | +5°C ± 3°C | ||
B0477000 | Benserazide hydrochloride | 1 | 50 mg | 1 | 1173 | Yes | +5°C ± 3°C | ||
B0477010 | Benserazide impurity A | 2 | 15 mg | 1 | (2RS)-2-amino-3-hydroxypropanohydrazide | 1173 | Yes | +5°C ± 3°C | |
Y0001071 | Benserazide impurity C | 1 | 10 mg | 1 | (2RS)-2-amino-3-hydroxy-2'-[(1EZ)-(2,3,4-trihydroxybenzylidene)] propanohydrazide | 1173 | Yes | +5°C ± 3°C | |
Y0001079 | Benserazide for peak identification | 1 | 10 mg | 1 | 1173 | Yes | +5°C ± 3°C | ||
Y0001064 | Benzaldehyde | 2 | 150 mg | 1 | 0372,0371,1 740 | Yes | +5°C ± 3°C | ||
Y0001060 | Benzalkonium chloride for system suitability | 4 | 20 mg | 1 | 0371.0372 | Yes | +5°C ± 3°C | ||
B0490000 | Benzarone | 1 | 10 mg | 1 | (2-ethylbenzofuran-3-yl)(4-hydroxyphenyl)methanone | 1393 | Yes | +5°C ± 3°C | |
B0500000 | Benzathine benzylpenicillin | 2 | 200 mg | 1 | See leaflet | 0373 | Yes | +5°C ± 3°C | |
Y0000775 | Benzbromarone | 1 | 10 mg | 1 | 1393 | Yes | +5°C ± 3°C | ||
B0550000 | Benzethonium chloride | 1 | 100 mg | 1 | 0974 | Yes | +5°C ± 3°C | ||
B0600000 | Benzocaine | 1 | 50 mg | 1 | 0011.1088 | Yes | +5°C ± 3°C | ||
Y0001470 | Benzoic acid | 1 | 30 mg | 1 | 0934 | Yes | +5°C ± 3°C | ||
Y0000647 | Benzophenone | 2 | 40 mg | 1 | 1784 | Yes | +5°C ± 3°C | ||
New | Y0000167 | Benzyl alcohol | 3 | 70 mg | 1 | See leaflet ; Batch 2 is valid until 31 October 2017 | 0256,0371,0 372,1827 | Yes | +5°C ± 3°C |
B0670000 | Benzyl benzoate - reference spectrum | 1 | n/a | 1 | 0705 | ||||
B0680000 | S-Benzylmercaptoacetyltriglycine | 1 | 10 mg | 1 | 1372 | Yes | +5°C ± 3°C | ||
Y0001889 | Benzylpenicillin for system suitability | 1 | 10 mg | 1 | 0113.0114 | Yes | +5°C ± 3°C | ||
B0700000 | Benzylpenicillin potassium | 2 | 100 mg | 1 | 0113,0148,0 149 | Yes | +5°C ± 3°C | ||
B0900000 | Benzylpenicillin sodium | 7 | 200 mg | 1 | See leaflet CŒÿHŒŸNœNaO÷S | 0113.0114 | Yes | +5°C ± 3°C | |
Y0001149 | Berberine chloride | 1 | 20 mg | 1 | See leaflet CœÐHŒ‡ClNO÷ | 1831,2500, 2715 | Yes | +5°C ± 3°C | |
B0950000 | Betadex | 4 | 200 mg | 1 | See leaflet [CÿHŒÐO—]Ÿ | 1070,1487,1 804 | Yes | +5°C ± 3°C | |
Y0000391 | Betahistine dihydrochloride | 2 | 50 mg | 1 | 1665 | Yes | +5°C ± 3°C | ||
B0990000 | Betahistine mesilate | 2 | 50 mg | 1 | 1071 | Yes | +5°C ± 3°C | ||
B1000000 | Betamethasone | 5 | 60 mg | 1 | 0312,0354,0 388, 0811 | Yes | +5°C ± 3°C | ||
B1030000 | Betamethasone acetate | 2 | 100 mg | 1 | 0548.0975 | Yes | +5°C ± 3°C | ||
B1040000 | Betamethasone dipropionate | 4 | 200 mg | 1 | See leaflet Cœ‡H–ŸFOŸ ; Batch 3 is valid until 31 August 2016 | 0809 | Yes | +5°C ± 3°C | |
Y0001416 | Betamethasone dipropionate for peak identification | 1 | 10 mg | 1 | 0809 | Yes | +5°C ± 3°C | ||
Y0001418 | Betamethasone dipropionate for system suitability | 2 | 10 mg | 1 | Batch 1 is valid until 30 November 2016 | 0809 | Yes | +5°C ± 3°C | |
B1045000 | Betamethasone sodium phosphate | 4 | 100 mg | 1 | 0549.0810 | Yes | +5°C ± 3°C | ||
B1054000 | Betamethasone 17-valerate | 3 | 100 mg | 1 | 0322.0811 | Yes | +5°C ± 3°C | ||
B1055000 | Betamethasone 21-valerate | 3 | 15 mg | 1 | 0811 | Yes | +5°C ± 3°C | ||
Y0001027 | Betamethasone valerate for system suitability | 1 | 25 mg | 1 | 0811 | Yes | +5°C ± 3°C | ||
Y0001065 | Betamethasone valerate impurity mixture | 2 | 0.018 mg | 1 | 0811 | Yes | +5°C ± 3°C | ||
B1103000 | Betaxolol hydrochloride | 2 | 60 mg | 1 | 1072 | Yes | +5°C ± 3°C | ||
B1103100 | Betaxolol impurity A | 3 | 10 mg | 1 | (2RS)-1-(4-ethylphenoxy)-3-[(1-methylethyl)amino]propan-2-ol ; Batch 2 is valid until 28 February 2017 | 1072 | Yes | +5°C ± 3°C | |
Y0001354 | Betaxolol impurity C | 1 | 5 mg | 1 | (2RS)-2-[[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]methyl]oxirane | 1072 | Yes | -20°C ± 5°C | |
Y0001360 | Betaxolol for peak identification | 1 | 15 mg | 1 | 1072 | Yes | +5°C ± 3°C | ||
B1115000 | Bezafibrate | 2 | 100 mg | 1 | Batch 1 is valid until 31 August 2017 | 1394 | Yes | +5°C ± 3°C | |
Y0001444 | Bicalutamide | 1 | 100 mg | 1 | See leaflet CŒ‡HŒ÷F÷NœO÷S | 2196 | Yes | +5°C ± 3°C | |
Y0001448 | Bicalutamide for system suitability | 1 | 15 mg | 1 | 2196 | Yes | +5°C ± 3°C | ||
Y0001078 | Bicisate labelling kit | 1 | 24 mg | 1 | 2123 | Yes | +5°C ± 3°C | ||
B1110000 | Bifonazole | 2 | 50 mg | 1 | 1395 | Yes | +5°C ± 3°C | ||
Y0001421 | Bifonazole for system suitability | 1 | 10 mg | 1 | 1395 | Yes | +5°C ± 3°C | ||
Y0001788 | Bilberry dry extract HRS | 1 | 250 mg | 1 | see leaflet | 2394,1588,1 602 | Yes | -20°C ± 5°C | |
B1116000 | Biotin | 2 | 20 mg | 1 | Vitamin H | 1073 | Yes | +5°C ± 3°C | |
B1120000 | Biperiden hydrochloride | 1 | 60 mg | 1 | 1074 | Yes | +5°C ± 3°C | ||
B1121000 | Biperiden impurity A | 2 | 20 mg | 1 | (1RS)-1-[(1SR,2SR,4SR)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl- 3- (piperidin-1-yl)propan-1-ol (endo form) | 1074 | Yes | +5°C ± 3°C | |
B1140000 | Bisacodyl | 3 | 50 mg | 1 | 0595 | Yes | +5°C ± 3°C | ||
Y0000608 | Bisacodyl for peak identification | 1 | 10 mg | 1 | 0595 | Yes | +5°C ± 3°C | ||
Y0000694 | Bisacodyl for system suitability | 2 | 5 mg | 1 | 0595 | Yes | +5°C ± 3°C | ||
Y0000812 | Bisoprolol fumarate | 1 | 50 mg | 1 | 1710 | Yes | +5°C ± 3°C | ||
Y0000877 | Bisoprolol for peak identification | 3 | 1.007 mg | 1 | Bisoprolol for system suitability method A CRS has been renamed as Bisoprolol for peak identification CRS. | 1710 | Yes | +5°C ± 3°C | |
New | Y0000813 | Bisoprolol for system suitability | 4 | 1.003 mg | 1 | Bisoprolol for system suitability method B CRS has been renamed as Bisoprolol for system suitability CRS ; Batch 3 is valid until 31 October 2017 | 1710 | Yes | +5°C ± 3°C |
B1141000 | Bleomycin sulfate | 2 | 7 mg | 1 | See leaflet | 0976.20702 | Yes | -20°C ± 5°C | |
Y0000434 | Boldine | 3 | 30 mg | 1 | See leaflet | 1396, 1816 | Yes | +5°C ± 3°C | |
Y0001780 | Boldo leaf dry extract HRS | 1 | 550 mg | 1 | 1816.1396 | Yes | -20°C ± 5°C | ||
B1142000 | Bordela pertussis mouse antiserum BRP | 1 | 0.5 mg | 1 | See leaflet | See leaflet, 20716 | Yes | -20°C ± 5°C | |
Y0001634 | Brimonidine for system suitability | 1 | 1.3 mg | 1 | 2760 | Yes | +5°C ± 3°C | ||
Y0001658 | Brimonidine tartrate | 1 | 5 mg | 1 | 2760 | Yes | +5°C ± 3°C | ||
B1143000 | Bromazepam - * psy | 4 | 60 mg | 1 | 0778.0879 | Yes | +5°C ± 3°C | ||
Y0000645 | Bromazepam for system suitability - * psy | 2 | 10 mg | 1 | 0879 | Yes | +5°C ± 3°C | ||
B1145000 | Bromhexine hydrochloride | 4 | 200 mg | 1 | Batch 3 is valid until 31 March 2017 | 0706 | Yes | +5°C ± 3°C | |
Y0001757 | Bromhexine for system suitability | 2 | 15 mg | 1 | Batch 1 is valid until 30 September 2017 | 0706 | Yes | +5°C ± 3°C | |
B1150000 | Bromocriptine mesilate | 2 | 30 mg | 1 | 0596 | Yes | -20°C ± 5°C | ||
Y0000677 | Bromocriptine mesilate for system suitability | 1 | 5 mg | 1 | 0596 | Yes | -20°C ± 5°C | ||
B1152000 | Bromperidol | 1 | 100 mg | 1 | 0616.1178 | Yes | +5°C ± 3°C | ||
B1152050 | Bromperidol decanoate | 1 | 60 mg | 1 | 1397.1431 | Yes | +5°C ± 3°C | ||
B1153000 | Brompheniramine maleate | 1 | 100 mg | 1 | 0977.1196 | Yes | +5°C ± 3°C | ||
Y0000468 | Brotizolam - * psy | 1 | 10 mg | 1 | 2197 | Yes | +5°C ± 3°C | ||
Y0000470 | Brotizolam impurity B | 1 | 10 mg | 1 | 2-bromo-4-(2-chlorophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine (desmethylbrotizolam) | 2197 | Yes | +5°C ± 3°C | |
Y0001196 | Brucine | 1 | 40 mg | 1 | see leaflet | 2513.2514 | Yes | +5°C ± 3°C | |
B1157300 | Budesonide | 5 | 110 mg | 1 | See leaflet Cœ—H–÷Oÿ ; Batch 4 is valid until 31 January 2017 | 1075 | Yes | +5°C ± 3°C | |
Y0001148 | Budesonide for system suitability | 1 | 10 mg | 1 | 1075 | Yes | +5°C ± 3°C | ||
B1156000 | Bufexamac | 1 | 100 mg | 1 | 1179 | Yes | +5°C ± 3°C | ||
Y0001729 | Bufexamac impurity A | 1 | 10 mg | 1 | 2-(4-butoxyphenyl)acetic acid | 1179 | Yes | +5°C ± 3°C | |
Y0001730 | Bufexamac impurity B | 1 | 15 mg | 1 | methyl 2-(4-butoxyphenyl)acetate | 1179 | Yes | +5°C ± 3°C | |
B1157400 | Buflomedil hydrochloride | 2 | 100 mg | 1 | 1398 | Yes | +5°C ± 3°C | ||
Y0001731 | Bufexamac impurity C | 1 | 15 mg | 1 | butyl 2-(4-butoxyphenyl)acetate | 1179 | Yes | +5°C ± 3°C | |
Y0001732 | Bufexamac impurity D | 1 | 10 mg | 1 | 2-(4-butoxyphenyl)acetamide | 1179 | Yes | +5°C ± 3°C | |
B1157410 | Buflomedil impurity B | 3 | 20 mg | 1 | 1-(4-hydroxy-2,6-dimethoxyphenyl)-4-(pyrrolidin-1-yl)butan-1-one | 1398 | Yes | +5°C ± 3°C | |
Y0001529 | Buflomedil for peak identification | 1 | 0.45 mg | 1 | 1398 | Yes | +5°C ± 3°C | ||
B1158000 | Bumetanide | 1 | 150 mg | 1 | 1076 | Yes | +5°C ± 3°C | ||
Y0000309 | Bumetanide impurity A | 1 | 5 mg | 1 | 3-nitro-4-phenoxy-5-sulphamoylbenzoic acid | 1076 | Yes | +5°C ± 3°C | |
Y0000310 | Bumetanide impurity B | 1 | 5 mg | 1 | 3-amino-4-phenoxy-5-sulphamoylbenzoic acid | 1076 | Yes | +5°C ± 3°C | |
B1160000 | Bupivacaine hydrochloride | 2 | 100 mg | 1 | 0541, 2335 | Yes | +5°C ± 3°C | ||
Y0000088 | Bupivacaine impurity B | 3 | 20 mg | 1 | (2RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide | 0541 | Yes | +5°C ± 3°C | |
Y0000089 | Bupivacaine impurity E | 3 | 20 mg | 1 | 6-(butylamino)-N-(2,6-dimethylphenyl)hex* | 0541 | Yes | +5°C ± 3°C | |
Y0001575 | Bupivacaine impurity F | 1 | 70 mg | 1 | 2,6-dimethylaniline | 0541 | Yes | +5°C ± 3°C | |
Y0001108 | Buprenorphine - * psy | 1 | 10 mg | 1 | 1180 | Yes | +5°C ± 3°C | ||
Y0001122 | Buprenorphine for system suitability - * psy | 2 | 10 mg | 1 | Batch 1 is valid until 31 October 2016 | 1180.1181 | Yes | +5°C ± 3°C | |
Y0001109 | Buprenorphine hydrochloride - * psy | 1 | 10 mg | 1 | 1181 | Yes | +5°C ± 3°C | ||
B1168000 | Buserelin | 2 | 2 mg | 1 | See leaflet CÿÐH‡ÿNŒÿOŒ– | 1077 | Yes | -20°C ± 5°C | |
Y0001814 | Buserelin for NMR identification | 1 | 2 mg | 1 | 1077 | Yes | -20°C ± 5°C | ||
Y0001740 | Buserelin for peak identification | 1 | 1 mg | 1 | 1077 | Yes | -20°C ± 5°C | ||
B1168020 | D-His-Buserelin | 2 | 0.5 mg | 1 | 1077 | Yes | -20°C ± 5°C | ||
Y0000131 | Buspirone hydrochloride | 1 | 5 mg | 1 | 1711 | Yes | +5°C ± 3°C | ||
Y0000471 | Buspirone for system suitability | 2 | 2.018 mg | 1 | 1711 | Yes | +5°C ± 3°C | ||
B1170000 | Busulfan | 3 | 50 mg | 1 | Batch 1 is valid until 30 September 2016 Batch 2 is valid until 31 March 2017 | 0542 | Yes | +5°C ± 3°C | |
Y0001487 | Butyl methacrylate | 1 | 100 mg | 1 | 1975 | Yes | +5°C ± 3°C | ||
Y0001304 | Butyl methanesulfonate | 1 | 30 µL | 1 | 20537,2053 8, 20539, 20540,2054 | Yes | +5°C ± 3°C | ||
B1217000 | Butyl parahydroxybenzoate | 3 | 150 mg | 1 | See leaflet ; Batch 2 is valid until 31 December 2016 | 0881.1216 | Yes | +5°C ± 3°C | |
Y0001357 | Butyl parahydroxybenzoate impurity E | 1 | 15 mg | 1 | 2-methylpropyl 4-hydroxybenzoate (iso-butyl parahydroxybenzoate) | 0881 | Yes | +5°C ± 3°C | |
B1212000 | Butylhydroxyanisole | 4 | 60 mg | 1 | 0880 | Yes | +5°C ± 3°C | ||
B1215000 | Butylhydroxytoluene | 1 | 50 mg | 1 | Plastic additive 07 | 0581,30103, 30105,3010 6, 30107 | Yes | +5°C ± 3°C | |
Y0000472 | Cabergoline | 2 | 160 mg | 1 | See leaflet | 1773 | Yes | -20°C ± 5°C | |
C0100000 | Caffeine | 4 | 70 mg | 1 | See leaflet | 0267,0268,1 504,2412 | Yes | +5°C ± 3°C | |
Y0000787 | Caffeine for system suitability | 4 | 10 mg | 1 | Batch 3 is valid until 31 August 2016 | 0267, 0268 | Yes | +5°C ± 3°C | |
C0166000 | Calcifediol | 6 | 5 mg | 1 | See leaflet ; Batch 5 is valid until 30 June 2017 | 1295 | Yes | -20°C ± 5°C | |
C0166001 | Calcifediol - reference spectrum | 1 | n/a | 1 | 1295 | ||||
Y0000499 | Calcipotriol (anhydrous) - reference spectrum | 1 | n/a | 1 | 2011 | ||||
Y0000473 | Calcipotriol monohydrate | 2 | 10 mg | 1 | See leaflet CœŸH÷ÐO– | 2011.2284 | Yes | -20°C ± 5°C | |
Y0000474 | Calcipotriol monohydrate - reference spectrum | 1 | n/a | 1 | 2284 | ||||
C0200000 | Calcitonin (salmon) | 11 | 1 mg | 2 | See leaflet | 0471 | Yes | -20°C ± 5°C | |
Y0000632 | Calcitonin-Gly | 2 | 1 ml | 1 | About 0.9 mg per ml | 0471 | Yes | -20°C ± 5°C | |
C0200010 | N-acetyl-cys1-calcitonin | 5 | 0.1 mg | 1 | See leaflet | 0471 | Yes | -20°C ± 5°C | |
C0225000 | Calcitriol | 9 | 10 mg | 1 | See leaflet | 0883 | Yes | -20°C ± 5°C | |
C0226000 | Calcitriol - reference spectrum | 1 | n/a | 1 | 0883 | ||||
C0249000 | Calcium ascorbate - reference spectrum | 1 | n/a | 1 | 1182 | ||||
New | C0250000 | Calcium folinate | 7 | 130 mg | 1 | See leaflet ; Batch 6 is valid until 31 October 2017 | 0978.1606 | Yes | +5°C ± 3°C |
C0299000 | Calcium glucoheptonate | 2 | 60 mg | 1 | Batch 1 is valid until 7 February 2017 | 1399 | Yes | +5°C ± 3°C | |
C0300000 | Calcium gluconate | 3 | 50 mg | 1 | Calcium digluconate ; Batch 2 is valid until 30 April 2017 | 0172,0658,0 979,1399,21 61,2162,216 4,2364 | Yes | +5°C ± 3°C | |
C0340000 | Calcium levulinate dihydrate | 1 | 250 mg | 1 | 1296 | Yes | +5°C ± 3°C | ||
C0350000 | Calcium oxalate monohydrate | 1 | 500 mg | 1 | See leaflet | 20234 | Yes | +5°C ± 3°C | |
C0400000 | Calcium pantothenate | 4 | 50 mg | 1 | 0470 | Yes | +5°C ± 3°C | ||
C0405000 | Camphor (racemic) | 2 | 50 mg | 1 | 0655.1400 | Yes | +5°C ± 3°C | ||
Y0001388 | Candesartan cilexetil | 1 | 60 mg | 1 | 2573 | Yes | +5°C ± 3°C | ||
Y0001387 | Candesartan cilexetil for peak identification | 2 | 10 mg | 1 | Batch 1 is valid until 31 August 2016 | 2573 | Yes | +5°C ± 3°C | |
Y0001389 | Candesartan cilexetil for system suitability | 1 | 10 mg | 1 | 2573 | Yes | +5°C ± 3°C | ||
C0410000 | Canrenone | 4 | 15 mg | 1 | 0688 | Yes | +5°C ± 3°C | ||
Y0001858 | Cape jasmine fruit for system suitability | 1 | 260 mg | 1 | 2565 | Yes | +5°C ± 3°C | ||
Y0001642 | Capecitabine | 1 | 150 mg | 1 | See leaflet CŒÐHœœFN–Oÿ | 2762 | Yes | +5°C ± 3°C | |
Y0001643 | Capecitabine impurity A | 1 | 5 mg | 1 | 4-ami-(5-deoxy-β-D-ribofuranosyl)-5-fluoropyrimidin-2(1H)-one (5?- deoxy-5-fluorocytidine) | 2762 | Yes | +5°C ± 3°C | |
Y0001644 | Capecitabine impurity B | 1 | 5 mg | 1 | 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoropyrimidine-2,4(1H,3H)-dione (5?- deoxy-5-fluorouridine) | 2762 | Yes | +5°C ± 3°C | |
Y0001645 | Capecitabine impurity D | 1 | 10 mg | 1 | (2RS)-2-methylbutyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2- dihydropyrimidin-4-yl]carbamate | 2762 | Yes | +5°C ± 3°C | |
C0426000 | Caprylic acid | 2 | 100 mg | 1 | 1401.1471 | Yes | +5°C ± 3°C | ||
Y0000671 | Capsaicin | 2 | 50 mg | 1 | See leaflet CŒ‡HœŸNO– ; (E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8- methylnon-6-enamide | 1859,2336,2 337, 2529 | Yes | +5°C ± 3°C | |
C0430000 | Captopril | 2 | 10 mg | 1 | 1079 | Yes | +5°C ± 3°C | ||
Y0001219 | Captopril impurity B | 1 | 10 mg | 1 | See leaflet C„HŒ÷BrNO–; (2S)1-[(2S)-3-bromo-2-methylpropanoyl] pyrrolidine-2-carboxylic acid | 1079 | Yes | +5°C ± 3°C | |
New | Y0001220 | Captopril impurity C | 2 | 15 mg | 1 | See leaflet C÷H‡OœS; (2RS)-2-methyl-3-sulfanylpropanoic acid ; Batch 1 is valid until 21 January 2017 | 1079 | Yes | -20°C ± 5°C |
Y0001221 | Captopril impurity D | 2 | 15 mg | 1 | See leaflet C÷HŸBrOœ; (2RS)-3-bromo-2-methylpropanoic acid ; Batch 1 is valid until 30 September 2017 | 1079 | Yes | +5°C ± 3°C | |
Y0000435 | Captopril impurity E | 1 | 10 mg | 1 | (2S)-1-(2-methylpropanoyl)pyrrolidine-2-carboxylic acid | 1079 | Yes | +5°C ± 3°C | |
Y0001450 | Captopril impurity J | 2 | 10 mg | 1 | See leaflet CŒŒHŒŸNO÷S; (2S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl] pyrrolidine-2-carboxylic acid (acetylcaptopril) ; Batch 1 is valid until 31 May 2017 | 1079 | Yes | +5°C ± 3°C | |
Y0001182 | Captopril for system suitability | 2 | 20 mg | 1 | 1079 | Yes | +5°C ± 3°C | ||
Y0000113 | Carbachol | 1 | 50 mg | 1 | 1971 | Yes | +5°C ± 3°C | ||
C0450000 | Carbamazepine | 5 | 200 mg | 1 | See leaflet CŒ—HŒœNœO | 0543 | Yes | +5°C ± 3°C | |
Y0000033 | Carbamazepine impurity A | 6 | 20 mg | 1 | 10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide (10,11- dihydrocarbamazepine) ; Batch 5 is valid until 30 November 2016 | 0543 | Yes | +5°C ± 3°C | |
C0451000 | Carbasalate calcium - reference spectrum | 1 | n/a | 1 | 1185 | ||||
Y0001161 | Carbasalate impurity B | 1 | 5 mg | 1 | 2-[[2-(acetyloxy)benzoyl]oxy]benzoic acid (acetylsalicylsalicylic acid) | 1185 | Yes | +5°C ± 3°C | |
C0455000 | Carbenicillin sodium | 2 | 50 mg | 1 | 0956 | Yes | -20°C ± 5°C | ||
C0460000 | Carbidopa | 2 | 50 mg | 1 | 0755 | Yes | +5°C ± 3°C | ||
Y0001713 | Carbidopa for system suitability | 1 | 10 mg | 1 | 0755 | Yes | +5°C ± 3°C | ||
New | Y0001716 | Carbidopa impurity mixture | 2 | 0.008 mg | 1 | Batch 1 is valid until 30 November 2017 | 0755 | Yes | +5°C ± 3°C |
C0465000 | Carbimazole | 2 | 120 mg | 1 | See leaflet CŸHŒÐNœOœS | 0884 | Yes | +5°C ± 3°C | |
C0470000 | Carbocisteine | 2 | 60 mg | 1 | 0885 | Yes | +5°C ± 3°C | ||
C0499900 | Carbon dioxide - reference spectrum | 1 | n/a | 1 | 0375 | ||||
C0550000 | Carboplatin - reference spectrum | 1 | n/a | 1 | 1081 | ||||
Y0000475 | Carboprost trometamol | 1 | 40 mg | 1 | See leaflet Cœ—H÷ŸNO‡ | 1712 | Yes | -20°C ± 5°C | |
Y0000536 | Carboprost trometamol - reference spectrum | 1 | n/a | 1 | 1712 | ||||
Y0000035 | Carisoprodol | 1 | 50 mg | 1 | 1689 | Yes | +5°C ± 3°C | ||
Y0000036 | Carisoprodol impurity A | 2 | 10 mg | 1 | (2RS)-2-(hydroxymethyl)-2-methylpentyl(1-methylethyl)- carbamate | 1689 | Yes | +5°C ± 3°C | |
Y0001214 | Carmellose | 1 | 10 mg | 1 | 2360 | Yes | +5°C ± 3°C | ||
C0580004 | Carmustine - reference spectrum | 1 | n/a | 1 | 1187 | ||||
C0580010 | Carmustine impurity A | 1 | 20 mg | 1 | 1,3-bis(2-chloroethyl)urea | 1187 | Yes | -20°C ± 5°C | |
Y0000846 | Carprofen | 1 | 30 mg | 1 | 2201 | Yes | +5°C ± 3°C | ||
Y0000884 | Carprofen for system suitability | 1 | 5 mg | 1 | 2201 | Yes | +5°C ± 3°C | ||
Y0000192 | Carteolol hydrochloride - reference spectrum | 1 | n/a | 1 | 1972 | ||||
Y0000193 | Carteolol for system suitability | 1 | 30 mg | 1 | 1972 | Yes | +5°C ± 3°C | ||
Y0001427 | Carvedilol | 1 | 50 mg | 1 | 1745 | Yes | +5°C ± 3°C | ||
Y0000103 | Carvedilol impurity C | 2 | 15 mg | 1 | (2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H- carbazol-4-yloxy) propan-2-ol | 1745 | Yes | +5°C ± 3°C | |
Y0001426 | Carvedilol for system suitability | 2 | 10 mg | 1 | 1745 | Yes | +5°C ± 3°C | ||
C0600000 | Casein BRP | 3 | 100000 mg | 1 | 0350 | Yes | +5°C ± 3°C | ||
C0630000 | Cefaclor | 3 | 450 mg | 1 | See leaflet CŒ—HŒ÷ClN–O÷S | 0986 | Yes | +5°C ± 3°C | |
C0640000 | Delta-3-Cefaclor | 4 | 20 mg | 1 | 0986 | Yes | -20°C ± 5°C | ||
C0650000 | Cefadroxil | 3 | 250 mg | 1 | see leaflet | 0260,0577,0 813,2342 | Yes | +5°C ± 3°C | |
C0675000 | Cefalexin monohydrate | 4 | 150 mg | 1 | See leaflet | 0708.0814 | Yes | +5°C ± 3°C | |
C0682000 | Cefalotin sodium | 3 | 170 mg | 1 | See leaflet | 0987 | Yes | +5°C ± 3°C | |
Y0000505 | Cefalotin for impurity B identification | 1 | 10 mg | 1 | 0987 | Yes | +5°C ± 3°C | ||
C0682300 | Cefamandole nafate | 3 | 125 mg | 1 | See leaflet CŒ„HŒŸNÿNaOÿSœ | 1402 | Yes | +5°C ± 3°C | |
Y0000240 | Cefapirin sodium | 2 | 100 mg | 1 | See leaflet CŒŸHŒÿN–NaOÿSœ ; Batch 1 is valid until 31 October 2016 | 1650 | Yes | +5°C ± 3°C | |
C0682400 | Cefatrizine propylene glycol | 2 | 150 mg | 1 | see leaflet CŒ‡HŒ‡NÿO—Sœ | 1403 | Yes | +5°C ± 3°C | |
C0682410 | Cefatrizine impurity A | 1 | 60 mg | 1 | acide (6R,7R)-7-amino-8-oxo-3-[[(1H-1,2,3-triazol-4-yl)sulfanyl]méthyl]-5- thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique (7-ACA triazole) | 1403 | Yes | +5°C ± 3°C | |
C0682800 | Cefazolin | 3 | 150 mg | 1 | See leaflet CŒ÷HŒ÷N‡O÷S– | 0988 | Yes | +5°C ± 3°C | |
Y0000633 | Cefepime dihydrochloride monohydrate | 3 | 150 mg | 1 | See leaflet ; Batch 2 is valid until 31 January 2017 | 2126 | Yes | +5°C ± 3°C | |
Y0001336 | Cefepime impurity E | 1 | 10 mg | 1 | (6R,7R)-7-amino-3-[(1-methylpyrrolidinio)methyl]-8-oxo-5- thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | 2126 | Yes | -20°C ± 5°C | |
Y0000634 | Cefepime dihydrochloride monohydrate for system suitability | 2 | 15 mg | 1 | 2126 | Yes | +5°C ± 3°C | ||
C0684000 | Cefixime | 4 | 200 mg | 1 | See leaflet CŒÿHŒ—N—OŸSœ ; Batch 3 is valid until 30 June 2017 | 1188 | Yes | -20°C ± 5°C | |
C0684750 | Cefoperazone dihydrate | 2 | 100 mg | 1 | See leaflet Cœ—HœŸN„O‡Sœ | 1404 | Yes | +5°C ± 3°C | |
C0684800 | Cefoperazone sodium - reference spectrum | 1 | n/a | 1 | 1404 | ||||
C0685000 | Cefotaxime sodium | 5 | 20 mg | 1 | 0708.0989 | Yes | +5°C ± 3°C | ||
Y0000420 | Cefotaxime acid | 2 | 20 mg | 1 | See leaflet CŒÿHŒŸN—OŸSœ | 0989 | Yes | +5°C ± 3°C | |
Y0000506 | Cefotaxime for peak identification | 1 | 10 mg | 1 | 0989 | Yes | +5°C ± 3°C | ||
C0688000 | Cefoxitin sodium | 3 | 100 mg | 1 | See leaflet CŒÿHŒÿN–NaOŸSœ | 0990 | Yes | +5°C ± 3°C | |
Y0001496 | Cefoxitin for peak identification | 1 | 15 mg | 1 | 0990 | Yes | +5°C ± 3°C | ||
Y0001305 | Cefpodoxime proxetil | 1 | 70 mg | 1 | See leaflet CœŒHœŸN—O„Sœ | 2341 | Yes | -20°C ± 5°C | |
Y0001318 | Cefpodoxime proxetil for impurity H identification | 1 | 10 mg | 1 | 2341 | Yes | -20°C ± 5°C | ||
Y0001306 | Cefpodoxime proxetil for peak identification | 1 | 10 mg | 1 | 2341 | Yes | -20°C ± 5°C | ||
Y0001371 | Cefprozil | 1 | 120 mg | 1 | See leaflet | 2342 | Yes | +5°C ± 3°C | |
Y0001372 | Cefprozil impurity A | 1 | 20 mg | 1 | (2R)-2-amino-2-(4-hydroxyphenyl)acetic acid (p-hydroxyphenylglycine) | 2342 | Yes | +5°C ± 3°C | |
Y0001367 | Cefprozil for peak identification | 2 | 10 mg | 1 | Batch 1 is valid until 31 January 2017 | 2342 | Yes | +5°C ± 3°C | |
Y0001368 | Cefprozil impurity mixture | 2 | 10 mg | 1 | Batch 1 is valid until 30 April 2017 | 2342 | Yes | +5°C ± 3°C | |
C0690000 | Cefradine | 5 | 300 mg | 1 | See leaflet ; Batch 4 is valid until 31 August 2017 | 0167,0168,0 578, 0708,0814 | Yes | +5°C ± 3°C | |
Y0000568 | Cefradine for peak identification | 2 | 15 mg | 1 | 0814 | Yes | +5°C ± 3°C | ||
Y0001174 | Cefradine impurity mixture | 1 | 0.04 mg | 1 | 0814 | Yes | +5°C ± 3°C | ||
C0690500 | Ceftazidime | 3 | 200 mg | 1 | See leaflet CœœHœœNÿOŸSœ ; Batch 2 is valid until 31 July 2017 | 1405, 2344 | Yes | +5°C ± 3°C | |
Y0001111 | Ceftazidime for peak identification | 2 | 13 mg | 1 | Batch 1 is valid until 30 November 2016 | 1405, 2344 | Yes | +5°C ± 3°C | |
C0691000 | Ceftriaxone sodium | 3 | 100 mg | 1 | See leaflet CŒ‡HŒÿN‡NaœOŸS– | 0991 | Yes | +5°C ± 3°C | |
C0692000 | Ceftriaxone impurity A | 5 | 10 mg | 1 | (6R,7R)-7-[[(2E)-(2-aminothiazol-4-yl)(methoxyimino)acetyl]amino]-3-[[(2- methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl]-8- oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid ((E)-isomer) ; Batch 4 is valid until 30 September 2017 | 0991 | Yes | +5°C ± 3°C | |
C0694990 | Cefuroxime axetil | 4 | 60 mg | 1 | See leaflet CœÐHœœN÷OŒÐS | 1300 | Yes | +5°C ± 3°C | |
C0695000 | Cefuroxime sodium | 4 | 70 mg | 1 | See leaflet CŒÿHŒ—N÷NaO‡S | 0988.0992 | Yes | +5°C ± 3°C | |
Y0001445 | Celecoxib | 2 | 200 mg | 1 | See leaflet | 2591 | Yes | +5°C ± 3°C | |
Y0001446 | Celecoxib impurity A | 2 | 10 mg | 1 | 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 2591 | Yes | +5°C ± 3°C | |
Y0001447 | Celecoxib impurity B | 2 | 10 mg | 1 | 4-[3-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 2591 | Yes | +5°C ± 3°C | |
Y0000311 | Celiprolol hydrochloride | 1 | 10 mg | 1 | 1632 | Yes | +5°C ± 3°C | ||
Y0000312 | Celiprolol impurity I | 1 | 0.02 mg | 1 | 1-acetyl-1-(4-ethoxyphenyl)-3,3-diethylurea | 1632 | Yes | +5°C ± 3°C | |
Y0000239 | Celiprolol for peak identification | 2 | 20 mg | 1 | 1632 | Yes | +5°C ± 3°C | ||
Y0000784 | Cellulose acetate | 1 | 40 mg | 1 | 0887 | Yes | +5°C ± 3°C | ||
Y0001585 | Cellulose acetate butyrate | 1 | 60 mg | 1 | 1406 | Yes | +5°C ± 3°C | ||
Y0001054 | Cellulose acetate phthalate | 1 | 10 mg | 1 | 0314 | Yes | +5°C ± 3°C | ||
Y0001764 | Cenla dry extract | 1 | 150 mg | 1 | 1498 | Yes | -20°C ± 5°C | ||
C0700000 | Cephaeline hydrochloride | 4 | 15 mg | 1 | 0081,0093, 0094,1530,1 875 | Yes | +5°C ± 3°C | ||
C0980650 | Cetirizine dihydrochloride | 4 | 100 mg | 1 | 1084 | Yes | +5°C ± 3°C | ||
C0980651 | Cetirizine impurity A | 5 | 10 mg | 1 | (RS)-1-[(4-chlorophenyl)phenylmethyl]piperazine | 1084 | Yes | +5°C ± 3°C | |
Y0001197 | Cetirizine for peak identification | 2 | 1.01 mg | 1 | 1084 | Yes | +5°C ± 3°C | ||
C0984100 | Cetostearyl isononanoate - reference spectrum | 1 | n/a | 1 | 1085 | ||||
C0990000 | Cetyl alcohol | 2 | 300 mg | 1 | See leaflet CŒÿH–÷O | 0540,0702,0 801, 0802,0847,0 969, 1411 | Yes | +5°C ± 3°C | |
Y0000073 | Cetyl palmitate 15 | 1 | 60 mg | 1 | 1906 | Yes | +5°C ± 3°C | ||
Y0000074 | Cetyl palmitate 95 | 2 | 50 mg | 1 | Batch 1 is valid until 31 July 2017 | 1906 | Yes | +5°C ± 3°C | |
C1000000 | Cetylpyridinium chloride | 2 | 20 mg | 1 | 0379 | Yes | +5°C ± 3°C | ||
New | C1050000 | Chenodeoxycholic acid | 4 | 125 mg | 1 | Batch 3 is valid until 31 October 2017 | 1189.1275 | Yes | +5°C ± 3°C |
Y0000104 | Chitosan hydrochloride | 1 | 30 mg | 1 | 1774 | Yes | +5°C ± 3°C | ||
C1100000 | Chlorambucil | 1 | 100 mg | 1 | 0137 | Yes | +5°C ± 3°C | ||
Y0001298 | Chlorambucil for system suitability | 1 | 10 mg | 1 | 0137 | Yes | +5°C ± 3°C | ||
Y0001299 | Chlorambucil with impurity G | 1 | 10 mg | 1 | 0137 | Yes | +5°C ± 3°C | ||
C1200000 | Chloramphenicol | 4 | 100 mg | 1 | Batch 3 is valid until 31 March 2017 | 0071,0473,0 709 | Yes | +5°C ± 3°C | |
C1300000 | Chloramphenicol dipalmitate | 1 | 100 mg | 1 | 0473 | Yes | +5°C ± 3°C | ||
C1350000 | Chloramphenicol disodium disuccinate | 3 | 25 mg | 1 | See leaflet CŒ„HŒ‡ClœNœNaœOŒŒ | 0709 | Yes | +5°C ± 3°C | |
Y0001869 | Chloramphenicol for peak identification | 1 | 15 mg | 1 | 0071 | Yes | +5°C ± 3°C | ||
C1400000 | Chloramphenicol palmitate isomer | 1 | 100 mg | 1 | 0473 | Yes | +5°C ± 3°C | ||
C1425000 | Chloramphenicol sodium succinate | 2 | 30 mg | 1 | 0709 | Yes | +5°C ± 3°C | ||
C1435000 | Chlorcyclizine hydrochloride | 1 | 100 mg | 1 | 1086 | Yes | +5°C ± 3°C | ||
C1450000 | Chlordiazepoxide - * psy | 1 | 50 mg | 2 | 0656.1974 | Yes | +5°C ± 3°C | ||
C1500000 | Chlordiazepoxide hydrochloride - * psy | 1 | 100 mg | 1 | 0474 | Yes | +5°C ± 3°C | ||
Y0000476 | Chlordiazepoxide impurity A | 2 | 10 mg | 1 | 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 4-oxide | 0474.0656 | Yes | +5°C ± 3°C | |
C1510000 | Chlorhexidine | 5 | 50 mg | 1 | Batch 4 is valid until 30 September 2017 | 0658 | Yes | +5°C ± 3°C | |
C1520000 | Chlorhexidine diacetate | 2 | 10 mg | 1 | 01/2015:0657 | Yes | +5°C ± 3°C | ||
C1540000 | Chlorhexidine dihydrochloride | 2 | 50 mg | 1 | 0659 | Yes | +5°C ± 3°C | ||
New | Y0001545 | Chlorhexidine for system suitability | 2 | 10 mg | 1 | Batch 1 is valid until 31 December 2017 | 0658, 0657, 0659 | Yes | +5°C ± 3°C |
Y0001653 | Chlormadinone acetate | 1 | 120 mg | 1 | See leaflet | 2702 | Yes | +5°C ± 3°C | |
Y0001656 | Chlormadinone acetate impurity G | 2 | 10 mg | 1 | 3,20-dioxopregn-4-en-17-yl acetate ; Batch 1 is valid until 31 July 2017 | 2702 | Yes | +5°C ± 3°C | |
Y0001638 | Chlormadinone acetate for system suitability | 1 | 10 mg | 1 | 2702 | Yes | +5°C ± 3°C | ||
Y0000569 | Chlorogenic acid | 2 | 25 mg | 1 | See leaflet CŒÿHŒ‡O„ ; (1S,3R,4R,5R)-3-[(3,4-Dihydroxycinnamoyl)oxy]-1,4,5- trihydroxycyclohexanecarboxylic acid | 1821,1822,1 823, 1824,1866,1 897, 2389 | Yes | +5°C ± 3°C | |
C1650000 | Chloroquine sulfate | 3 | 200 mg | 1 | 0544.0545 | Yes | +5°C ± 3°C | ||
C1700000 | Chlorothiazide | 3 | 10 mg | 1 | 0394 | Yes | +5°C ± 3°C | ||
C1800000 | Chlorphenamine maleate | 2 | 20 mg | 1 | 0386,0977,1 084, 1196 | Yes | +5°C ± 3°C | ||
Y0000436 | Chlorphenamine impurity A | 4 | 0.01 mg | 1 | 2-(4-chlorophenyl)-4-(dimethylamino)-2-[2-(dimethylamino) ethyl]butanenitrile | 0386 | Yes | +5°C ± 3°C | |
Y0000437 | Chlorphenamine impurity C | 2 | 10 mg | 1 | (3RS)-3-(4-chlorophenyl)-N-methyl-3-(pyridin-2-yl)propan-1-amine | 0386 | Yes | +5°C ± 3°C | |
C1900000 | Chlorpromazine hydrochloride | 1 | 200 mg | 1 | 0475 | Yes | +5°C ± 3°C | ||
Y0000507 | Chlorpromazine impurity A | 1 | 15 mg | 1 | 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1- amine S-oxide (chlorpromazine sulphoxide) | 0475 | Yes | +5°C ± 3°C | |
Y0000479 | Chlorpromazine impurity D | 1 | 10 mg | 1 | 3-(2-chloro-10H-phenothiazin-10-yl)-N-methypropan-1-amine (desmethylchlorpromazine) | 0475 | Yes | +5°C ± 3°C | |
Y0000508 | Chlorpromazine impurity E | 1 | 10 mg | 1 | 2-chloro-10H-phenothiazine | 0475 | Yes | +5°C ± 3°C | |
Y0001449 | Chlorpromazine impurity F | 1 | 2 mg | 1 | 3-(4-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine | 0475 | Yes | +5°C ± 3°C | |
C1905000 | Chlorpropamide | 1 | 100 mg | 1 | 1087 | Yes | +5°C ± 3°C | ||
New | C1905020 | Chlorpropamide impurity B | 2 | 30 mg | 1 | 1,3-Dipropylurea ; Batch 1 is valid until 31 December 2017 | 1087 | Yes | +5°C ± 3°C |
C1915000 | Chlorprothixene hydrochloride | 5 | 50 mg | 1 | See leaflet | 0815.1365 | Yes | +5°C ± 3°C | |
C1950000 | Chlortalidone | 3 | 150 mg | 1 | See leaflet CŒ÷HŒŒClNœO÷S | 0546 | Yes | +5°C ± 3°C | |
Y0000779 | Chlortalidone for peak identification | 3 | 1.017 mg | 1 | 0546 | Yes | +5°C ± 3°C | ||
C2000000 | Chlortetracycline hydrochloride | 5 | 100 mg | 1 | See leaflet | 0173 | Yes | +5°C ± 3°C | |
Y0001451 | Chlortetracycline for system suitability | 2 | 10 mg | 1 | 0173 | Yes | +5°C ± 3°C | ||
C2100000 | Cholecalciferol | 9 | 500 mg | 1 | See leaflet; Vitamin D3 | 0072, 0574, 0575, 0598, 1192, 1193, 2398 | Yes | -20°C ± 5°C | |
C2150000 | Cholecalciferol for system suitability | 7 | 1 mL | 1 | 0072, 0574, 0575,0598 | Yes | -20°C ± 5°C | ||
C2155000 | Cholesterol | 4 | 100 mg | 1 | See leaflet | 0593, 0993, 2397 | Yes | +5°C ± 3°C | |
C2158000 | Cholic acid | 2 | 60 mg | 1 | 1189 | Yes | +5°C ± 3°C | ||
Y0000280 | Chondroitin sulfate sodium | 2 | 250 mg | 1 | See leaflet HœO(CŒ÷HŒ„NNaœOŒ÷S)¨ | 2064.2090 | Yes | +5°C ± 3°C | |
Y0000593 | Chondroitin sulfate sodium (marine) | 1 | 100 mg | 1 | 2064 | Yes | +5°C ± 3°C | ||
New | C2160000 | Chymotrypsin BRP | 3 | 100 mg | 1 | See leaflet ; Batch 2 is valid until 30 November 2017 | 0476.0694 | Yes | +5°C ± 3°C |
Y0001553 | Ciclesonide | 1 | 150 mg | 1 | See leaflet C–œH÷÷OŸ | 2703 | Yes | +5°C ± 3°C | |
Y0001554 | Ciclesonide containing impurity A | 1 | 15 mg | 1 | (2′S)-2′-cyclohexyl-11β-hydroxy-3,20-dioxo-16βH-[1,3]dioxolo[4′,5′:16,17] pregna-1,4-dien-21-yl 2-methylpropanoate (S-epimer of ciclesonide) | 2703 | Yes | +5°C ± 3°C | |
Y0001555 | Ciclesonide impurity B | 1 | 10 mg | 1 | (2'R)-2'-cyclohexyl-11β,21-dihydroxy-16βH-[1,3]dioxolo[4',5':16,17] pregna-1,4-diene-3,20-dione | 2703 | Yes | +5°C ± 3°C | |
Y0001556 | Ciclesonide impurity C | 1 | 10 mg | 1 | (2′R)-2′-[(1RS)-cyclohex-3-enyl]-11β-hydroxy-3,20-dioxo-16βH-[1,3] dioxolo[4′,5′:16,17]pregna-1,4-dien-21-yl 2-methylpropanoate | 2703 | Yes | +5°C ± 3°C | |
New | Y0000040 | Ciclopirox | 2 | 75 mg | 1 | Batch 1 is valid until 30 November 2017 | 1407 | Yes | +5°C ± 3°C |
C2162701 | Ciclopirox impurity A | 4 | 40 mg | 1 | [(5RS)-3-cyclohexyl-5-methyl-4,5-dihydro-1,2-oxazol-5-yl]acetic acid ; Batch 3 is valid until 31 July 2017 | 1302.1407 | Yes | +5°C ± 3°C | |
C2162702 | Ciclopirox impurity B | 3 | 20 mg | 1 | 6-cyclohexyl-4-methyl-2H-pyran-2-one | 1302.1407 | Yes | -20°C ± 5°C | |
C2162700 | Ciclopirox olamine | 2 | 150 mg | 1 | 1302 | Yes | +5°C ± 3°C | ||
C2163000 | Ciclosporin | 3 | 120 mg | 1 | See leaflet | 0994 | Yes | +5°C ± 3°C | |
Y0000361 | Ciclosporin for system suitability | 1 | 5 mg | 1 | 0994 | Yes | +5°C ± 3°C | ||
C2170000 | Cilastatin sodium | 2 | 10 mg | 1 | 1408 | Yes | +5°C ± 3°C | ||
Y0001651 | Cilastatin for system suitability 1 | 1 | 5 mg | 1 | 1408 | Yes | +5°C ± 3°C | ||
Y0001652 | Cilastatin for system suitability 2 | 1 | 5 mg | 1 | 1408 | Yes | +5°C ± 3°C | ||
C2174000 | Cilazapril | 1 | 50 mg | 1 | 1499 | Yes | +5°C ± 3°C | ||
C2174002 | Cilazapril impurity A | 1 | 25 mg | 1 | 1,1-dimethylethyl (1S,9S)-9-[[(S)-1-(ethoxycarbonyl)-3-phenylpropyl] amino]-10-oxooctahydro-6H-pyridazi,2-a][1,2]diazepine-1-carboxylate | 1499 | Yes | +5°C ± 3°C | |
C2174005 | Cilazapril impurity D | 1 | 10 mg | 1 | (1S,9S)-9-[[(R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-10- oxooctahydro-6H-pyridazi,2-a][1,2]diazepine-1-carboxylic acid | 1499 | Yes | +5°C ± 3°C | |
C2175000 | Cimetidine | 1 | 50 mg | 1 | 0756 | Yes | +5°C ± 3°C | ||
C2175500 | Cimetidine hydrochloride | 1 | 100 mg | 1 | 1500 | Yes | +5°C ± 3°C | ||
Y0001130 | Cimetidine for peak identification | 1 | 10 mg | 1 | 0756, 1500 | Yes | +5°C ± 3°C | ||
Y0001146 | Cimetidine for system suitability | 1 | 0.5085 mg | 1 | 0756, 1500 | Yes | +5°C ± 3°C | ||
C2177000 | Cinchocaine hydrochloride | 2 | 60 mg | 1 | 1088 | Yes | +5°C ± 3°C | ||
Y0000176 | Cineole | 2 | 180 mg | 1 | 1973 | Yes | +5°C ± 3°C | ||
C2180000 | Cinnarizine | 2 | 100 mg | 1 | 0816 | Yes | +5°C ± 3°C | ||
Y0000362 | Ciprofibrate | 1 | 5 mg | 1 | 2013 | Yes | +5°C ± 3°C | ||
Y0000363 | Ciprofibrate for system suitability | 1 | 5 mg | 1 | 2013 | Yes | +5°C ± 3°C | ||
Y0000198 | Ciprofloxacin | 1 | 20 mg | 1 | 1089 | Yes | +5°C ± 3°C | ||
New | C2190000 | Ciprofloxacin hydrochloride | 6 | 100 mg | 1 | See leaflet ; Batch 5 is valid until 30 November 2017 | 0888.1353 | Yes | +5°C ± 3°C |
Y0000199 | Ciprofloxacin hydrochloride for peak identification | 2 | 15 mg | 1 | 0888.1089 | Yes | +5°C ± 3°C | ||
C2190050 | Ciprofloxacin impurity A | 5 | 25 mg | 1 | 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (fluoroquinolonic acid) ; Batch 4 is valid until 31 December 2016 | 0888,1089,2 229 | Yes | +5°C ± 3°C | |
Y0001766 | Cisatracurium besilate | 1 | 170 mg | 1 | See leaflet | 2763 | Yes | -20°C ± 5°C | |
Y0001768 | Cisatracurium for peak identification | 1 | 5 mg | 1 | 2763 | Yes | -20°C ± 5°C | ||
Y0001767 | cisatracurium for system suitability | 1 | 5 mg | 1 | 2763 | Yes | -20°C ± 5°C | ||
C2210000 | Cisplatin | 6 | 100 mg | 1 | See leaflet [PtClœ(NH–)œ] | 0599 | Yes | +5°C ± 3°C | |
Y0001018 | Cisplatin impurity A | 2 | 15 mg | 1 | trans-diamminedichloroplatinum(II) (transplatin), ; Batch 1 is valid until 31 May 2017 | 0599 | Yes | +5°C ± 3°C | |
Y0001019 | Cisplatin impurity B | 2 | 15 mg | 1 | See leaflet [PtCl–(NH–)]-; amminetrichloroplatinate(-) | 0599 | Yes | +5°C ± 3°C | |
Y0001008 | Citalopram hydrobromide | 1 | 5 mg | 1 | 2288,2758,2 733 | Yes | +5°C ± 3°C | ||
Y0001007 | Citalopram hydrochloride | 1 | 5 mg | 1 | 2203 | Yes | +5°C ± 3°C | ||
Y0000855 | Citalopram for system suitability | 3 | 0.065 mg | 1 | 2203.2288 | Yes | +5°C ± 3°C | ||
A1202000 | Citric acid (anhydrous) | 2 | 50 mg | 1 | 0455 | Yes | +5°C ± 3°C | ||
C2219000 | Citric acid monohydrate | 1 | 50 mg | 1 | 0456 | Yes | +5°C ± 3°C | ||
Y0000639 | Cladribine | 2 | 50 mg | 1 | See leaflet CŒÐHŒœClN—O– | 2174 | Yes | -20°C ± 5°C | |
Y0000610 | Cladribine impurity C | 1 | 5 mg | 1 | 2-chloro-7H-purin-6-amine (2-chloroadenine) | 2174 | Yes | -20°C ± 5°C | |
Y0000609 | Cladribine for peak identification | 1 | 10 mg | 1 | 2174 | Yes | -20°C ± 5°C | ||
Y0000320 | Clarithromycin | 3 | 160 mg | 1 | See leaflet C–‡Hÿ„NOŒ– | 1651 | Yes | +5°C ± 3°C | |
New | Y0000321 | Clarithromycin for peak identification | 3 | 10 mg | 1 | Batch 2 is valid until 31 December 2017 | 1651 | Yes | +5°C ± 3°C |
Y0001193 | Clazuril | 1 | 10 mg | 1 | 1714 | Yes | +5°C ± 3°C | ||
Y0000269 | Clazuril for system suitability | 1 | 10 mg | 1 | 1714 | Yes | +5°C ± 3°C | ||
C2221000 | Clebopride malate | 1 | 100 mg | 1 | 1303 | Yes | +5°C ± 3°C | ||
C2223000 | Clemastine fumarate | 1 | 100 mg | 1 | 1190 | Yes | +5°C ± 3°C | ||
Y0001613 | Clemastine for system suitability | 1 | 0.165 mg | 1 | 1190 | Yes | +5°C ± 3°C | ||
C2248000 | Clenbuterol hydrochloride | 2 | 30 mg | 1 | 1409 | Yes | +5°C ± 3°C | ||
C2248010 | Clenbuterol impurity B | 2 | 10 mg | 1 | 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino] ethanone | 1409 | Yes | +5°C ± 3°C | |
C2250000 | Clindamycin hydrochloride | 5 | 200 mg | 1 | See leaflet ; Batch 4 is valid until 31 January 2017 | 0582 | Yes | +5°C ± 3°C | |
C2269000 | Clindamycin phosphate | 2 | 250 mg | 1 | see leaflet | 0996 | Yes | +5°C ± 3°C | |
Y0001680 | Clindamycin phosphate for system suitability | 1 | 10 mg | 1 | 0996 | Yes | +5°C ± 3°C | ||
Y0000364 | Clioquinol | 1 | 5 mg | 1 | 2111 | Yes | +5°C ± 3°C | ||
Y0000205 | Clobazam - reference spectrum | 1 | n/a | 1 | 1974 | ||||
Y0000241 | Clobazam impurity A | 1 | 10 mg | 1 | 7-chloro-5-phenyl-1,5-dihydro-3H-1,5-benzodiazepine-2,4-dione | 1974 | Yes | +5°C ± 3°C | |
Y0000559 | Clobetasol propionate | 2 | 50 mg | 1 | See leaflet Cœ—H–œClFO— ; Batch 1 is valid until 31 December 2016 | 2127 | Yes | +5°C ± 3°C | |
New | Y0000571 | Clobetasol impurity J | 3 | 0.4 mg | 1 | (17R)-4'-chloro-5'-ethyl-9-fluoro-11ß-hydroxy-16ß-methylspiro [androsta-1,4-diene-17,2'(3'H)-furan]-3,3'-dione (17 alpha-spiro compound) ; Batch 2 is valid until 30 September 2017 | 2127 | Yes | +5°C ± 3°C |
New | Y0000570 | Clobetasol for peak identification | 3 | 2 mg | 1 | Batch 2 is valid until 30 September 2017 | 2127 | Yes | +5°C ± 3°C |
C2285000 | Clobetasone butyrate | 1 | 50 mg | 1 | 1090 | Yes | +5°C ± 3°C | ||
Y0001137 | Clobetasone butyrate for system suitability | 1 | 30 mg | 1 | 1090 | Yes | +5°C ± 3°C | ||
Y0000888 | Clodronate disodium tetrahydrate | 1 | 5 mg | 1 | 1777 | Yes | +5°C ± 3°C | ||
Y0000885 | Clodronate impurity D | 1 | 5 mg | 1 | (chloromethylene)bis(phosphonic acid) | 1777 | Yes | +5°C ± 3°C | |
Y0000313 | Clofazimine | 1 | 150 mg | 1 | 2054 | Yes | +5°C ± 3°C | ||
Y0000358 | Clofazimine for system suitability | 1 | 10 mg | 1 | 2054 | Yes | +5°C ± 3°C | ||
C2300000 | Clofibrate | 1 | 0.5 ml | 1 | 0318 | Yes | +5°C ± 3°C | ||
C2320000 | Clomifene citrate | 2 | 50 mg | 1 | See leaflet C–œH–ÿClNO‡ | 0997.1046 | Yes | +5°C ± 3°C | |
C2332000 | Clomifene citrate for performance test | 1 | 50 mg | 1 | 0997 | Yes | +5°C ± 3°C | ||
C2360000 | Clomipramine hydrochloride | 1 | 100 mg | 1 | 0889 | Yes | +5°C ± 3°C | ||
Y0000132 | Clomipramine impurity C | 2 | 20 mg | 1 | 3-(3-chloro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine | 0889 | Yes | +5°C ± 3°C | |
Y0000133 | Clomipramine impurity D | 2 | 10 mg | 1 | See leaflet CŒ„HœœClœNœ; 3-(3,7-dichloro-10,11-dihydro-5H-dibenzo[b,f] azepin-5-yl)-N,N-dimethylpropan-1-amine | 0889 | Yes | +5°C ± 3°C | |
Y0000134 | Clomipramine impurity F | 1 | 5 mg | 1 | 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine | 0889 | Yes | +5°C ± 3°C | |
C2385000 | Clonazepam - * psy | 1 | 50 mg | 1 | 1974.0415 | Yes | +5°C ± 3°C | ||
Y0000286 | Clonazepam - reference spectrum | 1 | n/a | 1 | 0890 | ||||
C2385015 | Clonazepam impurity B | 2 | 5 mg | 1 | 3-amino-4-(2-chlorophenyl)-6-nitroquinolin-2(1H)-one | 0890 | Yes | +5°C ± 3°C | |
C2400000 | Clonidine hydrochloride | 1 | 100 mg | 1 | 0477 | Yes | +5°C ± 3°C | ||
Y0000801 | Clonidine impurity B | 1 | 20 mg | 1 | 1-acetyl-2-[(2,6-dichlorophenyl)amino]-4,5-dihydro-1H-imidazole | 0477 | Yes | +5°C ± 3°C | |
Y0000833 | Clopamide | 1 | 40 mg | 1 | 1747 | Yes | +5°C ± 3°C | ||
Y0000848 | Clopamide for system suitability | 1 | 10 mg | 1 | 1747 | Yes | +5°C ± 3°C | ||
Y0001852 | Clopidogrel besilate | 1 | 10 mg | 1 | 2790 | Yes | +5°C ± 3°C | ||
Y0001334 | Clopidogrel for system suitability | 2 | 100 mg | 1 | 2531,2790,2 791 | Yes | +5°C ± 3°C | ||
Y0001857 | Clopidogrel hydrochloride | 1 | 100 mg | 1 | see leaflet | 2790.2791 | Yes | +5°C ± 3°C | |
Y0001333 | Clopidogrel hydrogen sulfate | 1 | 60 mg | 1 | 2531 | Yes | +5°C ± 3°C | ||
Y0001335 | Clopidogrel impurity A | 2 | 10 mg | 1 | (2S)-2-(2-chlorophenyl)-2-[6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]acetic ac | 2531,2790,2 791 | Yes | +5°C ± 3°C | |
Y0000392 | Closan sodium dihydrate | 1 | 20 mg | 1 | 1716 | Yes | +5°C ± 3°C | ||
Y0000393 | Closan for system suitability | 1 | 20 mg | 1 | 1716 | Yes | +5°C ± 3°C | ||
C2424400 | Clostridia (multi-component) rabbit antiserum(for vaccines-vet.use)BRP | 1 | 1 mg | 1 | See leaflet | 0362,0363,0 364, 0697 | Yes | -20°C ± 5°C | |
C2424550 | Clostridium tetani guinea pig antiserum (for vaccines - human use) BRP | 1 | 1 mg | 3 | See leaflet | 20708 | Yes | -20°C ± 5°C | |
C2424500 | Clostridium tetani guinea pig antiserum (for vaccines - vet. use) BRP | 1 | 1 mg | 1 | See leaflet | See leaflet, 0697 | Yes | -20°C ± 5°C | |
C2425600 | Clostridium tetani rabbit antiserum (for vaccines - vet. use) BRP | 1 | 1 mg | 1 | See leaflet | See leaflet, 0697 | Yes | -20°C ± 5°C | |
C2430000 | Clotrimazole | 4 | 100 mg | 1 | Batch 3 is valid until 28 February 2017 | 0757 | Yes | +5°C ± 3°C | |
New | Y0000818 | Clotrimazole impurity E | 3 | 15 mg | 1 | (2-chlorophenyl)phenylmethanone (2-chlorobenzophenone) ; Batch 2 is valid until 30 September 2017 | 0757 | Yes | +5°C ± 3°C |
Y0000849 | Clotrimazole for peak identification | 2 | 1.005 mg | 1 | 0757 | Yes | +5°C ± 3°C | ||
C2450000 | Cloxacillin sodium | 4 | 200 mg | 1 | see leaflet | 0661, 0663, 0668, 2260, 2346 | Yes | +5°C ± 3°C | |
C2460000 | Clozapine | 2 | 60 mg | 1 | 1191 | Yes | +5°C ± 3°C | ||
Y0000758 | Clozapine for peak identification | 2 | 0.41 mg | 1 | 1191 | Yes | +5°C ± 3°C | ||
Y0001472 | Coagulation Factors V, VIII, XI and XIII plasma | 1 | 1 mg | 2 | See leaflet | 0903,1646,2 0740,20722 | Yes | -20°C ± 5°C | |
Y0000162 | Cocaine hydrochloride - reference spectrum | 1 | n/a | 1 | 0073 | ||||
C2480000 | Cocoyl caprylocaprate | 1 | 40 mg | 1 | 1411 | Yes | +5°C ± 3°C | ||
Y0000722 | Codeine - * narc | 1 | 20 mg | 1 | See leaflet | 0076,0777,1 839,1840,18 | Yes | +5°C ± 3°C | |
C2500000 | Codeine - reference spectrum | 1 | n/a | 1 | 0074.0075 | ||||
Y0000334 | Codeine impurity A | 4 | 15 mg | 1 | 7,8-didehydro-4,5α-epoxy-3,6α-dimethoxy-17-methylmorphinan (methylcodeine) | 0074,0075,0 076, 1412 | Yes | +5°C ± 3°C | |
C2500100 | Codeine hydrochloride dihydrate - reference spectrum | 1 | n/a | 1 | 1412 | ||||
C2510000 | Codergocrine mesilate | 2 | 60 mg | 1 | 1416.2060 | Yes | +5°C ± 3°C | ||
Y0001500 | Coix seed HRS | 1 | 1300 mg | 1 | 2454 | Yes | +5°C ± 3°C | ||
C2580000 | Colchicine | 2 | 15 mg | 1 | 0758 | Yes | +5°C ± 3°C | ||
Y0000209 | Colchicine for system suitability | 2 | 10 mg | 1 | 0758 | Yes | +5°C ± 3°C | ||
Y0000374 | Colestyramine | 1 | 10 mg | 1 | 1775 | Yes | +5°C ± 3°C | ||
C2600000 | Colistimethate sodium | 2 | 20 mg | 1 | See leaflet | 0319.20702 | Yes | +5°C ± 3°C | |
New | Y0001888 | Colistimethate sodium for peak identification | 1 | 20 mg | 1 | 0319, 20702 | Yes | +5°C ± 3°C | |
Y0000277 | Colistin sulfate | 4 | 25 mg | 1 | See leaflet | 0320 | Yes | -20°C ± 5°C | |
C2700000 | Colistin sulfate for microbiological assay | 2 | 25 mg | 1 | See leaflet; For microbiological assay only | 0320 | Yes | -20°C ± 5°C | |
C2725000 | Copovidone - reference spectrum | 1 | n/a | 1 | 0891 | ||||
Y0001748 | Copper tetramibi tetrafluoroborate | 1 | 15 mg | 1 | 2547 | Yes | -20°C ± 5°C | ||
C2800000 | Cortisone acetate | 6 | 250 mg | 1 | 0321,0736,0 767 | Yes | +5°C ± 3°C | ||
Y0001307 | Costunolide | 1 | 10 mg | 1 | See leaflet CŒ—HœÐOœ | 1797 | Yes | -20°C ± 5°C | |
C2900000 | Cotton wool standard for neps | 1 | 1000 mg | 1 | 0036 | Yes | +5°C ± 3°C | ||
Y0000438 | Coumarin | 1 | 110 mg | 1 | See leaflet C„HÿOœ | 2120 | Yes | +5°C ± 3°C | |
Y0001053 | Crospovidone | 4 | 25 mg | 1 | see leaflet ; Batch 1 is valid until 30 September 2017 | 0892 | Yes | +5°C ± 3°C | |
C2970000 | Crotamiton | 3 | 100 mg | 1 | see leaflet CŒ–HŒŸNO | 1194 | Yes | -20°C ± 5°C | |
C2970005 | Crotamiton impurity A | 5 | 35 mg | 1 | See leaflet; N-ethyl-N-(2-methylphenyl)but-3-enamide | 1194 | Yes | -20°C ± 5°C | |
Y0001061 | Cyanidin chloride | 3 | 25 mg | 1 | See leaflet CŒ—HŒŒClOÿ ; Batch 2 is valid until 31 July 2016 | 2394 | Yes | +5°C ± 3°C | |
C3000000 | Cyanocobalamin | 5 | 20 mg | 1 | Vitamin B12 | 0269,0270,0 547, 0710,1505 | Yes | +5°C ± 3°C | |
C3090000 | Cyclizine hydrochloride | 1 | 50 mg | 1 | 1092 | Yes | +5°C ± 3°C | ||
Y0000886 | Cyclizine impurity A | 1 | 15 mg | 1 | 1-methylpiperazine | 1092 | Yes | +5°C ± 3°C | |
Y0000887 | Cyclizine impurity B | 1 | 15 mg | 1 | diphenylmethanol (benzhydrol) | 1092 | Yes | +5°C ± 3°C | |
C3200000 | Cyclobenzaprine hydrochloride | 1 | 100 mg | 1 | 0408.0464 | Yes | +5°C ± 3°C | ||
C3230000 | Cyclohexa-1,4-dienylglycine | 3 | 15 mg | 1 | (2R)-amino(cyclohexa-1,4-dienyl)acetic acid (d-dihydrophenylglycine) | 0814 | Yes | -20°C ± 5°C | |
C3245000 | Cyclopentolate hydrochloride | 2 | 50 mg | 2 | 1093 | Yes | +5°C ± 3°C | ||
Y0001088 | Cyclopentolate for system suitability | 2 | 20 mg | 1 | 1093 | Yes | +5°C ± 3°C | ||
C3250000 | Cyclophosphamide | 3 | 50 mg | 1 | 0711 | Yes | +5°C ± 3°C | ||
C3280000 | Cyproheptadine hydrochloride | 2 | 15 mg | 1 | 0817.0846 | Yes | +5°C ± 3°C | ||
Y0001095 | Cyproheptadine impurity C | 1 | 5 mg | 1 | 5-(1-methylpiperidin-4-yl)-5H-dibenzo[a,d][7]annulen-5-ol | 0817 | Yes | +5°C ± 3°C | |
C3283000 | Cyproterone acetate | 2 | 30 mg | 1 | 1094 | Yes | +5°C ± 3°C | ||
Y0001390 | Cyproterone acetate for peak identification | 1 | 5 mg | 1 | 1094 | Yes | +5°C ± 3°C | ||
Y0001223 | Cyproterone impurity mixture | 2 | 0.01 mg | 1 | Batch 1 is valid until 30 November 2016 | 1094 | Yes | +5°C ± 3°C | |
C3290000 | Cysteine hydrochloride monohydrate | 2 | 100 mg | 1 | 0895 | Yes | +5°C ± 3°C | ||
C3300000 | Cystine | 2 | 100 mg | 1 | 0998 | Yes | +5°C ± 3°C | ||
C3350000 | Cytarabine | 2 | 150 mg | 1 | Batch 1 is valid until 31 July 2016 | 0760 | Yes | +5°C ± 3°C | |
Y0000733 | Dacarbazine | 1 | 20 mg | 1 | 1691 | Yes | +5°C ± 3°C | ||
Y0000734 | Dacarbazine impurity A | 2 | 20 mg | 1 | See leaflet C÷H–N—O; 3,7-dihydro-4H-imidazo[4,5-d]-1,2,3-triazin-4-one (2- azahypoxanthine) | 1691 | Yes | +5°C ± 3°C | |
Y0000735 | Dacarbazine impurity B | 1 | 10 mg | 1 | See leaflet; 5-amiH-imidazole-4-carboxamide | 1691 | Yes | +5°C ± 3°C | |
D0070000 | Dalteparin sodium | 3 | 250 mg | 1 | 1195 | Yes | +5°C ± 3°C | ||
Y0000600 | Danaparoid sodium | 2 | 10.5 mg | 1 | See leaflet | 2090 | Yes | +5°C ± 3°C | |
D0100000 | Dapsone | 2 | 100 mg | 1 | 0077 | Yes | +5°C ± 3°C | ||
D0125000 | Daunorubicin hydrochloride | 4 | 120 mg | 1 | See leaflet CœŸH–ÐClNOŒÐ | 0662 | Yes | +5°C ± 3°C | |
D0120000 | Daunorubicinone | 3 | 10 mg | 1 | Daunorubicin aglycone | 0662 | Yes | +5°C ± 3°C | |
D0160000 | Deferoxamine mesilate | 2 | 30 mg | 1 | 0896 | Yes | +5°C ± 3°C | ||
Y0001934 | Deferoxamine for system suitability | n/a | n/a | 1 | 0896 | Yes | -20°C ± 5°C | ||
D0201000 | Dehydrohexetidine | 2 | 50 mg | 1 | 2-ethyl-N-[[1-(2-ethylhexyl)-4-methyl-4,5-dihydro-1H-imidazol-4-yl]methyl] hexan-1-amine | 1221 | Yes | +5°C ± 3°C | |
Y0000611 | Dembrexine hydrochloride monohydrate | 1 | 10 mg | 1 | 2169 | Yes | +5°C ± 3°C | ||
Y0001707 | Demeclocycline for system suitability | 1 | 10 mg | 1 | 0176 | Yes | +5°C ± 3°C | ||
D0300000 | Demeclocycline hydrochloride | 4 | 100 mg | 1 | see leaflet | 0211,0210,0 176, 0173,1654 | Yes | +5°C ± 3°C | |
D0350000 | N-Demethylerythromycin A | 3 | 15 mg | 1 | 0274 | Yes | +5°C ± 3°C | ||
Y0000228 | Demethylflumazenil - reference spectrum | 1 | n/a | 1 | 1917 | ||||
D0406200 | Deptropine citrate | 1 | 60 mg | 1 | 1308 | Yes | +5°C ± 3°C | ||
D0430000 | Dequalinium chloride | 1 | 50 mg | 1 | 1413 | Yes | +5°C ± 3°C | ||
D0431000 | Dequalinium chloride for performance test | 1 | 50 mg | 1 | 1413 | Yes | +5°C ± 3°C | ||
Y0001321 | Dermatan sulfate and over-sulfated chondroitin sulfate | 2 | 1 mL | 1 | See leaflet | 0332.0333 | Yes | -20°C ± 5°C | |
D0480000 | Desacetylvinblastine | 1 | 1 mg | 2 | 1276 | Yes | -80°C ± 10°C | ||
Y0000879 | Desflurane - reference spectrum | 1 | n/a | 1 | 1666 | ||||
Y0000807 | Desflurane impurity A | 2 | 1 mL | 1 | 1,1'-oxybis(1,2,2,2-tetrafluoroethane) | 1666 | Yes | +5°C ± 3°C | |
D0500000 | Desipramine hydrochloride | 1 | 100 mg | 1 | 0481 | Yes | +5°C ± 3°C | ||
D0600000 | Deslanoside | 2 | 150 mg | 1 | See leaflet C÷ŸHŸ÷OŒ„ | 0482 | Yes | +5°C ± 3°C | |
Y0001584 | Desloratadine | 2 | 100 mg | 1 | See leaflet | 2570 | Yes | +5°C ± 3°C | |
D0630000 | Desmethylmetrifonate | 2 | 25 mg | 1 | 1133 | Yes | +5°C ± 3°C | ||
Y0001582 | Desloratadine for system suitability | 1 | 5 mg | 1 | 2570 | Yes | +5°C ± 3°C | ||
D0650000 | Desmopressin | 9 | 1 mg | 1 | See leaflet C÷ÿHÿ÷NŒ÷OŒœSœ ; Batch 8 is valid until 30 June 2017 | 0712 | Yes | -20°C ± 5°C | |
Y0000509 | Desogestrel | 1 | 50 mg | 1 | See leaflet CœœH–ÐO | 1717 | Yes | +5°C ± 3°C | |
Y0000510 | Desogestrel for system suitability | 2 | 10 mg | 1 | 1717 | Yes | +5°C ± 3°C | ||
New | D0400000 | Desoxycortone acetate | 4 | 100 mg | 1 | Batch 2 is valid until 31 December 2017 | 0322, 1327 | Yes | +5°C ± 3°C |
Y0000001 | Detomidine hydrochloride | 2 | 100 mg | 1 | 1414 | Yes | +5°C ± 3°C | ||
D0660020 | Detomidine impurity B | 1 | 20 mg | 1 | (RS)-(1-benzyl-1H-imidazol-5-yl)(2,3-dimethylphenyl)methanol | 1414 | Yes | +5°C ± 3°C | |
D0700000 | Dexamethasone | 5 | 50 mg | 1 | 0312,0388,0 548, 0768,1376,2 237,0549 | Yes | +5°C ± 3°C | ||
Y0001593 | Dexamethasone for peak identification | 1 | 10 mg | 1 | 0388 | Yes | +5°C ± 3°C | ||
Y0001177 | Dexamethasone for system suitability | 2 | 10 mg | 1 | 0388 | Yes | +5°C ± 3°C | ||
D0710000 | Dexamethasone acetate | 4 | 100 mg | 2 | Batch 3 is valid until 31 May 2017 | 0548,0933,0 975, 2237 | Yes | +5°C ± 3°C | |
Y0001842 | Dexamethasone acetate for peak identification | 1 | 10 mg | 1 | 0548 | +5°C ± 3°C | |||
Y0001169 | Dexamethasone acetate impurity E | 1 | 0.013 mg | 1 | 9-fluoro-11β,17-dihydroxy-16α-methyl-3,20-dioxopregn-4-en-21-yl acetate | 0548 | Yes | +5°C ± 3°C | |
Y0000538 | Dexamethasone isonicotinate | 1 | 10 mg | 1 | 2237 | Yes | +5°C ± 3°C | ||
Y0000511 | Dexamethasone isonicotinate for impurity C identificatio | 1 | 10 mg | 1 | 2237 | Yes | +5°C ± 3°C | ||
D0718000 | Dexamethasone pivalate | 1 | 50 mg | 1 | 1327 | Yes | +5°C ± 3°C | ||
D0720000 | Dexamethasone sodium phosphate | 6 | 130 mg | 1 | See leaflet | 0549,0735,0 810 | Yes | +5°C ± 3°C | |
Y0001477 | Dexamethasone sodium phosphate for peak identification | 1 | 10 mg | 1 | 0549 | Yes | +5°C ± 3°C | ||
D0720800 | Dexchlorpheniramine maleate | 1 | 60 mg | 1 | 1196 | Yes | +5°C ± 3°C | ||
D0730000 | Dexpanthenol | 5 | 5 mg | 1 | 0761 | Yes | +5°C ± 3°C | ||
D0731000 | Dextran | 1 | 25 mg | 1 | 0999,1000,1 001 | Yes | +5°C ± 3°C | ||
D0731005 | Dextran 1 | 1 | 50 mg | 1 | See leaflet; Average molecule mass : 930-1000 Fraction with less than 3 glucose units : 8.0 to 10.5% Fraction with more than 9 glucose units : 10.0 to 12.5% | 1506 | Yes | +5°C ± 3°C | |
D0733000 | Dextran 4 for calibration | 1 | 50 mg | 1 | See leaflet | 20239 | Yes | +5°C ± 3°C | |
D0734000 | Dextran 10 for calibration | 1 | 50 mg | 1 | See leaflet | 20239 | Yes | +5°C ± 3°C | |
D0735000 | Dextran 40 for calibration | 1 | 50 mg | 1 | See leaflet | 20239 | Yes | +5°C ± 3°C | |
D0738000 | Dextran 40 for performance test | 1 | 50 mg | 1 | 20239 | Yes | +5°C ± 3°C | ||
D0739000 | Dextran 60/70 for performance test | 1 | 50 mg | 1 | 20239 | Yes | +5°C ± 3°C | ||
D0736000 | Dextran 70 for calibration | 1 | 50 mg | 1 | See leaflet | 20239 | Yes | +5°C ± 3°C | |
D0737000 | Dextran 250 for calibration | 1 | 50 mg | 1 | See leaflet | 20239 | Yes | +5°C ± 3°C | |
D0732000 | Dextran Vo | 1 | 10 mg | 1 | 20239 | Yes | +5°C ± 3°C | ||
Y0000744 | Dextranomer | 1 | 50 mg | 1 | 2238 | Yes | +5°C ± 3°C | ||
D0740000 | Dextromethorphan hydrobromide | 4 | 100 mg | 1 | 0020 | Yes | +5°C ± 3°C | ||
Y0000261 | Dextromethorphan impurity A | 2 | 5 mg | 1 | ent-3-methoxymorphinan | 0020 | Yes | +5°C ± 3°C | |
Y0001058 | Dextropropoxyphene hydrochloride - * narc | 1 | 10 mg | 1 | 0713 | Yes | +5°C ± 3°C | ||
Y0001150 | Dextropropoxyphene for system suitability - * narc | 1 | 5 mg | 1 | 0713 | Yes | +5°C ± 3°C | ||
Y0001595 | Diacerein | 1 | 150 mg | 1 | See leaflet CŒ„HŒœO‡ | 2409 | Yes | +5°C ± 3°C | |
Y0001596 | Diacerein impurity B | 1 | 20 mg | 1 | see leaflet; 1,8-dihydroxy-3-(hydroxymethyl)-anthracene-9,10-dione (aloe- emodin) | 2409 | Yes | +5°C ± 3°C | |
Y0001597 | Diacerein impurity mixture | 1 | 0.014 mg | 1 | 2409 | Yes | -20°C ± 5°C | ||
Y0000454 | Diacetylfluorescein | 1 | 100 mg | 1 | See leaflet | 1213 | Yes | +5°C ± 3°C | |
D0940000 | Diazepam - * psy | 1 | 30 mg | 1 | 0022 | Yes | +5°C ± 3°C | ||
Y0000596 | Diazepam for system suitability - * psy | 2 | 0.5 mg | 1 | 0022 | Yes | +5°C ± 3°C | ||
D0950000 | Diazoxide | 1 | 50 mg | 1 | 0550 | Yes | +5°C ± 3°C | ||
D0970000 | Dibenzocycloheptene | 3 | 20 mg | 1 | Batch 2 is valid until 31 August 2016 | 0817 | Yes | +5°C ± 3°C | |
New | D1000000 | Dibenzosuberone | 3 | 30 mg | 1 | Batch 2 is valid until 31 October 2017 | 0464,0817,0 941 | Yes | +5°C ± 3°C |
Y0000480 | Dibrompropamidine diisetionate | 1 | 10 mg | 1 | 2300 | Yes | +5°C ± 3°C | ||
Y0000481 | Dibrompropamidine for system suitability | 1 | 20 mg | 1 | 2300 | Yes | +5°C ± 3°C | ||
D1010000 | Dibutyl phthalate | 1 | 1 ml | 1 | 0762 | Yes | +5°C ± 3°C | ||
Y0001620 | 2,4-dichlorobenzyl alcohol | 1 | 250 mg | 1 | See leaflet CŸHÿClœO | 2410 | Yes | +5°C ± 3°C | |
Y0001621 | 2,4-Dichlorobenzyl alcohol impurity A | 1 | 25 mg | 1 | (2,5-dichlorophenyl)methanol | 2410 | Yes | +5°C ± 3°C | |
Y0001622 | 2,4-Dichlorobenzyl alcohol impurity C | 1 | 25 mg | 1 | (3,4-dichlorophenyl)methanol | 2410 | Yes | +5°C ± 3°C | |
Y0000275 | Dichlorodiaminocyclohexaneplatinum | 5 | 15 mg | 1 | Batch 4 is valid until 31 October 2016 | 2017 | Yes | +5°C ± 3°C | |
Y0000264 | Diclazuril for veterinary use - reference spectrum | 1 | n/a | 1 | 1718 | ||||
Y0000259 | Diclazuril for system suitability | 1 | 20 mg | 1 | 1718 | Yes | +5°C ± 3°C | ||
D1039990 | Diclofenac potassium | 3 | 70 mg | 1 | 1508 | Yes | +5°C ± 3°C | ||
S0765000 | Diclofenac sodium | 4 | 100 mg | 1 | 1002.1281 | Yes | +5°C ± 3°C | ||
D1040000 | Diclofenac impurity A | 9 | 0.005 mg | 1 | 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one ; Batch 8 is valid until 30 June 2017 | 1281 | Yes | +5°C ± 3°C | |
Y0001635 | Diclofenac for system suitability | 2 | 1 mg | 1 | Batch 1 is valid until 31 August 2016 | 1002.1508 | Yes | +5°C ± 3°C | |
D1050000 | Dicloxacillin sodium | 5 | 250 mg | 1 | See leaflet CŒ„HŒÿClœN–NaO—S | 0661, 0663, 0668, 2346 | Yes | -20°C ± 5°C | |
D1060000 | Dicycloverine hydrochloride | 2 | 100 mg | 1 | 1197 | Yes | +5°C ± 3°C | ||
Y0001864 | Dicycloverine for system suitability | 1 | 15 mg | 1 | 1197 | Yes | +5°C ± 3°C | ||
Y0001900 | Dicycloverine impurity A | 1 | 20 mg | 1 | 1197 | Yes | +5°C ± 3°C | ||
Y0000439 | Didanosine | 1 | 10 mg | 1 | 2200 | Yes | +5°C ± 3°C | ||
Y0000441 | Didanosine impurity A | 1 | 10 mg | 1 | 1,7-dihydro-6H-purin-6-one (hypoxanthine) | 2200 | Yes | +5°C ± 3°C | |
Y0000442 | Didanosine impurity G | 1 | 10 mg | 1 | 9-(2,3-dideoxy-ß-D-glycero-pentofuranosyl)-9H-purin-6-amine (2',3'- dideoxyadenosine) | 2200 | Yes | +5°C ± 3°C | |
Y0000440 | Didanosine for system suitability | 1 | 10 mg | 1 | 2200 | Yes | +5°C ± 3°C | ||
D1200000 | Dienestrol | 3 | 150 mg | 1 | See leaflet CŒ‡HŒ‡Oœ | 0484 | Yes | +5°C ± 3°C | |
Y0001785 | Dienogest | 1 | 80 mg | 1 | See leaflet CœÐHœ—NOœ | 2732 | Yes | +5°C ± 3°C | |
Y0001782 | Dienogest for system suitability | 1 | 10 mg | 1 | 2732 | Yes | +5°C ± 3°C | ||
D1410000 | Diethyl phthalate | 2 | 1 mL | 1 | Batch 1 is valid until 31 July 2017 | 0897 | Yes | +5°C ± 3°C | |
D1300000 | Diethylcarbamazine citrate | 2 | 250 mg | 1 | See leaflet CŒÿHœ„N–O‡ | 0271 | Yes | +5°C ± 3°C | |
Y0000217 | Diethylene glycol (monoethyl ether) - reference spectru | 1 | n/a | 1 | 1198 | ||||
D1500000 | Diethylstilbestrol | 1 | 100 mg | 1 | See leaflet CŒ‡HœÐOœ | 0484 | Yes | +5°C ± 3°C | |
D1600000 | Diethylstilbestrol dimethyl ether | 1 | 10 mg | 1 | 0484 | Yes | +5°C ± 3°C | ||
D1700000 | Diethylstilbestrol monomethyl ether | 1 | 10 mg | 1 | 0484 | Yes | +5°C ± 3°C | ||
Y0001423 | Difloxacin hydrochloride | 1 | 60 mg | 1 | 2239 | Yes | +5°C ± 3°C | ||
Y0001429 | Difloxacin impurity G | 1 | 15 mg | 1 | 7-chloro-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 2239 | Yes | +5°C ± 3°C | |
D1750000 | Diflunisal | 1 | 30 mg | 1 | 0864 | Yes | +5°C ± 3°C | ||
D1800000 | Digitoxin | 4 | 200 mg | 1 | See leaflet C÷ŒHÿ÷OŒ– | 0078.0117 | Yes | +5°C ± 3°C | |
Y0000640 | Digoxigenin | 3 | 10 mg | 1 | See leaflet | 0079 | Yes | +5°C ± 3°C | |
D1900000 | Digoxin | 7 | 30 mg | 1 | See leaflet C÷ŒHÿ÷OŒ÷ | 0079 | Yes | +5°C ± 3°C | |
Y0000554 | Digoxin for peak identification | 1 | 10 mg | 1 | 0079 | Yes | +5°C ± 3°C | ||
D1940001 | Dihydralazine sulfate (hydrated) - reference spectrum | 1 | n/a | 1 | 1310 | ||||
Y0000232 | Dihydralazine for system suitability | 1 | 10 mg | 1 | 1310 | Yes | +5°C ± 3°C | ||
Y0000216 | Dihydrocodeine hydrogen tartrate - reference spectrum | 1 | n/a | 1 | 1776 | ||||
Y0000053 | 17 alpha-dihydroequilin | 1 | 10 mg | 1 | See leaflet | 1512 | Yes | -20°C ± 5°C | |
D1945000 | Dihydroergocristine mesilate | 3 | 250 mg | 1 | 1416.2060 | Yes | +5°C ± 3°C | ||
D1950000 | Dihydroergotamine mesilate | 4 | 50 mg | 1 | 0551 | Yes | +5°C ± 3°C | ||
Y0000831 | Dihydroergotamine for peak identification | 1 | 10 mg | 1 | 0551 | Yes | +5°C ± 3°C | ||
D1952000 | Dihydroergotamine tartrate | 2 | 150 mg | 1 | 0600 | Yes | +5°C ± 3°C | ||
D1954000 | Dihydrostreptomycin sulfate | 5 | 25 mg | 1 | See leaflet C÷œH‡‡NŒ÷O–ÿS– | 0485 | Yes | -20°C ± 5°C | |
Y0000544 | Dihydrotachysterol | 2 | 30 mg | 1 | See leaflet Cœ‡H÷ÿO | 2014 | Yes | -20°C ± 5°C | |
Y0000482 | Dihydrotachysterol for system suitability | 1 | 5 mg | 1 | 2014 | Yes | -20°C ± 5°C | ||
D1980000 | Diltiazem hydrochloride | 5 | 300 mg | 1 | 1004 | Yes | +5°C ± 3°C | ||
Y0001439 | Diltiazem impurity F | 2 | 15 mg | 1 | (2S,3S)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3- dihydro-1,5-benzothiazepin-4(5H)-one ; Batch 1 is valid until 31 March 2017 | 1004 | Yes | +5°C ± 3°C | |
Y0001141 | Diltiazem for system suitability | 2 | 10 mg | 1 | Replaces Diltiazem impurity A CRS | 1004 | Yes | +5°C ± 3°C | |
D2000000 | Dimenhydrinate | 1 | 100 mg | 1 | 0601 | Yes | +5°C ± 3°C | ||
Y0001103 | Dimenhydrinate for peak identification | 2 | 1 mg | 1 | Batch 1 is valid until 30 April 2017 | 0601 | Yes | +5°C ± 3°C | |
Y0000234 | N,N-Dimethylacetamide - reference spectrum | 1 | n/a | 1 | 1667 | ||||
D2050000 | Dimethyl sulfoxide | 3 | 1 mL | 1 | 0763 | Yes | +5°C ± 3°C | ||
Y0001489 | 2-(Dimethylamino)ethyl methacrylate | 1 | 50 mg | 1 | 1975 | Yes | +5°C ± 3°C | ||
Y0001879 | (25R)-spirost-5-en-3-one | 1 | 10 mg | 1 | 2890 | Yes | +5°C ± 3°C | ||
D2200000 | Dimeticone | 4 | 200 mg | 1 | See leaflet | 0138.1470 | Yes | +5°C ± 3°C | |
D2205000 | Dimetindene maleate | 1 | 50 mg | 1 | 1417 | Yes | +5°C ± 3°C | ||
D2255000 | Dinoprost trometamol | 1 | 60 mg | 1 | See leaflet Cœ÷H÷—NO‡ | 1312 | Yes | -20°C ± 5°C | |
New | D2250000 | Dinoprostone | 3 | 60 mg | 1 | See leaflet CœÐH–œO ; Batch 2 is valid until 30 November 2017 | 1311 | Yes | -20°C ± 5°C |
D2250015 | Dinoprostone impurity C | 2 | 10 mg | 1 | (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]-5- oxocyclopentyl]hept-5-enoic acid (5-trans-PGE2; (5E)-PGE2) | 1311.1488 | Yes | -20°C ± 5°C | |
Y0001871 | Diosgenin | 1 | 15 mg | 1 | see leaflet CœŸH÷œO– | 2890 | Yes | +5°C ± 3°C | |
Y0000094 | Diosmin | 5 | 70 mg | 1 | See leaflet ; Batch 4 is valid until 17 June 2017 | 1611 | Yes | +5°C ± 3°C | |
Y0000095 | Diosmin for system suitability | 2 | 5 mg | 1 | 1611 | Yes | +5°C ± 3°C | ||
D2600000 | Diphenhydramine hydrochloride | 1 | 100 mg | 1 | 0023.0601 | Yes | +5°C ± 3°C | ||
Y0000135 | Diphenhydramine impurity A | 4 | 10 mg | 1 | 2-(diphenylmethoxy)-N-methylethanamine | 0023.0601 | Yes | +5°C ± 3°C | |
Y0001415 | Diphenoxylate hydrochloride - * narc | 1 | 15 mg | 1 | 0819 | Yes | +5°C ± 3°C | ||
D2630000 | Diphenoxylate hydrochloride - reference spectrum | 1 | n/a | 1 | 0819 | ||||
Y0001430 | Diphenoxylate for system suitability - * narc | 1 | 10 mg | 1 | 0819 | Yes | +5°C ± 3°C | ||
Y0000258 | Diphtheria toxin BRP | 1 | 1 ml | 1 | See leaflet | See leaflet, 0443 | Yes | +5°C ± 3°C | |
D2700000 | Diphtheria vaccine (adsorbed) BRP | 4 | 32 mg | 1 | See leaflet | See leaflet, 20706 | Yes | -20°C ± 5°C | |
Y0000376 | Dipivefrine hydrochloride | 1 | 100 mg | 1 | See leaflet CŒ„H–ÐClNO— | 1719 | Yes | +5°C ± 3°C | |
Y0000394 | Dipivefrine for system suitability | 1 | 10 mg | 1 | 1719 | Yes | +5°C ± 3°C | ||
D2750100 | Dipotassium clorazepate - reference spectrum | 1 | n/a | 1 | 0898 | ||||
D2800000 | Diprophylline | 1 | 100 mg | 1 | 0486 | Yes | +5°C ± 3°C | ||
D2850000 | Dipyridamole | 1 | 50 mg | 1 | 1199 | Yes | +5°C ± 3°C | ||
Y0000802 | Dipyridamole for peak identification | 2 | 2.04 mg | 1 | 1199 | Yes | +5°C ± 3°C | ||
D2880000 | Dirithromycin | 1 | 100 mg | 1 | See leaflet C÷œHŸ‡NœOŒ÷ | 1313 | Yes | +5°C ± 3°C | |
D2900000 | Disodium edetate | 1 | 100 mg | 1 | 0232 | Yes | +5°C ± 3°C | ||
D2920000 | Disopyramide | 1 | 100 mg | 1 | 1006 | Yes | +5°C ± 3°C | ||
D2922000 | Disopyramide phosphate | 1 | 100 mg | 1 | 1005 | Yes | +5°C ± 3°C | ||
D2950000 | Disulfiram | 1 | 100 mg | 1 | 0603 | Yes | +5°C ± 3°C | ||
D2953000 | Dithranol | 3 | 55 mg | 1 | 1007 | Yes | +5°C ± 3°C | ||
D2953025 | Dithranol impurity C | 4 | 15 mg | 1 | See leaflet; 4,4',5,5'-tetrahydroxy-9,9'-bianthracenyl-10,10'(9H,9'H)-dione | 1007 | Yes | +5°C ± 3°C | |
D2953050 | Dithranol impurity D | 4 | 20 mg | 1 | 1-hydroxyanthracen-9(10H)-one | 1007 | Yes | +5°C ± 3°C | |
D2954000 | Dobutamine hydrochloride | 1 | 100 mg | 1 | 1200 | Yes | +5°C ± 3°C | ||
Y0001239 | Dobutamine impurity mixture | 1 | 0.1 mg | 1 | 1200 | Yes | -20°C ± 5°C | ||
Y0001133 | Docetaxel trihydrate | 3 | 160 mg | 1 | See leaflet C÷–H—–NOŒ÷.3HœO ; Batch 2 is valid until 31 July 2017 | 2449, 2593 | Yes | +5°C ± 3°C | |
Y0001155 | Docetaxel for system suitability | 2 | 10 mg | 1 | 2449.2593 | Yes | +5°C ± 3°C | ||
Y0001452 | Docetaxel impurity E | 1 | 15 mg | 1 | 5ß,20-epoxy-4-(acetyloxy)-1,7ß,10ß,13¶-tetrahydroxy-9-oxotax-11-en-2¶-yl benzoate (10-desacetyl-baccatin III) | 2593 | Yes | +5°C ± 3°C | |
D2954600 | Docosahexaenoic acid ethyl ester | 5 | 150 mg | 1 | See leaflet ; Batch 4 is valid until 31 July 2016 | 20429 | Yes | -20°C ± 5°C | |
Y0001567 | Docusate sodium | 1 | 10 mg | 1 | 1418 | Yes | +5°C ± 3°C | ||
Y0000365 | Dodecyl gallate | 1 | 30 mg | 1 | 2078 | Yes | +5°C ± 3°C | ||
D2955000 | Domperidone | 3 | 120 mg | 1 | 1009 | Yes | +5°C ± 3°C | ||
New | D2957000 | Domperidone maleate | 2 | 150 mg | 1 | Batch 1 is valid until 30 November 2017 | 1008 | Yes | +5°C ± 3°C |
D2960000 | Dopamine hydrochloride | 2 | 20 mg | 1 | 0664.1200 | Yes | +5°C ± 3°C | ||
Y0000612 | Dopexamine dihydrochloride | 1 | 10 mg | 1 | 1748 | Yes | +5°C ± 3°C | ||
Y0000613 | Dopexamine impurity B | 1 | 10 mg | 1 | 2-methoxy-4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]phenol | 1748 | Yes | -20°C ± 5°C | |
Y0000614 | Dopexamine impurity F | 1 | 10 mg | 1 | 4-chloro-5-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]benzene-1,2-diol | 1748 | Yes | -20°C ± 5°C | |
Y0000726 | Dorzolamide hydrochloride | 1 | 50 mg | 1 | 2359 | Yes | +5°C ± 3°C | ||
Y0000727 | Dorzolamide impurity A | 2 | 5 mg | 1 | (4R,6R)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2- sulphonamide 7,7-dioxide | 2359 | Yes | +5°C ± 3°C | |
Y0000750 | Dorzolamide for system suitability | 1 | 5 mg | 1 | 2359 | Yes | +5°C ± 3°C | ||
D2962000 | Dosulepin hydrochloride | 1 | 100 mg | 1 | 1314 | Yes | +5°C ± 3°C | ||
D2962005 | Dosulepin impurity A | 2 | 30 mg | 1 | (E)-3-(5-oxo-5λ4-dibenzo[b,e]thiepin-11(6H)-ylidene)-N,N- dimethylpropan-1-amine | 1314 | Yes | +5°C ± 3°C | |
D2963000 | Doxapram hydrochloride | 1 | 50 mg | 1 | 1201 | Yes | +5°C ± 3°C | ||
Y0000208 | Doxapram impurity B | 2 | 10 mg | 1 | (4RS)-1-ethyl-4-[2-[(2-hydroxyethyl)amino]ethyl]-3,3-diphenylpyrolidin-2-one | 1201 | Yes | +5°C ± 3°C | |
Y0000553 | Doxazosin mesilate | 1 | 60 mg | 1 | See leaflet | 2125 | Yes | +5°C ± 3°C | |
Y0000551 | Doxazosin impurity D | 1 | 10 mg | 1 | 6,7-dimethoxyquinazoline-2,4(1H,3H)-dione | 2125 | Yes | +5°C ± 3°C | |
Y0000552 | Doxazosin impurity F | 2 | 15 mg | 1 | 2-chloro-6,7-dimethoxyquinazolin-4-amine | 2125 | Yes | +5°C ± 3°C | |
Y0000838 | Doxepin hydrochloride | 1 | 5 mg | 1 | 1096 | Yes | +5°C ± 3°C | ||
Y0000851 | Doxepin for system suitability | 1 | 1 mg | 1 | 1096 | Yes | +5°C ± 3°C | ||
D2975000 | Doxorubicin hydrochloride | 7 | 150 mg | 1 | See leaflet CœŸH–ÐClNOŒŒ ; Batch 6 is valid until 30 September 2016 | 0714,0662,1 590 | Yes | -20°C ± 5°C | |
D3000000 | Doxycycline hyclate | 6 | 50 mg | 1 | see leaflet | 0272, 0820 | Yes | +5°C ± 3°C | |
New | Y0001714 | Doxycycline for system suitability | 3 | 10 mg | 1 | Batch 2 is valid until 30 September 2017 | 0272.0820 | Yes | +5°C ± 3°C |
Y0001562 | Doxylamine hydrogen succinate | 1 | 60 mg | 1 | 1589 | Yes | +5°C ± 3°C | ||
Y0000163 | Doxylamine hydrogen succinate - reference spectrum | 1 | n/a | 1 | 1589 | ||||
Y0001492 | Doxylamine for system suitability | 3 | 110 mg | 1 | Batch 2 is valid until 31 December 2016 | 1589 | Yes | +5°C ± 3°C | |
D3100000 | Droperidol | 3 | 150 mg | 1 | 1008,1009,1 010, 1172 | Yes | +5°C ± 3°C | ||
Y0001105 | Drospirenone | 1 | 60 mg | 1 | See leaflet Cœ÷H–ÐO– | 2404 | Yes | +5°C ± 3°C | |
Y0001115 | Drospirenone impurity E | 1 | 0.06 mg | 1 | 3-oxo-6α,7α,15α,16α-tetrahydro-3′H,3″H dicyclopropa[6,7:15,16]pregn-4- ene-21,17-carbolactone (17-epidrospirenone) | 2404 | Yes | +5°C ± 3°C | |
Y0001718 | Drospirenone for peak identification | 1 | 10 mg | 1 | 2404 | Yes | +5°C ± 3°C | ||
Y0001453 | Duloxetine hydrochloride | 2 | 120 mg | 1 | See leaflet CŒ‡HœÐClNOS | 2594 | Yes | +5°C ± 3°C | |
Y0001455 | Duloxetine impurity A | 2 | 10 mg | 1 | (3R)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine | 2594 | Yes | +5°C ± 3°C | |
Y0001454 | Duloxetine for system suitability | 1 | 40 mg | 1 | 2594 | Yes | +5°C ± 3°C | ||
New | Y0001598 | Dutasteride | 2 | 150 mg | 1 | See leaflet ; Batch 1 is valid until 30 November 2017 | 2641 | Yes | +5°C ± 3°C |
Y0001603 | Dutasteride for system suitability | 1 | 10 mg | 1 | 2641 | Yes | +5°C ± 3°C | ||
Y0001004 | Dydrogesterone | 1 | 50 mg | 1 | See leaflet CœŒHœ‡Oœ | 2357 | Yes | +5°C ± 3°C | |
Y0001005 | Dydrogesterone impurity A | 1 | 6 mg | 1 | 9β,10α-pregna-4,6,8(14)-triene-3,20-dione | 2357 | Yes | +5°C ± 3°C | |
Y0001006 | Dydrogesterone impurity B | 1 | 5 mg | 1 | pregna-4,6-diene-3,20-dione | 2357 | Yes | +5°C ± 3°C | |
New | Y0001887 | E1 Colistimethate sodium for peak identification | 1 | 5 mg | 1 | 0319, 20702 | Yes | +5°C ± 3°C | |
New | Y0001886 | E2 Colistimethate sodium for peak identification | 1 | 5 mg | 1 | 0319, 20702 | Yes | +5°C ± 3°C | |
Y0000249 | Ebastine - reference spectrum | 1 | n/a | 1 | 2015 | ||||
Y0000247 | Ebastine impurity C | 1 | 10 mg | 1 | 4-(diphenylmethoxy)piperidine | 2015 | Yes | +5°C ± 3°C | |
Y0000248 | Ebastine impurity D | 1 | 10 mg | 1 | 1-[4-(1,1-dimethylethyl)phenyl]-4-(4-hydroxypiperidin-1-yl)butan-1-one | 2015 | Yes | +5°C ± 3°C | |
Y0001236 | Econazole | 1 | 10 mg | 1 | 2049 | Yes | +5°C ± 3°C | ||
Y0000254 | Econazole for system suitability | 1 | 20 mg | 1 | 0665.2049 | Yes | +5°C ± 3°C | ||
E0050000 | Econazole nitrate | 3 | 100 mg | 1 | 0513,0665,0 921, 0935, 1017,1018 | Yes | +5°C ± 3°C | ||
Y0001738 | Edrophonium chloride | 1 | 10 mg | 1 | 2106 | Yes | +5°C ± 3°C | ||
E0085000 | Eicosapentaenoic acid ethyl ester | 4 | 200 mg | 1 | See leaflet CœœH–÷Oœ | 20429 | Yes | -20°C ± 5°C | |
Y0000537 | Emedastine difumarate | 1 | 10 mg | 1 | 2242 | Yes | +5°C ± 3°C | ||
Y0000512 | Emedastine impurity E | 1 | 10 mg | 1 | 1-(2-ethoxyethyl)-2-(hexahydro-1H-1,4-diazepin-1-yl)-1H-benzimidazole | 2242 | Yes | +5°C ± 3°C | |
E0100000 | Emetine hydrochloride | 2 | 100 mg | 1 | 0081,0093, 0094,1530,1 875 | Yes | +5°C ± 3°C | ||
Y0001837 | Emodin | 1 | 15 mg | 1 | see leaflet CŒ—HŒÐO— | 2724 | Yes | +5°C ± 3°C | |
E0109000 | Enalapril maleate | 3 | 15 mg | 1 | 1420 | Yes | +5°C ± 3°C | ||
E0110000 | Enalapril for system suitability | 2 | 10 mg | 1 | Batch 1 is valid until 31 August 2016 | 1420 | Yes | +5°C ± 3°C | |
New | Y0001853 | Enalapril impurity mixture A | 2 | 0.024 mg | 1 | Batch 1 is valid until 31 October 2017 | 1420 | Yes | +5°C ± 3°C |
Y0001829 | Enalapril impurity G | 1 | 15 mg | 1 | (2S)-2-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]propanoic acid | 1420 | +5°C ± 3°C | ||
Y0000615 | Enalaprilat dihydrate | 1 | 100 mg | 1 | 1749 | Yes | +5°C ± 3°C | ||
Y0000678 | Enalaprilat impurity G | 1 | 0.005 mg | 1 | (2SR)-2-[(3SR,8aRS)-3-methyl-1,4-dioxohexahydropyrrolo[1,2-a] pyrazin-2 (1H)-yl]-4-phenylbutanoic acid | 1749 | Yes | +5°C ± 3°C | |
Y0000629 | Enalaprilat for system suitability | 1 | 10 mg | 1 | 1749 | Yes | +5°C ± 3°C | ||
E0150000 | Endotoxin standard BRP | 5 | 10 mg | 1 | See leaflet | 20614, 20630 | Yes | -20°C ± 5°C | |
Y0000136 | Enilconazole | 1 | 60 mg | 1 | 1720 | Yes | +5°C ± 3°C | ||
Y0000137 | Enilconazole impurity E | 1 | 20 mg | 1 | (1RS)-1-(2,4-dichlorophenyl)-2-(-1H-imidazol-1-yl)ethanol | 1720 | Yes | +5°C ± 3°C | |
E0180000 | Enoxaparin sodium | 5 | 200 mg | 1 | 1097 | Yes | +5°C ± 3°C | ||
New | E0180500 | Enoxolone | 3 | 220 mg | 1 | Batch 2 is valid until 30 September 2017 | 1511 | Yes | +5°C ± 3°C |
Y0001259 | Enrofloxacin | 1 | 5 mg | 1 | 2229 | Yes | +5°C ± 3°C | ||
Y0001160 | Enrofloxacin for system suitability | 1 | 10 mg | 1 | 2229 | Yes | +5°C ± 3°C | ||
Y0001249 | Entacapone | 1 | 160 mg | 1 | See leaflet CŒ÷HŒ—N–O— | 2574 | Yes | +5°C ± 3°C | |
Y0001250 | Entacapone impurity A | 1 | 10 mg | 1 | (2Z)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide | 2574 | Yes | +5°C ± 3°C | |
Y0001800 | Entecavir monohydrate | 1 | 160 mg | 1 | see leaflet CŒœHŒ—N—O–,HœO | 2815 | Yes | +5°C ± 3°C | |
Y0001802 | Entecavir impurity F | 2 | 10 mg | 1 | Batch 1 is valid until 31 May 2017 | 2815 | Yes | +5°C ± 3°C | |
Y0001801 | Entecavir for system suitability | 1 | 1 mg | 1 | 2815 | Yes | +5°C ± 3°C | ||
E0200000 | Enterokinase BRP | 2 | 200 mg | 1 | Batch 1 is valid until 30 June 2016 | 0350 | Yes | +5°C ± 3°C | |
E0300000 | Ephedrine hydrochloride - * Drug Precursor | 3 | 150 mg | 1 | See leaflet | 0487,0488,0 489,1367,24 | Yes | +5°C ± 3°C | |
E0305000 | Ephedrine hydrochloride (racemic) - * Drug Precursor | 1 | 50 mg | 1 | 0715 | Yes | +5°C ± 3°C | ||
E0400000 | 4-Epianhydrotetracycline hydrochloride | 7 | 25 mg | 1 | See leaflet ; Batch 6 is valid until 31 July 2017 | 0210,0211,1 654 | Yes | +5°C ± 3°C | |
Y0001139 | Epinastine hydrochloride | 1 | 20 mg | 1 | 2411 | Yes | +5°C ± 3°C | ||
Y0001128 | Epinastine for system suitability | 1 | 10 mg | 1 | 2411 | Yes | +5°C ± 3°C | ||
E0550000 | Epirubicin hydrochloride | 6 | 100 mg | 1 | See leaflet CœŸH–ÐClNOŒŒ | 0662,0714,1 590 | Yes | -20°C ± 5°C | |
E0600000 | 4-Epitetracycline hydrochloride | 9 | 30 mg | 1 | Batch 8 is valid until 30 June 2016 | 0210,0211,1 654 | Yes | +5°C ± 3°C | |
Y0001704 | Eplerenone | 1 | 75 mg | 1 | see leaflet Cœ÷H–ÐOÿ | 2765 | Yes | +5°C ± 3°C | |
Y0001706 | Eplerenone for peak identification | 1 | 10 mg | 1 | 2765 | Yes | +5°C ± 3°C | ||
Y0001705 | Eplerenone for system suitability | 1 | 10 mg | 1 | 2765 | Yes | +5°C ± 3°C | ||
P1609010 | trans-Epoxyphytomenadione | 3 | 5 mg | 1 | 1036 | Yes | +5°C ± 3°C | ||
E0850010 | Eq Influenza Subtype 1 Strain A/eq/Newmarket/77 Horse Antiserum BRP | 2 | 1 mg | 3 | See leaflet; Common standard OIE Strain A/eq/Newmarket/77 | See leaflet, 0249 | Yes | -20°C ± 5°C | |
E0850021 | Eq Influenza Subtype 2 American-like/Newmarket Horse Antiserum BRP | 2 | 1 mg | 3 | See leaflet; Common standard OIE Strain A/eq/Newmarket/1/93 | See leaflet, 0249 | Yes | -20°C ± 5°C | |
Y0000712 | Eq Influenza Subtype 2 American-like/South Africa Horse Antiserum BRP | 1 | 1 mg | 3 | See leaflet | See leaflet, 0249 | Yes | -20°C ± 5°C | |
E0850022 | Eq Influenza Subtype 2 European-like/Newmarket Horse Antiserum BRP | 2 | 1 mg | 3 | See leaflet; Common standard OIE Strain A/eq/Newmarket/2/93 | See leaflet, 0249 | Yes | -20°C ± 5°C | |
Y0000052 | Equilin | 1 | 15 mg | 1 | See leaflet CŒ‡HœÐOœ | 1512 | Yes | -20°C ± 5°C | |
Y0001325 | Equisetum palustre | 1 | 200 mg | 1 | 1825 | Yes | +5°C ± 3°C | ||
E0900000 | Ergocalciferol | 9 | 150 mg | 1 | See leaflet; Vitamin D2 ; Batch 8 is valid until 30 June 2016 | 0082,0574,0 575, 0598,1192,1 193, 2398 | Yes | -20°C ± 5°C | |
Y0001375 | Ergocalciferol for system suitability | 1 | 10 mg | 1 | 0082 | Yes | -20°C ± 5°C | ||
E1000000 | Ergometrine maleate - * Drug Precursor | 2 | 50 mg | 1 | 0223 | Yes | +5°C ± 3°C | ||
E1100000 | Ergosterol | 6 | 20 mg | 1 | See leaflet Cœ‡H÷÷O ; Batch 5 is valid until 30 June 2016 | 0082 | Yes | -20°C ± 5°C | |
Y0001851 | Ergotamine for system suitability - * Drug precursor | 1 | 10 mg | 1 | 0224 | Yes | -20°C ± 5°C | ||
E1200000 | Ergotamine tartrate - * Drug Precursor | 2 | 100 mg | 1 | 0224, 0551 | Yes | +5°C ± 3°C | ||
Y0000051 | Erysipelas ELISA coating antigen BRP | 1 | 0.4 mg | 1 | See leaflet | See leaflet, 0064 | Yes | -20°C ± 5°C | |
Y0000177 | Erythritol | 1 | 1000 mg | 1 | See leaflet C÷HŒÐO÷ | 1803 | Yes | +5°C ± 3°C | |
E1400000 | Erythromycin estolate | 1 | 100 mg | 1 | 0552 | Yes | +5°C ± 3°C | ||
E1500000 | Erythromycin ethylsuccinate | 2 | 10 mg | 1 | 0274 | Yes | +5°C ± 3°C | ||
E1500800 | Erythromycin stearate | 1 | 50 mg | 1 | 0490 | Yes | +5°C ± 3°C | ||
Y0001848 | Erythromycin lactobionate | 1 | 15 mg | 1 | 1098 | Yes | +5°C ± 3°C | ||
Y0001912 | Erythromycin A | 4 | 250 mg | 1 | see leaflet | 0179, 0274, 0293, 0490, 0552, 1098 | Yes | -20°C ± 5°C | |
E1310000 | Erythromycin B | 4 | 50 mg | 1 | See leaflet | 0179,0274,0 490, 0552,1098 | Yes | -20°C ± 5°C | |
Y0001849 | Erythromycin stearate for impurity S identification | 1 | 15 mg | 1 | 0490 | Yes | +5°C ± 3°C | ||
E1320000 | Erythromycin C | 6 | 25 mg | 1 | See leaflet ; Batch 5 is valid until 31 August 2017 | 0179,0274,0 490, 0552,1098 | Yes | -20°C ± 5°C | |
Y0001845 | Erythromycin ethylsuccinate for impurity P identification | 1 | 15 mg | 1 | 0274 | Yes | +5°C ± 3°C | ||
Y0001846 | Erythromycin for impurity M identification | 1 | 15 mg | 1 | 0179 | Yes | -20°C ± 5°C | ||
E1300000 | Erythromycin for microbiological assay | 5 | 100 mg | 1 | See leaflet ; Batch 4 is valid until 30 November 2016 | 20702 | Yes | -20°C ± 5°C | |
Y0001847 | Erythromycin for system suitability | 1 | 15 mg | 1 | 0179, 0552, 0274, 1098, 0490 | Yes | -20°C ± 5°C | ||
New | E1515000 | Erythropoietin BRP | 4 | 15 mg | 1 | see leaflet | 1316 | Yes | -20°C ± 5°C |
Y0001725 | Erythropoietin for physicochemical tests | 1 | 0.1 mg | 3 | 1316 | Yes | -20°C ± 5°C | ||
Y0001844 | Escitalopram | 1 | 10 mg | 1 | 2758 | Yes | +5°C ± 3°C | ||
Y0001797 | Escitalopram for system suitability | 1 | 15 mg | 1 | 2733 | Yes | +5°C ± 3°C | ||
Y0001796 | Escitalopram oxalate | 1 | 10 mg | 1 | 2733 | Yes | +5°C ± 3°C | ||
Y0001611 | Esculetin | 1 | 25 mg | 1 | See leaflet C„HÿO÷ | 2452 | Yes | +5°C ± 3°C | |
Y0001612 | Esculin | 1 | 25 mg | 1 | See leaflet CŒ—HŒÿO„ | 2452 | Yes | +5°C ± 3°C | |
Y0000324 | Esketamine hydrochloride - reference spectrum | 1 | n/a | 1 | 1742 | ||||
Y0000338 | Esketamine impurity D - * narc | 1 | 10 mg | 1 | (2R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone ((R)-ketamine) | 1742 | Yes | +5°C ± 3°C | |
Y0001660 | Esomeprazole magnesium dihydrate | 1 | 15 mg | 1 | 2787 | Yes | +5°C ± 3°C | ||
Y0001028 | Esomeprazole magnesium trihydrate | 2 | 5 mg | 1 | 2372 | Yes | +5°C ± 3°C | ||
Y0000749 | Essential oil | 2 | 1000 mg | 1 | 2098 | Yes | +5°C ± 3°C | ||
E1600000 | Estradiol benzoate | 2 | 250 mg | 1 | 0139 | Yes | +5°C ± 3°C | ||
Y0000852 | Estradiol benzoate for system suitability | 1 | 10 mg | 1 | 0139 | Yes | +5°C ± 3°C | ||
E1620000 | Estradiol hemihydrate | 3 | 100 mg | 1 | 0821.1203 | Yes | +5°C ± 3°C | ||
Y0000314 | Estradiol for peak identification | 2 | 10 mg | 1 | Batch 1 is valid until 30 November 2016 | 0821 | Yes | +5°C ± 3°C | |
Y0000046 | Estradiol valerate | 2 | 120 mg | 1 | See leaflet Cœ–H–œO– | 1614 | Yes | +5°C ± 3°C | |
Y0001823 | Estradiol valerate for system suitability | 2 | 10 mg | 1 | 1614 | +5°C ± 3°C | |||
E1680000 | Estriol | 3 | 50 mg | 1 | Batch 2 is valid until 31 March 2017 | 1203 | Yes | +5°C ± 3°C | |
E1680005 | Estriol impurity A | 2 | 20 mg | 1 | See leaflet; estra-1,3,5(10),9(11)-tetraene-3,16α,17β-triol (9,11- didehydroestriol) | 1203 | Yes | +5°C ± 3°C | |
E1700000 | Estrone | 5 | 20 mg | 1 | See leaflet | 1512.0140 | Yes | +5°C ± 3°C | |
E1800000 | Etacrynic acid | 1 | 100 mg | 1 | 0457 | Yes | +5°C ± 3°C | ||
Y0001263 | Etacrynic acid for system suitability | 1 | 10 mg | 1 | 0457 | Yes | +5°C ± 3°C | ||
E1830000 | Etamsylate | 2 | 10 mg | 1 | 1204 | Yes | +5°C ± 3°C | ||
E1840000 | Ethacridine lactate monohydrate | 1 | 50 mg | 1 | 1591 | Yes | +5°C ± 3°C | ||
E1850000 | Ethambutol hydrochloride | 3 | 250 mg | 1 | 0553 | Yes | +5°C ± 3°C | ||
Y0000803 | Ethambutol for system suitability | 2 | 10 mg | 1 | Batch 1 is valid until 31 October 2016 | 0553 | Yes | +5°C ± 3°C | |
A1202800 | Ethanol (anhydrous) - reference spectrum | 1 | n/a | 1 | 1318 | ||||
E1860100 | Ethanol 96% - reference spectrum | 1 | n/a | 1 | 1317 | ||||
E1900000 | Ethinylestradiol | 5 | 200 mg | 1 | See leaflet | 0140, 0821, 0940, 0926 | Yes | +5°C ± 3°C | |
Y0001124 | Ethinylestradiol for system suitability | 2 | 1.0124 mg | 1 | 0140 | Yes | +5°C ± 3°C | ||
E2000000 | Ethionamide | 1 | 100 mg | 1 | 0141 | Yes | +5°C ± 3°C | ||
Y0001686 | Ethionamide for system suitability | 1 | 10 mg | 1 | 0141 | Yes | +5°C ± 3°C | ||
E2150000 | Ethosuximide | 1 | 30 mg | 1 | 0764 | Yes | +5°C ± 3°C | ||
E2250000 | Ethosuximide impurity A | 4 | 30 mg | 1 | (2RS)-2-ethyl-2-methylbutanedioic acid | 0764 | Yes | +5°C ± 3°C | |
E2195000 | Ethyl acetate - reference spectrum | 1 | n/a | 1 | 0899 | ||||
Y0000617 | Ethyl indole-3-carboxylate | 1 | 10 mg | 1 | 2102 | Yes | +5°C ± 3°C | ||
E2425000 | Ethyl parahydroxybenzoate | 3 | 150 mg | 1 | See leaflet C„HŒÐO– | 0409,0431,0 900, 1262,1263,2 134 | Yes | +5°C ± 3°C | |
Y0001633 | Ethylcellulose | 1 | 100 mg | 1 | 0822 | Yes | +5°C ± 3°C | ||
E2202000 | 1-N-Ethylgaramine sulfate | 3 | 50 mg | 1 | See leaflet | 1351 | Yes | +5°C ± 3°C | |
E2205500 | 1,1'-Ethylidenebistryptophan | 7 | 0.002 mg | 2 | See leaflet Cœ÷HœÿN÷O÷ ; Batch 5 is valid until 30 June 2017 | 1272.1383 | Yes | +5°C ± 3°C | |
E2300000 | Ethylmorphine hydrochloride - reference spectrum | 1 | n/a | 1 | 0491 | ||||
E2400000 | Ethylnicotinamide | 1 | 150 mg | 1 | 0233 | Yes | +5°C ± 3°C | ||
Y0000572 | Etidronate disodium | 1 | 10 mg | 1 | 1778 | Yes | +5°C ± 3°C | ||
E2450000 | Etifenin | 1 | 25 mg | 2 | 0585 | Yes | +5°C ± 3°C | ||
E2451000 | Etilefrine hydrochloride | 2 | 75 mg | 1 | 1205 | Yes | +5°C ± 3°C | ||
E2451010 | Etilefrine impurity A | 1 | 20 mg | 1 | 2-(ethylamino)-1-(3-hydroxyphenyl)ethanone (etilefrone) | 1205 | Yes | +5°C ± 3°C | |
E2470000 | Etodolac | 1 | 60 mg | 1 | 1422 | Yes | +5°C ± 3°C | ||
E2470050 | Etodolac impurity H | 1 | 10 mg | 1 | 2-(7-ethyl-1H-indol-3-yl)ethanol | 1422 | Yes | +5°C ± 3°C | |
Y0000768 | Etodolac for peak identification | 2 | 0.41 mg | 1 | 1422 | Yes | +5°C ± 3°C | ||
E2499900 | Etofenamate | 1 | 40 mg | 1 | 1513 | Yes | +5°C ± 3°C | ||
E2499914 | Etofenamate impurity G | 2 | 25 mg | 1 | 2-hydroxyethyl 2-[[3-(trifluoromethyl)phenyl]amino]-benzoate | 1513 | Yes | +5°C ± 3°C | |
E2499901 | Etofenamate for peak identification | 2 | 20 mg | 1 | 1513 | Yes | +5°C ± 3°C | ||
E2500000 | Etofylline | 1 | 100 mg | 1 | 0486 | Yes | +5°C ± 3°C | ||
E2503000 | Etomidate | 2 | 50 mg | 1 | 1514 | Yes | +5°C ± 3°C | ||
E2503004 | Etomidate impurity B | 1 | 25 mg | 1 | methyl 1-[(1RS)-1-phenylethyl]-1H-imidazole-5-carboxylate (metomidate) | 1514 | Yes | +5°C ± 3°C | |
E2600000 | Etoposide | 7 | 150 mg | 1 | See leaflet | 0823 | Yes | +5°C ± 3°C | |
Y0001365 | Etoposide for system suitability | 1 | 10 mg | 1 | 0823 | Yes | +5°C ± 3°C | ||
Y0001747 | Exemestane | 1 | 70 mg | 1 | see lealet CœÿH–‡O÷ | 2766 | Yes | +5°C ± 3°C | |
Y0001605 | Eucommia bark HRS | 1 | 2100 mg | 1 | 2412 | Yes | +5°C ± 3°C | ||
E5000000 | Eugenol | 2 | 500 µl | 1 | 1100 | Yes | +5°C ± 3°C | ||
Y0001756 | Exemestane for system suitability | 1 | 10 mg | 1 | 2766 | Yes | +5°C ± 3°C | ||
Y0001908 | Evodiamine | 1 | 15 mg | 1 | see leaflet | 2718 | Yes | +5°C ± 3°C | |
F0005000 | Famotidine | 2 | 100 mg | 1 | 1012 | Yes | +5°C ± 3°C | ||
Y0000409 | Famotidine impurity D | 2 | 10 mg | 1 | 3-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]sulphanyl]prop* | 1012 | Yes | +5°C ± 3°C | |
Y0000382 | Famotidine for system suitability | 2 | 15 mg | 1 | 1012 | Yes | +5°C ± 3°C | ||
Y0000556 | Feban | 2 | 150 mg | 1 | See leaflet | 2176 | Yes | +5°C ± 3°C | |
Y0000660 | Feban for system suitability | 1 | 10 mg | 1 | 2176 | Yes | +5°C ± 3°C | ||
Y0000731 | Felbinac | 1 | 10 mg | 1 | 2304 | Yes | +5°C ± 3°C | ||
Y0000732 | Felbinac impurity A | 1 | 20 mg | 1 | 4-acetyl biphenyl | 2304 | Yes | +5°C ± 3°C | |
F0030000 | Felodipine | 2 | 120 mg | 1 | 1013 | Yes | +5°C ± 3°C | ||
Y0000415 | Felypressin | 1 | 0.994 mg | 1 | See leaflet C÷ÿHÿ—NŒ–OŒŒSœ | 1634 | Yes | -20°C ± 5°C | |
F0040000 | Fenbendazole | 3 | 150 mg | 1 | 1208.1458 | Yes | +5°C ± 3°C | ||
F0040010 | Fenbendazole impurity A | 1 | 20 mg | 1 | methyl(1§-benzimidazol-2-yl)carbamate | 1208 | Yes | +5°C ± 3°C | |
F0040020 | Fenbendazole impurity B | 1 | 25 mg | 1 | methyl (5-chloro-1H-benzimidazol-2-yl)carbamate | 1208 | Yes | +5°C ± 3°C | |
F0041000 | Fenbufen | 1 | 100 mg | 1 | 1209 | Yes | +5°C ± 3°C | ||
F0048000 | Fenofibrate | 3 | 100 mg | 1 | See leaflet CœÐHœŒClO÷ | 1322 | Yes | +5°C ± 3°C | |
F0048005 | Fenofibrate impurity A | 4 | 15 mg | 1 | (4-chlorophenyl)(4-hydroxyphenyl)methanone | 1322 | Yes | +5°C ± 3°C | |
F0048010 | Fenofibrate impurity B | 4 | 10 mg | 1 | 2[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid (fenofibric acid) | 1322 | Yes | +5°C ± 3°C | |
F0048035 | Fenofibrate impurity G | 4 | 25 mg | 1 | 1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl] oxy]-2-methylpropanoate | 1322 | Yes | +5°C ± 3°C | |
F0050000 | Fenoterol hydrobromide | 3 | 50 mg | 1 | 0901 | Yes | +5°C ± 3°C | ||
Y0000756 | Fenoterol for peak identification | 1 | 1.2 mg | 1 | 0901 | Yes | +5°C ± 3°C | ||
F0054990 | * - reference spectrum | 1 | n/a | 1 | 1210 | ||||
F0055000 | * citrate - reference spectrum | 1 | n/a | 1 | 1103 | ||||
New | Y0001509 | * for system suitability - * narc | 3 | 15 mg | 1 | Batch 2 is valid until 31 October 2017 | 1210.1103 | Yes | +5°C ± 3°C |
F0060000 | Fenticonazole nitrate | 1 | 50 mg | 1 | 1211 | Yes | +5°C ± 3°C | ||
F0060040 | Fenticonazole impurity D | 2 | 0.01 mg | 1 | (¢£)-1-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]-3-[4-(phenylsufanyl)benzyl] imidazolium nitrate | 1211 | Yes | +5°C ± 3°C | |
F0100000 | Ferrous gluconate | 1 | 100 mg | 1 | 0493 | Yes | +5°C ± 3°C | ||
Y0001013 | Ferulic acid | 1 | 20 mg | 1 | See leaflet CŒÐHŒÐO÷ | 1834.2558 | Yes | +5°C ± 3°C | |
Y0000789 | Fexofenadine hydrochloride | 1 | 60 mg | 1 | See leaflet C–œH÷ÐClNO÷ | 2280 | Yes | +5°C ± 3°C | |
Y0000751 | Fexofenadine impurity A | 2 | 5 mg | 1 | 2-[4-[4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butanoyl]phenyl]-2- methylpropanoic acid ; Batch 1 is valid until 28 February 2017 | 2280 | Yes | +5°C ± 3°C | |
Y0000752 | Fexofenadine impurity B | 1 | 0.01 mg | 1 | 2-[3-[(1RS)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl] phenyl]-2-methylpropanoic acid | 2280 | Yes | +5°C ± 3°C | |
Y0000753 | Fexofenadine impurity C | 1 | 5 mg | 1 | (1RS)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]-1-[4-(1-methylethyl) phenyl]butan-1-ol | 2280 | Yes | +5°C ± 3°C | |
Y0001173 | Filgrastim | 2 | 0.2 mL | 1 | See leaflet | 2206 | Yes | -80°C ± 10°C | |
Y0000090 | Finasteride | 3 | 120 mg | 1 | See leaflet | 1615 | Yes | +5°C ± 3°C | |
Y0001604 | Finasteride for peak identification | 1 | 15 mg | 1 | 1615 | Yes | +5°C ± 3°C | ||
Y0000736 | Flavoxate hydrochloride | 1 | 10 mg | 1 | 1692 | Yes | +5°C ± 3°C | ||
Y0000737 | Flavoxate impurity A | 1 | 10 mg | 1 | 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid | 1692 | Yes | +5°C ± 3°C | |
Y0000738 | Flavoxate impurity B | 1 | 10 mg | 1 | ethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate | 1692 | Yes | +5°C ± 3°C | |
F0120000 | Flecainide acetate | 2 | 10 mg | 1 | 1324 | Yes | +5°C ± 3°C | ||
F0120005 | Flecainide impurity A | 4 | 20 mg | 1 | (8aRS)-3-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-1,5,6,7,8,8a- hexahydroimidazo[1,5-a]pyridine ; Batch 3 is valid until 31 March 2017 | 1324 | Yes | +5°C ± 3°C | |
F0120010 | Flecainide impurity B | 1 | 25 mg | 1 | (RS)-(piperidin-2-yl)methanamine | 1324 | Yes | +5°C ± 3°C | |
Y0001274 | Flecainide for system suitability | 1 | 10 mg | 1 | 1324 | Yes | +5°C ± 3°C | ||
Y0001606 | Fleeceflower root HRS | 1 | 300 mg | 1 | 2433 | Yes | +5°C ± 3°C | ||
Y0000138 | Flubendazole | 1 | 25 mg | 1 | 1721 | Yes | +5°C ± 3°C | ||
Y0000139 | Flubendazole for system suitability | 1 | 20 mg | 1 | 1721 | Yes | +5°C ± 3°C | ||
Y0000892 | Flucloxacillin magnesium octahydrate | 1 | 5 mg | 1 | 2346 | Yes | +5°C ± 3°C | ||
Y0000889 | Flucloxacillin impurity C | 1 | 5 mg | 1 | (2S,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid (6-aminopenicillanic acid) | 2346 | Yes | +5°C ± 3°C | |
Y0000890 | Flucloxacillin impurity D | 1 | 5 mg | 1 | 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid | 2346 | Yes | +5°C ± 3°C | |
Y0000891 | Flucloxacillin impurity E | 1 | 5 mg | 1 | (2S,5R,6R)-6-[[[(2S,5R,6R)-6-[[[3-(2-chloro-6-fluorophenyl)-5- methylisoxazol-4-yl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]hept-2-yl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2-carboxylic acid (6-APA flucloxacillin amide) | 2346 | Yes | -20°C ± 5°C | |
F0150000 | Flucloxacillin sodium | 8 | 250 mg | 1 | See leaflet CŒ„HŒÿClFN–NaO—S ; Batch 7 is valid until 30 April 2017 | 0661,0663,0 668,2346 | Yes | -20°C ± 5°C | |
Y0000557 | Fluconazole | 2 | 50 mg | 1 | 2287 | Yes | +5°C ± 3°C | ||
Y0000573 | Fluconazole impurity B | 3 | 10 mg | 1 | See leaflet; 2-[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1H-1,2,4 - triazol-1-yl)propan-2-ol | 2287 | Yes | +5°C ± 3°C | |
Y0000574 | Fluconazole impurity C | 3 | 5 mg | 2 | 1,1'-(1,3-phenylene)di-1H-1,2,4-triazole ; Batch 2 is valid until 31 August 2016 | 2287 | Yes | +5°C ± 3°C | |
Y0000558 | Fluconazole for peak identification | 1 | 10 mg | 1 | 2287 | Yes | +5°C ± 3°C | ||
F0175000 | Flucytosine | 2 | 50 mg | 1 | Batch 1 is valid until 31 August 2016 | 0766 | Yes | +5°C ± 3°C | |
Y0001262 | Flucytosine for system suitability | 1 | 0.3 mg | 1 | 0766 | Yes | +5°C ± 3°C | ||
Y0000419 | Fludarabine phosphate | 3 | 120 mg | 1 | see leaflet | 1781 | Yes | +5°C ± 3°C | |
Y0001536 | Fludarabine for system suitability | 1 | 15 mg | 1 | 1781 | Yes | +5°C ± 3°C | ||
F0180000 | Fludrocortisone acetate | 2 | 100 mg | 1 | 0767 | Yes | +5°C ± 3°C | ||
F0188000 | Flumazenil - reference spectrum | 1 | n/a | 1 | 1326 | ||||
Y0000335 | Flumazenil impurity B | 2 | 5 mg | 1 | ethyl 8-hydroxy-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4] benzodiazepine-3-carboxylate | 1326 | Yes | +5°C ± 3°C | |
F0189000 | Flumequine | 1 | 60 mg | 1 | 1517 | Yes | +5°C ± 3°C | ||
F0189020 | Flumequine impurity B | 2 | 0.1 mg | 1 | ethyl(RS)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-benzo[i,j] quinolizine-2-carboxylate | 1517 | Yes | +5°C ± 3°C | |
F0188500 | Flumetasone pivalate | 2 | 100 mg | 1 | Batch 1 is valid until 31 May 2017 | 1327 | Yes | +5°C ± 3°C | |
F0189900 | Flunarizine dihydrochloride | 3 | 100 mg | 1 | 0816 | Yes | +5°C ± 3°C | ||
Y0000265 | Flunarizine dihydrochloride - reference spectrum | 1 | n/a | 1 | 1722 | ||||
Y0000266 | Flunarizine dihydrochloride for system suitability | 1 | 20 mg | 1 | 1722 | Yes | +5°C ± 3°C | ||
F0190000 | Flunitrazepam - * psy | 2 | 100 mg | 1 | 1280 | Yes | +5°C ± 3°C | ||
Y0000169 | Flunitrazepam - reference spectrum | 1 | n/a | 1 | 0717 | ||||
Y0000443 | Flunixin meglumine | 1 | 10 mg | 1 | 1696 | Yes | +5°C ± 3°C | ||
Y0000444 | Flunixin impurity B | 1 | 10 mg | 1 | 2-methyl-3-(trifluoromethyl)aniline | 1696 | Yes | +5°C ± 3°C | |
Y0000445 | Flunixin impurity C | 2 | 55 mg | 1 | ethyl 2-chloropyridine-3-carboxylate | 1696 | Yes | +5°C ± 3°C | |
F0200000 | Fluocinolone acetonide | 5 | 110 mg | 1 | see leaflet | 0494 | Yes | +5°C ± 3°C | |
Y0001711 | Fluocinolone acetonide for peak identification | 1 | 10 mg | 1 | 0494 | Yes | +5°C ± 3°C | ||
Y0001710 | Fluocinolone acetonide for system suitability | 1 | 10 mg | 1 | 0494 | Yes | +5°C ± 3°C | ||
F0230000 | Fluocortolone pivalate | 1 | 100 mg | 1 | 1212 | Yes | +5°C ± 3°C | ||
Y0000796 | Fluorescein | 1 | 120 mg | 1 | See leaflet CœÐHŒœO— | 2348 | Yes | +5°C ± 3°C | |
Y0000804 | Fluorescein impurity C | 1 | 0.01 mg | 1 | 2-(2,4-dihydroxybenzoyl)benzoic acid | 2348 | Yes | +5°C ± 3°C | |
F0245000 | Fluoresceine sodium - reference spectrum | 1 | n/a | 1 | 1213 | ||||
F0250000 | Fluorouracil | 3 | 40 mg | 1 | Batch 2 is valid until 30 November 2016 | 0611.0766 | Yes | +5°C ± 3°C | |
Y0000762 | Fluorouracil impurity A | 1 | 10 mg | 1 | pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) | 0611 | Yes | +5°C ± 3°C | |
Y0000763 | Fluorouracil impurity B | 1 | 15 mg | 1 | dihydropyrimidine-2,4,5(3H)-trione (isobarbituric acid or 5-hydroxyuracil) | 0611 | Yes | +5°C ± 3°C | |
Y0000764 | Fluorouracil impurity C | 1 | 10 mg | 1 | pyrimidine-2,4(1H,3H)-dione (uracil) | 0611 | Yes | +5°C ± 3°C | |
Y0000765 | Fluorouracil impurity F | 1 | 10 mg | 1 | 2-ethoxy-5-fluoropyrimidin-4(1H)-one (2-ethoxy-5-fluorouracil) | 0611 | Yes | +5°C ± 3°C | |
Y0000791 | Fluorouracil impurity mixture | 2 | 0.0002 mg | 1 | Batch 1 is valid until 30 June 2017 | 0611 | Yes | +5°C ± 3°C | |
F0253000 | Fluoxetine hydrochloride | 5 | 250 mg | 1 | See leaflet | 1104 | Yes | +5°C ± 3°C | |
F0253020 | Fluoxetine impurity B | 6 | 10 mg | 1 | N-methyl-3-phenylpropan-1-amine | 1104 | Yes | +5°C ± 3°C | |
F0253030 | Fluoxetine impurity C | 4 | 5 mg | 1 | (3RS)-N-methyl-3-phenyl-3-[3-(trifluoromethyl)phenoxy]propan-1-amine | 1104 | Yes | +5°C ± 3°C | |
Y0000064 | Flupentixol dihydrochloride | 1 | 100 mg | 1 | See leaflet | 1693 | Yes | +5°C ± 3°C | |
Y0000067 | Flupentixol impurity D | 2 | 15 mg | 1 | 2-[2-[4-[3-[(EZ)-2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl] piperazin-1-yl]ethoxy]ethanol | 1693 | Yes | +5°C ± 3°C | |
Y0000078 | Flupentixol impurity F | 2 | 25 mg | 1 | See leaflet Cœ–Hœ—F–NœOS; mixture of 2-[4-[(E)-3-[(9RS)-2- (trifluoromethyl)-9H-thioxanthen-9-yl]prop-2-enyl]piperazin-1-yl]ethanol and 2-[4-[(Z)-3-[(9RS)-2-(trifluoromethyl)-9H-thioxanthen-9-yl]prop-2-enyl] | 1693 | Yes | +5°C ± 3°C | |
F0260000 | Fluphenazine decanoate | 3 | 100 mg | 1 | Batch 2 is valid until 31 January 2017 | 1014.1015 | Yes | +5°C ± 3°C | |
F0280000 | Fluphenazine dihydrochloride | 2 | 50 mg | 1 | 0904.1014 | Yes | +5°C ± 3°C | ||
Y0000708 | Fluphenazine impurity mixture | 1 | 0.07 mg | 1 | 0904 | Yes | +5°C ± 3°C | ||
Y0000009 | Fluphenazine enantate | 3 | 100 mg | 1 | Batch 2 is valid until 31 January 2017 | 1014.1015 | Yes | +5°C ± 3°C | |
Y0000298 | Fluphenazine octanoate | 4 | 20 mg | 1 | 1014.1015 | Yes | +5°C ± 3°C | ||
Y0000299 | Fluphenazine sulfoxide | 2 | 15 mg | 1 | Batch 1 is valid until 31 December 2016 | 0904,1014,1 015 | Yes | +5°C ± 3°C | |
Y0000211 | Flurazepam monohydrochloride - reference spectrum | 1 | n/a | 1 | 0905 | ||||
F0285200 | Flurbiprofen | 1 | 50 mg | 1 | 1519 | Yes | +5°C ± 3°C | ||
F0285202 | Flurbiprofen impurity A | 2 | 25 mg | 1 | (2RS)-2-(biphenyl-4-yl)propanoic acid | 1519 | Yes | +5°C ± 3°C | |
Y0000236 | Fluspirilene | 1 | 20 mg | 1 | 1723 | Yes | +5°C ± 3°C | ||
Y0000375 | Fluspirilene impurity C | 1 | 10 mg | 1 | 8-[4,4-bis(4-fluorophenyl)butyl]-3-(hydroxymethyl)-1-phenyl-1,3,8- triazaspiro[4.5]decan-4-one | 1723 | Yes | +5°C ± 3°C | |
F0285600 | Flutamide | 2 | 100 mg | 1 | See leaflet | 1423 | Yes | +5°C ± 3°C | |
Y0001591 | Flutamide for system suitability | 1 | 10 mg | 1 | 1423 | Yes | +5°C ± 3°C | ||
Y0000284 | Fluticasone propionate | 4 | 100 mg | 1 | See leaflet Cœ—H–ŒF–O—S ; Batch 3 is valid until 31 October 2016 | 1750 | Yes | +5°C ± 3°C | |
Y0001754 | Fluticasone propionate for impurity C identification | 1 | 5 mg | 1 | 1750 | +5°C ± 3°C | |||
Y0000221 | Fluticasone impurity D | 3 | 5 mg | 1 | 6α,9-difluoro-11β-hydroxy-16α-methyl-17- [(methylsulfanyl)carbonyl]-3-oxoandrosta-1,4-dien-17α-yl propanoate | 1750 | Yes | +5°C ± 3°C | |
Y0001755 | Fluticasone propionate for impurity G identification | 1 | 5 mg | 1 | 1750 | Yes | +5°C ± 3°C | ||
F0290000 | Flutrimazole | 1 | 100 mg | 1 | 1424 | Yes | +5°C ± 3°C | ||
F0290010 | Flutrimazole impurity B | 1 | 60 mg | 1 | (RS)-(2-fluorophenyl)(4-fluorophenyl)phenylmethanol | 1424 | Yes | +5°C ± 3°C | |
Y0001090 | Fluvastatin sodium | 1 | 110 mg | 1 | 2333 | Yes | +5°C ± 3°C | ||
Y0001082 | Fluvastatin for system suitability | 1 | 0.5 mg | 1 | 2333 | Yes | +5°C ± 3°C | ||
Y0000854 | Fluvoxamine maleate | 1 | 5 mg | 1 | 1977 | Yes | +5°C ± 3°C | ||
Y0000853 | Fluvoxamine for system suitability | 1 | 1.004 mg | 1 | 1977 | Yes | +5°C ± 3°C | ||
Y0000916 | Fluvoxamine impurity D | 1 | 10 mg | 1 | 5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one | 1977 | Yes | +5°C ± 3°C | |
Y0000386 | Foeniculin for peak identification | 1 | 100 mg | 1 | Anise oil | 0804 | Yes | +5°C ± 3°C | |
F0300000 | Folic acid | 8 | 300 mg | 2 | See leaflet CŒ„HŒ„NŸOÿ | 0067 | Yes | +5°C ± 3°C | |
Y0001242 | Folic acid impurity A | 1 | 15 mg | 1 | (2S)-2-[(4-aminobenzoyl)amino]pentanedioic acid (N-(4-aminobenzoyl)-L- glutamic acid) | 0067 | Yes | +5°C ± 3°C | |
Y0001243 | Folic acid impurity D | 3 | 70 mg | 1 | 4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic acid (pteroic acid) | 0067 | Yes | +5°C ± 3°C | |
Y0001629 | Follitropin | 1 | 0.2 mL | 1 | See leaflet | 2285, 2286 | Yes | -20°C ± 5°C | |
Y0001627 | Follitropin for peptide mapping and glycan analysis | 1 | 0.5 mL | 1 | 2285 | Yes | -20°C ± 5°C | ||
F0372000 | Formoterol fumarate dihydrate | 2 | 10 mg | 1 | 1293.1724 | Yes | +5°C ± 3°C | ||
Y0000339 | Formoterol for impurity I identification | 2 | 10 mg | 1 | 1724 | Yes | +5°C ± 3°C | ||
Y0000340 | Formoterol fumarate for system suitability | 2 | 10 mg | 1 | 1724 | Yes | +5°C ± 3°C | ||
F0380000 | Formylfolic acid | 3 | 30 mg | 1 | See leaflet CœÐHŒ„NŸOŸ; 10-Formylfolic acid | 0978.1606 | Yes | -20°C ± 5°C | |
F0389000 | Foscarnet sodium hexahydrate | 1 | 50 mg | 1 | 1520 | Yes | +5°C ± 3°C | ||
F0389004 | Foscarnet impurity B | 1 | 10 mg | 1 | disodium (ethoxyoxydophosphanyl)formate | 1520 | Yes | +5°C ± 3°C | |
Y0001222 | Foscarnet impurity D | 1 | 50 mg | 1 | ethyl (diethoxyphosphoryl)formate | 1520 | Yes | +5°C ± 3°C | |
Y0001213 | Foscarnet impurity mixture | 1 | 0.012 mg | 1 | 1520 | Yes | +5°C ± 3°C | ||
Y0000782 | Fosfomycin calcium | 1 | 10 mg | 1 | 1328 | Yes | +5°C ± 3°C | ||
F0399950 | Fosfomycin sodium - reference spectrum | 1 | n/a | 1 | 1329 | ||||
F0400000 | Fosfomycin trometamol | 3 | 1500 mg | 1 | See leaflet | 1425 | Yes | +5°C ± 3°C | |
Y0001227 | Fosinopril sodium | 1 | 60 mg | 1 | 1751 | Yes | +5°C ± 3°C | ||
Y0001228 | Fosinopril impurity A | 1 | 5 mg | 1 | (2S,4S)-4-cyclohexyl-1-[[(R)-hydroxy(4-phenylbutyl)phosphoryl]acetyl] pyrrolidine-2-carboxylic acid | 1751 | Yes | +5°C ± 3°C | |
Y0001229 | Fosinopril impurity B | 1 | 5 mg | 1 | (2RS,4RS)-4-cyclohexyl-1-[[(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy) propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | 1751 | Yes | +5°C ± 3°C | |
Y0001230 | Fosinopril impurity C | 1 | 10 mg | 1 | mixture of (2S,4S)-4-cyclohexyl-1-[[(S)-[(1S)-2-methyl-1-(1-oxopropoxy) propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid and (2S,4S)-4-cyclohexyl-1-[[(R)-[(1R)-2-methyl-1-(1-oxopropoxy)propoxy](4- phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | 1751 | Yes | +5°C ± 3°C | |
Y0001231 | Fosinopril impurity D | 1 | 10 mg | 1 | (2S,4R)-4-cyclohexyl-1-[[(R)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4- phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | 1751 | Yes | +5°C ± 3°C | |
Y0001232 | Fosinopril impurity I | 1 | 5 mg | 1 | [(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl] acetic acid | 1751 | Yes | +5°C ± 3°C | |
Y0001233 | Fosinopril impurity K | 1 | 5 mg | 1 | (2S,4S)-4-cyclohexyl-1-(2,2-dimethyl-1-oxopropyl)pyrrolidine-2-carboxylic acid | 1751 | Yes | +5°C ± 3°C | |
Y0001212 | Fosinopril impurity mixture | 1 | 0.02 mg | 1 | 1751 | Yes | +5°C ± 3°C | ||
F0450000 | Framycetin sulfate | 7 | 25 mg | 2 | See leaflet ; Batch 6 is valid until 28 February 2017 | 0180,0197,2 0702 | Yes | -20°C ± 5°C | |
F0550000 | Fructose | 1 | 100 mg | 1 | 0188, 0924 | Yes | +5°C ± 3°C | ||
Y0001399 | Fulvestrant | 1 | 120 mg | 1 | See leaflet C–œH÷ŸF—O–S | 2443 | Yes | +5°C ± 3°C | |
Y0001413 | Fulvestrant for system suitability | 1 | 40 mg | 1 | 2443 | Yes | +5°C ± 3°C | ||
F0600000 | Fumaric acid | 3 | 120 mg | 1 | 0365,0902,1 190 | Yes | +5°C ± 3°C | ||
F0700000 | Furosemide | 2 | 100 mg | 1 | 0391.2185 | Yes | +5°C ± 3°C | ||
F0702000 | Furosemide impurity A | 4 | 5 mg | 1 | 2-chloro-4-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid | 0391 | Yes | +5°C ± 3°C | |
Y0001493 | Furosemide for peak identification | 2 | 10 mg | 1 | 0391 | Yes | +5°C ± 3°C | ||
Y0001411 | Fusidic acid | 1 | 10 mg | 1 | 0798 | Yes | -20°C ± 5°C | ||
Y0001394 | Fusidic acid for peak identification | 1 | 5 mg | 1 | 0798.0848 | Yes | -20°C ± 5°C | ||
Y0001384 | Fusidic acid impurity mixture | 2 | 0.048 mg | 1 | 0798.0848 | Yes | -20°C ± 5°C | ||
Y0001280 | Gabapentin | 2 | 300 mg | 1 | See leaflet C„HŒŸNOœ ; Batch 1 is valid until 31 December 2016 | 2173 | Yes | +5°C ± 3°C | |
Y0001281 | Gabapentin impurity A | 1 | 20 mg | 1 | 2-azaspiro[4.5]decan-3-one | 2173 | Yes | +5°C ± 3°C | |
Y0001348 | Gabapentin impurity B | 2 | 20 mg | 1 | (1-cyanocyclohexyl)acetic acid | 2173 | Yes | -20°C ± 5°C | |
Y0001349 | Gabapentin impurity D | 1 | 10 mg | 1 | [1-[(3-oxo-2-azaspiro[4.5]dec-2-yl)methyl]cyclohexyl]acetic acid | 2173 | Yes | +5°C ± 3°C | |
Y0001803 | Gadobutrol monohydrate | 1 | 210 mg | 1 | See leaflet CŒ‡H–ŒGdN÷O„,HœO | 2735 | Yes | +5°C ± 3°C | |
Y0001804 | Gadobutrol for peak identification | 1 | 20 mg | 1 | 2735 | Yes | +5°C ± 3°C | ||
Y0001875 | Gadodiamide | 1 | 300 mg | 1 | see leaflet | 2225 | Yes | +5°C ± 3°C | |
Y0001876 | Gadodiamide impurity A | 1 | 15 mg | 1 | see leaflet; hydrogen[3,6-bis(carboxylatomethyl)-9-[(methylcarbamoyl) methyl]-3,6,9-triazaundecanedioato-κ3N3,N6,N9-gadolinate](1-) (Gd-DTPA- MMA) | 2225 | Yes | +5°C ± 3°C | |
Y0001877 | Gadodiamide impurity B | 1 | 15 mg | 1 | see leaflet; dihydrogen[3,6,9-tris(carboxylatomethyl)-3,6,9- triazaundecanedioato-κ3N3,N6,N9-gadolinate](2-) (Gd-DTPA), | 2225 | Yes | +5°C ± 3°C | |
G0049000 | Galactitol | 2 | 50 mg | 1 | 1381 | Yes | +5°C ± 3°C | ||
G0050000 | Galactose | 3 | 100 mg | 1 | See leaflet CÿHŒœ0ÿ ; Batch 2 is valid until 30 June 2016 | 1215 | Yes | +5°C ± 3°C | |
Y0001279 | Galantamine hydrobromide | 1 | 10 mg | 1 | 2366 | Yes | +5°C ± 3°C | ||
Y0001190 | Galantamine natural for system suitability | 1 | 10 mg | 1 | 2366 | Yes | +5°C ± 3°C | ||
Y0001201 | Galantamine racemic mixture | 1 | 10 mg | 1 | 2366 | Yes | +5°C ± 3°C | ||
Y0001191 | Galantamine synthetic for system suitability | 2 | 5 mg | 1 | Batch 1 is valid until 30 June 2017 | 2366 | Yes | +5°C ± 3°C | |
G0150000 | Gammacyclodextrin | 2 | 60 mg | 1 | See leaflet C÷‡H‡ÐOŒÐ | 1070.1487 | Yes | +5°C ± 3°C | |
Y0001129 | Ganciclovir | 1 | 220 mg | 1 | 1752 | Yes | +5°C ± 3°C | ||
Y0001144 | Ganciclovir impurity mixture | 1 | 0.005 mg | 1 | 1752 | Yes | +5°C ± 3°C | ||
Y0001813 | Gefitinib | 1 | 100 mg | 1 | See leaflet CœœHœ÷ClFN÷O– | 2866 | Yes | +5°C ± 3°C | |
Y0001809 | Gefitinib for system suitability | 1 | 0.351 mg | 1 | 2866 | Yes | +5°C ± 3°C | ||
Y0000675 | Gemcitabine hydrochloride | 1 | 50 mg | 1 | See leaflet | 2306 | Yes | +5°C ± 3°C | |
Y0000676 | Gemcitabine impurity A | 1 | 20 mg | 1 | 4-aminopyrimidin-2(1H)-one (cytosine) | 2306 | Yes | +5°C ± 3°C | |
Y0001682 | Gemcitabine impurity C | 1 | 5 mg | 1 | 1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2,4(1H,3H)- dione (2′-deoxy-2′,2′-difluorouridine) (β-uridine) | 2306 | Yes | +5°C ± 3°C | |
Y0000513 | Gemfibrozil | 1 | 5 mg | 1 | 1694 | Yes | +5°C ± 3°C | ||
Y0000514 | Gemfibrozil for system suitability | 2 | 0.196 mg | 1 | 1694 | Yes | +5°C ± 3°C | ||
Y0001835 | Geniposide | 1 | 15 mg | 1 | See leaflet CŒŸHœ÷OŒÐ | 2565 | Yes | +5°C ± 3°C | |
G0200000 | Gentamicin sulfate | 14 | 25 mg | 2 | see leaflet ; Batch 9 is valid until 28 February 2017 | 0331.20702 | Yes | -20°C ± 5°C | |
Y0001363 | Gentamicin for peak identification | 2 | 10 mg | 1 | 0331 | Yes | -20°C ± 5°C | ||
Y0001112 | Gestodene | 2 | 100 mg | 1 | see leaflet | 1726 | Yes | +5°C ± 3°C | |
New | Y0001116 | Gestodene impurity I | 2 | 0.01 mg | 1 | 13-ethyl-17-hydroxy-5-methoxy-18,19-dinor-5α,17α-pregn-15-en-20-yn-3- one (5-methoxy-gestodene) ; Batch 1 is valid until 31 October 2017 | 1726 | Yes | +5°C ± 3°C |
Y0001110 | Gestodene for system suitability | 1 | 10 mg | 1 | 1726 | Yes | +5°C ± 3°C | ||
Y0001012 | Ginkgo dry extract for peak identification | 2 | 150 mg | 1 | 1827 | Yes | -20°C ± 5°C | ||
New | Y0001010 | Ginkgolic Acids | 3 | 50 mg | 1 | See leaflet ; Batch 2 is valid until 30 November 2017 | 1827 | Yes | -20°C ± 5°C |
Y0001029 | Ginseng dry extract HRS | 1 | 500 mg | 1 | 2356 | Yes | -20°C ± 5°C | ||
Y0001347 | Ginsenoside Rb1 | 2 | 30 mg | 1 | See leaflet C—÷H„œOœ– ; Batch 1 is valid until 30 September 2017 | 2356 | Yes | +5°C ± 3°C | |
G0300000 | Gitoxin | 3 | 30 mg | 1 | Batch 2 is valid until 31 July 2016 | 0078.2168 | Yes | +5°C ± 3°C | |
G0325000 | Glibenclamide | 3 | 100 mg | 1 | 0718 | Yes | +5°C ± 3°C | ||
G0325010 | Glibenclamide impurity A | 4 | 10 mg | 1 | 5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide ; Batch 3 is valid until 28 February 2017 | 0718 | Yes | +5°C ± 3°C | |
Y0000242 | Glibenclamide impurity B | 3 | 10 mg | 1 | methyl [[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]sulphonyl] carbamate ; Batch 2 is valid until 31 December 2016 | 0718 | Yes | +5°C ± 3°C | |
Y0001511 | Glibenclamide for peak identification | 1 | 30 mg | 1 | 0718 | Yes | +5°C ± 3°C | ||
Y0001406 | Glucosamine hydrochloride | 1 | 15 mg | 1 | 2446 | Yes | +5°C ± 3°C | ||
G0326000 | Gliclazide | 2 | 20 mg | 1 | 1524 | Yes | +5°C ± 3°C | ||
G0326004 | Gliclazide impurity B | 4 | 50 mg | 1 | 2-nitroso-octahydrocyclopenta[c]pyrrole ; Batch 3 is valid until 31 August 201 | 1524 | Yes | +5°C ± 3°C | |
G0326012 | Gliclazide impurity F | 5 | 50 mg | 1 | 1-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(2-methylphenyl) sulphonyl] urea | 1524 | Yes | +5°C ± 3°C | |
Y0001685 | Glucosamine sulfate potassium chloride | 1 | 10 mg | 1 | 2708 | Yes | +5°C ± 3°C | ||
Y0000515 | Glimepiride | 2 | 110 mg | 1 | See leaflet | 2223 | Yes | +5°C ± 3°C | |
Y0001742 | Glimepiride for impurity A identification | 1 | 5 mg | 1 | 2223 | Yes | +5°C ± 3°C | ||
Y0000516 | Glimepiride for system suitability | 4 | 0.012 mg | 1 | Batch 3 is valid until 28 February 2017 | 2223 | Yes | +5°C ± 3°C | |
G0340000 | Glipizide | 1 | 50 mg | 1 | 0906 | Yes | +5°C ± 3°C | ||
G0342000 | Glipizide impurity A | 1 | 10 mg | 1 | 5-methyl-N-[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide | 0906 | Yes | +5°C ± 3°C | |
Y0000523 | Glipizide impurity C | 1 | 10 mg | 1 | ethyl [2-[4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl]ethyl] carbamate | 0906 | Yes | +5°C ± 3°C | |
Y0000643 | Glipizide impurity D | 1 | 10 mg | 1 | 6-methyl-N-[2-(4-sulphamoylfenyl)ethyl]pyrazine-2-carboxamide | 0906 | Yes | +5°C ± 3°C | |
Y0001140 | Glipizide impurity mixture | 1 | 0.002 mg | 1 | 0906 | Yes | +5°C ± 3°C | ||
Y0001407 | Glucosamine sulfate sodium chloride | 1 | 15 mg | 1 | 2447 | Yes | +5°C ± 3°C | ||
Y0001381 | Glucosamine for system suitability | 2 | 3 mg | 1 | Batch 1 is valid until 30 September 2017 | 2446,2447,2 708 | Yes | +5°C ± 3°C | |
Y0001745 | Glucose monohydrate | 1 | 750 mg | 1 | See leaflet CÿHŒœOÿ,HœO | 0177,0178,0 209 | Yes | +5°C ± 3°C | |
G0355000 | Glutamic acid | 2 | 50 mg | 1 | 0750,0797,1 445, 2076 | Yes | +5°C ± 3°C | ||
Y0000517 | Glutathione | 1 | 10 mg | 1 | 1670 | Yes | +5°C ± 3°C | ||
G0360000 | Glutethimide - * psy | 1 | 50 mg | 1 | 1291 | Yes | +5°C ± 3°C | ||
G0400000 | Glycerol (85 per cent) - reference spectrum | 1 | n/a | 1 | 0496.0497 | ||||
Y0001391 | Glycerol formal | 1 | 20 mg | 2 | 1671 | Yes | +5°C ± 3°C | ||
Y0000794 | Glycerol monocaprylate | 1 | 400 mg | 1 | 2213 | Yes | +5°C ± 3°C | ||
Y0000795 | Glycerol monocaprylocaprate | 2 | 500 mg | 1 | 2392 | Yes | +5°C ± 3°C | ||
G0400006 | Glycerol monolinoleate | 1 | 2000 mg | 1 | 1429 | Yes | +5°C ± 3°C | ||
G0400007 | Glycerol mono-oleate | 2 | 2500 mg | 1 | 1430 | Yes | +5°C ± 3°C | ||
G0400008 | Glycerol monostearate 40-55 | 4 | 2000 mg | 1 | Batch 3 is valid until 31 March 2017 | 0495 | Yes | +5°C ± 3°C | |
Y0001786 | Glyceryl trinitrate for system suitability | 1 | 0.5 mL | 1 | 1331 | Yes | +5°C ± 3°C | ||
G0400100 | Glyceryl trinitrate solution | 3 | 0.5 mL | 1 | 1331.1355 | Yes | +5°C ± 3°C | ||
G0400101 | Glyceryl trinitrate - reference spectrum | 1 | n/a | 1 | 1331 | ||||
G0450000 | Glycine | 3 | 50 mg | 1 | 0614, 0813 | Yes | +5°C ± 3°C | ||
Y0001308 | Glycopyrronium bromide | 1 | 10 mg | 1 | 1783 | Yes | +5°C ± 3°C | ||
Y0001358 | Glycopyrronium impurity N | 1 | 10 mg | 1 | See leaflet CŒ„Hœ‡BrNO–; (3RS)-3-[(2RS)-(2-cyclopentyl-2-hydroxy-2- phenylacetyl)oxy]-1,1-dimethylpyrrolidinium | 1783 | Yes | +5°C ± 3°C | |
Y0000433 | Ammonium glycyrrhizate | 2 | 70 mg | 1 | 1772 | Yes | +5°C ± 3°C | ||
Y0001309 | Glycopyrronium for peak identification | 1 | 10 mg | 1 | 1783 | Yes | +5°C ± 3°C | ||
G0460000 | Glycyrrhizate (monoammonium) | 4 | 300 mg | 1 | see leaflet | 0277, 2378 | Yes | +5°C ± 3°C | |
G0525000 | Gonadorelin | 5 | 5 mg | 1 | See leaflet C——HŸ—NŒŸOŒ– | 0827 | Yes | -20°C ± 5°C | |
Y0000125 | Goserelin | 3 | 2 mg | 1 | See leaflet C—„H‡÷NŒ‡OŒ÷ ; Batch 2 is valid until 30 November 2016 | 1636 | Yes | -20°C ± 5°C | |
Y0000126 | Gosereline - reference spectrum | 1 | n/a | 1 | 1636 | ||||
Y0001473 | Goserelin for NMR identification | 1 | 14 mg | 1 | 1636 | Yes | -20°C ± 5°C | ||
Y0000194 | Goserelin validation mixture | 2 | 1 mg | 1 | Supplied with the Ph. Eur. reference chromatogram | 1636 | Yes | -20°C ± 5°C | |
Y0000019 | 4-D-Ser-goserelin | 1 | 0.1 mg | 1 | 1636 | Yes | -20°C ± 5°C | ||
G0550000 | Gramicidin | 1 | 250 mg | 1 | See leaflet | 0907,1662,2 0702 | Yes | +5°C ± 3°C | |
Y0000396 | Granisetron hydrochloride | 2 | 120 mg | 1 | See leaflet | 1695 | Yes | +5°C ± 3°C | |
Y0000477 | Granisetron impurity A | 3 | 1 mg | 1 | 2-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2H- indazole-3-carboxamide | 1695 | Yes | +5°C ± 3°C | |
Y0000478 | Granisetron impurity B | 3 | 1 mg | 1 | N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3- carboxamide | 1695 | Yes | +5°C ± 3°C | |
Y0000395 | Granisetron impurity E | 3 | 15 mg | 2 | (1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine | 1695 | Yes | +5°C ± 3°C | |
G0600000 | Griseofulvin | 2 | 50 mg | 1 | 0182 | Yes | +5°C ± 3°C | ||
Y0000619 | Guaiacol | 2 | 1500 mg | 1 | See leaflet CŸH‡Oœ | 1978 | Yes | +5°C ± 3°C | |
G0700000 | Guaifenesin | 1 | 100 mg | 1 | 0615 | Yes | +5°C ± 3°C | ||
Y0000117 | Halofantrine hydrochloride | 1 | 125 mg | 1 | See leaflet CœÿH–ŒCl–F–NO | 1979 | Yes | +5°C ± 3°C | |
Y0000118 | Halofantrine impurity C | 1 | 10 mg | 1 | [1,3-dichloro-6-(trifluoromethyl)phenantren-9-yl]methanol | 1979 | Yes | +5°C ± 3°C | |
H0100000 | Haloperidol | 2 | 60 mg | 1 | 0616.1178 | Yes | +5°C ± 3°C | ||
Y0001518 | Haloperidol for peak identification | 2 | 20 mg | 1 | 0616 | Yes | +5°C ± 3°C | ||
Y0001517 | Haloperidol for system suitability | 1 | 25 mg | 1 | 0616 | Yes | +5°C ± 3°C | ||
H0100100 | Haloperidol decanoate | 1 | 60 mg | 1 | 1397.1431 | Yes | +5°C ± 3°C | ||
H0150000 | Halothane - reference spectrum | 2 | n/a | 1 | 0393 | ||||
New | Y0000673 | Harpagoside | 2 | 1.05 mg | 1 | See leaflet Cœ÷H–ÐOŒŒ ; Batch 1 is valid until 30 November 2017 | 1095, 1871 | Yes | +5°C ± 3°C |
H0200000 | Heparin sodium BRP | 3 | 2 ml | 1 | See leaflet | 0569, 20705 | Yes | +5°C ± 3°C | |
Y0001283 | Heparin sodium for NMR identification | 1 | 30 mg | 1 | 0333 | Yes | +5°C ± 3°C | ||
Y0001287 | Heparin calcium for NMR identification | 1 | 30 mg | 1 | 0332 | Yes | +5°C ± 3°C | ||
Y0001282 | Heparin for physico-chemical analysis | 2 | 300 mg | 1 | 0332, 0333 | Yes | +5°C ± 3°C | ||
H0185000 | Heparin Low-Molecular-Mass for assay BRP | 9 | 1 mg | 5 | See leaflet | 0828 | Yes | +5°C ± 3°C | |
New | H0190000 | Heparin Low-Molecular-Mass for calibration CRS | 4 | 10 mg | 1 | See leaflet ; Batch 3 is valid until 30 November 2017 | 0828 | Yes | +5°C ± 3°C |
H0205010 | Hepatitis A vaccine (inactivated, adsorbed) Type B BRP | 2 | 0.5 ml | 3 | See leaflet; Please contact us for information on the type needed for your use | See leaflet, 20714 | Yes | +5°C ± 3°C | |
Y0001192 | Hepatitis A Vaccine (Inactivated, Non-Adsorbed) BRP | 2 | 1 mL | 1 | To be stored below -50°C | 20714,1526, 1935, 1107 | Yes | -80°C ± 10°C | |
Y0001624 | Hepatitis A virus Coating Reagent for ELISA - BRR | 1 | 1 mL | 1 | Yes | -20°C ± 5°C | |||
Y0001623 | Set of Hepatitis A virus Detection Antibodies for ELISA - BRR | 3 | 275 µL | 1 | See leaflet | 20714 | Yes | -20°C ± 5°C | |
Y0001872 | Hepatitis A virus RNA for NAT testing BRP | 1 | 45 mg | 5 | See leaflet | 1646 | Yes | -20°C ± 5°C | |
Y0000389 | Hepatitis B vaccine (rDNA) BRP method A (thiomersal free) | 2 | 0.5 ml | 2 | See leaflet; Ph. Eur. BRPs are established in the context of specific methods. The method used to establish this BRP (refer to leaflet) is no longer available. Reference to the BRP has therefore been removed from the relevant monograph and general chapter of the Ph. Eur. and upon depletion of stocks this BRP will not be replaced. Users are encouraged to find alternative reference material to address their future needs. | See leaflet, 20715 | Yes | +5°C ± 3°C | |
H0210010 | Hepatitis B vaccine (rDNA) BRP method B | 2 | 1 ml | 2 | See leaflet; Ph. Eur. BRPs are established in the context of specific methods. The method used to establish this BRP (refer to leaflet) is no longer available. Reference to the BRP has therefore been removed from the relevant monograph and general chapter of the Ph. Eur. and upon depletion of stocks this BRP will not be replaced. Users are encouraged to find alternative reference material to address their future needs. | See leaflet, 1056 | Yes | +5°C ± 3°C | |
H0215000 | Hepatitis C Virus RNA for NAT testing BRP | 1 | 40 mg | 5 | See leaflet; For plasma pool testing by NAT | See leaflet, 20621 | Yes | -20°C ± 5°C | |
Y0001873 | Hepatitis E virus RNA for NAT testing BRP | 1 | 45 mg | 1 | See leaflet | 1646 | Yes | -20°C ± 5°C | |
New | Y0000063 | Heptaminol hydrochloride | 2 | 150 mg | 1 | 1980 | Yes | +5°C ± 3°C | |
Y0000057 | Heptaminol impurity A | 2 | 20 mg | 1 | See leaflet C‡HŒŸN; (2RS)-6-methylhept-5-en-2-amine | 1980 | Yes | +5°C ± 3°C | |
Y0001203 | Hesperidin | 1 | 20 mg | 1 | See leaflet Cœ‡H–÷OŒ— | 2430 | Yes | +5°C ± 3°C | |
H0330000 | Hexamidine diisetionate | 2 | 20 mg | 1 | 1436 | Yes | +5°C ± 3°C | ||
H0325000 | Hexetidine | 2 | 100 mg | 1 | 1221 | Yes | +5°C ± 3°C | ||
H0420000 | Hexylresorcinol | 1 | 100 mg | 1 | 1437 | Yes | +5°C ± 3°C | ||
Y0001746 | Hexylresorcinol for system suitability | 1 | 1 mg | 1 | 1437 | Yes | -20°C ± 5°C | ||
H0500000 | Hide powder | 4 | 500 mg | 1 | 20814 | Yes | +5°C ± 3°C | ||
Y0001779 | Histamine | 1 | 15 mg | 1 | 2671 | Yes | -20°C ± 5°C | ||
H0600000 | Histamine dihydrochloride | 3 | 250 mg | 1 | Batch 2 is valid until 30 April 2017 | 0143 | Yes | +5°C ± 3°C | |
H0750000 | Histidine | 3 | 25 mg | 1 | 0911 | Yes | +5°C ± 3°C | ||
H0755000 | Histidine hydrochloride monohydrate | 2 | 100 mg | 1 | 0910.2671 | Yes | +5°C ± 3°C | ||
H0800000 | Homatropine hydrobromide | 1 | 100 mg | 1 | 0500.0720 | Yes | +5°C ± 3°C | ||
H0830000 | Homatropine methylbromide | 1 | 25 mg | 1 | 0720 | Yes | +5°C ± 3°C | ||
H0837000 | L-Homocysteine thiolactone hydrochloride - reference spectrum | 1 | n/a | 1 | 1617 | ||||
Y0001383 | Homatropine methylbromide for system suitability | 1 | 5 mg | 1 | 0720 | Yes | +5°C ± 3°C | ||
Y0001290 | Honokiol | 1 | 20 mg | 1 | See leaflet CŒ‡HŒ‡Oœ | 2567.2568 | Yes | -20°C ± 5°C | |
H0900000 | Human albumin for electrophoresis BRP | 3 | 50 mg | 1 | See leaflet ; Batch 2 is valid until 31 March 2017 | 0255 | Yes | -20°C ± 5°C | |
Y0000219 | Human anti-D immunoglobulin BRP | 1 | 40 mg | 1 | See leaflet | See leaflet, 20713 | Yes | -20°C ± 5°C | |
Y0000667 | Human coagulation factor VII concentrate BRP | 2 | 25 mg | 2 | See leaflet | See leaflet, 20710 | Yes | -20°C ± 5°C | |
Y0001663 | Human coagulation factor VIIa (rDNA) | 1 | 42 mg | 1 | See leaflet | 2534 | Yes | -20°C ± 5°C | |
H0920000 | Human coagulation factor VIII concentrate BRP | 5 | 37 mg | 3 | See leaflet | 20704 | Yes | -20°C ± 5°C | |
H0920500 | Human coagulation factor IX concentrate BRP | 3 | 30 mg | 3 | See leaflet; Common standard with FDA and WHO (4th IS) ; Batch 2 is valid until 31 October 2016 | 2.7.11 | Yes | -20°C ± 5°C | |
Y0001659 | Human coagulation factor IX (rDNA) | 1 | 10 mg | 1 | see leaflet | 2522 | Yes | -20°C ± 5°C | |
Y0000191 | Human glucagon | 2 | 2.94 mg | 2 | See leaflet CŒ—–Hœœ—N÷–O÷„S | 1635 | Yes | -20°C ± 5°C | |
H0950000 | Human hepatitis A immunoglobulin BRP | 1 | 10 mg | 3 | See leaflet | See leaflet, 0338, 0769, 1646 | Yes | -20°C ± 5°C | |
Y0001414 | Human Hepatitis B immunoglobulin BRP | 1 | 100 mg | 1 | See leaflet | 0722, 1016 | Yes | -20°C ± 5°C | |
Y0001504 | Human immunoglobulin BRP (ACA and Molecular size) | 1 | 6000 mg | 1 | See leaflet, 0338, 0918 | Yes | +5°C ± 3°C | ||
Y0001512 | Human Immunoglobulin BRP (Fc Function and Molecular size) | 2 | 5000 mg | 1 | See leaflet ; Batch 1 is valid until 30 September 2016 | See leaflet, 0338, 0918 | Yes | +5°C ± 3°C | |
Y0000488 | Human immunoglobulin (molecular size) BRP | 1 | 700 mg | 3 | Each vial contains 0.7 gram of immunoglobulin G | See leaflet, 0338, 0918,1928 | Yes | +5°C ± 3°C | |
H1000000 | Human immunoglobulin for electrophoresis BRP | 3 | 50 mg | 1 | See leaflet | 0338.0918 | Yes | +5°C ± 3°C | |
H1005000 | Human Plasma Pools for NAT validation | 1 | 3502 mg | 1 | Set of 103 plasma pool samples | See leaflet, 20621 | Yes | -20°C ± 5°C | |
H1100000 | Human rabies immunoglobulin BRP | 1 | 170 mg | 3 | See leaflet | See leaflet, 0723 | Yes | -20°C ± 5°C | |
H1110000 | Human tetanus immunoglobulin BRP | 1 | 87 mg | 1 | See leaflet | 0398 | Yes | -20°C ± 5°C | |
Y0000502 | Human vaccinia immunoglobulin | 1 | 1 ml | 3 | See leaflet | See leaflet | Yes | -20°C ± 5°C | |
H1115000 | Hyaluronidase BRP | 2 | 50 mg | 1 | See leaflet ; Batch 1 is valid until 31 October 2016 | 0912 | Yes | +5°C ± 3°C | |
H1120000 | Hydralazine hydrochloride | 1 | 20 mg | 1 | 0829 | Yes | +5°C ± 3°C | ||
Y0001151 | Hydrastine hydrochloride | 2 | 25 mg | 1 | See leaflet CœŒHœœClNOÿ ; Batch 1 is valid until 31 May 2017 | 1831.2500 | Yes | -20°C ± 5°C | |
New | H1200000 | Hydrochlorothiazide | 8 | 300 mg | 1 | See leaflet CŸH‡ClN–O÷Sœ ; Batch 7 is valid until 30 November 2017 | 0394 | Yes | +5°C ± 3°C |
Y0001494 | Hydrochlorothiazide for peak identification | 3 | 10 mg | 1 | Batch 2 is valid until 30 November 2016 | 0394 | Yes | +5°C ± 3°C | |
Y0000646 | Hydrocodone hydrogen tartrate 2.5-hydrate - * narc | 1 | 10 mg | 1 | 1784 | Yes | +5°C ± 3°C | ||
Y0000710 | Hydrocodone for peak identification - * narc | 1 | 10 mg | 1 | 1784 | Yes | +5°C ± 3°C | ||
H1300000 | Hydrocortisone | 8 | 100 mg | 1 | 0335 | Yes | +5°C ± 3°C | ||
Y0001092 | Hydrocortisone for peak identification | 2 | 5 mg | 1 | 0335 | Yes | +5°C ± 3°C | ||
H1400000 | Hydrocortisone acetate | 9 | 125 mg | 1 | See leaflet | 0321,0334,0 335, 0734,0767 | Yes | +5°C ± 3°C | |
Y0001482 | Hydrocortisone acetate for peak identification | 2 | 15 mg | 1 | Batch 1 is valid until 30 November 2016 | 0334 | Yes | +5°C ± 3°C | |
H1425000 | Hydrocortisone hydrogen succinate | 2 | 100 mg | 1 | 0768 | Yes | -20°C ± 5°C | ||
H1426000 | Hydrogenated wool fat | 1 | 250 mg | 1 | 0969 | Yes | +5°C ± 3°C | ||
Y0000446 | Hydromorphone hydrochloride - * narc | 1 | 10 mg | 1 | 2099 | Yes | +5°C ± 3°C | ||
B0650000 | Hydrous benzoyl peroxide - reference spectrum | 2 | n/a | 1 | Batch 1 is valid until 30 November 2017 | 0704 | |||
H1428000 | Hydroxocobalamin | 1 | 10 mg | 1 | 0913,0914,0 915 | Yes | -20°C ± 5°C | ||
Y0000119 | Hydroxycarbamide | 2 | 360 mg | 1 | See leaflet | 1616 | Yes | +5°C ± 3°C | |
Y0001841 | Hydroxychloroquine for system suitability | 1 | 15 mg | 1 | 2849 | Yes | +5°C ± 3°C | ||
Y0001839 | Hydroxychloroquine sulfate | 1 | 70 mg | 1 | see leaflet CŒ‡HœÿClN–O.HœSO÷ | 2849 | Yes | +5°C ± 3°C | |
H1429400 | Hydroxyethyl salicylate | 1 | 125 mg | 1 | 1225 | Yes | +5°C ± 3°C | ||
Y0001322 | Hydroxyethyl starch (high Mw) | 1 | 800 mg | 1 | See leaflet | 1785 | Yes | +5°C ± 3°C | |
Y0001277 | Hydroxyethyl starch (medium MW) | 1 | 1200 mg | 1 | See leaflet | 1785 | Yes | +5°C ± 3°C | |
H1430000 | D-alpha-(4-Hydroxy-phenyl)glycine | 1 | 50 mg | 1 | (2R)-2-amino-2-(4-hydroxyphenyl)acetic acid - Cefadroxyl impurity A | 0813 | Yes | +5°C ± 3°C | |
Y0000186 | Hydroxypropylbetadex | 2 | 200 mg | 1 | 1804 | Yes | +5°C ± 3°C | ||
Y0001720 | Hydroxypropylcellulose | 1 | 150 mg | 1 | 0337, 2083 | Yes | +5°C ± 3°C | ||
Y0001798 | Low-substituted hydroxypropylcellulose | 1 | 100 mg | 1 | 2083 | Yes | +5°C ± 3°C | ||
H1435000 | Hydroxyzine hydrochloride | 3 | 600 mg | 1 | 0916.1086 | Yes | +5°C ± 3°C | ||
Y0000011 | Hymecromone | 1 | 100 mg | 1 | 1786 | Yes | +5°C ± 3°C | ||
Y0000012 | Hymecromone impurity A | 1 | 25 mg | 1 | benzene-1,3-diol (resorcinol) | 1786 | Yes | +5°C ± 3°C | |
Y0000013 | Hymecromone impurity B | 2 | 25 mg | 1 | 7-hydroxy-2-methyl-4H-1-benzopyran-4-one. | 1786 | Yes | +5°C ± 3°C | |
Y0000483 | Hyoscine | 1 | 10 mg | 1 | 2167 | Yes | +5°C ± 3°C | ||
Y0000484 | Hyoscine impurity A | 1 | 15 mg | 1 | (1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate (norhyoscine) | 2167 | Yes | +5°C ± 3°C | |
H1450000 | Hyoscine butylbromide | 2 | 20 mg | 1 | 0737 | Yes | +5°C ± 3°C | ||
Y0000447 | Hyoscine butylbromide impurity E | 1 | 10 mg | 1 | (1R,2R,4S,5S,7s)-9-butyl -3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (2S)-3- hydroxy-2-phenylpropanoate (N-butylhyoscine) | 0737 | Yes | +5°C ± 3°C | |
H1500000 | Hyoscine hydrobromide | 1 | 50 mg | 1 | 0106.0500 | Yes | +5°C ± 3°C | ||
Y0000448 | Hyoscine hydrobromide impurity B | 1 | 10 mg | 1 | (1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl (2S)-3-hydroxy-2- phenylpropanoate (norhyoscine) | 0106 | Yes | +5°C ± 3°C | |
H1600000 | Hyoscyamine sulfate | 1 | 100 mg | 1 | 0501, 2489 | Yes | +5°C ± 3°C | ||
Y0000449 | Hyoscyamine impurity E | 1 | 10 mg | 1 | (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoate (norhyoscyamine) | 0501 | Yes | +5°C ± 3°C | |
Y0000915 | Hypromellose phthalate | 1 | 10 mg | 1 | 347 | Yes | +5°C ± 3°C | ||
I0020000 | Ibuprofen | 5 | 250 mg | 1 | 0721 | Yes | +5°C ± 3°C | ||
B1220000 | Ibuprofen impurity B | 9 | 1.15 mL | 1 | See leaflet; (2RS)-2-(4-Butylphenyl)propanoic acid | 0721 | Yes | +5°C ± 3°C | |
Y0000140 | Ibuprofen impurity F | 2 | 5 mg | 1 | 3-[4-(2-methylpropyl)phenyl]propanoic acid | 0721 | Yes | +5°C ± 3°C | |
Y0000881 | Ibuprofen for peak identification | 7 | 0.09 mg | 1 | Batch 6 is valid until 31 March 2017 | 0721 | Yes | +5°C ± 3°C | |
I0050000 | Idoxuridine | 1 | 50 mg | 1 | 0669 | Yes | +5°C ± 3°C | ||
I0060000 | Ifosfamide | 1 | 50 mg | 1 | See leaflet CŸHŒ—ClœNœOœP | 1529 | Yes | +5°C ± 3°C | |
I0060100 | Ifosfamide - reference spectrum | 1 | n/a | 1 | 1529 | ||||
I0060002 | Ifosfamide impurity A | 4 | 100 mg | 2 | 3-[(2-chloroethyl)amino]propyl dihydrogen phosphate | 1529 | Yes | -20°C ± 5°C | |
I0060004 | Ifosfamide impurity B | 2 | 40 mg | 1 | bis[3-[(2-chloroethyl)amino]propyl] dihydrogen diphosphate | 1529 | Yes | +5°C ± 3°C | |
I0060010 | Ifosfamide impurity E | 1 | 20 mg | 2 | 3-chloro-N-(2-chloroethyl)propan-1-amine | 1529 | Yes | +5°C ± 3°C | |
I0060012 | Ifosfamide impurity F | 2 | 10 mg | 1 | (RS)-2-chloro-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide | 1529 | Yes | +5°C ± 3°C | |
Y0001691 | Imatinib mesilate | 2 | 120 mg | 1 | see leaflet C–ÐH–—NŸSO÷ ; Batch 1 is valid until 31 May 2017 | 2736 | Yes | +5°C ± 3°C | |
Y0001695 | Imatinib impurity A | 1 | 0.03 mg | 1 | (2E)-3-(dimethylamino)-1-(pyridin-3-yl)prop-2-ene-1-one | 2736 | Yes | -20°C ± 5°C | |
Y0001693 | Imatinib impurity F | 3 | 10 mg | 1 | 4-methyl-N3-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine ; Batch 2 is valid until 31 July 2016 | 2736 | Yes | +5°C ± 3°C | |
Y0001694 | Imatinib impurity H | 1 | 130 mg | 1 | 1-(pyridin-3-yl)ethan-1-one | 2736 | Yes | +5°C ± 3°C | |
Y0001692 | Imatinib for system suitability | 1 | 5 mg | 1 | 2736 | Yes | +5°C ± 3°C | ||
I0086000 | Imidazole | 2 | 60 mg | 1 | 0757,1424, 2270 | Yes | +5°C ± 3°C | ||
I0090000 | Imipenem | 3 | 70 mg | 1 | See leaflet | 1226 | Yes | -20°C ± 5°C | |
I0100000 | Imipramine hydrochloride | 2 | 50 mg | 1 | 0029, 0408, 0889,1787 | Yes | +5°C ± 3°C | ||
Y0001689 | Immunoglobulin (anti-A, anti-B antibodies test) Negative control | 1 | 50 mg | 1 | 20620 | Yes | -20°C ± 5°C | ||
Y0001688 | Immunoglobulin (anti-A, anti-B antibodies test) Positive control | 1 | 46 mg | 1 | 20620 | Yes | -20°C ± 5°C | ||
Y0000893 | Imipramine for system suitability | 1 | 10 mg | 1 | 0029 | Yes | +5°C ± 3°C | ||
Y0001153 | Immunoglobulin for anti-A, anti-B antibodies limit test BRP | 1 | 45 mg | 1 | 20620 | Yes | -20°C ± 5°C | ||
Y0000540 | Immunoglobulin panel for anti-D antibodies test BRP | 1 | 2000 mg | 1 | See leaflet, 20626 | Yes | -20°C ± 5°C | ||
Y0001205 | Imperatorin | 1 | 20 mg | 1 | See leaflet CŒÿHŒ÷O÷ | 2556 | Yes | +5°C ± 3°C | |
I0150000 | Indapamide | 5 | 150 mg | 1 | See leaflet CŒÿHŒÿClN–O–S | 1108 | Yes | +5°C ± 3°C | |
Y0001828 | Indapamide Impurity C | 1 | 25 mg | 1 | (2RS)-2-methyl-2,3-dihydro-1H-indol-1-amine | 1108 | Yes | +5°C ± 3°C | |
I0150020 | Indapamide impurity B | 4 | 5 mg | 1 | 4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulfamoylbenzamide | 1108 | Yes | +5°C ± 3°C | |
Y0001752 | Indigo | 1 | 15 mg | 1 | see leaflet CŒÿHŒÐNœOœ | 2727 | Yes | +5°C ± 3°C | |
Y0000788 | Indinavir | 1 | 100 mg | 1 | see leaflet | 2214 | Yes | +5°C ± 3°C | |
Y0000880 | Indinavir sulfate - reference spectrum | 1 | n/a | 1 | 2214 | ||||
Y0000746 | Indinavir for system suitability | 1 | 20 mg | 1 | 2214 | Yes | +5°C ± 3°C | ||
I0200000 | Indometacin | 3 | 70 mg | 1 | Batch 2 is valid until 18 January 2017 | 0092,0922,1 686 | Yes | +5°C ± 3°C | |
Y0001640 | Indometacine impurity mixture | 1 | 0.002 mg | 1 | 0092 | Yes | +5°C ± 3°C | ||
Y0000349 | Insulin aspart | 2 | 8 mg | 1 | See leaflet | 2084 | Yes | -20°C ± 5°C | |
I0305000 | Insulin (bovine) | 3 | 7.99 mg | 1 | See leaflet Cœ—÷H–ŸŸNÿ—OŸ—Sÿ | 0854.1637 | Yes | -20°C ± 5°C | |
New | Y0001542 | Insulin glargine | 2 | 50 mg | 1 | See leaflet ; Batch 1 is valid until 30 November 2017 | 2571 | Yes | -20°C ± 5°C |
Y0001544 | Insulin glargine for peak identification | 1 | 3.2 mg | 1 | 2571 | Yes | -20°C ± 5°C | ||
I0310000 | Insulin (human) | 4 | 8 mg | 1 | see leaflet | 0838, 0854, 1637, 1638 | Yes | -20°C ± 5°C | |
Y0000348 | Insulin lispro | 2 | 5.75 mg | 1 | See leaflet Cœ—ŸH–‡–Nÿ—OŸŸSÿ | 2085 | Yes | -20°C ± 5°C | |
I0320000 | Insulin (porcine) | 4 | 9 mg | 1 | See leaflet Cœ—ÿH–‡ŒNÿ—OŸÿSÿ; For qualitative use see insulin porcine for system suitability CRS Y0001717 | 0854.1638 | Yes | -20°C ± 5°C | |
Y0001717 | Insulin porcine for system suitability | 2 | 9 mg | 1 | For intended use: see leaflet. | 0838,0854,1 637, 1638 | Yes | -20°C ± 5°C | |
I0320301 | Interferon alfa-2b | 6 | 200 µL | 1 | About 9.74 mg per mL | 1110 | Yes | -80°C ± 10°C | |
Y0001101 | Interferon beta-1a | 3 | 0.6 mL | 1 | See leaflet | 1639 | Yes | -80°C ± 10°C | |
I0320330 | Interferon gamma-1b | 2 | 0.5 mL | 2 | about 1 mg per ml | 1440 | Yes | -80°C ± 10°C | |
Y0001664 | Interferon gamma-1b for system suitability | 1 | 0.6 mg | 1 | 1440 | Yes | -20°C ± 5°C | ||
I0328000 | Iobenguane sulfate | 3 | 25 mg | 1 | See leaflet ; Batch 2 is valid until 31 May 2017 | 1111,1112,11 13,2351 | Yes | +5°C ± 3°C | |
Y0000839 | Iobenguane sulfate - reference spectrum | 1 | n/a | 1 | 2351 | ||||
Y0001294 | Iodixanol | 1 | 60 mg | 1 | 2215 | Yes | +5°C ± 3°C | ||
Y0001292 | Iodixanol impurity C | 1 | 10 mg | 1 | 5-[acetyl[3-[[3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl] amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6- triiodobenzene-1,3-dicarboxamide | 2215 | Yes | +5°C ± 3°C | |
Y0001291 | Iodixanol impurity E | 1 | 10 mg | 1 | 5-[acetyl[3-[acetyl[3-carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6- triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3- dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide | 2215 | Yes | +5°C ± 3°C | |
Y0001293 | Iodixanol impurity H | 1 | 10 mg | 1 | 5-[acetyl[3-[acetyl[3-[[3-[3-[acetyl[3,5-bis[(2,3-dihydroxypropyl) carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropoxy]-2-hydroxypropyl] carbamoyl]-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl] amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6- triiodobenzene-1,3-dicarboxamide | 2215 | Yes | +5°C ± 3°C | |
I0320800 | Iohexol | 2 | 150 mg | 1 | 1114 | Yes | +5°C ± 3°C | ||
I0320810 | Iohexol impurity A | 1 | 50 mg | 1 | 5-(acetylamino)-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3- dicarboxamide | 1114 | Yes | +5°C ± 3°C | |
I0320820 | Iohexol impurity J | 1 | 125 mg | 1 | 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3- dicarboxamide | 1114.2215 | Yes | +5°C ± 3°C | |
Y0000672 | Iohexol for peak identification | 1 | 10 mg | 1 | 1114 | Yes | +5°C ± 3°C | ||
I0329000 | Iopamidol | 1 | 50 mg | 1 | 1115 | Yes | +5°C ± 3°C | ||
I0329010 | Iopamidol impurity A | 2 | 15 mg | 1 | 5-amino-N,N’-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6- triiodobenzene-1,3-dicarboxamide ; Batch 1 is valid until 31 October 2016 | 1115, 1754 | Yes | +5°C ± 3°C | |
New | Y0000406 | Iopamidol impurity H | 2 | 15 mg | 1 | 4-chloro-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2- hydroxypropanoyl]amino]-2,6-diiodobenzene-1,3-dicarboxamide ; Batch 1 is valid until 23 September 2017 | 1115 | Yes | +5°C ± 3°C |
I0330000 | Iopanoic acid | 1 | 100 mg | 1 | 0700 | Yes | +5°C ± 3°C | ||
Y0001297 | Iopentol | 1 | 10 mg | 1 | 2215 | Yes | +5°C ± 3°C | ||
Y0001020 | Iopromide | 1 | 100 mg | 1 | See leaflet CŒ‡Hœ÷I–N–O‡ | 1753 | Yes | +5°C ± 3°C | |
Y0001077 | Iopromide impurity A | 1 | 0.125 mg | 1 | 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methylbenzene-1,3- dicarboxamide | 1753 | Yes | +5°C ± 3°C | |
Y0001021 | Iopromide for system suitability 1 | 1 | 5 mg | 1 | 1753 | Yes | +5°C ± 3°C | ||
Y0001022 | Iopromide for system suitability 2 | 1 | 5 mg | 1 | 1753 | Yes | +5°C ± 3°C | ||
Y0000555 | Iotrolan | 1 | 100 mg | 1 | See leaflet | 1754 | Yes | +5°C ± 3°C | |
Y0000658 | Iotrolan for system suitability | 1 | 5 mg | 1 | 1754 | Yes | +5°C ± 3°C | ||
Y0000141 | Ioxaglic acid | 2 | 125 mg | 1 | 2009 | Yes | +5°C ± 3°C | ||
Y0000142 | Ioxaglic acid impurity A | 1 | 20 mg | 1 | 3-amino-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic acid | 2009 | Yes | +5°C ± 3°C | |
I0360000 | Ipratropium bromide | 5 | 120 mg | 1 | 0919 | Yes | +5°C ± 3°C | ||
I0361000 | Ipratropium impurity B | 3 | 10 mg | 1 | (1R,3r,5S,8s)-3-[[(2RS)-3-hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1- methylethyl)-8-azoniabicyclo[3.2.1]octane | 0919 | Yes | +5°C ± 3°C | |
Y0000276 | Ipratropium impurity A | 3 | 15 mg | 1 | (1R,3r,5S,8r)-3-hydroxy-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1] octane ; Batch 2 is valid until 31 August 2017 | 0919 | Yes | +5°C ± 3°C | |
Y0001166 | Irbesartan | 1 | 60 mg | 1 | 2465 | Yes | +5°C ± 3°C | ||
Y0001156 | Irbesartan impurity A | 3 | 10 mg | 1 | 1-(pentanoylamino)-N-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl] cyclopentane-1-carboxamide | 2465 | Yes | +5°C ± 3°C | |
Y0001831 | Irinotecan for peak identification | 1 | 1 mg | 1 | 2675 | Yes | +5°C ± 3°C | ||
Y0001830 | Irinotecan for system suitability 1 | 1 | 1.51 mg | 1 | 2675 | Yes | +5°C ± 3°C | ||
Y0001833 | Irinotecan for system suitability 2 | 1 | 10 mg | 1 | 2675 | Yes | +5°C ± 3°C | ||
Y0001832 | Irinotecan hydrochloride trihydrate | 1 | 170 mg | 1 | see leaflet C––H–„ClN÷Oÿ,3HœO | 2675 | Yes | +5°C ± 3°C | |
Y0001616 | Irisflorentin | 1 | 15 mg | 1 | See leaflet CœÐHŒ‡O‡ | 2561 | Yes | +5°C ± 3°C | |
I0375000 | Isoconazole | 1 | 200 mg | 1 | 1018 | Yes | +5°C ± 3°C | ||
I0380000 | Isoconazole nitrate | 1 | 200 mg | 1 | 1017 | Yes | +5°C ± 3°C | ||
I0400000 | Isoemetine hydrobromide | 1 | 25 mg | 1 | 0081 | Yes | +5°C ± 3°C | ||
Y0000858 | Isoflurane | 2 | 1.4 mL | 1 | 1666 | Yes | +5°C ± 3°C | ||
Y0000037 | Isoflurane - reference spectrum | 1 | n/a | 1 | 1673 | ||||
I0460000 | Isoleucine | 2 | 30 mg | 1 | 0770 | Yes | +5°C ± 3°C | ||
I0465000 | Isomalt | 5 | 3000 mg | 1 | See leaflet | 1531 | Yes | +5°C ± 3°C | |
Y0000070 | Isomaltooligosaccharide | 1 | 0.9 mg | 1 | 1506 | Yes | +5°C ± 3°C | ||
I0500000 | Isoniazid | 1 | 100 mg | 1 | 0146 | Yes | +5°C ± 3°C | ||
I0599990 | Isoprenaline hydrochloride | 1 | 50 mg | 1 | 1332 | Yes | +5°C ± 3°C | ||
Y0001577 | Isoprenaline impurity A | 1 | 15 mg | 1 | 1-(3,4-dihydroxyphenyl)-2-[(1-methylethyl)amino]ethanone | 1332 | Yes | +5°C ± 3°C | |
I0600000 | Isoprenaline sulfate | 3 | 510 mg | 1 | 0502 | Yes | +5°C ± 3°C | ||
Y0001728 | Isopropyl alcohol | 1 | 100 mg | 1 | 0970 | Yes | +5°C ± 3°C | ||
I0725000 | Isopropyl hexadecanoate | 2 | 100 mg | 1 | See leaflet CŒ„H–‡Oœ | 0839 | Yes | +5°C ± 3°C | |
Y0001907 | Isopropyl isostearate | 1 | 0.5 mL | 1 | 2867 | Yes | +5°C ± 3°C | ||
I0750000 | Isopropyl tetradecanoate | 4 | 2 ml | 1 | See leaflet CŒŸH–÷Oœ | 0725 | Yes | +5°C ± 3°C | |
Y0001568 | Isoquercitroside | 1 | 15 mg | 1 | See leaflet CœŒHœÐOŒœ | 2528 | Yes | +5°C ± 3°C | |
Y0001836 | Isorhynchophylline | 1 | 15 mg | 1 | see leaflet | 2729 | Yes | -20°C ± 5°C | |
I0775000 | Isosorbide dinitrate | 4 | 350 mg | 1 | See leaflet CÿH‡NœO‡ ; Batch 3 is valid until 28 February 2017 | 1117.1118 | Yes | +5°C ± 3°C | |
I0775010 | Isosorbide mononitrate | 5 | 150 mg | 1 | See leaflet CÿH„NOÿ; Isosorbide-5-nitrate. Can only be sent by road. ; Batch 4 is valid until 30 September 2017 | 1117.1118 | Yes | +5°C ± 3°C | |
I0775020 | Isosorbide-2-nitrate | 3 | 50 mg | 1 | 1117.1118 | Yes | +5°C ± 3°C | ||
I0800000 | Isotretinoin | 5 | 50 mg | 1 | 0693.1019 | Yes | +5°C ± 3°C | ||
Y0001218 | Isotretinoin for peak identification | 2 | 10 mg | 1 | 1019 | Yes | +5°C ± 3°C | ||
I0900000 | Isoxsuprine hydrochloride | 1 | 50 mg | 1 | 1119 | Yes | +5°C ± 3°C | ||
Y0000366 | Isradipine | 1 | 125 mg | 1 | See leaflet CŒ„HœŒN–O— | 2110 | Yes | +5°C ± 3°C | |
Y0000367 | Isradipine impurity D | 1 | 5 mg | 1 | methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl) -2,6-dimethylpyridine-3,5-dicarboxylate | 2110 | Yes | +5°C ± 3°C | |
I7000000 | Itraconazole | 3 | 20 mg | 1 | 1335 | Yes | +5°C ± 3°C | ||
New | Y0001100 | Itraconazole for system suitability | 3 | 25 mg | 1 | Batch 2 is valid until 31 October 2017 | 1335 | Yes | +5°C ± 3°C |
I8000010 | Ivermectin | 2 | 150 mg | 1 | See leaflet | 1336 | Yes | +5°C ± 3°C | |
Y0001592 | Ivy leaf dry extract HRS | 1 | 70 mg | 1 | See leaflet | 2148 | Yes | -20°C ± 5°C | |
Y0000041 | Josamycin | 2 | 150 mg | 1 | See leaflet | 1982,1983,2 0702 | Yes | -20°C ± 5°C | |
Y0001315 | Josamycin for peak identification | 1 | 25 mg | 1 | 1983 | Yes | +5°C ± 3°C | ||
Y0000042 | Josamycin propionate | 3 | 150 mg | 1 | See leaflet ; Batch 2 is valid until 31 January 2017 | 1982,1983,2 0702 | Yes | -20°C ± 5°C | |
K0100000 | Kanamycin B sulfate | 3 | 20 mg | 1 | 0032,0033,0 645 | Yes | +5°C ± 3°C | ||
K0200000 | Kanamycin monosulfate | 3 | 150 mg | 1 | See leaflet CŒ‡H–‡N÷OŒ—S,HœO | 0032,0033,0 053, 0485,0645,1 289, 1290,20702 | Yes | +5°C ± 3°C | |
Y0000450 | Ketamine hydrochloride - * narc | 1 | 10 mg | 1 | 1020 | Yes | +5°C ± 3°C | ||
New | K0551000 | Ketamine impurity A | 3 | 20 mg | 1 | 1-(2-chloro-N-methylbenzimidoyl)cyclopentanol ; Batch 2 is valid until 30 September 2017 | 1020.1742 | Yes | +5°C ± 3°C |
Y0000246 | Ketobemidone hydrochloride - reference spectrum | 1 | n/a | 1 | 1746 | ||||
Y0000244 | Ketobemidone impurity B | 1 | 5 mg | 1 | 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]ethanone | 1746 | Yes | +5°C ± 3°C | |
Y0000245 | Ketobemidone impurity C | 1 | 5 mg | 1 | 1-[4-(3-hydroxyphenyl)piperidin-4-yl]propan-1-one | 1746 | Yes | +5°C ± 3°C | |
K0600000 | Ketoconazole | 2 | 150 mg | 1 | 0921.1270 | Yes | +5°C ± 3°C | ||
K2000000 | Ketoprofen | 2 | 50 mg | 1 | 0922,1157,1 209 | Yes | +5°C ± 3°C | ||
K2000010 | Ketoprofen impurity A | 5 | 10 mg | 1 | 1-(3-benzoylphenyl)ethanone | 0922 | Yes | +5°C ± 3°C | |
K2000015 | Ketoprofen impurity C | 4 | 15 mg | 1 | 3-[(1RS)-1-carboxyethyl]benzoic acid ; Batch 3 is valid until 31 May 2017 | 0922 | Yes | +5°C ± 3°C | |
New | Y0000486 | Ketorolac trometamol | 2 | 10 mg | 1 | Batch 1 is valid until 31 December 2017 | 1755 | Yes | +5°C ± 3°C |
Y0000626 | Ketorolac trometamol for peak identification | 2 | 5 mg | 1 | 1755 | Yes | +5°C ± 3°C | ||
Y0001619 | Ketotifen hydrogen fumarate | 1 | 10 mg | 1 | 1592 | Yes | +5°C ± 3°C | ||
Y0000161 | Ketotifen impurity G | 5 | 0.0225 mg | 1 | 4-(1-methylpiperidin-4-ylidene)-4H-benzo(4,5)cyclohepta(1,2-b) thiophen-9,10-dione | 1592 | Yes | +5°C ± 3°C | |
Y0001617 | Ketotifen for peak identification | 1 | 15 mg | 1 | 1592 | Yes | +5°C ± 3°C | ||
Y0001200 | Kudzuvine root dry extract | 1 | 200 mg | 1 | See leaflet | 2434.2483 | Yes | -20°C ± 5°C | |
L0050000 | Labetalol hydrochloride | 2 | 120 mg | 1 | See leaflet CŒ„Hœ—ClNœO– | 0923 | Yes | +5°C ± 3°C | |
Y0001548 | Labetalol impurity A | 1 | 10 mg | 1 | mixture of 4 stereoisomers of 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3- phenylpropyl)amino]ethyl]benzoic acid | 0923 | Yes | +5°C ± 3°C | |
L0129000 | Lactitol monohydrate | 2 | 60 mg | 1 | See leaflet CŒœHœ÷OŒŒ | 1337 | Yes | +5°C ± 3°C | |
New | Y0000257 | Lactobionic acid | 2 | 100 mg | 1 | Batch 1 is valid until 30 September 2017 | 1647 | Yes | +5°C ± 3°C |
A1206000 | Lactose (anhydrous) | 2 | 30 mg | 1 | Batch 1 is valid until 31 July 2016 | 1061 | Yes | +5°C ± 3°C | |
Y0001750 | Lactose monohydrate | 1 | 100 mg | 1 | 0187 | Yes | +5°C ± 3°C | ||
L0130000 | Lactulose | 4 | 3000 mg | 1 | See leaflet | 0924.1230 | Yes | +5°C ± 3°C | |
Y0001510 | Lactulose for peak identification | 1 | 2600 mg | 1 | 0924 | Yes | +5°C ± 3°C | ||
Y0000425 | Lamivudine | 2 | 150 mg | 1 | See leaflet C‡HŒŒN–O–S ; Batch 1 is valid until 31 July 2017 | 2217 | Yes | +5°C ± 3°C | |
Y0000518 | Lamivudine for system suitability 1 | 1 | 10 mg | 1 | 2217 | Yes | +5°C ± 3°C | ||
Y0000426 | Lamivudine for system suitability 2 | 2 | 10.3 mg | 1 | 2217 | Yes | +5°C ± 3°C | ||
Y0001030 | Lamotrigine | 1 | 10 mg | 1 | 1756 | Yes | +5°C ± 3°C | ||
Y0001032 | Lamotrigine impurity E | 1 | 15 mg | 1 | 2,3-dichlorobenzoic acid | 1756 | Yes | +5°C ± 3°C | |
Y0001031 | Lamotrigine for peak identification | 1 | 20 mg | 1 | 1756 | Yes | +5°C ± 3°C | ||
Y0001085 | Lamotrigine for system suitability | 2 | 10 mg | 1 | 1756 | Yes | +5°C ± 3°C | ||
Y0000773 | Lansoprazole | 1 | 60 mg | 1 | 2219 | Yes | +5°C ± 3°C | ||
Y0000774 | Lansoprazole for peak identification | 2 | 1.01 mg | 1 | 2219 | Yes | +5°C ± 3°C | ||
Y0001765 | Laudanosine | 1 | 15 mg | 1 | 2763 | Yes | +5°C ± 3°C | ||
Y0001474 | Lauric acid | 1 | 1500 mg | 1 | see leaflet | 1848, 2579 | Yes | +5°C ± 3°C | |
Y0000654 | Leflunomide | 1 | 100 mg | 1 | See leaflet | 2330 | Yes | +5°C ± 3°C | |
Y0000487 | Leflunomide impurity A | 2 | 25 mg | 1 | 4-(trifluoromethyl)aniline | 2330 | Yes | +5°C ± 3°C | |
Y0000674 | Leflunomide for peak identification | 1 | 1 mg | 1 | 2330 | Yes | +5°C ± 3°C | ||
Y0000685 | Letrozole | 1 | 70 mg | 1 | See leaflet CŒŸHŒŒN— | 2334 | Yes | +5°C ± 3°C | |
L0375000 | Leucine | 2 | 50 mg | 1 | 0771.0874 | Yes | +5°C ± 3°C | ||
L0376000 | Leuprorelin | 5 | 1 mg | 1 | See leaflet C—„H‡÷NŒÿOŒœ | 1442 | Yes | -20°C ± 5°C | |
L0376001 | Leuprorelin - reference spectrum | 1 | n/a | 1 | 1442 | ||||
Y0000048 | Levamisole - reference spectrum | 1 | n/a | 1 | 1728 | ||||
L0380000 | Levamisole hydrochloride | 1 | 50 mg | 1 | 0726 | Yes | +5°C ± 3°C | ||
Y0000047 | Levamisole hydrochloride for system suitability | 5 | 15 mg | 1 | 0726.1728 | Yes | +5°C ± 3°C | ||
Y0001253 | Levetiracetam | 3 | 120 mg | 1 | See leaflet ; Batch 2 is valid until 31 March 2017 | 2535 | Yes | +5°C ± 3°C | |
Y0001254 | Levetiracetam impurity A | 3 | 10 mg | 1 | (2RS)-2-(2-oxopyrrolidin-1-yl)butanoic acid | 2535 | Yes | +5°C ± 3°C | |
Y0001255 | Levetiracetam impurity B | 2 | 15 mg | 1 | (2Z)-2-(2-oxopyrrolidin-1-yl)but-2-enamide | 2535 | Yes | +5°C ± 3°C | |
Y0001256 | Levetiracetam impurity C | 2 | 15 mg | 1 | pyridin-2-ol | 2535 | Yes | +5°C ± 3°C | |
Y0001257 | Levetiracetam impurity D | 3 | 15 mg | 1 | (2R)-2-(2-oxopyrrolidin-1-yl)but* ((R)-etiracetam) | 2535 | Yes | +5°C ± 3°C | |
L0390000 | Levocabastine hydrochloride | 1 | 125 mg | 1 | 1484 | Yes | +5°C ± 3°C | ||
Y0001636 | Levocabastine for system suitability 1 | 1 | 5.028 mg | 1 | 1484 | Yes | +5°C ± 3°C | ||
Y0001637 | Levocabastine for system suitability 2 | 1 | 5.005 mg | 1 | 1484 | Yes | +5°C ± 3°C | ||
L0399900 | Levocarnitine | 3 | 125 mg | 1 | 1339 | Yes | +5°C ± 3°C | ||
L0399905 | Levocarnitine impurity A | 4 | 50 mg | 1 | (E)- or (Z)-4-(trimethylammonio)but-2-enoate | 1339 | Yes | +5°C ± 3°C | |
L0400000 | Levodopa | 3 | 20 mg | 1 | Batch 2 is valid until 31 May 2017 | 0038 | Yes | +5°C ± 3°C | |
L0420000 | Levodropropizine | 1 | 60 mg | 1 | 1535 | Yes | +5°C ± 3°C | ||
L0420002 | Levodropropizine impurity A | 3 | 25 mg | 1 | (2R)-3-(4-phenylpiperazin-1-yl)propan-1,2-diol (dextrodropropizine) | 1535 | Yes | +5°C ± 3°C | |
Y0001033 | Levodropropizine impurity B | 1 | 50 mg | 1 | 1-phenylpiperazine | 1535 | Yes | +5°C ± 3°C | |
Y0001048 | Levodropropizine impurity C | 1 | 300 mg | 1 | [(2RS)-oxiran-2-yl]methanol (glycidol) | 1535 | Yes | -20°C ± 5°C | |
L0500000 | Levomepromazine hydrochloride | 1 | 100 mg | 1 | 0505 | Yes | +5°C ± 3°C | ||
L0505000 | Levomepromazine maleate | 1 | 50 mg | 1 | 0925 | Yes | +5°C ± 3°C | ||
L0551000 | Levonorgestrel | 2 | 30 mg | 1 | 0926 | Yes | +5°C ± 3°C | ||
Y0001379 | Levonorgestrel impurity B | 2 | 15 mg | 1 | 13-ethyl-17-hydroxy-18,19-dinor-17α-pregn-5(10)-en-20-yn-3-one | 0926 | Yes | +5°C ± 3°C | |
Y0001431 | Levonorgestrel for system suitability 1 | 2 | 10 mg | 1 | 0926 | Yes | +5°C ± 3°C | ||
Y0001618 | Levonorgestrel for system suitability 2 | 1 | 10 mg | 1 | 0926 | Yes | +5°C ± 3°C | ||
L0570000 | Levothyroxine sodium | 4 | 100 mg | 1 | see leaflet | 0401.0728 | Yes | -20°C ± 5°C | |
Y0001382 | Levothyroxine for peak identification | 1 | 10 mg | 1 | 0401 | Yes | -20°C ± 5°C | ||
L0595000 | Lidocaine | 2 | 10 mg | 1 | 0727 | Yes | +5°C ± 3°C | ||
L0600000 | Lidocaine hydrochloride | 3 | 40 mg | 1 | 0227,1242,1 363 | Yes | +5°C ± 3°C | ||
L0650000 | Lincomycin hydrochloride | 4 | 100 mg | 1 | See leaflet | 0582,0583,0 996 | Yes | +5°C ± 3°C | |
Y0001393 | Lincomycin hydrochloride for system suitability | 2 | 10 mg | 1 | 0583 | Yes | -20°C ± 5°C | ||
L0700000 | Liothyronine sodium | 8 | 60 mg | 1 | See leaflet | 0401.0728 | Yes | -20°C ± 5°C | |
Y0000860 | Liothyronine for peak identification | 1 | 0.0046 mg | 1 | 0728 | Yes | -20°C ± 5°C | ||
L0702000 | Lisinopril dihydrate | 2 | 50 mg | 1 | 1120 | Yes | +5°C ± 3°C | ||
Y0001234 | Lisinopril impurity F | 2 | 0.01 mg | 1 | (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-cyclohexylpropyl]amino] hexanoyl]pyrrolidine-2-carboxylic acid (cyclohexyl analogue) | 1120 | Yes | +5°C ± 3°C | |
Y0001701 | Lisinopril for peak identification | 1 | 10 mg | 1 | 1120 | Yes | +5°C ± 3°C | ||
Y0001709 | Lisinopril for system suitability A | 1 | 10 mg | 1 | 1120 | Yes | +5°C ± 3°C | ||
L0720000 | Lithium clavulanate | 8 | 125 mg | 1 | See leaflet; 1 mg of C‡H‡LiNO— corresponds to 1.157 mg of C‡H‡KNO— ; Batch 6 is valid until 31 January 2017 | 1140.1653 | Yes | +5°C ± 3°C | |
New | L0720800 | Lithocholic acid | 3 | 60 mg | 1 | Batch 2 is valid until 31 October 2017 | 1189.1275 | Yes | +5°C ± 3°C |
Y0000112 | Lobeline hydrochloride | 1 | 50 mg | 1 | 1988 | Yes | +5°C ± 3°C | ||
L0745000 | Lomustine | 2 | 50 mg | 1 | 0928 | Yes | +5°C ± 3°C | ||
Y0001438 | Long pepper for system suitability HRS | 1 | 600 mg | 1 | 2477, 2453 | Yes | +5°C ± 3°C | ||
L0750000 | Loperamide hydrochloride | 2 | 50 mg | 1 | 0921,0929,1 729 | Yes | +5°C ± 3°C | ||
Y0000322 | Loperamide hydrochloride for system suitability | 2 | 15 mg | 1 | 0929 | Yes | +5°C ± 3°C | ||
Y0000341 | Loperamide oxide monohydrate | 1 | 20 mg | 1 | 1729 | Yes | +5°C ± 3°C | ||
Y0001498 | Lopinavir | 1 | 200 mg | 1 | See leaflet C–ŸH÷‡N÷O— | 2615 | Yes | +5°C ± 3°C | |
Y0001506 | Lopinavir for peak identification | 1 | 10 mg | 1 | 2615 | Yes | +5°C ± 3°C | ||
Y0001505 | Lopinavir for system suitability | 1 | 10 mg | 1 | 2615 | Yes | +5°C ± 3°C | ||
Y0000688 | Loratadine | 4 | 60 mg | 1 | Batch 3 is valid until 31 August 2016 | 2124 | Yes | +5°C ± 3°C | |
Y0000604 | Loratadine impurity F | 1 | 10 mg | 1 | ethyl 4-[(11RS)-8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta [1,2-b]pyridin-11-yl]piperidine-1-carboxylate | 2124 | Yes | +5°C ± 3°C | |
Y0000605 | Loratadine impurity H | 2 | 50 mg | 1 | ethyl 4-oxopiperidine-1-carboxylate ; Batch 1 is valid until 30 November 2016 | 2124 | Yes | +5°C ± 3°C | |
Y0000603 | Loratadine for system suitability | 2 | 15 mg | 1 | Batch 1 is valid until 31 December 2016 | 2124 | Yes | +5°C ± 3°C | |
L0750500 | Lorazepam - * psy | 2 | 15 mg | 1 | 1121 | Yes | +5°C ± 3°C | ||
Y0000718 | Lorazepam impurity D | 2 | 10 mg | 1 | (5RS)-7-chloro-5-(2-chlorophenyl)-4,5-dihydro-1H-1,4-benzodiazepine-2,3- dione | 1121 | Yes | +5°C ± 3°C | |
Y0000576 | Lorazepam for system suitability - * psy | 2 | 0.8 mg | 1 | 1121 | Yes | +5°C ± 3°C | ||
Y0001062 | Losartan potassium | 2 | 50 mg | 1 | Batch 1 is valid until 30 April 2017 | 2232 | Yes | +5°C ± 3°C | |
New | Y0001072 | Losartan impurity D | 4 | 10 mg | 1 | 2-butyl-4-chloro-1H-imidazole-5-carbaldehyde ; Batch 3 is valid until 30 November 2017 | 2232 | Yes | +5°C ± 3°C |
Y0001076 | Losartan for system suitability | 3 | 0.0015 mg | 1 | 2232 | Yes | +5°C ± 3°C | ||
L0790000 | Lovastatin | 4 | 60 mg | 1 | See leaflet Cœ÷H–ÿO— ; Batch 3 is valid until 31 July 2017 | 1538.1563 | Yes | -20°C ± 5°C | |
Y0001136 | Lovastatin for peak identification | 1 | 20 mg | 1 | 1538 | Yes | -20°C ± 5°C | ||
Y0001284 | Lufenuron | 1 | 140 mg | 1 | See leaflet CŒŸH‡ClœF‡NœO– | 2177 | Yes | +5°C ± 3°C | |
Y0001261 | Lufenuron for peak identification | 1 | 0.4028 mg | 1 | 2177 | Yes | +5°C ± 3°C | ||
Y0001265 | Lufenuron impurity G | 1 | 15 mg | 1 | 2,5-dichloro-4-[[[(2,6-difluorophenyl)carbonyl]carbamoyl]amino]phenyl phenyl carbonate | 2177 | Yes | +5°C ± 3°C | |
L0800000 | Lynestrenol | 1 | 50 mg | 1 | 0558 | Yes | +5°C ± 3°C | ||
Y0001034 | Lynestrenol for peak identification | 1 | 20 mg | 1 | 0558 | Yes | +5°C ± 3°C | ||
Y0000397 | Lysine acetate | 2 | 60 mg | 1 | 2114 | Yes | +5°C ± 3°C | ||
L0900000 | Lysine hydrochloride | 3 | 50 mg | 1 | 0930, 1654 | Yes | +5°C ± 3°C | ||
Y0001369 | Macrogol 30 dipolyhydroxystearate | 1 | 100 mg | 1 | 2584 | Yes | +5°C ± 3°C | ||
Y0000745 | Macrogol 40 sorbitol heptaoleate | 1 | 20 mg | 1 | 2396 | Yes | +5°C ± 3°C | ||
Y0001684 | High-molecular-mass macrogol CRS | 1 | 10 mg | 1 | 2444 | Yes | +5°C ± 3°C | ||
Y0001157 | Macrogol polyvinyl alcohol grafted copolymer | 1 | 400 mg | 1 | 2523 | Yes | +5°C ± 3°C | ||
M0088000 | Magnesium aspartate dihydrate | 1 | 60 mg | 1 | 1445 | Yes | +5°C ± 3°C | ||
Y0001289 | Magnolol | 1 | 20 mg | 1 | See leaflet CŒ‡HŒ‡Oœ | 2567.2568 | Yes | -20°C ± 5°C | |
M0120000 | Malathion | 3 | 250 mg | 1 | See leaflet CŒÐHŒ„OÿPSœ | 1343 | Yes | -20°C ± 5°C | |
M0120005 | Malathion impurity A | 3 | 15 mg | 1 | see leaflet; diethyl (2RS)-2-[(methoxy)(methylsulfanyl)-S-phosphinothioyl] butanedioate (isomalathion) | 1343 | Yes | -20°C ± 5°C | |
M0120010 | Malathion impurity B | 3 | 10 mg | 1 | diethyl (2RS)-2-(dimethoxy-S-phosphinothioyl)-butanedioate (maloxon) | 1343 | Yes | -20°C ± 5°C | |
M0100000 | Maleic acid | 2 | 100 mg | 1 | 0365.0925 | Yes | +5°C ± 3°C | ||
Y0000143 | Malic acid - reference spectrum | 1 | n/a | 1 | 2080 | ||||
M0160000 | Maltitol | 4 | 1200 mg | 1 | See leaflet CŒœHœ÷OŒŒ | 1235.1236 | Yes | +5°C ± 3°C | |
Y0001751 | Mangiferin | 1 | 15 mg | 1 | see leaflet CŒ„HŒ‡OŒŒ | 2661 | Yes | +5°C ± 3°C | |
M0200000 | Mannitol | 5 | 1200 mg | 1 | See leaflet CÿHŒ÷Oÿ | 0435,0559,1 381, 1531 | Yes | +5°C ± 3°C | |
M0206000 | Maprotiline hydrochloride | 1 | 100 mg | 1 | 1237 | Yes | +5°C ± 3°C | ||
M0206040 | Maprotiline impurity D | 1 | 25 mg | 1 | 3-(9,10-ethanoanthracen-9(10H)-yl)-N-methylprop-2-en-1-amine (dehydromaprotiline) | 1237 | Yes | +5°C ± 3°C | |
Y0000819 | Marbofloxacin | 1 | 10 mg | 1 | 2233 | Yes | +5°C ± 3°C | ||
Y0000820 | Marbofloxacin for peak identification | 1 | 20 mg | 1 | 2233 | Yes | +5°C ± 3°C | ||
M0210000 | Measles vaccine (live) BRP | 1 | 400 mg | 1 | See leaflet; One sale unit is composed of a bag of 5 vials. The unit quantity of each vial is 80 mg. | 1057,0213,2 442 | Yes | -20°C ± 5°C | |
M0215000 | Mebendazole | 1 | 20 mg | 1 | 1208,1254, 0845 | Yes | +5°C ± 3°C | ||
Y0000144 | Mebendazole for system suitability | 1 | 20 mg | 1 | 0845 | Yes | +5°C ± 3°C | ||
Y0001086 | Mebrofenin | 1 | 120 mg | 1 | 2393 | Yes | +5°C ± 3°C | ||
M0220000 | Meclozine dihydrochloride | 2 | 150 mg | 1 | 0622 | Yes | +5°C ± 3°C | ||
Y0001310 | Meclozine impurity B | 1 | 15 mg | 1 | (RS)-(4-chlorophenyl)phenylmethanol | 0622 | Yes | +5°C ± 3°C | |
Y0001311 | Meclozine impurity H | 1 | 15 mg | 1 | 1-[(RS)-(4-chlorophenyl)phenylmethyl]piperazine | 0622 | Yes | +5°C ± 3°C | |
Y0001770 | Medronate for radiochemical purity testing | 1 | 5 mg | 1 | 0641 | Yes | +5°C ± 3°C | ||
M0240000 | Medronic acid | 2 | 20 mg | 1 | 2350 | Yes | +5°C ± 3°C | ||
Y0001107 | Medronic acid impurity A | 2 | 60 µL | 1 | see leaflet C„HœŒO–P; Tris(1-methylethoxy)phosphane | 2350 | Yes | -20°C ± 5°C | |
Y0001106 | Medronic acid impurity B | 1 | 40 µl | 1 | Tetrakis(1-methylethyl)methylenediphosphonate | 2350 | Yes | -20°C ± 5°C | |
M0250000 | Medroxyprogesterone acetate | 3 | 100 mg | 1 | 0673 | Yes | +5°C ± 3°C | ||
Y0001484 | Medroxyprogesterone acetate for peak identification | 1 | 25 mg | 1 | 0673 | Yes | +5°C ± 3°C | ||
Y0000598 | Medroxyprogesterone acetate for system suitability | 2 | 10 mg | 1 | 0673 | Yes | -20°C ± 5°C | ||
M0252600 | Mefenamic acid | 2 | 50 mg | 1 | 1240 | Yes | +5°C ± 3°C | ||
Y0001081 | Mefenamic acid impurity A | 1 | 100 mg | 1 | 2,3-dimethylaniline | 1240 | Yes | +5°C ± 3°C | |
M0253000 | Mefloquine hydrochloride | 2 | 100 mg | 1 | 1241 | Yes | +5°C ± 3°C | ||
Y0001514 | Megestrol acetate | 1 | 120 mg | 1 | See leaflet Cœ÷H–œO÷ | 1593 | Yes | +5°C ± 3°C | |
Y0001594 | Megestrol acetate for impurity K identification | 1 | 0.01 mg | 1 | 1593 | Yes | +5°C ± 3°C | ||
Y0001507 | Megestrol acetate for peak identification | 1 | 25 mg | 1 | 1593 | Yes | +5°C ± 3°C | ||
New | Y0001524 | Megestrol acetate for system suitability | 2 | 50 mg | 1 | Batch 1 is valid until 31 October 2017 | 1593 | Yes | +5°C ± 3°C |
Y0001209 | Meglumine | 1 | 10 mg | 1 | 2055 | Yes | +5°C ± 3°C | ||
Y0001670 | Meldonium dihydrate | 1 | 10 mg | 1 | 2624 | Yes | +5°C ± 3°C | ||
Y0001671 | Meldonium impurity A | 1 | 25 mg | 1 | N,N-dimethylmethanaminium | 2624 | Yes | +5°C ± 3°C | |
Y0001672 | Meldonium impurity B | 1 | 25 mg | 1 | 1,1,1-trimethylhydrazin-1-ium | 2624 | Yes | +5°C ± 3°C | |
Y0001673 | Meldonium impurity C | 1 | 25 mg | 1 | see leaflet CŸHŒŸNœOœBr; 2-(3-methoxy-3-oxopropyl)-1,1,1- trimethylhydrazin-1-ium | 2624 | Yes | +5°C ± 3°C | |
Y0001674 | Meldonium impurity D | 1 | 25 mg | 1 | see leaflet C‡HŒ„NœOœBr; 2-(3-ethoxy-3-oxopropyl)-1,1,1-trimethylhydrazin-1- ium | 2624 | Yes | +5°C ± 3°C | |
Y0001675 | Meldonium impurity E | 1 | 25 mg | 1 | see leaflet C„HœŒBrNœOœ; 1,1,1-trimethyl-2-[3-(1-methylethoxy)-3-oxopropyl] hydrazin-1-ium | 2624 | Yes | +5°C ± 3°C | |
Y0001676 | Meldonium impurity F | 1 | 25 mg | 1 | see leaflet C—HŒÐNœO; 1,1-dimethyl-4,5-dihydro-1H-pyrazol-1-ium-3-olate | 2624 | Yes | +5°C ± 3°C | |
Y0001080 | Meloxicam | 1 | 50 mg | 1 | 2373 | Yes | +5°C ± 3°C | ||
Y0001035 | Meloxicam impurity A | 2 | 5 mg | 1 | ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide | 2373 | Yes | +5°C ± 3°C | |
Y0001036 | Meloxicam impurity B | 2 | 5 mg | 1 | 5-methylthiazol-2-amine | 2373 | Yes | +5°C ± 3°C | |
Y0001037 | Meloxicam impurity C | 3 | 10 mg | 1 | N-[(2Z)-3,5-dimethylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide | 2373 | Yes | +5°C ± 3°C | |
Y0001039 | Meloxicam impurity D | 3 | 5 mg | 1 | N-[(2Z)-3-ethyl-5-methylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide | 2373 | Yes | +5°C ± 3°C | |
Y0001158 | Melphalan hydrochloride | 2 | 100 mg | 1 | see leaflet ; Batch 1 is valid until 28 February 2017 | 1698 | Yes | +5°C ± 3°C | |
Y0001513 | Melphalan - reference spectrum | 1 | 1 uc | 1 | 1698 | ||||
Y0001457 | Melphalan for system suitability | 1 | 10 mg | 1 | 1698 | Yes | +5°C ± 3°C | ||
M0300000 | Menadione | 1 | 100 mg | 1 | 0507 | Yes | +5°C ± 3°C | ||
M0350000 | Menthol | 5 | 150 mg | 1 | 0619.0623 | Yes | +5°C ± 3°C | ||
M0370000 | Mepivacaine hydrochloride | 1 | 100 mg | 1 | 1242 | Yes | +5°C ± 3°C | ||
M0370020 | Mepivacaine impurity B | 1 | 60 mg | 1 | (RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide | 1242 | +5°C ± 3°C | ||
M0400000 | Meprobamate - * psy | 1 | 100 mg | 1 | 0407.1689 | Yes | +5°C ± 3°C | ||
M0500000 | Mepyramine maleate | 1 | 1000 mg | 1 | 0278 | Yes | +5°C ± 3°C | ||
Y0000679 | Mepyramine impurity A | 1 | 10 mg | 1 | N-(4-methoxybenzyl)pyridin-2-amine | 0278 | Yes | +5°C ± 3°C | |
Y0000680 | Mepyramine impurity C | 1 | 10 mg | 1 | pyridin-2-amine | 0278 | Yes | +5°C ± 3°C | |
Y0001252 | Meropenem trihydrate | 1 | 110 mg | 1 | See leaflet | 2234 | Yes | +5°C ± 3°C | |
Y0000297 | Mesalazine | 2 | 125 mg | 1 | 1699.1993 | Yes | +5°C ± 3°C | ||
Y0001563 | Mesalazine impurity A | 2 | 15 mg | 1 | 4-aminophenol ; Batch 1 is valid until 30 September 2017 | 1699 | Yes | +5°C ± 3°C | |
Y0001569 | Mesalazine impurity C | 1 | 15 mg | 1 | 2-aminophenol | 1699 | Yes | +5°C ± 3°C | |
Y0001574 | Mesalazine for system suitability | 4 | 10 mg | 1 | Batch 3 is valid until 31 October 2016 | 1699 | Yes | +5°C ± 3°C | |
Y0001040 | Mesityl oxide | 2 | 100 mg | 1 | see leaflet CÿHŒÐO ; Batch 1 is valid until 31 July 2017 | 2358 | Yes | +5°C ± 3°C | |
Y0000337 | Mesna - reference spectrum | 1 | n/a | 1 | 1674 | ||||
Y0000316 | Mesna impurity C | 1 | 10 mg | 1 | 2-(acetylsulfanyl)ethanesulfonic acid | 1674 | Yes | +5°C ± 3°C | |
Y0000317 | Mesna impurity D | 1 | 10 mg | 1 | 2,2'-(disulfanediyl)bis(ethanesulfonic acid) | 1674 | Yes | +5°C ± 3°C | |
Y0000227 | Meso-rich exametazime | 1 | 0.5 mg | 1 | 1925 | Yes | +5°C ± 3°C | ||
Y0000097 | Mesterolone | 2 | 120 mg | 1 | See leaflet CœÐH–œOœ | 1730 | Yes | +5°C ± 3°C | |
Y0000096 | Mesterolone impurity A | 1 | 30 mg | 1 | 17ß-hydroxy-1α-methylandrost-4-en-3-one | 1730 | Yes | +5°C ± 3°C | |
M0600000 | Mestranol | 1 | 100 mg | 1 | 0509 | Yes | +5°C ± 3°C | ||
Y0000301 | Metacresol - reference spectrum | 1 | n/a | 1 | 2077 | ||||
M0600900 | Metamizole sodium | 4 | 10 mg | 1 | 1346 | Yes | +5°C ± 3°C | ||
M0600905 | Metamizole impurity A | 4 | 15 mg | 1 | 4-(formylamino)-1,5-dimethyl-2-phenyl-2,3-dihydro-1H-pyrazol-3-one | 1346 | Yes | +5°C ± 3°C | |
Y0001481 | Metamizole impurity E | 3 | 0.01 mg | 1 | [(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino] methanesulfonic acid (4-N-desmethylmetamizole). | 1346 | Yes | +5°C ± 3°C | |
M0605000 | Metformin hydrochloride | 3 | 50 mg | 1 | 0931 | Yes | +5°C ± 3°C | ||
Y0001590 | Metformin impurity A | 1 | 25 mg | 1 | Cyanoguanidine | 0931 | Yes | +5°C ± 3°C | |
Y0001600 | Metformin impurity F | 2 | 2 mL | 1 | N-methylmethanamine (dimethylamine) | 0931 | Yes | +5°C ± 3°C | |
Y0001820 | Methacrylic acid - methylmethacrylate copolymer (1:1) | 1 | 120 mg | 1 | 1127 | Yes | +5°C ± 3°C | ||
Y0001821 | Methacrylic acid - methylmethacrylate copolymer (1:2) | 1 | 120 mg | 1 | 1130 | Yes | +5°C ± 3°C | ||
Y0000770 | Methacrylic acid-ethyl acrylate copolymer (1:1) - type A | 1 | 200 mg | 1 | 1128 | Yes | +5°C ± 3°C | ||
Y0000323 | Methacrylic acid-ethyl acrylate copolymer (1:1) - type B | 1 | 200 mg | 1 | 1128 | Yes | +5°C ± 3°C | ||
M0610030 | Methacrylic acid-ethylacrylate copolymer (1:1), dispersion 30%-ref.sp | 1 | n/a | 1 | 1129 | ||||
M0800000 | Methadone hydrochloride - reference spectrum | 1 | n/a | 1 | 0408.1787 | ||||
Y0000428 | Methanol - reference spectrum | 1 | n/a | 1 | 1989 | ||||
Y0000754 | Methenamine | 1 | 10 mg | 1 | 1545 | Yes | +5°C ± 3°C | ||
M0960000 | Methionine | 2 | 50 mg | 1 | 0788.1027 | Yes | +5°C ± 3°C | ||
M0950000 | DL-Methionine | 1 | 50 mg | 1 | 0624 | Yes | +5°C ± 3°C | ||
M1000000 | Methotrexate | 7 | 100 mg | 1 | See leaflet CœÐHœœN‡O— | 0560 | Yes | +5°C ± 3°C | |
New | Y0000663 | Methotrexate impurity C | 3 | 10 mg | 1 | (2S)-2-[[4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]methylamino] benzoyl]amino]pentanedioic acid (N-methylfolic acid, methopteridine) ; Batch 2 is valid until 31 October 2017 | 0560 | Yes | +5°C ± 3°C |
M1000008 | Methotrexate impurity D | 4 | 10 mg | 1 | 4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]methylamino]benzoic acid (N10-methylpteroic acid) ; Batch 3 is valid until 31 October 2016 | 0560 | Yes | +5°C ± 3°C | |
Y0000664 | Methotrexate impurity E | 1 | 10 mg | 1 | 4-[[(2,4-diaminopteridin-6-yl)methyl]methylamino]benzoic acid (4-amino- N10-methylpteroic acid, APA) | 0560 | Yes | +5°C ± 3°C | |
Y0000602 | Methotrexate for peak identification | 1 | 20 mg | 1 | 0560 | Yes | +5°C ± 3°C | ||
Y0001668 | Methotrexate for system suitability | 1 | 100 mg | 1 | 0560 | Yes | +5°C ± 3°C | ||
M1470000 | Methyl 2-(4-chlorophenoxy)-2-methylpropionate | 1 | 0.5 ml | 1 | 0318 | Yes | +5°C ± 3°C | ||
M1556000 | Methyl 12-hydroxystearate | 2 | 100 mg | 1 | 1497 | Yes | +5°C ± 3°C | ||
Y0001488 | Methyl methacrylate | 1 | 50 mg | 1 | 1975 | Yes | +5°C ± 3°C | ||
Y0000398 | Methyl nicotinate | 1 | 25 mg | 1 | 2129 | Yes | +5°C ± 3°C | ||
M1650000 | Methyl parahydroxybenzoate | 4 | 150 mg | 1 | See leaflet | 0409,1262,2 134,1999 | Yes | +5°C ± 3°C | |
M1770180 | Methyl ricinoleate | 3 | 125 mg | 1 | Batch 2 is valid until 30 September 2016 | 0051.2367 | Yes | +5°C ± 3°C | |
M1770200 | Methyl stearate | 3 | 100 mg | 1 | 0051,1497, 2367 | Yes | +5°C ± 3°C | ||
M1300000 | Methylatropine bromide | 1 | 100 mg | 1 | 0919 | Yes | +5°C ± 3°C | ||
M1500000 | Methyldopa | 2 | 50 mg | 1 | 0045 | Yes | +5°C ± 3°C | ||
Y0001083 | Methyldopa for system suitability | 2 | 0.024 mg | 1 | Batch 1 is valid until 31 May 2017 | 0045 | Yes | +5°C ± 3°C | |
Y0001374 | Racemic methyldopa | 1 | 5 mg | 1 | 0045 | Yes | +5°C ± 3°C | ||
M1550000 | Methylene chloride | 3 | 5 mL | 1 | 0932 | Yes | +5°C ± 3°C | ||
Y0000776 | Methylergometrine maleate | 1 | 10 mg | 1 | 1788 | Yes | +5°C ± 3°C | ||
Y0000777 | Methylergometrine for system suitability | 1 | 0.53 mg | 1 | 1788 | Yes | +5°C ± 3°C | ||
M1625000 | Methylnitrosoindoline | 3 | 110 mg | 1 | 1108 | Yes | +5°C ± 3°C | ||
Y0001017 | Methylphenidate hydrochloride - * narc | 1 | 40 mg | 1 | 2235 | Yes | +5°C ± 3°C | ||
Y0001490 | Methylphenidate impurity C | 1 | 10 mg | 1 | (2RS)-2-phenyl-2-[(2RS)-piperidin-2-yl]acetamide | 2235 | Yes | +5°C ± 3°C | |
Y0000910 | Methylphenidate impurity mixture | 1 | 0.04 mg | 1 | 2235 | Yes | +5°C ± 3°C | ||
M1700000 | Methylphenobarbital - * psy | 1 | 500 mg | 1 | 0189 | Yes | +5°C ± 3°C | ||
M1750000 | Methylprednisolone | 3 | 120 mg | 1 | See leaflet | 0312.0561 | Yes | -20°C ± 5°C | |
Y0001799 | Methylprednisolone for system suitability A | 1 | 10 mg | 1 | 0561 | Yes | -20°C ± 5°C | ||
M1755000 | Methylprednisolone acetate | 2 | 110 mg | 1 | See leaflet Cœ÷H–œOÿ | 0933 | Yes | +5°C ± 3°C | |
Y0001736 | Methylprednisolone acetate for peak identification | 1 | 0.01 mg | 1 | 0933 | Yes | +5°C ± 3°C | ||
Y0001760 | Methylprednisolone acetate for system suitability | 1 | 10 mg | 1 | 0933 | Yes | +5°C ± 3°C | ||
M1755200 | Methylprednisolone hydrogen succinate | 3 | 60 mg | 1 | See leaflet CœÿH–÷O‡ | 0768.1131 | Yes | +5°C ± 3°C | |
Y0001759 | Methylprednisolone hydrogen succinate for peak identification | 1 | 10 mg | 1 | 1131 | Yes | +5°C ± 3°C | ||
M1755220 | Methylprednisolone hydrogen succinate for performance test | 2 | 20 mg | 1 | Batch 1 is valid until 31 August 2017 | 1131 | Yes | +5°C ± 3°C | |
Y0001376 | 2-methylpyrazine | 1 | 100 mg | 1 | 2446,2447,2 708 | Yes | +5°C ± 3°C | ||
Y0000190 | N-Methylpyrrolidone - reference spectrum | 1 | n/a | 1 | 1675 | ||||
Y0000418 | Methylrosanilinium chloride | 1 | 40 mg | 1 | 1990 | Yes | +5°C ± 3°C | ||
Y0000407 | Methylrosanilinium for system suitability | 1 | 10 mg | 1 | 1990 | Yes | +5°C ± 3°C | ||
M1800000 | Methyltestosterone | 2 | 10 mg | 1 | Batch 1 is valid until 28 February 2017 | 0410 | Yes | +5°C ± 3°C | |
Y0000861 | Methyltestosterone for system suitability | 1 | 10 mg | 1 | 0410 | Yes | +5°C ± 3°C | ||
M1800900 | Methylthioninium chloride | 2 | 130 mg | 1 | See leaflet CŒÿHŒ‡ClN–S,xHœO | 1132 | Yes | +5°C ± 3°C | |
Y0001744 | Methylthioninium for system suitability | 1 | 15 mg | 1 | 1132 | Yes | +5°C ± 3°C | ||
M1808000 | Metixene hydrochloride | 1 | 75 mg | 1 | 1347 | Yes | +5°C ± 3°C | ||
M1824990 | Metoclopramide | 1 | 100 mg | 1 | 1348 | Yes | +5°C ± 3°C | ||
M1825000 | Metoclopramide hydrochloride | 2 | 50 mg | 1 | 0674,0856,1 303 | Yes | +5°C ± 3°C | ||
M1824995 | Metoclopramide impurity A | 2 | 25 mg | 1 | 4-(acetylamino)-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide | 1348 | Yes | +5°C ± 3°C | |
New | M1825010 | Metoclopramide impurity E | 2 | 40 mg | 1 | N,N-diethylethane-1,2-diamine ; Batch 1 is valid until 31 October 2017 | 1575 | Yes | +5°C ± 3°C |
Y0000701 | Metolazone | 1 | 80 mg | 1 | See leaflet CŒÿHŒÿClN–O–S | 1757 | Yes | +5°C ± 3°C | |
Y0000702 | Metolazone for system suitability | 1 | 10 mg | 1 | 1757 | Yes | +5°C ± 3°C | ||
Y0000171 | Metoprolol succinate - reference spectrum | 1 | n/a | 1 | 1448 | ||||
M1830000 | Metoprolol tartrate | 2 | 60 mg | 1 | 1028 | Yes | +5°C ± 3°C | ||
Y0000145 | Metoprolol impurity A | 4 | 5 mg | 1 | (2RS)-1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol ; Batch 3 is valid until 31 July 2016 | 1028.1448 | Yes | +5°C ± 3°C | |
M1845000 | Metrifonate | 1 | 100 mg | 1 | 1133 | Yes | +5°C ± 3°C | ||
M1850000 | Metronidazole | 2 | 50 mg | 1 | 0675.0934 | Yes | +5°C ± 3°C | ||
Y0000087 | Metronidazole impurity A | 3 | 10 mg | 1 | 2-methyl-4-nitroimidazole | 0675, 0934 | Yes | +5°C ± 3°C | |
M1851000 | Metronidazole benzoate | 1 | 50 mg | 1 | 1424 | Yes | +5°C ± 3°C | ||
Y0000069 | Metronidazole benzoate - reference spectrum | 1 | n/a | 1 | 0934 | ||||
M1860000 | Mexiletine hydrochloride | 1 | 100 mg | 1 | 1029 | Yes | +5°C ± 3°C | ||
Y0000202 | Mexiletine impurity C | 3 | 10 mg | 1 | see leaflet CœœH–œNœOœ; 1,1'-[(3,3',5,5'-tetramethylbiphenyl-4,4'-diyl)bisoxy] dipropan-2-amine ; Batch 2 is valid until 31 July 2017 | 1029 | Yes | +5°C ± 3°C | |
Y0000203 | Mexiletine impurity D | 1 | 2 mg | 1 | (2RS)-2-(2,6-dimethylphenoxy)propan-1-amine | 1029 | Yes | +5°C ± 3°C | |
M1875000 | Mianserin hydrochloride | 3 | 100 mg | 1 | 0846 | Yes | +5°C ± 3°C | ||
Y0001041 | Mianserin impurity B | 1 | 10 mg | 1 | (14bRS)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazi,2-a] azepine-8-sulfonic acid | 0846 | Yes | +5°C ± 3°C | |
Y0000862 | Mianserin for system suitability | 1 | 1.01 mg | 1 | 0846 | Yes | +5°C ± 3°C | ||
M1880000 | Miconazole | 1 | 70 mg | 1 | 0935 | Yes | +5°C ± 3°C | ||
M1900000 | Miconazole nitrate | 2 | 100 mg | 1 | 0513.1148 | Yes | +5°C ± 3°C | ||
M2200000 | Midazolam - * psy | 3 | 50 mg | 1 | Batch 2 is valid until 28 February 2017 | 0936.1065 | Yes | +5°C ± 3°C | |
Y0000562 | Midazolam impurity C | 3 | 0.08 mg | 1 | 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4] benzodiazepine-3-carboxylic acid | 0936 | Yes | +5°C ± 3°C | |
Y0000599 | Midazolam for system suitability - * psy | 3 | 1 mg | 1 | 0936 | Yes | +5°C ± 3°C | ||
Y0001882 | Milbemycin oxime for system suitability | 1 | 10 mg | 1 | 2536 | Yes | +5°C ± 3°C | ||
New | Y0001893 | Milbemycin oxime | 1 | 100 mg | 1 | 2536 | Yes | +5°C ± 3°C | |
Y0001687 | Milk thistle dry extract HRS | 2 | 120 mg | 1 | See leaflet | 1860.2071 | Yes | -20°C ± 5°C | |
Y0001878 | Minocycline for system suitability | 1 | 10 mg | 1 | 1030 | Yes | +5°C ± 3°C | ||
M2280000 | Minocycline hydrochloride | 3 | 125 mg | 1 | See leaflet Cœ–Hœ‡ClN–OŸ; The reference standard M2280000 will be deleted from the monograph 07/2017 :1030 on 2017/06/30 and will be replaced by Minocycline hydrochloride Y0001930. | 1030 | Yes | +5°C ± 3°C | |
M2300000 | Minoxidil | 1 | 50 mg | 1 | 0937 | Yes | +5°C ± 3°C | ||
Y0001432 | Minoxidil for system suitability | 1 | 10 mg | 1 | 0937 | Yes | +5°C ± 3°C | ||
Y0000705 | Mirtazapine | 1 | 10 mg | 1 | 2338 | Yes | +5°C ± 3°C | ||
Y0000721 | Mirtazapine for system suitability | 1 | 10 mg | 1 | 2338 | Yes | +5°C ± 3°C | ||
Y0000490 | Misoprostol | 3 | 60 mg | 1 | See leaflet CœœH–‡O— | 1731 | Yes | -20°C ± 5°C | |
Y0001162 | Misoprostol for system suitability | 1 | 5 mg | 1 | 1731 | Yes | -20°C ± 5°C | ||
Y0000378 | Mitomycin | 2 | 120 mg | 1 | See leaflet CŒ—HŒ‡N÷O— | 1655 | Yes | +5°C ± 3°C | |
M2305000 | Mitoxantrone hydrochloride | 4 | 60 mg | 1 | See leaflet | 1243 | Yes | +5°C ± 3°C | |
M2305005 | Mitoxantrone impurity A | 4 | 5 mg | 1 | 1-amino-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl] amino] anthracene-9,10-dione ; Batch 3 is valid until 30 June 2017 | 1243 | Yes | +5°C ± 3°C | |
Y0000635 | Modafinil | 1 | 110 mg | 1 | See leaflet CŒ—HŒ—NOœS | 2307 | Yes | +5°C ± 3°C | |
Y0000636 | Modafinil for system suitability | 1 | 0.1 mg | 1 | 2307 | Yes | +5°C ± 3°C | ||
Y0000251 | Molgramostim | 1 | 0.3 ml | 1 | 13.45 mg protein per ml Cÿ–„HŒÐПNŒŸŒOŒ„ÿS‡ | 1641 | Yes | -80°C ± 10°C | |
Y0000821 | Molsidomine | 1 | 5 mg | 1 | 1701 | Yes | +5°C ± 3°C | ||
Y0000822 | Molsidomine impurity B | 1 | 10 mg | 1 | 4-nitrosomorpholine | 1701 | Yes | +5°C ± 3°C | |
Y0000823 | Molsidomine impurity D | 1 | 10 mg | 1 | morpholine-4-carbaldehyde | 1701 | Yes | +5°C ± 3°C | |
M2900000 | Mometasone furoate | 3 | 60 mg | 1 | Batch 2 is valid until 31 July 2016 | 1449 | Yes | +5°C ± 3°C | |
Y0001436 | Monukast dicyclohexylamine | 2 | 150 mg | 1 | See leaflet | 2583 | Yes | +5°C ± 3°C | |
Y0001433 | Monukast racemate | 3 | 0.1 mg | 1 | Batch 2 is valid until 31 July 2016 | 2583 | Yes | +5°C ± 3°C | |
Y0001434 | Monukast sodium | 2 | 20 mg | 1 | 2583 | Yes | +5°C ± 3°C | ||
Y0001435 | Monukast for peak identification | 3 | 20 mg | 1 | 2583 | Yes | +5°C ± 3°C | ||
Y0000028 | Moran hydrogen tartrate | 2 | 50 mg | 1 | 1546 | Yes | +5°C ± 3°C | ||
Y0000451 | Morphine hydrochloride trihydrate - * narc | 3 | 25 mg | 1 | See leaflet ; Batch 2 is valid until 30 November 2016 | 1839, 1840, 0777, 1841, 0097 | Yes | +5°C ± 3°C | |
Y0000452 | Morphine sulfate - * narc | 1 | 40 mg | 1 | 1244.1784 | Yes | +5°C ± 3°C | ||
Y0000830 | Morphine for system suitability - * narc | 3 | 15 mg | 1 | 1244, 0097 | Yes | +5°C ± 3°C | ||
Y0000772 | Moxidectin | 3 | 70 mg | 1 | See leaflet | 1656 | Yes | -20°C ± 5°C | |
Y0000747 | Moxidectin for system suitability | 2 | 10 mg | 1 | 1656 | Yes | +5°C ± 3°C | ||
Y0000703 | Moxifloxacin hydrochloride | 3 | 120 mg | 1 | See leaflet CœŒHœ—ClFN–O÷ ; Batch 2 is valid until 30 June 2016 | 2254 | Yes | +5°C ± 3°C | |
Y0000717 | Moxifloxacin for peak identification | 2 | 10 mg | 1 | 2254 | Yes | +5°C ± 3°C | ||
Y0000226 | Moxonidine | 2 | 50 mg | 1 | See leaflet C„HŒœClN—O ; Batch 1 is valid until 30 June 2017 | 1758 | Yes | +5°C ± 3°C | |
Y0000222 | Moxonidine impurity A | 1 | 10 mg | 1 | 4,6-dichloro-N-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-amine (6- chloromoxonidine) | 1758 | Yes | +5°C ± 3°C | |
M3600000 | Mumps vaccine (live) BRP | 1 | 165 mg | 1 | See leaflet | 0538,1057, 2442 | Yes | -80°C ± 10°C | |
M3805000 | Mupirocin - reference spectrum | 1 | n/a | 1 | 1450 | ||||
M3805500 | Mupirocin calcium - reference spectrum | 1 | n/a | 1 | 1451 | ||||
M3806000 | Mupirocin lithium | 2 | 100 mg | 1 | See leaflet CœÿH÷–O„Li | 1450.1451 | Yes | +5°C ± 3°C | |
Y0000489 | Mycophenolate mofetil | 3 | 30 mg | 1 | 1700 | Yes | +5°C ± 3°C | ||
Y0000519 | Mycophenolate mofetil for peak identification | 6 | 10 mg | 1 | Batch 5 is valid until 31 July 2016 | 1700 | Yes | +5°C ± 3°C | |
Y0001810 | Mycophenolate sodium | 1 | 200 mg | 1 | See leaflet CŒŸHœÐOÿNa | 2813 | Yes | +5°C ± 3°C | |
Y0000692 | Mycoplasma fermentans BRP | 1 | 1 ml | 1 | 20607 | Yes | -80°C ± 10°C | ||
Y0000690 | Mycoplasma hyorhinis BRP | 1 | 1 ml | 1 | 20607 | Yes | -80°C ± 10°C | ||
Y0000691 | Mycoplasma orale BRP | 1 | 1 ml | 1 | 20607 | Yes | -80°C ± 10°C | ||
Y0000689 | Mycoplasma synoviae BRP | 1 | 1 ml | 1 | 20607 | Yes | -80°C ± 10°C | ||
Y0000485 | Myo-inositol | 1 | 1020 mg | 1 | See leaflet | 1805 | Yes | +5°C ± 3°C | |
N0020000 | Nabumetone | 1 | 60 mg | 1 | See leaflet CŒ—HŒÿOœ | 1350 | Yes | +5°C ± 3°C | |
New | N0020020 | Nabumetone impurity D | 3 | 10 mg | 1 | (E)-4-(6-methoxynaphthalen-2-yl)but-3-en-2-one ; Batch 2 is valid until 31 October 2017 | 1350 | Yes | +5°C ± 3°C |
N0020030 | Nabumetone impurity F | 5 | 10 mg | 1 | See leaflet; 6,6'-dimethoxy-2,2'-binaphthalenyl | 1350 | Yes | +5°C ± 3°C | |
Y0000146 | Nadolol | 1 | 100 mg | 1 | 1789 | Yes | +5°C ± 3°C | ||
Y0001215 | Nadolol impurity mixture | 1 | 0.01 mg | 1 | 1789 | Yes | +5°C ± 3°C | ||
N0025000 | Nadroparin calcium | 3 | 450 mg | 1 | Batch 2 is valid until 31 July 2017 | 0828.1134 | Yes | +5°C ± 3°C | |
Y0000077 | Naftidrofuryl - reference spectrum | 1 | n/a | 1 | 1594 | ||||
New | Y0000120 | Naftidrofuryl impurity A | 2 | 10 mg | 1 | 2-[(naphtalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoic acid | 1594 | Yes | +5°C ± 3°C |
Y0000121 | Naftidrofuryl impurity B | 2 | 25 mg | 1 | ethyl 2-[(naphtalen-1-yl)methyl]- 3-(tetrahydrofuran-2-yl)propanoate | 1594 | Yes | +5°C ± 3°C | |
Y0000331 | Naftidrofuryl impurity F | 1 | 10 mg | 1 | 2-(diethylamino)ethyl 2-[(naphthalen-2-yl)methyl]-3- (tetrahydrofuran-2-yl) propanoate | 1594 | Yes | +5°C ± 3°C | |
N0050000 | Nalidixic acid | 1 | 100 mg | 1 | 0701 | Yes | +5°C ± 3°C | ||
Y0001792 | Nalidixic acid impurity C | 1 | 20 mg | 1 | diethyl (ethoxymethylidene)propanedioate | 0701 | Yes | +5°C ± 3°C | |
N0075000 | Naloxone hydrochloride dihydrate | 3 | 100 mg | 1 | Batch 2 is valid until 28 February 2017 | 0729.2099 | Yes | +5°C ± 3°C | |
Y0001571 | Naloxone impurity D | 2 | 25 mg | 1 | 7,8-didehydro-4,5α-epoxy-3,14-dihydroxy-17-(prop-2-enyl)morphinan-6-one (7,8-didehydronaloxone) | 0729 | Yes | +5°C ± 3°C | |
Y0000695 | Naloxone for peak identification | 3 | 5.1 mg | 1 | Batch 2 is valid until 31 May 2017 | 0729 | Yes | +5°C ± 3°C | |
Y0000400 | Naltrexone hydrochloride | 2 | 50 mg | 1 | 1790 | Yes | +5°C ± 3°C | ||
Y0000410 | Naltrexone impurity C | 1 | 15 mg | 1 | 17-but-3-enyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one | 1790 | Yes | +5°C ± 3°C | |
Y0000542 | Nandrolone decanoate | 1 | 5 mg | 1 | 1992 | Yes | -20°C ± 5°C | ||
Y0000547 | Nandrolone decanoate for peak identification | 1 | 10 mg | 1 | 1992 | Yes | -20°C ± 5°C | ||
Y0000548 | Nandrolone decanoate for system suitability | 1 | 10 mg | 1 | 1992 | Yes | -20°C ± 5°C | ||
N0080000 | Naphazoline hydrochloride | 3 | 50 mg | 1 | 0730.1162 | Yes | +5°C ± 3°C | ||
N0100000 | Naphazoline nitrate | 2 | 10 mg | 1 | 0147 | Yes | +5°C ± 3°C | ||
N0200000 | Naphazoline impurity A | 5 | 15 mg | 1 | N-(2-aminoethyl)-2-(naphthalen-1-yl)acetamide (naphthylacetylethylenediamine) | 0147.0730 | Yes | +5°C ± 3°C | |
N0250000 | Naproxen | 3 | 50 mg | 1 | 0731.1702 | Yes | +5°C ± 3°C | ||
Y0000399 | Naproxen (racemic) | 1 | 10 mg | 1 | 0731.1702 | Yes | +5°C ± 3°C | ||
Y0000631 | Naproxen impurity L | 1 | 10 mg | 1 | 1-(6-methoxynaphthalen-2-yl)ethanone | 0731.1702 | Yes | +5°C ± 3°C | |
Y0001378 | Naringin | 1 | 20 mg | 1 | See leaflet CœŸH–œOŒ÷ | 2563 | Yes | +5°C ± 3°C | |
Y0001437 | Nateglinide | 1 | 200 mg | 1 | See leaflet CŒ„HœŸNO– | 2575 | Yes | +5°C ± 3°C | |
Y0001440 | Nateglinide impurity A | 1 | 10 mg | 1 | trans-4-(1-methylethyl)cyclohexanecarboxylic acid | 2575 | Yes | +5°C ± 3°C | |
Y0001441 | Nateglinide impurity B | 1 | 15 mg | 1 | N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-Lphenylalanine (L- phenylalanine isomer) | 2575 | Yes | +5°C ± 3°C | |
Y0001442 | Nateglinide impurity C | 1 | 10 mg | 1 | N-[[cis-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine (cis-isomer) | 2575 | Yes | +5°C ± 3°C | |
N0300000 | Neamine | 5 | 0.5 mg | 1 | see leaflet | 0180.0197 | Yes | +5°C ± 3°C | |
N0399000 | Neohesperidin-dihydrochalcone | 2 | 125 mg | 1 | See leaflet Cœ‡H–ÿOŒ— | 1547 | Yes | -20°C ± 5°C | |
N0399004 | Neohesperidin-dihydrochalcone impurity B | 2 | 10 mg | 1 | See leaflet Cœ‡H–œOŒ— ; 7-[[2-O-(6-deoxy-¶-L-mannopyranosyl) -ß-D- glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1- benzopyran-4-one (neodiosmin) | 1547 | Yes | +5°C ± 3°C | |
N0400000 | Neomycin sulfate | 3 | 50 mg | 1 | Not to be used for microbiological assay | 0032,0033,0 053, 0180,0197,0 485, 0645 | Yes | -20°C ± 5°C | |
N0401000 | Neomycin sulfate for microbiological assay | 5 | 25 mg | 1 | See leaflet ; Batch 4 is valid until 31 May 2017 | 20702 | Yes | -20°C ± 5°C | |
N0500000 | Neostigmine bromide | 1 | 50 mg | 1 | 0046 | Yes | +5°C ± 3°C | ||
N0550000 | Neostigmine metilsulfate | 1 | 50 mg | 1 | 0626 | Yes | +5°C ± 3°C | ||
Y0001639 | Neostigmine impurity A | 1 | 0.0025 mg | 1 | 3-hydroxy-N,N,N-trimethylanilinium | 0046.0626 | Yes | +5°C ± 3°C | |
New | Y0001890 | Netilmicin for peak identification | 1 | 15 mg | 1 | 1351, 20702 | Yes | -20°C ± 5°C | |
N0559000 | Netilmicin sulfate | 1 | 25 mg | 2 | See leaflet; The reference standard N0559000 will be deleted from the monograph 07/2017:1351 on 06/30/2017. ; Batch 1 is valid until 30 June 2017 | 1351.20702 | Yes | -20°C ± 5°C | |
New | Y0001894 | Netilmicin sulfate for LC assay | 1 | 25 mg | 1 | See leaflet | 1351, 20702 | Yes | -20°C ± 5°C |
Y0000520 | Nevirapine (Anhydrous) | 1 | 30 mg | 1 | See leaflet CŒ—HŒ÷N÷O | 2255, 2479 | Yes | +5°C ± 3°C | |
Y0001499 | Nevirapine hemihydrate | 1 | 15 mg | 1 | 2479 | Yes | +5°C ± 3°C | ||
Y0000521 | Nevirapine for peak identification | 1 | 0.058 mg | 1 | 2255, 2479 | Yes | +5°C ± 3°C | ||
Y0000388 | Newcastle Disease Vaccine (inactivated) BRP | 1 | 40 mg | 1 | The kit contains :1 vial BRP1 NDV reference antigen, 1 vial BRP1 NDV control antigen, 1 vial BRP1 NDV coating antibody, 1 vial BRP1 NDV conjugated, detection antibody | 0870 | Yes | -20°C ± 5°C | |
New | Y0001917 | Nicardipine for system suitability | 1 | 10 mg | 1 | 2776 | Yes | +5°C ± 3°C | |
Y0001373 | Nicergoline | 1 | 50 mg | 1 | 1998 | Yes | +5°C ± 3°C | ||
Y0001356 | Nicergoline impurity D | 1 | 20 mg | 1 | 5-bromopyridine-3-carboxylic acid | 1998 | Yes | +5°C ± 3°C | |
Y0001362 | Nicergoline for peak identification | 1 | 1 mg | 1 | 1998 | Yes | +5°C ± 3°C | ||
Y0001352 | Nicergoline for system suitability | 1 | 10 mg | 1 | 1998 | Yes | +5°C ± 3°C | ||
N0560000 | Niclosamide (anhydrous) | 3 | 50 mg | 1 | 0679.0680 | Yes | +5°C ± 3°C | ||
Y0001761 | Nicorandil | 1 | 5 mg | 1 | 2332 | Yes | -20°C ± 5°C | ||
Y0001762 | Nicorandil impurity A | 1 | 5 mg | 1 | 2-[(pyridin-4-ylcarbonyl)amino]ethyl nitrate | 2332 | Yes | -20°C ± 5°C | |
N0600000 | Nicotinamide | 1 | 50 mg | 1 | 0047 | Yes | +5°C ± 3°C | ||
N0590000 | Nicotine - reference spectrum | 1 | n/a | 1 | 1452.1792 | ||||
N0590200 | Nicotine ditartrate | 5 | 120 mg | 1 | See leaflet CŒÐHŒ÷Nœ x 2 C÷HÿOÿ ; Batch 4 is valid until 30 November 2016 | 1792 | Yes | +5°C ± 3°C | |
Y0001425 | Nicotine ditartrate dihydrate | 1 | 15 mg | 1 | 2599 | Yes | +5°C ± 3°C | ||
Y0001023 | Nicotine for system suitability | 4 | 1 mg | 1 | Batch 3 is valid until 31 October 2016 | 1452, 1792, 2599 | Yes | -20°C ± 5°C | |
N0700000 | Nicotinic acid | 1 | 100 mg | 1 | 0459 | Yes | +5°C ± 3°C | ||
Y0001268 | Nicotinic acid impurity mixture | 1 | 0.12 mg | 1 | 0459 | Yes | +5°C ± 3°C | ||
N0750000 | Nifedipine | 1 | 50 mg | 1 | 0627.1013 | Yes | +5°C ± 3°C | ||
N0750010 | Nifedipine impurity A | 1 | 25 mg | 1 | Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate (nitrophenylpyridine analogue) | 0627 | Yes | +5°C ± 3°C | |
N0750015 | Nifedipine impurity B | 1 | 25 mg | 1 | Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate (nitrosophenylpyridine analogue) | 0627 | Yes | +5°C ± 3°C | |
Y0000824 | Niflumic acid | 1 | 10 mg | 1 | 2115 | Yes | +5°C ± 3°C | ||
Y0000825 | Niflumic acid impurity A | 1 | 10 mg | 1 | 2-chloropyridine-3-carboxylic acid | 2115 | Yes | +5°C ± 3°C | |
Y0000826 | Niflumic acid impurity B | 1 | 10 mg | 1 | 2-hydroxy-N-(3-(trifluoromethyl)phenyl)pyridine-3-carboxamide | 2115 | Yes | +5°C ± 3°C | |
Y0000827 | Niflumic acid impurity E | 1 | 15 mg | 1 | 6-((3-(trifluoromethyl)phenyl)amino)pyridine-3-carboxylic acid | 2115 | Yes | +5°C ± 3°C | |
Y0000836 | Nifuroxazide | 1 | 10 mg | 1 | 1999 | Yes | +5°C ± 3°C | ||
N0800000 | Nikethamide | 1 | 1 ml | 1 | 0233 | Yes | +5°C ± 3°C | ||
Y0000829 | Nilutamide | 1 | 110 mg | 1 | See leaflet CŒœHŒÐF–N–O÷ | 2256 | Yes | +5°C ± 3°C | |
Y0000894 | Nilutamide impurity B | 1 | 5 mg | 1 | 4-nitro-3-(trifluoromethyl)aniline (nifeline) | 2256 | Yes | +5°C ± 3°C | |
N0845000 | Nimesulide | 2 | 100 mg | 1 | 1548 | Yes | +5°C ± 3°C | ||
N0845008 | Nimesulide impurity D | 5 | 0.004 mg | 1 | 4-nitro-2-phenoxyaniline ; Batch 4 is valid until 31 October 2016 | 1548 | Yes | +5°C ± 3°C | |
Y0001237 | Nimesulide for peak identification | 1 | 10 mg | 1 | 1548 | Yes | +5°C ± 3°C | ||
N0850000 | Nimodipine | 2 | 50 mg | 1 | 1245 | Yes | +5°C ± 3°C | ||
Y0001784 | Nimodipine for peak identification | 1 | 15 mg | 1 | 1245 | Yes | +5°C ± 3°C | ||
N0850010 | Nimodipine impurity A | 4 | 1 mL | 1 | 2-methoxyethyl 1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5- dicarboxylate | 1245 | Yes | +5°C ± 3°C | |
N0900000 | Nitrazepam - * psy | 2 | 100 mg | 1 | 0415.0898 | Yes | +5°C ± 3°C | ||
N0905000 | Nitrendipine | 2 | 60 mg | 1 | 1246 | Yes | +5°C ± 3°C | ||
N0905005 | Nitrendipine impurity A | 3 | 30 mg | 1 | ethyl methyl-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5- dicarboxylate | 1246 | Yes | +5°C ± 3°C | |
Y0001456 | Nitrendipine for peak identification | 1 | 10 mg | 1 | 1246 | Yes | +5°C ± 3°C | ||
N0930000 | Nitric oxide - reference spectrum | 1 | n/a | 1 | 1550 | ||||
N0950000 | Nitrofural | 2 | 150 mg | 1 | See leaflet CÿHÿN÷O÷ | 1135 | Yes | +5°C ± 3°C | |
Y0001570 | Nitrofural impurity B | 1 | 30 mg | 1 | See leaflet C„H„OŸN; (5-nitrofuran-2-yl)methylene diacetate | 1135 | Yes | +5°C ± 3°C | |
Y0001377 | Nitrofural for peak identification | 1 | 0.11 mg | 1 | 1135 | Yes | +5°C ± 3°C | ||
N1000000 | Nitrosotriaminopyrimidine | 1 | 50 mg | 1 | 0058 | Yes | +5°C ± 3°C | ||
N1090000 | Nizatidine | 1 | 250 mg | 1 | See leaflet CŒœHœŒN—OœSœ | 1453 | Yes | +5°C ± 3°C | |
N1090060 | Nizatidine impurity F | 1 | 10 mg | 1 | (EZ)-N-methyl-N'-[2-[[[4-[[[2-[[(EZ)-1-(methylamino)-2-nitroethenyl]amino] ethyl]sulfanyl]methyl]thiazol-2-yl]methyl]sulfanyl]ethyl]-2-nitroethene-1,1- diamine | 1453 | Yes | +5°C ± 3°C | |
Y0001278 | Nizatidine for system suitability | 1 | 10 mg | 1 | 1453 | Yes | +5°C ± 3°C | ||
N1080000 | Nomegestrol acetate | 2 | 100 mg | 1 | 1551 | Yes | +5°C ± 3°C | ||
N1080005 | Nomegestrol acetate impurity A | 2 | 50 mg | 1 | 6α-methyl-3,20-dioxo-19-norpregn-4-en-17-yl acetate | 1551 | Yes | +5°C ± 3°C | |
Y0001314 | 1-nonadecanol | 2 | 425 mg | 1 | 0801,0802,0 847 | Yes | +5°C ± 3°C | ||
Y0000670 | Nonivamide | 1 | 10 mg | 2 | See leaflet CŒŸHœŸNO– | 1859,2336,2 337, 2529 | Yes | +5°C ± 3°C | |
Y0000755 | Nonoxinol 9 | 1 | 10 mg | 1 | 1454 | Yes | +5°C ± 3°C | ||
New | N1100000 | Noradrenaline tartrate | 7 | 200 mg | 1 | Batch 6 is valid until 31 October 2017 | 0254,0285,0 732, 2303 | Yes | +5°C ± 3°C |
Y0000681 | Noradrenaline impurity D | 2 | 15 mg | 1 | 4[(1R)-2-ami-methoxyethyl]benzene-1,2-diol (noradrenaline methyl ether) ; Batch 1 is valid until 31 August 2016 | 0285.0732 | Yes | +5°C ± 3°C | |
Y0000682 | Noradrenaline impurity E | 1 | 10 mg | 1 | 2-chloro-1-(3,4-dihydroxyphenyl)ethanone | 0285.0732 | Yes | +5°C ± 3°C | |
Y0000686 | Noradrenaline impurity F | 1 | 10 mg | 1 | N-benzyl-1-phenylmethanamine | 0285.0732 | Yes | +5°C ± 3°C | |
N1130000 | Norcyclobenzaprine | 1 | 25 mg | 1 | 0941 | Yes | +5°C ± 3°C | ||
N1140000 | Nordazepam -* psy | 1 | 50 mg | 1 | Dipotassium clorazepate impurity B | 0898 | Yes | +5°C ± 3°C | |
N1200000 | Norethisterone | 3 | 25 mg | 1 | 0234,1212,0 926 | Yes | +5°C ± 3°C | ||
Y0000522 | Norethisterone for system suitability | 1 | 10 mg | 1 | 0234 | Yes | -20°C ± 5°C | ||
N1225000 | Norethisterone acetate | 2 | 110 mg | 1 | See leaflet CœœHœ‡O– ; Batch 1 is valid until 31 December 2016 | 0850 | Yes | +5°C ± 3°C | |
Y0001532 | Norethisterone acetate for system suitability | 1 | 2.585 mg | 1 | 0850 | Yes | +5°C ± 3°C | ||
N1230000 | Norfloxacin | 2 | 20 mg | 1 | Batch 1 is valid until 20 June 2017 | 1248 | Yes | +5°C ± 3°C | |
N1230010 | Norfloxacin impurity A | 1 | 20 mg | 1 | 7-chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 1460 | Yes | +5°C ± 3°C | |
Y0001301 | Norfloxacin for peak identification | 1 | 10 mg | 1 | 1248 | Yes | +5°C ± 3°C | ||
Y0001015 | Norfloxacin for system suitability | 3 | 10 mg | 1 | Batch 2 is valid until 30 November 2016 | 1248 | Yes | +5°C ± 3°C | |
Y0001609 | Norflurane - reference spectrum | 1 | n/a | 1 | |||||
Y0000724 | Norgestimate | 1 | 10 mg | 1 | 1732 | Yes | +5°C ± 3°C | ||
Y0000725 | Norgestimate for system suitability | 1 | 5 mg | 1 | 1732 | Yes | +5°C ± 3°C | ||
N1250000 | Norgestrel | 1 | 30 mg | 1 | 0940 | Yes | +5°C ± 3°C | ||
N1279000 | Norpseudoephedrine hydrochloride - * psy | 2 | 50 mg | 1 | Cathine hydrochloride | 0683 | Yes | +5°C ± 3°C | |
N1280000 | Nortriptyline hydrochloride | 2 | 10 mg | 1 | 0941 | Yes | +5°C ± 3°C | ||
Y0001296 | Nortriptyline for system suitability | 1 | 20 mg | 1 | 0941 | Yes | +5°C ± 3°C | ||
N1300000 | Noscapine | 2 | 100 mg | 1 | 0102,0515,0 516 | Yes | +5°C ± 3°C | ||
N1400000 | Nystatin | 7 | 100 mg | 1 | See leaflet | 0517,1292,2 0702 | Yes | -20°C ± 5°C | |
O0100900 | Octoxinol 10 | 3 | 310 mg | 1 | Batch 2 is valid until 24 June 2017 | 1553 | Yes | +5°C ± 3°C | |
Y0000368 | Octyl gallate | 1 | 30 mg | 1 | 2057 | Yes | +5°C ± 3°C | ||
O0101000 | Octyldodecanol | 5 | 500 mg | 1 | See leaflet CœÐH÷œO ; Batch 4 is valid until 30 June 2016 | 1136 | Yes | +5°C ± 3°C | |
O0120000 | Ofloxacin | 1 | 50 mg | 1 | 1455 | Yes | +5°C ± 3°C | ||
O0120010 | Ofloxacin impurity A | 3 | 20 mg | 1 | (3RS)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4- benzoxazine-6-carboxylic acid (FPA) | 1455 | Yes | +5°C ± 3°C | |
O0120050 | Ofloxacin impurity E | 4 | 20 mg | 1 | (3RS)-9-fluoro-3-methyl-7-oxo-10-(piperazin-1-yl)-2,3-dihydro-7H-pyrido [1,2,3-de]-1,4-benzoxazine-6-carboxylic acid | 1455 | Yes | +5°C ± 3°C | |
Y0001370 | Olanzapine | 2 | 200 mg | 1 | See leaflet | 2258 | Yes | +5°C ± 3°C | |
Y0001392 | Olanzapine impurity A | 2 | 5 mg | 1 | 5-methyl-2-[(2-nitrophenyl)amino]thiophene-3-carbonitrile ; Batch 1 is valid until 31 October 2016 | 2258 | Yes | +5°C ± 3°C | |
Y0001380 | Olanzapine for system suitability | 2 | 10 mg | 1 | Batch 1 is valid until 31 August 2016 | 2258 | Yes | +5°C ± 3°C | |
Y0001204 | Oleanolic acid | 1 | 20 mg | 2 | See leaflet | 2463.2472 | Yes | +5°C ± 3°C | |
New | Y0001479 | Oleic acid | 2 | 2000 mg | 1 | See leaflet CŒ‡H–÷Oœ ; Batch 1 is valid until 31 December 2017 | 2579, 1848 | Yes | +5°C ± 3°C |
Y0000805 | Oleuropein | 2 | 25 mg | 1 | See leaflet Cœ—H–œOŒ– | 1878 | Yes | +5°C ± 3°C | |
Y0001405 | Olmesartan medoxomil | 3 | 100 mg | 1 | see leaflet ; Batch 2 is valid until 30 June 2017 | 2600 | Yes | +5°C ± 3°C | |
Y0001424 | Olmesartan medoxomil for system suitability | 3 | 10 mg | 1 | Batch 2 is valid until 31 August 2017 | 2600 | Yes | +5°C ± 3°C | |
O0146000 | Olsalazine sodium | 2 | 70 mg | 1 | 1457 | Yes | +5°C ± 3°C | ||
O0146010 | Olsalazine sodium for performance test | 1 | 60 mg | 1 | 1457 | Yes | +5°C ± 3°C | ||
O0150000 | Omeprazole | 4 | 50 mg | 1 | See leaflet | 0942,1032,2 372, 2374,2787 | Yes | -20°C ± 5°C | |
Y0001043 | Omeprazole magnesium | 1 | 10 mg | 1 | 2374 | Yes | +5°C ± 3°C | ||
O0151000 | Omeprazole impurity D | 2 | 10 mg | 1 | 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1H- benzimidazole (omeprazole sulfone) | 0942,1032, 2372, 2374, 2787 | Yes | -20°C ± 5°C | |
Y0000218 | Ondansetron hydrochloride dihydrate | 4 | 200 mg | 1 | See leaflet CŒ‡HœÐClN–O | 2016 | Yes | +5°C ± 3°C | |
Y0001042 | Omeprazole for peak identification | 2 | 10 mg | 1 | Batch 1 is valid until 31 July 2017 | 0942, 1032, 2372, 2374, 2787 | Yes | -20°C ± 5°C | |
Y0001345 | Ondansetron impurity A | 2 | 10 mg | 1 | (3RS)-3-[(dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H- carbazol-4-one ; Batch 1 is valid until 31 January 2017 | 2016 | Yes | +5°C ± 3°C | |
Y0000195 | Ondansetron impurity D | 3 | 15 mg | 1 | 9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one | 2016 | Yes | +5°C ± 3°C | |
New | Y0001326 | Ondansetron impurity E | 2 | 10 mg | 1 | 1H-imidazole ; Batch 1 is valid until 30 November 2017 | 2016 | Yes | +5°C ± 3°C |
Y0001320 | Ondansetron impurity F | 1 | 10 mg | 1 | 2-methyl-1H-imidazole | 2016 | Yes | +5°C ± 3°C | |
Y0001346 | Ondansetron impurity G | 2 | 10 mg | 1 | (3RS)-3-[(1H-imidazol-1-yl)methyl]-9-methyl-1,2,3,9-tetrahydro-4H- carbazol-4-one (C-desmethylondansetron) ; Batch 1 is valid until 30 November 2016 | 2016 | Yes | +5°C ± 3°C | |
Y0000197 | Ondansetron for LC system suitability | 1 | 10 mg | 1 | 2016 | Yes | +5°C ± 3°C | ||
Y0000196 | Ondansetron for TLC system suitability | 2 | 30 mg | 1 | 2016 | Yes | +5°C ± 3°C | ||
Y0001125 | Orbifloxacin | 1 | 200 mg | 1 | 2259 | Yes | +5°C ± 3°C | ||
Y0001147 | Orbifloxacin impurity mixture | 1 | 0.0008 mg | 1 | 2259 | Yes | +5°C ± 3°C | ||
O0180000 | Orciprenaline sulfate | 3 | 100 mg | 1 | Batch 2 is valid until 31 March 2017 | 1033.1332 | Yes | +5°C ± 3°C | |
Y0000895 | Orciprenaline for system suitability | 1 | 5 mg | 1 | 1033 | Yes | +5°C ± 3°C | ||
Y0001501 | Orientvine stem HRS | 1 | 600 mg | 1 | 2450 | Yes | +5°C ± 3°C | ||
Y0000101 | Orphenadrine citrate | 1 | 100 mg | 1 | 1759 | Yes | +5°C ± 3°C | ||
Y0000100 | Orphenadrine hydrochloride | 1 | 100 mg | 1 | 1760 | Yes | +5°C ± 3°C | ||
Y0000102 | Orphenadrine impurity E | 2 | 60 mg | 1 | (RS)-N,N-dimethyl-2-[(3-methylphenyl)phenylmethoxy] ethanamine (meta- methylbenzyl isomer) | 1759.1760 | Yes | +5°C ± 3°C | |
Y0001181 | Orphenadrine for peak identification | 2 | 0.44 mg | 1 | Batch 1 is valid until 30 June 2016 | 1759.1760 | Yes | +5°C ± 3°C | |
Y0001337 | Oseltamivir phosphate (impurity B-free) | 2 | 300 mg | 1 | See leaflet CŒÿH–ŒNœO‡P ; Batch 1 is valid until 30 September 2017 | 2422 | Yes | +5°C ± 3°C | |
Y0001338 | Oseltamivir impurity A | 2 | 10 mg | 1 | (3R,4R,5S)-5-acetamido-4-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1- carboxylic acid ; Batch 1 is valid until 30 June 2017 | 2422 | Yes | +5°C ± 3°C | |
Y0001339 | Oseltamivir impurity B | 1 | 10 mg | 1 | ethyl (1R,2R,3S,4R,5S)-4-acetamido-5-amino-2-azido-3- (1-ethylpropoxy)cyclohexanecarboxylate | 2422 | Yes | +5°C ± 3°C | |
Y0001340 | Oseltamivir impurity C | 2 | 10 mg | 1 | See leaflet CŒ÷HœœNœO÷; (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy) cyclohex-1-ene-1-carboxylic acid ; Batch 1 is valid until 31 October 2016 | 2422 | Yes | +5°C ± 3°C | |
Y0001341 | Oseltamivir impurity H | 1 | 30 mg | 1 | tributylphosphane oxide | 2422 | Yes | +5°C ± 3°C | |
Y0001207 | Osthole | 1 | 20 mg | 1 | See leaflet CŒ—HŒÿO– | 2557 | Yes | +5°C ± 3°C | |
O0200000 | Ouabain | 2 | 150 mg | 1 | See leaflet Cœ„H÷÷OŒœ | 0048 | Yes | +5°C ± 3°C | |
Y0000638 | Oxacillin sodium monohydrate | 1 | 110 mg | 1 | See leaflet CŒ„HŒ‡N–NaO—S | 2260 | Yes | +5°C ± 3°C | |
Y0000560 | Oxacillin for peak identification | 1 | 10 mg | 1 | 2260 | Yes | -20°C ± 5°C | ||
Y0000271 | Oxaliplatin | 4 | 250 mg | 1 | See leaflet C‡HŒ÷NœO÷Pt | 2017 | Yes | +5°C ± 3°C | |
Y0000272 | Oxaliplatin impurity B | 10 | 22 mg | 1 | See leaflet CœÐHœ‡NœOÿPtSœ; (SP-4-2)-diaqua[(1R,2R)-cyclohexane-1,2- diamineκN,κN′]platinum (diaquodiaminocyclohexaneplatinum) ; Batch 9 is valid until 31 August 2016 | 2017 | Yes | +5°C ± 3°C | |
Y0000273 | Oxaliplatin impurity C | 6 | 25 mg | 1 | (OC-6-33)-[(1R,2R)-cyclohexane-1,2-diamineκN,κN′][ethanedioato(2-)- κO1,κO2]dihydroxyplatinum | 2017 | Yes | +5°C ± 3°C | |
Y0000274 | Oxaliplatin impurity D | 5 | 15 mg | 1 | (SP-4-2)-[(1S,2S)-cyclohexane-1,2-diamine-κN,κN'][ethanedioato(2-)- κO1,κO2]platinum (S,S-enantiomer of oxaliplatin) ; Batch 4 is valid until 31 July 2016 | 2017 | Yes | +5°C ± 3°C | |
O0225000 | Oxazepam - * psy | 2 | 50 mg | 1 | 0778 | Yes | +5°C ± 3°C | ||
Y0000543 | Oxazepam for peak identification | 2 | 0.008 mg | 1 | 0778 | Yes | +5°C ± 3°C | ||
Y0001576 | Oxcarbazepine | 1 | 120 mg | 1 | See leaflet CŒ—HŒœNœOœ | 2577 | Yes | +5°C ± 3°C | |
Y0001549 | Oxcarbazepine impurity mixture | 1 | 0.008 mg | 1 | 2577 | Yes | +5°C ± 3°C | ||
Y0000350 | Oxeladin hydrogen citrate | 1 | 50 mg | 1 | 1761 | Yes | +5°C ± 3°C | ||
Y0000404 | Oxeladin impurity C | 1 | 10 mg | 1 | 2-(diethylamino)ethyl 2-ethyl-2-phenylbutanoate | 1761 | Yes | +5°C ± 3°C | |
Y0000390 | Oxeladin impurity D | 1 | 20 mg | 1 | 2-[2-(diethylamino)ethoxy]ethyl (2RS)-2-phenylbutanoate | 1761 | Yes | +5°C ± 3°C | |
O0225800 | Oxfendazole CRS | 2 | 50 mg | 1 | 1458 | Yes | +5°C ± 3°C | ||
Y0000224 | Oxfendazole impurity B | 2 | 10 mg | 1 | See leaflet; methyl [5-(phenylsulfonyl)-1H-benzimidazole-2-yl]carbamate | 1458 | Yes | +5°C ± 3°C | |
Y0000225 | Oxfendazole with impurity D | 1 | 10 mg | 1 | 1458 | Yes | +5°C ± 3°C | ||
O0260000 | Oxibendazole | 2 | 100 mg | 1 | 1386 | Yes | +5°C ± 3°C | ||
Y0001771 | Oxidronate for radiochemical purity testing | 1 | 34 mg | 1 | 2376 | Yes | +5°C ± 3°C | ||
Y0000709 | Oxitropium bromide | 1 | 50 mg | 1 | 2170 | Yes | +5°C ± 3°C | ||
Y0000715 | Oxitropium bromide impurity B | 1 | 15 mg | 1 | (1R,2R,4S,5S,7s)-7-[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-9,9- dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane (methylhyoscine) | 2170 | Yes | +5°C ± 3°C | |
Y0000713 | Oxitropium bromide impurity D | 1 | 10 mg | 1 | (1R,2R,4S,5S,7s,9s)-9-ethyl-9-methyl-7-[(2-phenylacryloyl)oxy]-3-oxa-9- azoniatricyclo[3.3.1.02,4]nonane (apo-N-ethylhyoscine | 2170 | Yes | +5°C ± 3°C | |
O0240000 | Oxolinic acid | 1 | 50 mg | 1 | 1353 | Yes | +5°C ± 3°C | ||
O0240005 | Oxolinic acid impurity A | 1 | 20 mg | 1 | 8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid | 1353 | Yes | +5°C ± 3°C | |
O0240010 | Oxolinic acid impurity B | 1 | 20 mg | 1 | ethyl 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxolo[4,5-g]quinoline-7- carboxylate | 1353 | Yes | +5°C ± 3°C | |
O0250000 | Oxprenolol hydrochloride | 1 | 50 mg | 1 | 0628,0876,1 072 | Yes | +5°C ± 3°C | ||
O0270000 | Oxybuprocaine hydrochloride | 2 | 100 mg | 1 | 1251 | Yes | +5°C ± 3°C | ||
O0288000 | Oxybutynin hydrochloride | 2 | 50 mg | 1 | 1354 | Yes | +5°C ± 3°C | ||
O0288005 | Oxybutynin impurity A | 4 | 20 mg | 1 | See leaflet CœœH–ÿClNO–; 4-(diethylamino)but-2-ynyl(RS)-2-(cyclohex-3- enyl)-2- cyclohexyl-2-hydroxyacetate | 1354 | Yes | +5°C ± 3°C | |
Y0000492 | Oxycodone hydrochloride - * narc | 1 | 100 mg | 1 | 1784, 1793 | Yes | +5°C ± 3°C | ||
Y0000453 | Oxycodone impurity D | 3 | 50 mg | 1 | 7,8-didehydro-4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6- one (14-hydroxycodeinone) | 1793 | Yes | +5°C ± 3°C | |
O0290000 | Oxymetazoline hydrochloride | 2 | 80 mg | 1 | 0943 | Yes | +5°C ± 3°C | ||
New | Y0001044 | Oxymetazoline impurity A | 2 | 15 mg | 1 | N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl] acetamide ; Batch 1 is valid until 31 October 2017 | 0943 | Yes | +5°C ± 3°C |
Y0001896 | Oxytetracycline | 8 | 100 mg | 1 | see leaflet; This reference standard is suitable for use with monographs 01/2017:0199 and 01/2017:0198. | 0198, 0199 | Yes | +5°C ± 3°C | |
New | Y0001850 | Oxytetracycline for system suitability | 2 | 15 mg | 1 | Batch 1 is valid until 31 October 2017 | 0198.0199 | Yes | +5°C ± 3°C |
O0500000 | Oxytetracycline hydrochloride | 4 | 20 mg | 1 | 0198.1030 | Yes | +5°C ± 3°C | ||
O0700000 | Oxytocin | 5 | 41 mg | 1 | see leaflet | 0779.0780 | Yes | -20°C ± 5°C | |
O0770000 | Oxytocin/Desmopressin validation mixture | 4 | 20 mg | 1 | 0712,0779,0 780 | Yes | -20°C ± 5°C | ||
Y0000698 | Paclitaxel | 3 | 40 mg | 1 | See leaflet C÷ŸH—ŒNOŒ÷ ; Batch 2 is valid until 31 October 2016 | 1794 | Yes | +5°C ± 3°C | |
Y0000699 | Paclitaxel impurity C | 2 | 10 mg | 1 | N-debenzoyl-N-hexanoylpaclitaxel (paclitaxel C) | 1794 | Yes | +5°C ± 3°C | |
Y0000700 | Paclitaxel natural for peak identification | 1 | 10 mg | 1 | 1794 | Yes | +5°C ± 3°C | ||
Y0000719 | Paclitaxel semi-synthetic for peak identification | 2 | 10 mg | 1 | 1794 | Yes | +5°C ± 3°C | ||
Y0000739 | Paclitaxel semi-synthetic for system suitability | 2 | 1.013 mg | 1 | 1794 | Yes | +5°C ± 3°C | ||
Y0001856 | Paeoniflorin | 1 | 15 mg | 1 | see leaflet Cœ–Hœ‡OŒŒ | 2424, 2425 | Yes | +5°C ± 3°C | |
P0090000 | Palmitic acid | 4 | 100 mg | 1 | 0229,0882,1 474,1663,20 | Yes | +5°C ± 3°C | ||
Y0000524 | Pamidronate disodium pentahydrate | 1 | 10 mg | 1 | 1779 | Yes | +5°C ± 3°C | ||
Y0001632 | Pancreas powder (amylase) BRP | 4 | 2000 mg | 1 | See leaflet | 0350 | Yes | +5°C ± 3°C | |
Y0001631 | Pancreas powder (lipase) BRP | 4 | 2000 mg | 1 | See leaflet | 0350 | Yes | +5°C ± 3°C | |
P0200000 | Pancreas powder (protease) BRP | 4 | 2000 mg | 1 | See leaflet | 0350 | Yes | +5°C ± 3°C | |
P0250000 | Pancuronium bromide | 2 | 20 mg | 1 | Vecuronium impurity B | 0681.1769 | Yes | +5°C ± 3°C | |
Y0000577 | Pancuronium bromide for system suitability | 1 | 20 mg | 1 | 0681 | Yes | +5°C ± 3°C | ||
Y0000835 | Pantoprazole sodium sesquihydrate | 1 | 20 mg | 1 | 2296 | Yes | +5°C ± 3°C | ||
New | Y0001001 | Pantoprazole for system suitability | 7 | 0.51 mg | 1 | Batch 6 is valid until 30 September 2017 | 2296 | Yes | +5°C ± 3°C |
P0270000 | Papaverine hydrochloride | 1 | 25 mg | 1 | 0102,0573,0 515 | Yes | +5°C ± 3°C | ||
P0300000 | Paracetamol | 4 | 50 mg | 1 | 0049 | Yes | +5°C ± 3°C | ||
Y0001781 | Paracetamol for equipment qualification | 1 | 250 mg | 1 | 20248 | Yes | +5°C ± 3°C | ||
Y0000780 | Paraffin (hard) | 1 | 10 mg | 1 | 1034 | Yes | +5°C ± 3°C | ||
Y0000058 | Paraffin (liquid) - reference spectrum | 1 | n/a | 1 | 0239.0240 | ||||
Y0000913 | Paraffin (White soft) | 1 | 10 mg | 1 | 1799 | Yes | +5°C ± 3°C | ||
Y0000912 | Paraffin (Yellow soft) | 1 | 10 mg | 1 | 1554 | Yes | +5°C ± 3°C | ||
P0305000 | Parnaparin sodium | 2 | 200 mg | 1 | 1252 | Yes | +5°C ± 3°C | ||
Y0000578 | Paroxetine hydrochloride (anhydrous) | 1 | 100 mg | 1 | 2283 | Yes | +5°C ± 3°C | ||
Y0000579 | Paroxetine hydrochloride (anhydrous) impurity C | 1 | 10 mg | 1 | (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-1-benzyl-4-(4-fluorophenyl) piperidine (N-benzylparoxetine) | 2283 | Yes | +5°C ± 3°C | |
Y0000581 | Paroxetine hydrochloride (anhydrous) impurity H | 1 | 10 mg | 1 | [(3S,4R)-1-benzyl-4-(4-fluorophenyl)piperidin-3-yl]methanol | 2283 | Yes | +5°C ± 3°C | |
Y0000281 | Paroxetine hydrochloride hemihydrate | 3 | 200 mg | 1 | See leaflet CŒ„HœŒClFNO– ; Batch 2 is valid until 31 July 2016 | 2018.2283 | Yes | +5°C ± 3°C | |
Y0000233 | Paroxetine impurity A | 5 | 15 mg | 1 | (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-phenylpiperidine (desfluoroparoxetine) | 2018.2283 | Yes | +5°C ± 3°C | |
Y0000256 | Paroxetine impurity D | 3 | 10 mg | 1 | See leaflet; (3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl) piperidine ((+)-trans-paroxetine) | 2018.2283 | Yes | +5°C ± 3°C | |
Y0000580 | Paroxetine impurity E | 1 | 5 mg | 1 | (3RS,4RS)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine (cis-paroxetine) | 2283 | Yes | +5°C ± 3°C | |
Y0000630 | Paroxetine for system suitability | 1 | 5 mg | 1 | 2018 | Yes | +5°C ± 3°C | ||
P0309000 | Pefloxacin mesilate dihydrate | 1 | 200 mg | 1 | 1460 | Yes | +5°C ± 3°C | ||
P0309020 | Pefloxacin impurity B | 1 | 10 mg | 1 | 6-chloro-1-ethyl-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3- carboxylic acid (chlorinated homologue of pefloxacin) | 1460 | Yes | +5°C ± 3°C | |
P0309030 | Pefloxacin impurity C | 2 | 0.01 mg | 1 | 1-ethyl-6-fluoro-5-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3- carboxylic acid (isopefloxacin) | 1460 | Yes | +5°C ± 3°C | |
Y0001539 | Pemetrexed disodium heptahydrate | 2 | 200 mg | 1 | See leaflet ; Batch 1 is valid until 30 November 2016 | 2637 | Yes | +5°C ± 3°C | |
Y0001538 | Pemetrexed for system suitability | 1 | 20 mg | 1 | 2637 | Yes | +5°C ± 3°C | ||
Y0001535 | Pemetrexed impurity mixture | 2 | 0.002 mg | 1 | 2637 | Yes | +5°C ± 3°C | ||
P0307000 | Penbutolol sulfate | 1 | 100 mg | 1 | 1461 | Yes | +5°C ± 3°C | ||
P0307005 | Penbutolol impurity A | 2 | 20 mg | 1 | See leaflet CŒ‡HœŸNOœ; (2S)-1-[2-(cyclopent-1-enyl)phenoxy]-3-[(1,1- dimethylethyl) amino]propan-2-ol | 1461 | Yes | +5°C ± 3°C | |
P0310000 | Penicillamine | 1 | 100 mg | 1 | 0566 | Yes | +5°C ± 3°C | ||
P0320000 | Penicillamine disulfide | 3 | 100 mg | 1 | See leaflet CŒÐHœÐNœO÷Sœ; 3,3-(disulphanediyl)bis[(2S)-2-amino-3- methylbutanoic] acid | 0566 | Yes | +5°C ± 3°C | |
P0400100 | Pentaerythrityl tetranitrate diluted | 2 | 600 mg | 1 | See leaflet C—H‡N÷OŒœ | 1355 | Yes | +5°C ± 3°C | |
P0405000 | Pentamidine diisetionate | 2 | 30 mg | 1 | 1137.1436 | Yes | +5°C ± 3°C | ||
P0405500 | Pentazocine - reference spectrum | 1 | n/a | 1 | 1462 | ||||
P0405510 | Pentazocine hydrochloride - reference spectrum | 1 | n/a | 1 | 1463 | ||||
Y0000417 | Pentazocine lactate - reference spectrum | 1 | n/a | 1 | 2000 | +5°C ± 3°C | |||
Y0001051 | Pentetate sodium calcium | 1 | 100 mg | 1 | 2353 | Yes | +5°C ± 3°C | ||
P0500000 | Pentobarbital - * psy | 1 | 500 mg | 1 | 0200.0419 | Yes | +5°C ± 3°C | ||
P0510000 | Pentoxifylline | 2 | 100 mg | 1 | Batch 1 is valid until 31 January 2017 | 0851 | Yes | +5°C ± 3°C | |
Y0000076 | Pentoxyverine hydrogen citrate - reference spectrum | 1 | n/a | 1 | 1621 | ||||
Y0000098 | Pentoxyverine impurity A | 1 | 10 mg | 1 | 1-phenylcyclopentanecarboxylic acid | 1621 | Yes | +5°C ± 3°C | |
Y0000099 | Pentoxyverine impurity B | 1 | 10 mg | 1 | 2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate (caramiphen) | 1621 | Yes | +5°C ± 3°C | |
P0525000 | Pepsin powder BRP | 2 | 2000 mg | 1 | See leaflet | 0682 | Yes | +5°C ± 3°C | |
Y0000010 | Pergolide mesilate | 1 | 150 mg | 1 | See leaflet CœÐH–ÐNœO–Sœ | 1555 | Yes | +5°C ± 3°C | |
Y0000238 | Perindopril tert-butylamine | 3 | 40 | 1 | Batch 2 is valid until 31 March 2017 | 2019 | Yes | +5°C ± 3°C | |
Y0000237 | Perindopril impurity A | 2 | 10 mg | 1 | (2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid | 2019 | Yes | +5°C ± 3°C | |
Y0000771 | Perindopril for peak identification | 1 | 5 mg | 1 | 2019 | Yes | +5°C ± 3°C | ||
Y0000207 | Perindopril for stereochemical purity | 2 | 40 mg | 1 | 2019 | Yes | +5°C ± 3°C | ||
Y0001733 | Permethrin (25:75) | 1 | 350 mg | 1 | see leaflet | 1762 | Yes | +5°C ± 3°C | |
Y0001741 | Permethrin for system suitability | 2 | 60 mg | 1 | Batch 1 is valid until 30 June 2016 | 1762 | Yes | +5°C ± 3°C | |
P0550000 | Perphenazine | 1 | 100 mg | 1 | 0629.0904 | Yes | +5°C ± 3°C | ||
Y0001045 | Perphenazine for system suitability | 1 | 5 mg | 1 | 0629 | Yes | +5°C ± 3°C | ||
Y0000021 | Pertussis toxin BRP | 1 | 0.05 mg | 2 | See leaflet | See leaflet, 1356, 1595, 1931, 1932, 1933, 1934, 2065, 2067, 2329,2764 | Yes | -20°C ± 5°C | |
P0600000 | Pethidine hydrochloride - reference spectrum | 1 | n/a | 1 | 0420 | ||||
P0600002 | Pethidine impurity A | 2 | 20 mg | 1 | 1-methyl-4-phenylpiperidine (MPP) ; Batch 1 is valid until 28 February 2017 | 0420 | Yes | +5°C ± 3°C | |
P0800000 | Phenazone | 2 | 20 mg | 1 | 0421 | Yes | +5°C ± 3°C | ||
Y0001138 | Phenazone impurity A | 1 | 20 mg | 1 | 5-methyl-2-phenyl-2,4-dihydro-3§-pyrazol-3-one | 0421 | Yes | +5°C ± 3°C | |
P0850000 | Pheniramine maleate | 3 | 250 mg | 1 | Batch 2 is valid until 30 June 2017 | 1357, 0977 | Yes | +5°C ± 3°C | |
Y0001428 | Pheniramine impurity A | 1 | 20 mg | 1 | 2-benzylpyridine | 1357 | Yes | +5°C ± 3°C | |
P0900000 | Phenobarbital - * psy | 5 | 200 mg | 1 | See leaflet CŒœHŒœNœO– ; Batch 4 is valid until 30 June 2016 | 0189,0201,0 630 | Yes | +5°C ± 3°C | |
Y0001350 | Phenobarbital impurity A | 1 | 15 mg | 1 | See leaflet CŒœHŒ÷N÷O; (5RS)-5-ethyl-2,6-diimino-5- phenyltetrahydropyrimidin-4(1H)-one | 0201.0630 | Yes | +5°C ± 3°C | |
Y0001351 | Phenobarbital impurity B | 1 | 15 mg | 1 | (5RS)-5-ethyl-6-imino-5-phenyldihydropyrimidine-2,4(1H,3H)-dione | 0201.0630 | Yes | +5°C ± 3°C | |
P0950000 | Phenoxyethanol | 5 | 1 mL | 1 | Batch 4 is valid until 31 October 2016 | 0781 | Yes | +5°C ± 3°C | |
P1000000 | Phenoxymethylpenicillin | 2 | 250 mg | 1 | 0148 | Yes | +5°C ± 3°C | ||
Y0001868 | Phenoxymethylpenicillin for system suitability | 1 | 25 mg | 1 | 0148.0149 | Yes | +5°C ± 3°C | ||
P1100000 | Phenoxymethylpenicillin potassium | 4 | 250 mg | 1 | See leaflet CŒÿHŒŸKNœO—S | 0113,0114,0 148, 0149 | Yes | +5°C ± 3°C | |
Y0001127 | Phentolamine mesilate | 1 | 10 mg | 1 | 1138 | Yes | +5°C ± 3°C | ||
P1109000 | Phentolamine mesilate - reference spectrum | 1 | n/a | 1 | 1138 | ||||
Y0001251 | Phentolamine for system suitability | 1 | 10 mg | 1 | 1138 | Yes | +5°C ± 3°C | ||
P1150000 | Phenylalanine | 4 | 60 mg | 1 | 0782.2575 | Yes | +5°C ± 3°C | ||
P1200000 | Phenylbutazone | 1 | 100 mg | 1 | 0422.1574 | Yes | +5°C ± 3°C | ||
New | Y0000147 | Phenylbutazone impurity B | 2 | 20 mg | 1 | 4-butyl-4-hydroxy-1,2-diphenylpyrazolidine-3,5-dione ; Batch 1 is valid until 30 September 2017 | 0422 | Yes | +5°C ± 3°C |
P1240000 | Phenylephrine | 2 | 60 mg | 1 | 1035 | Yes | +5°C ± 3°C | ||
P1250000 | Phenylephrine hydrochloride | 3 | 50 mg | 1 | 0632.1205 | Yes | +5°C ± 3°C | ||
New | Y0000683 | Phenylephrine hydrochloride for peak identification | 5 | 2.004 mg | 1 | Batch 4 is valid until 30 November 2017 | 0632.1035 | Yes | +5°C ± 3°C |
Y0000229 | Phenylmercuric acetate - reference spectrum | 1 | n/a | 1 | 2042 | ||||
P1255100 | Phenylmercuric borate - reference spectrum | 1 | n/a | 1 | 0103 | ||||
P1260000 | Phenylpropanolamine hydrochloride - * Drug Precursor | 1 | 50 mg | 1 | Norephedrin hydrochloride | 0683 | Yes | +5°C ± 3°C | |
P1290000 | Phenytoin | 1 | 50 mg | 1 | 1253.1988 | Yes | +5°C ± 3°C | ||
P1300000 | Phenytoin sodium | 2 | 250 mg | 1 | 0521 | Yes | +5°C ± 3°C | ||
Y0001167 | Phenytoin for system suitability | 1 | 20 mg | 1 | 0521.1253 | Yes | +5°C ± 3°C | ||
Y0000493 | Phloroglucinol (anhydrous) | 2 | 220 mg | 1 | 2301.2302 | Yes | +5°C ± 3°C | ||
Y0000761 | Pholcodine - * narc | 1 | 10 mg | 1 | 0522 | Yes | +5°C ± 3°C | ||
Y0001865 | Pholcodine for impurity G identification - * narc | 1 | 15 mg | 1 | 0522 | Yes | +5°C ± 3°C | ||
Y0000798 | Pholcodine for peak identification - * narc | 1 | 10 mg | 1 | 0522 | Yes | +5°C ± 3°C | ||
Y0000766 | Phthalic acid | 1 | 20 mg | 1 | benzene-1,2-dicarboxylic acid | 2348 | Yes | +5°C ± 3°C | |
P1500000 | Phthalylsulfathiazole | 1 | 100 mg | 1 | 0352 | Yes | +5°C ± 3°C | ||
P1600000 | Physostigmine salicylate | 2 | 100 mg | 1 | 0286 | Yes | +5°C ± 3°C | ||
P1609000 | Phytomenadione | 4 | 150 mg | 1 | see leaflet; Vitamin K1 | 1036 | Yes | +5°C ± 3°C | |
Y0001104 | Picosulfate for system suitability | 2 | 0.5 mg | 1 | Batch 1 is valid until 28 February 2017 | 1031 | Yes | +5°C ± 3°C | |
P1645000 | Picotamide monohydrate | 1 | 125 mg | 1 | 1358 | Yes | +5°C ± 3°C | ||
P1645005 | Picotamide impurity A | 1 | 25 mg | 1 | 4-methoxybenzene-1,3-dicarboxylic acid | 1358 | Yes | +5°C ± 3°C | |
Y0001508 | Picrotin | 1 | 40 mg | 1 | 2486 | Yes | +5°C ± 3°C | ||
Y0001528 | Picrotoxinin | 1 | 40 mg | 1 | See leaflet CŒ—HŒÿOÿ | 2486 | Yes | +5°C ± 3°C | |
Y0000124 | Pidolate impurity B | 3 | 110 mg | 1 | (2S)-2-[[[(2S)-5-oxopyrrolidin-2-yl]carbonyl]amino]pentanedioic acid | 1619 | Yes | +5°C ± 3°C | |
Y0000123 | Pidolic acid | 2 | 125 mg | 1 | Batch 1 is valid until 30 April 2017 | 1619 | Yes | +5°C ± 3°C | |
P1650000 | Pilocarpine hydrochloride | 2 | 50 mg | 1 | 0633 | Yes | +5°C ± 3°C | ||
P1700000 | Pilocarpine nitrate | 1 | 50 mg | 1 | 0104 | Yes | +5°C ± 3°C | ||
Y0000106 | Pilocarpine nitrate for system suitability | 1 | 20 mg | 1 | 0104.0633 | Yes | +5°C ± 3°C | ||
Y0000525 | Pimobendan | 1 | 10 mg | 1 | 2179 | Yes | +5°C ± 3°C | ||
Y0000401 | Pimobendan for system suitability | 2 | 0.1 mg | 1 | Batch 1 is valid until 31 October 2016 | 2179 | Yes | +5°C ± 3°C | |
P1750000 | Pimozide | 1 | 150 mg | 1 | 1254 | Yes | +5°C ± 3°C | ||
P1800000 | Pindolol | 1 | 100 mg | 1 | 0634.0871 | Yes | +5°C ± 3°C | ||
Y0001520 | Pioglitazone hydrochloride | 1 | 120 mg | 1 | See leaflet CŒ„HœŒClNœO–S | 2601 | Yes | +5°C ± 3°C | |
Y0001519 | Pioglitazone for system suitability | 1 | 15 mg | 1 | 2601 | Yes | +5°C ± 3°C | ||
Y0001476 | Pipemidic acid trihydrate | 1 | 15 mg | 1 | 1743 | Yes | +5°C ± 3°C | ||
Y0000061 | Pipemidic acid trihydrate - reference spectrum | 1 | n/a | 1 | 1743 | ||||
P1890000 | Piperacillin | 4 | 100 mg | 1 | See leaflet Cœ–HœŸN—OŸS | 1168.1169 | Yes | +5°C ± 3°C | |
P1900000 | Piperazine adipate | 1 | 250 mg | 1 | 0423 | Yes | +5°C ± 3°C | ||
P2000000 | Piperazine citrate | 1 | 250 mg | 1 | 0424 | Yes | +5°C ± 3°C | ||
P2100000 | Piperazine hydrate | 1 | 250 mg | 1 | 0425 | Yes | +5°C ± 3°C | ||
Y0001217 | Piperine | 1 | 30 mg | 1 | See leaflet CŒŸHŒ„NO– | 2453.2477 | Yes | +5°C ± 3°C | |
Y0000288 | Piracetam | 3 | 150 mg | 1 | See leaflet CÿHŒÐNœOœ | 1733 | Yes | +5°C ± 3°C | |
Y0000038 | Pirenzepine dihydrochloride monohydrate | 1 | 250 mg | 1 | 2001 | Yes | +5°C ± 3°C | ||
P2120000 | Piretanide | 1 | 100 mg | 1 | 1556 | Yes | +5°C ± 3°C | ||
Y0001458 | Piretanide for system suitability | 1 | 10 mg | 1 | 1556 | Yes | +5°C ± 3°C | ||
Y0001769 | Pirfenidone | 1 | 120 mg | 1 | See Leaflet CŒœHŒŒNO | 2856 | Yes | +5°C ± 3°C | |
P2130000 | Piroxicam | 3 | 50 mg | 1 | 0944 | Yes | +5°C ± 3°C | ||
Y0001475 | Piroxicam for system suitability | 5 | 15 mg | 1 | Batch 4 is valid until 31 December 2016 | 0944 | Yes | +5°C ± 3°C | |
P2150000 | Pivampicillin | 1 | 125 mg | 2 | See leaflet | 0808.0852 | Yes | +5°C ± 3°C | |
P2152000 | Pivmecillinam hydrochloride | 2 | 100 mg | 1 | See leaflet CœŒH–÷ClN–O—S | 1359 | Yes | -20°C ± 5°C | |
P2152015 | Pivmecillinam impurity C | 2 | 10 mg | 1 | methylene 2,2-dimethylpropanoate (2RS,4S)-2-[[[(hexahydo- 1H-azepin-1-yl) methylene]amino]methyl]-5,5-dimethylthiazolidin-4-carboxylate | 1359 | Yes | +5°C ± 3°C | |
P2155001 | Plastic additive 01 | 1 | 2 ml | 1 | (2RS)-2-ethylhexyl) benzene-1,2-dicarboxylate | 90001,9000 2, 30114 | Yes | +5°C ± 3°C | |
P2155003 | Plastic additive 03 | 1 | 100 mg | 1 | N,N'-ethylenedialc* | 90001.30114 | Yes | +5°C ± 3°C | |
E0800000 | Plastic additive 04 | 1 | 500 mg | 1 | Epoxidised soya oil | 90001.30114 | Yes | +5°C ± 3°C | |
P2155005 | Plastic additive 05 | 1 | 500 mg | 1 | Epoxidised linseed oil | 90001.30114 | Yes | +5°C ± 3°C | |
P2155008 | Plastic additive 08 | 3 | 500 mg | 1 | ethylene bis[3,3-bis[3-(1,1-dimethylethyl)-4-hydroxyphenyl]butanoate] | 30103,3010 4, | Yes | +5°C ± 3°C | |
P2155009 | Plastic additive 09 | 3 | 250 mg | 1 | See leaflet; pentaerythrityl tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate] | 30103,3010 5, | Yes | +5°C ± 3°C | |
P2155010 | Plastic additive 10 | 2 | 250 mg | 1 | 4,4',4''-(2,4,6-trimethylbenzene-1,3,5-triyltrismethylene)trio[2,6-bis(1,1- dimethylethyl)phenol] | 30103,3010 5, | Yes | +5°C ± 3°C | |
P2155011 | Plastic additive 11 | 2 | 500 mg | 1 | Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate | 30103,3010 5, | Yes | +5°C ± 3°C | |
P2155012 | Plastic additive 12 | 4 | 250 mg | 1 | Tris (2,4-di-1,1-dimethylethylphenyl) phosphite R ; Batch 3 is valid until 30 June 2017 | 30103,3010 5, | Yes | +5°C ± 3°C | |
P2155013 | Plastic additive 13 | 2 | 250 mg | 1 | 1,3,5-tris(3,5-di-1,1-dimethylethyl-4-hydroxybenzyl)-1H,3H,5H-1,3,5- triazine-2,4,6-trione | 30103,3010 5, 30106 | Yes | +5°C ± 3°C | |
P2155014 | Plastic additive 14 | 2 | 250 mg | 1 | 2,2'-Di(octadecycloxy)-5,5'-spirobi(1,3,2-dioxaphosphorinane) R | 30103,3010 5, 30106 | Yes | +5°C ± 3°C | |
P2155015 | Plastic additive 15 | 2 | 500 mg | 1 | Dioctadecyl disulphide | 30103,3010 4, | Yes | +5°C ± 3°C | |
P2155016 | Plastic additive 16 | 2 | 250 mg | 1 | Didodecyl 3,3'-thiodipropionate R | 30103,3010 5, 30106 | Yes | +5°C ± 3°C | |
P2155017 | Plastic additive 17 | 2 | 250 mg | 1 | Dioctadecyl 3,3'-thiodipropionate R | 30103,3010 5, 30106 | Yes | +5°C ± 3°C | |
P2155018 | Plastic additive 18 | 2 | 50 mg | 1 | 30103 | Yes | +5°C ± 3°C | ||
O0140000 | Plastic additive 20 | 1 | 100 mg | 1 | Oleamide R | 30103,3010 5, | Yes | +5°C ± 3°C | |
E1260000 | Plastic additive 21 | 1 | 100 mg | 1 | Erucamide R | 30103, 30105, 30106, | Yes | +5°C ± 3°C | |
P2155022 | Plastic additive 22 | 1 | 100 mg | 1 | Copolymer of dimethyl butanedioate and 1-(2-hydroxyethyl)-2,2,6,6- tetramethylpiperidin-4-ol Synonyms: copolymer of dimethyl succinate and (4-hydroxy-2,2,6,6- tetramethylpiperidin-1-yl)ethanol | 30103 | Yes | +5°C ± 3°C | |
P2155023 | Plastic additive 23 | 3 | 200 mg | 1 | di(isooctyl)2,2'-[(dioctylstannylene)bis(thio)]diacetate containing about 27% of (tri(isooctyl)2,2',2''- [monooctyl- stannylidyne)tris (thio)] triacetate. ; Batch 2 is valid until 28 February 2017 | 30110.30111 | Yes | +5°C ± 3°C | |
P2160000 | Poliomyelitis vaccine (inactivated) BRP | 3 | 0.6 mL | 3 | See leaflet ; Batch 2 is valid until 28 February 2017 | 0214,2066,2 065, 2328,2061,2 067, 1934,2329,2 0720 | Yes | -80°C ± 10°C | |
P2163920 | Poloxamer 124 | 2 | 500 mg | 1 | Batch 1 is valid until 31 March 2017 | 1464 | Yes | +5°C ± 3°C | |
P2164009 | Poloxamer 188 | 2 | 50 mg | 1 | 1464 | Yes | +5°C ± 3°C | ||
P2164020 | Poloxamer 237 | 1 | 100 mg | 1 | 1464 | Yes | +5°C ± 3°C | ||
P2164021 | Poloxamer 338 | 2 | 100 mg | 1 | 1464 | Yes | +5°C ± 3°C | ||
P2164030 | Poloxamer 407 | 1 | 100 mg | 1 | 1464 | Yes | +5°C ± 3°C | ||
Y0001557 | Poly (vinyl acetate) | 1 | 100 mg | 1 | 1962 | Yes | +5°C ± 3°C | ||
Y0000792 | Poly(vinyl acetate) dispersion 30 per cent | 1 | 1500 mg | 1 | 2152 | Yes | +5°C ± 3°C | ||
Y0001550 | Poly(vinyl alcohol) | 1 | 100 mg | 1 | 1961 | Yes | +5°C ± 3°C | ||
P2600000 | Poly(vinyl chloride) | 1 | 100 mg | 1 | 90001,9000 2, 30114 | Yes | +5°C ± 3°C | ||
P2170000 | Polyacrylate - reference spectrum | 1 | n/a | 1 | 0733 | ||||
Y0001855 | Polydatin | 1 | 15 mg | 1 | see leaflet CœÐHœœO‡ | 2724 | Yes | +5°C ± 3°C | |
Y0001860 | Polygonum orientale fruit for system suitability | 1 | 510 mg | 1 | 2726 | Yes | +5°C ± 3°C | ||
P2400000 | Polymyxin B sulfate | 6 | 25 mg | 1 | see leaflet | 0203 | Yes | +5°C ± 3°C | |
Y0000355 | Polymyxin B sulfate for microbiological assay | 2 | 25 mg | 1 | See leaflet | 20702 | Yes | -20°C ± 5°C | |
Y0001712 | Polyoxypropylene stearyl ether | 1 | 250 mg | 1 | 2602 | Yes | +5°C ± 3°C | ||
Y0000289 | Polysorbate 20 - reference spectrum | 1 | n/a | 1 | 0426 | ||||
Y0000290 | Polysorbate 40 - reference spectrum | 1 | n/a | 1 | 1914 | ||||
Y0000291 | Polysorbate 60 - reference spectrum | 1 | n/a | 1 | 0427 | ||||
Y0000007 | Polysorbate 80 - reference spectrum | 1 | n/a | 1 | 0428 | ||||
P2649610 | Potassium clavulanate - reference spectrum | 1 | n/a | 1 | 1140 | ||||
Y0001168 | Potassium clavulanate impurity G | 2 | 5 mg | 1 | 4-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-4-oxobutanoic acid (N- (hydrogensuccinyl)tyrosine) | 1653.1140 | Yes | -20°C ± 5°C | |
Y0000315 | Potassium hydrogen aspartate hemihydrate | 1 | 50 mg | 1 | 2076 | Yes | +5°C ± 3°C | ||
P2650000 | Potassium sorbate | 2 | 100 mg | 1 | 0618 | Yes | +5°C ± 3°C | ||
Y0001275 | Potassium sucrose octasulfate | 1 | 100 mg | 1 | See leaflet CŒœHŒ÷K‡O–—S‡ | 1796 | Yes | +5°C ± 3°C | |
P2660000 | Povidone | 2 | 50 mg | 1 | 0685 | Yes | +5°C ± 3°C | ||
Y0000466 | Povidone (iodinated) | 1 | 10 mg | 1 | 1142 | Yes | +5°C ± 3°C | ||
Y0001266 | Pramipexole dihydrochloride monohydrate | 1 | 5 mg | 1 | 2416 | Yes | +5°C ± 3°C | ||
Y0001267 | Pramipexole impurity D | 2 | 5 mg | 1 | (6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine | 2416 | Yes | +5°C ± 3°C | |
Y0001187 | Pramipexole for system suitability | 1 | 15 mg | 1 | 2416 | Yes | +5°C ± 3°C | ||
Y0000215 | Pravastatin sodium - reference spectrum | 1 | n/a | 1 | 2059 | ||||
Y0000223 | Pravastatin impurity A | 5 | 0.1 mg | 1 | (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8- [[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl] heptanoic acid (6'-epipravastatin) | 2059 | Yes | -20°C ± 5°C | |
Y0000204 | Pravastatin 1,1,3,3-tetramethylbutylamine | 2 | 30 mg | 1 | See leaflet Cœ–H–ÿOŸ | 2059 | Yes | -20°C ± 5°C | |
P2669000 | Prazepam -* psy | 1 | 50 mg | 1 | 1466 | Yes | +5°C ± 3°C | ||
P2670000 | Praziquan | 3 | 200 mg | 1 | See leaflet | 0855 | Yes | +5°C ± 3°C | |
Y0001533 | Praziquan for system suitability | 1 | 10 mg | 1 | 0855 | Yes | +5°C ± 3°C | ||
P2680000 | Prazosin hydrochloride | 2 | 30 mg | 1 | 0856 | Yes | +5°C ± 3°C | ||
P2698000 | Prednicarbate | 2 | 100 mg | 1 | See leaflet CœŸH–ÿO‡ | 1467 | Yes | +5°C ± 3°C | |
Y0001630 | Prednicarbate for system suitability A | 1 | 10 mg | 1 | 1467 | Yes | +5°C ± 3°C | ||
P2700000 | Prednisolone | 8 | 150 mg | 1 | See leaflet | 0335,0353,0 354, 0735 | Yes | +5°C ± 3°C | |
Y0001359 | Prednisolone for peak identification | 1 | 10 mg | 1 | 0353 | Yes | +5°C ± 3°C | ||
Y0001355 | Prednisolone for system suitability | 2 | 10 mg | 1 | 0353 | Yes | +5°C ± 3°C | ||
P2800000 | Prednisolone acetate | 4 | 120 mg | 1 | 0734,0736,0 933, 0975,1467,0 334 | Yes | +5°C ± 3°C | ||
Y0000582 | Prednisolone acetate for peak identification | 1 | 10 mg | 1 | 0734 | Yes | +5°C ± 3°C | ||
P2804000 | Prednisolone hexanoate | 1 | 10 mg | 1 | 1212 | Yes | +5°C ± 3°C | ||
P2805000 | Prednisolone pivalate | 2 | 120 mg | 1 | 0734.0736 | Yes | +5°C ± 3°C | ||
P2810000 | Prednisolone sodium phosphate | 4 | 100 mg | 1 | 0549,0735,0 810 | Yes | +5°C ± 3°C | ||
P2900000 | Prednisone | 4 | 100 mg | 1 | 0354 | Yes | +5°C ± 3°C | ||
New | Y0001921 | Prednisone for peak identification | 1 | 15 mg | 1 | 0354 | Yes | +5°C ± 3°C | |
New | Y0001920 | Prednisone impurity B | 1 | 20 mg | 1 | 0354 | Yes | +5°C ± 3°C | |
Y0001805 | Pregabalin | 2 | 260 mg | 1 | See leaflet C‡HŒŸNOœ ; Batch 1 is valid until 30 April 2017 | 2777 | Yes | +5°C ± 3°C | |
Y0001806 | Pregabalin impurity A | 1 | 0.25 mg | 1 | See leaflet C‡HŒ—NO; (4S)-4-(2-methylpropyl)pyrrolidin-2-one | 2777 | Yes | +5°C ± 3°C | |
Y0001808 | Pregabalin impurity D | 1 | 10 mg | 1 | 1-methylethyl (2RS)-2-hydroxy-2-phenylacetate | 2777 | Yes | +5°C ± 3°C | |
P2920000 | Pregnenolone isobutyrate | 6 | 200 mg | 1 | 0593,0993,2 397 | Yes | -20°C ± 5°C | ||
Y0000263 | Prekallikrein activator in albumin BRP | 5 | 200 mg | 3 | See leaflet ; Batch 4 is valid until 31 August 2016 | See leaflet, 20615 | Yes | -20°C ± 5°C | |
P2939000 | Prilocaine | 1 | 150 mg | 1 | 1362 | Yes | +5°C ± 3°C | ||
P2939060 | Prilocaine hydrochloride | 1 | 100 mg | 1 | 1363 | Yes | +5°C ± 3°C | ||
Y0001408 | Prilocaine impurity B | 1 | 80 mg | 1 | 2-methylbenzenamine (o-toluidine) | 1362.1363 | Yes | +5°C ± 3°C | |
P2939025 | Prilocaine impurity E | 1 | 25 mg | 1 | (2RS)-N-(4-methylphenyl)-2-(propylamino)prop* | 1362.1363 | Yes | +5°C ± 3°C | |
Y0001681 | Prilocaine for peak identification | 1 | 20 mg | 1 | 1363 | Yes | +5°C ± 3°C | ||
P2940000 | Primaquine diphosphate | 3 | 500 mg | 1 | 0635 | Yes | +5°C ± 3°C | ||
P2950000 | Primidone | 2 | 150 mg | 1 | See leaflet | 0584 | Yes | +5°C ± 3°C | |
Y0000369 | Primidone for peak identification | 1 | 10 mg | 1 | 0584 | Yes | +5°C ± 3°C | ||
P3000000 | Probenecid | 1 | 100 mg | 1 | 0243 | Yes | +5°C ± 3°C | ||
P3050000 | Procainamide hydrochloride | 1 | 100 mg | 1 | 0567 | Yes | +5°C ± 3°C | ||
P3090000 | Procaine benzylpenicillin | 4 | 250 mg | 1 | See leaflet ; Batch 3 is valid until 30 June 2016 | 0115 | Yes | +5°C ± 3°C | |
P3100000 | Procaine hydrochloride | 1 | 100 mg | 1 | 0050 | Yes | +5°C ± 3°C | ||
P3200000 | Prochlorperazine maleate | 1 | 100 mg | 1 | 0244 | Yes | +5°C ± 3°C | ||
New | P3300000 | Progesterone | 4 | 120 mg | 1 | See leaflet ; Batch 3 is valid until 30 September 2017 | 0429 | Yes | +5°C ± 3°C |
Y0001667 | Progesterone for impurity H identification | 2 | 20 mg | 1 | see leaflet ; Batch 1 is valid until 31 January 2017 | 0429 | Yes | +5°C ± 3°C | |
Y0001666 | Progesterone for peak identification | 1 | 5 mg | 1 | 0429 | Yes | +5°C ± 3°C | ||
Y0001665 | Progesterone for system suitability | 1 | 5 mg | 1 | 0429 | Yes | +5°C ± 3°C | ||
Y0001885 | Proguanil for system suitability | 1 | 15 mg | 1 | 2002 | Yes | +5°C ± 3°C | ||
Y0001901 | Proguanil hydrochloride | 1 | 10 mg | 1 | 2002 | Yes | +5°C ± 3°C | ||
Y0000179 | Proguanil hydrochloride - reference spectrum | 1 | n/a | 1 | 2002 | ||||
Y0001909 | Proguanil impurity B | 1 | 15 mg | 1 | 4-chloroaniline | 2002 | Yes | +5°C ± 3°C | |
Y0000181 | Proguanil impurity C | 2 | 10 mg | 1 | 1,5-bis(4-chlorophenyl)biguanide The reference standard Y0000181 will be deleted from the monograph 01/2008:2002 on 30/06/2017. ; Batch 2 is valid until 30 June 2017 | 2002 | Yes | +5°C ± 3°C | |
Y0000182 | Proguanil impurity D | 2 | 10 mg | 1 | 1,5-bis(1-methylethyl)biguanide The reference standard Y0000182 will be deleted from the monograph 01/2008:2002 on 30/06/2017 ; Batch 2 is valid until 30 June 2017 | 2002 | Yes | +5°C ± 3°C | |
P3350000 | Proline | 3 | 60 mg | 1 | 0785 | Yes | +5°C ± 3°C | ||
P3390000 | Promazine hydrochloride | 2 | 40 mg | 1 | 0475.1365 | Yes | +5°C ± 3°C | ||
P3400000 | Promethazine hydrochloride | 2 | 50 mg | 1 | 0524 | Yes | +5°C ± 3°C | ||
Y0000769 | Promethazine impurity D | 2 | 15 mg | 1 | (2RS)-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine S-oxide | 0524 | Yes | +5°C ± 3°C | |
Y0000797 | Promethazine for peak identification | 2 | 5 mg | 1 | 0524 | Yes | +5°C ± 3°C | ||
P3490000 | Propacetamol hydrochloride - reference spectrum | 1 | n/a | 1 | 1366 | ||||
Y0000455 | Propafenone hydrochloride | 1 | 10 mg | 1 | 2103 | Yes | +5°C ± 3°C | ||
Y0000456 | Propafenone impurity B | 1 | 10 mg | 1 | (2E)-1-[2-[(2RS)-2-hydroxy-3-(propylamino)propoxy]phenyl]-3- phenylprop-2-en-1-one | 2103 | Yes | +5°C ± 3°C | |
Y0000278 | Propanol - reference spectrum | 1 | n/a | 1 | 2036 | ||||
Y0000016 | Propofol | 6 | 650 mg | 1 | See leaflet | 1558 | Yes | +5°C ± 3°C | |
Y0000018 | Propofol impurity J | 4 | 20 mg | 1 | 2,6-bis(1-methylethyl)benzene-1,4-dione | 1558 | Yes | +5°C ± 3°C | |
Y0000017 | Propofol for peak identification | 3 | 0.1 ml | 1 | 1558 | Yes | +5°C ± 3°C | ||
P3500000 | Propranolol hydrochloride | 2 | 30 mg | 1 | 0568.0923 | Yes | +5°C ± 3°C | ||
P3600000 | Propranolol hydrochloride for performance test | 3 | 15 mg | 1 | 0568 | Yes | +5°C ± 3°C | ||
Y0001547 | Propylene glycol | 1 | 150 mg | 1 | 1403,1804,2 645 | Yes | +5°C ± 3°C | ||
Y0000318 | Propylene glycol dilaurate | 1 | 100 mg | 1 | 2087 | Yes | +5°C ± 3°C | ||
Y0000319 | Propylene glycol monolaurate | 1 | 100 mg | 1 | 1915 | Yes | +5°C ± 3°C | ||
P3640000 | Propyl gallate | 3 | 50 mg | 1 | 1039 | Yes | +5°C ± 3°C | ||
P3650000 | Propyl parahydroxybenzoate | 4 | 150 mg | 1 | See leaflet CŒÐHŒœO– | 0431,0852,1 263 | Yes | +5°C ± 3°C | |
P3700000 | Propylthiouracil | 2 | 30 mg | 1 | 0525 | Yes | +5°C ± 3°C | ||
P3750000 | Propyphenazone | 4 | 200 mg | 1 | 0636 | Yes | +5°C ± 3°C | ||
P3760000 | Protirelin | 3 | 5.03 mg | 2 | See leaflet CŒÿHœœNÿO÷ | 1144 | Yes | -20°C ± 5°C | |
P3760020 | D-His-Protirelin | 2 | 0.1 mg | 1 | approx. 0.1 mg per vial | 1144 | Yes | -20°C ± 5°C | |
P3800000 | Proxyphylline | 1 | 100 mg | 1 | 0526 | Yes | +5°C ± 3°C | ||
P3850000 | Pseudoephedrine hydrochloride - * Drug Precursor | 3 | 50 mg | 1 | 0487.1367 | Yes | +5°C ± 3°C | ||
Y0000387 | Pseudoisoeugenyl 2-methylbutyrate for peak identification | 1 | 100 mg | 1 | Star anise oil | 2108 | Yes | +5°C ± 3°C | |
Y0001537 | Purified quillaia saponins | 1 | 30 mg | 1 | 1843 | Yes | -20°C ± 5°C | ||
P3900000 | Purpureaglycoside A | 1 | 25 mg | 1 | 0117 | Yes | +5°C ± 3°C | ||
P4000000 | Purpureaglycoside B | 1 | 25 mg | 1 | 0117 | Yes | +5°C ± 3°C | ||
Y0000402 | Pyran embonate | 1 | 10 mg | 1 | 1680 | Yes | +5°C ± 3°C | ||
Y0000403 | Pyran impurity A | 2 | 20 mg | 1 | 1-methyl-2-[(Z)-2-(thiophen-2-yl)eth-1-en-1-yl]-1,4,5,6-tetrahydropyrimidine | 1680 | Yes | +5°C ± 3°C | |
Y0001817 | Pyran impurity D | 1 | 20 mg | 1 | 1,2-dimethyl-1,4,5,6,-tetrahydropyrimidine | 1680 | Yes | +5°C ± 3°C | |
P4050000 | Pyrazinamide | 2 | 30 mg | 1 | 0859 | Yes | +5°C ± 3°C | ||
P4099900 | Pyridostigmine bromide | 4 | 30 mg | 1 | Batch 3 is valid until 31 October 2016 | 1255 | Yes | +5°C ± 3°C | |
P4099910 | Pyridostigmine impurity A | 1 | 20 mg | 1 | pyridin-3-yl-dimethylcarbamate | 1255 | Yes | +5°C ± 3°C | |
Y0001486 | Pyridostigmine impurity B | 1 | 10 mg | 1 | 3-hydroxy-1-methylpyridinium | 1255 | Yes | +5°C ± 3°C | |
P4100000 | Pyridoxine hydrochloride | 2 | 100 mg | 1 | 0245 | Yes | +5°C ± 3°C | ||
Y0001226 | Pyridoxine impurity A | 3 | 5 mg | 1 | 6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol | 0245 | Yes | +5°C ± 3°C | |
P4200000 | Pyrimethamine | 1 | 250 mg | 1 | 0288 | Yes | +5°C ± 3°C | ||
New | Y0000659 | Pyrrolidone | 2 | 20 mg | 1 | Batch 1 is valid until 23 September 2017 | 2180 | Yes | +5°C ± 3°C |
Y0001009 | Quercetin dihydrate | 3 | 25 mg | 1 | See leaflet CŒ—HŒÐOŸ | 1827 | Yes | +5°C ± 3°C | |
Y0001657 | Quetiapine fumarate | 2 | 50 mg | 1 | Batch 1 is valid until 31 August 2017 | 2541 | Yes | +5°C ± 3°C | |
Y0001419 | Quetiapine for system suitability | 3 | 2.005 mg | 1 | Batch 2 is valid until 31 July 2016 | 2541 | Yes | +5°C ± 3°C | |
Y0001564 | Quillaia saponin for assay | 1 | 30 mg | 1 | See leaflet C÷œHÿ—NOŒÿ; monoammonium glycyrrhizate | 1843 | Yes | +5°C ± 3°C | |
Y0001491 | Quinapril hydrochloride | 1 | 30 mg | 1 | 1763 | Yes | +5°C ± 3°C | ||
Y0001502 | Quinapril for peak identification | 1 | 5.075 mg | 1 | 1763 | Yes | +5°C ± 3°C | ||
Y0001503 | Quinapril for system suitability | 1 | 5.125 mg | 1 | 1763 | Yes | +5°C ± 3°C | ||
Q0100000 | Quinidine sulfate | 1 | 300 mg | 1 | 0017,0018,0 019 | Yes | +5°C ± 3°C | ||
Q0200000 | Quinine sulfate | 2 | 300 mg | 1 | 0017,0018,0 019 | Yes | +5°C ± 3°C | ||
Y0001783 | Rabeprazole sodium hydrate | 1 | 100 mg | 1 | See leaflet CŒ‡HœÐNaN–O–S | 2331.2868 | +5°C ± 3°C | ||
R0100000 | Rabies vaccine (inactivated) for veterinary use BRP | 5 | 86 mg | 2 | See leaflet | 0451 | Yes | -20°C ± 5°C | |
Y0000896 | Racecadotril | 2 | 120 mg | 1 | See leaflet CœŒHœ–NO÷S ; Batch 1 is valid until 31 January 2017 | 2171 | Yes | +5°C ± 3°C | |
Y0000897 | Racecadotril impurity A | 3 | 1.5 mL | 1 | ethanethioic acid (thioacetic acid) ; Batch 2 is valid until 31 August 2016 | 2171 | Yes | +5°C ± 3°C | |
Y0000898 | Racecadotril impurity G | 1 | 10 mg | 1 | benzyl [[(2RS)-2-benzyl-3-sulfanylpropanoyl]amino]acetate | 2171 | Yes | +5°C ± 3°C | |
Y0000902 | Racecadotril for peak identification | 1 | 5 mg | 1 | 2171 | Yes | +5°C ± 3°C | ||
Y0001134 | Raloxifene hydrochloride | 1 | 110 mg | 1 | See leaflet Cœ‡Hœ‡ClNO÷S | 2375 | Yes | +5°C ± 3°C | |
Y0001135 | Raloxifene for peak identification | 1 | 10 mg | 1 | 2375 | Yes | +5°C ± 3°C | ||
R0145000 | Ramipril | 2 | 20 mg | 1 | 1368 | Yes | +5°C ± 3°C | ||
R0145005 | Ramipril impurity A | 4 | 10 mg | 1 | (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-(methoxycarbonyl)-3-phenylpropyl]amino] propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril methyl ester) ; Batch 3 is valid until 30 October 2016 | 1368 | Yes | +5°C ± 3°C | |
R0145010 | Ramipril impurity B | 3 | 10 mg | 1 | (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-[(1-methylethoxy)carbonyl]-3-phenylpropyl] amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril isopropyl ester) | 1368 | Yes | +5°C ± 3°C | |
R0145015 | Ramipril impurity C | 3 | 10 mg | 1 | (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)-propyl] amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (hexahydroramipril) | 1368 | Yes | +5°C ± 3°C | |
R0145020 | Ramipril impurity D | 4 | 10 mg | 1 | ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro-2H-cyclopenta [4,5]pyrrolo[1,2-a]pyrazin-2-yl]-4-phenylbutanoate (ramipril diketopiperazine) | 1368 | Yes | +5°C ± 3°C | |
R0150000 | Ranitidine hydrochloride | 3 | 100 mg | 1 | 0946.1453 | Yes | +5°C ± 3°C | ||
Y0000416 | Ranitidine impurity J | 7 | 0.00025 mg | 1 | 1,1'-N-[methylenebis(sulfanediylethylene)]bis(N'-methyl-2-nitroethene-1,1- diamine) ; Batch 6 is valid until 31 January 2017 | 0946 | Yes | -20°C ± 5°C | |
Y0001787 | Ranitidine for impurity A identification | 1 | 15 mg | 1 | 0946 | Yes | +5°C ± 3°C | ||
Y0001565 | Recombinant Major Allergen rBet v 1 | 1 | 0.01025 mg | 1 | See leaflet | 1063 | Yes | -20°C ± 5°C | |
Y0001566 | Recombinant Major Allergen rPhl p 5a | 1 | 0.00856 mg | 1 | See leaflet | 1063 | Yes | -20°C ± 5°C | |
New | Y0001892 | * hydrochloride - * narc | 1 | 100 mg | 1 | 2644 | Yes | +5°C ± 3°C | |
Y0001884 | * impurity mixture - *narc | 1 | 15 mg | 1 | 2644 | Yes | +5°C ± 3°C | ||
Y0000457 | Repaglinide | 1 | 20 mg | 1 | 2135 | Yes | +5°C ± 3°C | ||
Y0000459 | Repaglinide impurity E | 3 | 10 mg | 1 | 2-ethoxy-4-[2-[[(1R)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2- oxoethyl]benzoic acid ; Batch 2 is valid until 31 August 2016 | 2135 | Yes | +5°C ± 3°C | |
Y0000458 | Repaglinide for system suitability | 3 | 6 mg | 1 | 2135 | Yes | +5°C ± 3°C | ||
R0200000 | Reserpine | 3 | 100 mg | 1 | See leaflet C––H÷ÐNœO„ | 0528 | Yes | +5°C ± 3°C | |
R0250000 | Residual solvent solution class 1 | 7 | 1.4 mL | 1 | Batch 6 is valid until 31 August 2017 | 20424 | Yes | +5°C ± 3°C | |
Y0000767 | Resorcinol | 1 | 20 mg | 1 | benzene-1,3-diol | 2348 | Yes | +5°C ± 3°C | |
Y0001194 | Resveratrol | 1 | 20 mg | 1 | See leaflet CŒ÷HŒœO– | 2433 | Yes | -20°C ± 5°C | |
R0300000 | Retinol acetate | 7 | 500 mg | 1 | See leaflet ; Batch 6 is valid until 31 December 2016 | 0218,0219,0 220,1192,11 93,2398 | Yes | -20°C ± 5°C | |
R0290000 | Retinol esters | 1 | 100 mg | 1 | 0217,0218,0 219, 0220 | Yes | +5°C ± 3°C | ||
Y0000377 | Ribavirin | 3 | 150 mg | 2 | See leaflet C‡HŒœN÷O— ; Batch 2 is valid until 30 November 2016 | 2109 | Yes | +5°C ± 3°C | |
R0600000 | Riboflavin | 4 | 130 mg | 1 | Vitamin B2 | 0292.0786 | Yes | +5°C ± 3°C | |
Y0000757 | Riboflavin for peak identification | 4 | 0.12 mg | 1 | Batch 3 is valid until 30 April 2017 | 0292 | Yes | +5°C ± 3°C | |
R0630000 | Riboflavin sodium phosphate | 2 | 250 mg | 1 | 0786 | Yes | +5°C ± 3°C | ||
Y0000662 | Ribonucleic acid | 1 | 100 mg | 1 | See leaflet | 2090 | Yes | +5°C ± 3°C | |
Y0000149 | Rifabutin | 2 | 150 mg | 1 | See leaflet C÷—HÿœN÷OŒŒ | 1657 | Yes | +5°C ± 3°C | |
Y0000184 | Rifabutin impurity A | 1 | 20 mg | 1 | 1-(2-methylpropyl)piperidin-4-one | 1657 | Yes | +5°C ± 3°C | |
R0700000 | Rifampicin | 2 | 100 mg | 1 | 0052 | Yes | +5°C ± 3°C | ||
R0800000 | Rifampicin quinone | 4 | 100 mg | 1 | 0052 | Yes | +5°C ± 3°C | ||
R1000000 | Rifamycin sodium | 4 | 150 mg | 1 | see leaflet C–ŸH÷ÿNNaOŒœ | 0432.20702 | Yes | -20°C ± 5°C | |
R0900000 | Rifamycin B | 3 | 25 mg | 1 | See leaflet C–„H÷„NOŒ÷; Rifamycin impurity A | 0432 | Yes | +5°C ± 3°C | |
R0950000 | Rifamycin S | 3 | 100 mg | 1 | 0432 | Yes | +5°C ± 3°C | ||
Y0001074 | Riimin | 2 | 160 mg | 1 | See leaflet | 2362 | Yes | +5°C ± 3°C | |
Y0001075 | Riimin for system suitability | 1 | 10 mg | 1 | 2362 | Yes | +5°C ± 3°C | ||
Y0000250 | Rilmenidine dihydrogenophosphate - reference spectru | 1 | n/a | 1 | 2020 | ||||
Y0000187 | Rilmenidine for system suitability | 1 | 30 mg | 1 | 2020 | Yes | +5°C ± 3°C | ||
Y0001541 | Risedronate sodium 2.5-hydrate | 1 | 15 mg | 1 | 2572 | Yes | +5°C ± 3°C | ||
Y0001558 | Risedronate impurity A | 1 | 15 mg | 1 | See leaflet; [(3RS,6RS and 3R,6S-meso)-2,5-dihydroxy-2,5-dioxo-3,6-bis [(pyridin-3-yl)methyl]-1,4,2λ5,5λ5-dioxadiphosphinane-3,6-diyl]bis (phosphonic acid) | 2572 | Yes | +5°C ± 3°C | |
Y0001540 | Risedronate impurity E | 1 | 15 mg | 1 | [2-(pyridin-3-yl)ethylidene]bis(phosphonic acid) | 2572 | Yes | +5°C ± 3°C | |
R1000600 | Risperidone | 2 | 50 mg | 1 | 1559 | Yes | +5°C ± 3°C | ||
Y0001276 | Risperidone impurity K | 2 | 0.015 mg | 1 | 3-[2-[4-(1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9- tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (desfluoro risperidone) | 1559 | Yes | +5°C ± 3°C | |
Y0000370 | Risperidone for system suitability | 5 | 20 mg | 1 | 1559 | Yes | +5°C ± 3°C | ||
Y0000714 | Ritonavir | 1 | 80 mg | 1 | See leaflet C–ŸH÷‡NÿO—Sœ | 2136 | Yes | +5°C ± 3°C | |
Y0000706 | Ritonavir for peak identification | 1 | 10 mg | 1 | 2136 | Yes | +5°C ± 3°C | ||
Y0001516 | Rivastigmine hydrogen tartrate | 2 | 350 mg | 1 | See leaflet CŒ‡Hœ‡NœO‡ | 2629.2630 | Yes | +5°C ± 3°C | |
Y0001515 | Rivastigmine impurity D | 1 | 10 mg | 1 | 3-[(1R)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate ((R)- enantiomer) | 2629.2630 | Yes | +5°C ± 3°C | |
Y0001485 | Rivastigmine for system suitability | 1 | 1.0114 mg | 1 | 2629.2630 | Yes | +5°C ± 3°C | ||
Y0001302 | Rizatriptan benzoate | 1 | 200 mg | 1 | See leaflet CœœHœ—N—Oœ | 2585 | Yes | +5°C ± 3°C | |
Y0001303 | Rizatriptan for system suitability | 1 | 15 mg | 1 | 2585 | Yes | +5°C ± 3°C | ||
R1300000 | RK 13 cells | 1 | 1 ml | 2 | cell lines (kidney, rabbit) titration of live measles, mumps and rubella vaccines | 0162.1057 | Yes | Liquid nitrogen | |
Y0001580 | Rocuronium bromide | 1 | 10 mg | 1 | 1764 | Yes | -20°C ± 5°C | ||
Y0000527 | Rocuronium for peak identification | 1 | 10 mg | 1 | 1764 | Yes | -20°C ± 5°C | ||
Y0001773 | Ropinirole hydrochloride | 1 | 125 mg | 1 | See leaflet CŒÿHœ—ClNœO | 2604 | Yes | +5°C ± 3°C | |
Y0001774 | Ropinirole impurity A | 1 | 25 mg | 1 | 4-[2-(dipropylamino)ethyl]-1H-indole-2,3-dione | 2604 | Yes | +5°C ± 3°C | |
Y0001775 | Ropinirole for peak identification 1 | 1 | 15 mg | 1 | 2604 | Yes | +5°C ± 3°C | ||
Y0001776 | Ropinirole for peak identification 2 | 1 | 15 mg | 1 | 2604 | Yes | +5°C ± 3°C | ||
Y0000742 | Ropivacaine hydrochloride monohydrate | 1 | 10 mg | 1 | 2335 | Yes | +5°C ± 3°C | ||
Y0000743 | Ropivacaine impurity G | 2 | 5 mg | 1 | (+)-(2R)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide ((R)- ropivacaine) ; Batch 1 is valid until 31 March 2017 | 2335 | Yes | +5°C ± 3°C | |
Y0000786 | Rosmarinic acid | 3 | 50 mg | 1 | See leaflet CŒ‡HŒÿO‡ | 1447,2382, 2524,1229, 2723 | Yes | +5°C ± 3°C | |
Y0001719 | Rosuvastatin Calcium | 2 | 100 mg | 1 | See leaflet C÷÷H—÷CaFœNÿOŒœSœ ; Batch 1 is valid until 30 June 2016 | 2631 | Yes | +5°C ± 3°C | |
Y0001721 | Rosuvastatin for system suitability | 3 | 15 mg | 1 | Batch 1 is valid until 30 September 2016 Batch 2 is valid until 31 May 2017 | 2631 | Yes | +5°C ± 3°C | |
Y0001722 | Rosuvastatin impurity G | 2 | 0.004 mg | 1 | (3S,5R,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid | 2631 | Yes | +5°C ± 3°C | |
R1500000 | Roxithromycin | 5 | 125 mg | 1 | See leaflet C÷ŒHŸÿNœOŒ— | 1146 | Yes | +5°C ± 3°C | |
Y0000220 | Roxithromycin for system suitability | 2 | 10 mg | 1 | 1146 | Yes | +5°C ± 3°C | ||
R2000000 | Rubella vaccine (live) BRP | 1 | 90 mg | 1 | See leaflet; One sale unit is composed of a bag of 5 vials. The unit quantity of each vial is 18 mg. | 1057,0162,2 442 | Yes | -80°C ± 10°C | |
New | Y0001919 | Rupatadine for system suitability | 1 | 10 mg | 1 | 2888 | Yes | +5°C ± 3°C | |
New | Y0001922 | Rupatadine fumarate | 1 | 10 mg | 1 | 2888 | Yes | +5°C ± 3°C | |
Y0000494 | Ruscogenins | 1 | 10 mg | 1 | See leaflet | 1847 | Yes | +5°C ± 3°C | |
Y0000105 | Rutoside trihydrate | 3 | 100 mg | 1 | See leaflet CœŸH–ÐOŒÿ | 1795,1874,2 184, 2427,2639 | Yes | +5°C ± 3°C | |
S0040000 | Saccharin | 1 | 30 mg | 1 | 0947 | Yes | +5°C ± 3°C | ||
S0050000 | Saccharin sodium | 2 | 50 mg | 1 | Batch 1 is valid until 31 July 2017 | 0787 | Yes | +5°C ± 3°C | |
S0100000 | Salbutamol | 2 | 50 mg | 1 | 0529.1033 | Yes | +5°C ± 3°C | ||
New | Y0000030 | Salbutamol impurity B | 6 | 5 mg | 1 | (1RS)-2-[(1,1-dimethylethyl)amino]-1-(4-hydroxyphenyl)ethanol ; Batch 5 is valid until 31 December 2017 | 0529 | Yes | +5°C ± 3°C |
Y0000071 | Salbutamol impurity D | 6 | 10 mg | 1 | 5-[(1RS)-2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2- hydroxybenzaldehyde ; Batch 5 is valid until 30 November 2016 | 0529.0687 | Yes | +5°C ± 3°C | |
Y0000031 | Salbutamol impurity F | 6 | 10 mg | 1 | See leaflet; 1,1'-[oxybis[methylene(4-hydroxy-1,3-phenylene)]]bis[2-[(1,1- dimethylethyl)amino]ethanol] ; Batch 5 is valid until 31 May 2017 | 0529.0687 | Yes | +5°C ± 3°C | |
Y0000034 | Salbutamol impurity G | 4 | 10 mg | 1 | See leaflet CœÐHœ—NO–; 2-[benzyl(1,1-dimethylethyl)amino]-1-[4-hydroxy-3- (hydroxymethyl)phenyl]ethanone ; Batch 3 is valid until 31 March 2017 | 0529 | Yes | +5°C ± 3°C | |
Y0000032 | Salbutamol impurity I | 4 | 0.006 mg | 1 | (1RS)-2-[(1,1-dimethylethyl)amino]-1-[4-(benzyloxy)-3-(hydroxymethyl) phenyl]ethanol | 0529 | Yes | +5°C ± 3°C | |
Y0001186 | Salbutamol impurity J | 3 | 0.00045 mg | 1 | 2-[(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-(hydroxymethyl)phenyl] ethanone (salbutamone) ; Batch 2 is valid until 31 July 2017 | 0687 | Yes | +5°C ± 3°C | |
S0150000 | Salbutamol sulfate | 3 | 50 mg | 1 | 0687 | Yes | +5°C ± 3°C | ||
Y0001288 | Salbutamol sulfate for system suitability | 2 | 10 mg | 1 | 0687 | Yes | +5°C ± 3°C | ||
Y0000669 | Salicin | 1 | 50 mg | 1 | See leaflet CŒ–HŒ‡OŸ | 2312.1583 | Yes | +5°C ± 3°C | |
S0200000 | Salicylic acid | 2 | 100 mg | 1 | 0366.1185 | Yes | +5°C ± 3°C | ||
Y0000405 | Salicylic acid impurity B | 2 | 10 mg | 1 | 4-hydroxyisophthalic acid | 0366 | Yes | +5°C ± 3°C | |
Y0000422 | Salmeterol xinafoate | 3 | 70 mg | 1 | see leaflet ; Batch 2 is valid until 31 August 2017 | 1765 | Yes | +5°C ± 3°C | |
Y0001625 | Salmeterol xinafoate for peak identification | 1 | 15 mg | 1 | 1765 | Yes | +5°C ± 3°C | ||
Y0000423 | Salmeterol xinafoate for system suitability | 2 | 25 mg | 1 | 1765 | Yes | +5°C ± 3°C | ||
Y0001559 | Salvianolic acid B | 2 | 15 mg | 1 | See leaflet C–ÿH–ÐOŒÿ ; Batch 1 is valid until 15 December 2016 | 2663 | Yes | -20°C ± 5°C | |
Y0001052 | Santonin | 1 | 20 mg | 1 | See leaflet | 1391.1809 | Yes | +5°C ± 3°C | |
Y0001049 | Saquinavir mesilate | 1 | 70 mg | 1 | See leaflet C–„H—÷NÿO‡S | 2267 | Yes | +5°C ± 3°C | |
Y0001056 | Saquinavir for system suitability | 1 | 0.3033 mg | 1 | 2267 | Yes | +5°C ± 3°C | ||
Y0001483 | Saw palmetto extract HRS | 1 | 8000 mg | 1 | 1848, 2579 | Yes | -20°C ± 5°C | ||
Y0001818 | Schisandrin | 1 | 15 mg | 1 | See leaflet Cœ÷H–œOŸ | 2428 | Yes | +5°C ± 3°C | |
Y0000814 | Selamectin | 2 | 120 mg | 1 | see leaflet | 2268 | Yes | +5°C ± 3°C | |
Y0001734 | Selamectin for peak identification | 1 | 5 mg | 1 | 2268 | Yes | +5°C ± 3°C | ||
Y0001661 | Selamectin impurity B | 1 | 0.005 mg | 1 | (2aE,2'S,4E,5'S,6S,6'R,7S,8E,11R,15S,17aR,20Z,20aR,20bS)-6'- cyclohexyl-7-[(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)oxy]-20b- hydroxy-20-(hydroxyimino)-5',6,8,19-tetramethyl-5',6,6',7,10,11,14,15,17a, 20,20a,20b-dodecahydrospiro[2H,17H-11,15-methanofuro[4,3,2-pq][2,6] benzodioxacyclooctadecine-13,2'-pyran]-17-one ((5Z,25R)-25-cyclohexyl-4'- O-de(2,6-dideoxy-3-O-methyl-α-L-arabino-hexopyranosyl)-5-demethoxy-25- de(1-methylpropyl)-5-(hydroxyimino)avermectin A1a) | 2268 | Yes | +5°C ± 3°C | |
New | S0360000 | Selegiline hydrochloride | 2 | 50 mg | 2 | Batch 1 is valid until 30 November 2017 | 1260 | Yes | +5°C ± 3°C |
S0360090 | (RS)-Selegiline hydrochloride | 2 | 25 mg | 1 | 1260 | Yes | +5°C ± 3°C | ||
S0400000 | Senna extract | 1 | 50 mg | 1 | 0206,0207,0 208, 1261 | Yes | -20°C ± 5°C | ||
New | S0450000 | Serine | 2 | 50 mg | 1 | Batch 1 is valid until 31 December 2017 | 0788 | Yes | +5°C ± 3°C |
S0460000 | Sertaconazole nitrate | 2 | 125 mg | 1 | 1148 | Yes | +5°C ± 3°C | ||
Y0000828 | Sertraline hydrochloride | 3 | 200 mg | 1 | See leaflet | 1705 | Yes | +5°C ± 3°C | |
Y0001285 | Sertraline impurity E | 1 | 15 mg | 1 | (2R)-hydroxyphenylacetic acid ((R)-mandelic acid) | 1705 | Yes | +5°C ± 3°C | |
Y0000866 | Sertraline for peak identification | 5 | 5.4 mg | 1 | Batch 4 is valid until 31 March 2017 | 1705 | Yes | +5°C ± 3°C | |
Y0000867 | Sertraline for system suitability | 3 | 6.2 mg | 1 | 1705 | Yes | +5°C ± 3°C | ||
Y0000371 | Sestamibi labelling kit | 3 | 22 mg | 1 | 1926 | Yes | +5°C ± 3°C | ||
Y0001046 | Sevoflurane | 2 | 1 mL | 1 | 2269 | Yes | +5°C ± 3°C | ||
Y0001578 | Sildenafil citrate | 1 | 100 mg | 1 | See leaflet | 2270 | Yes | +5°C ± 3°C | |
Y0001891 | Sildenafil for peak identification | 1 | 15 mg | 1 | 2270 | Yes | +5°C ± 3°C | ||
Y0001579 | Sildenafil impurity A | 1 | 10 mg | 1 | 5-[2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2- methylpropyl)-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one | 2270 | Yes | +5°C ± 3°C | |
S0500000 | Silicone elastomer | 3 | 2000 mg | 1 | 30109 | Yes | +5°C ± 3°C | ||
S0600000 | Silicone oil | 2 | 1 mL | 1 | 30108 | Yes | +5°C ± 3°C | ||
New | S0650000 | Simvastatin | 6 | 200 mg | 1 | See leaflet ; Batch 5 is valid until 30 November 2017 | 1563 | Yes | -20°C ± 5°C |
Y0001066 | Simvastatin for peak identification | 1 | 10 mg | 1 | 1563 | Yes | -20°C ± 5°C | ||
Y0001208 | Sinomenine | 1 | 20 mg | 1 | See leaflet CŒ„Hœ–NO÷ | 2450 | Yes | +5°C ± 3°C | |
S0660000 | Sisomicin sulfate | 3 | 60 mg | 1 | See leaflet C–‡H‡÷NŒÐO–÷S— | 0331.1351 | Yes | -20°C ± 5°C | |
Y0001615 | Beta-sitosterol | 1 | 25 mg | 1 | See leaflet Cœ„H—ÐO | 2579 | Yes | -20°C ± 5°C | |
Y0001812 | Sitagliptin phosphate monohydrate | 1 | 160 mg | 1 | See leaflet CŒÿHŒ‡FÿN—O—, HœO | 2778.2927 | Yes | +5°C ± 3°C | |
Y0001811 | Sitagliptin containing impurity A | 1 | 15 mg | 1 | 2778 | Yes | +5°C ± 3°C | ||
Y0001727 | Sodium alendronate trihydrate | 2 | 150 mg | 1 | see leaflet C÷HŒœNNaOŸPœ,3HœO ; Batch 1 is valid until 31 December 2016 | 1564 | Yes | +5°C ± 3°C | |
Y0001678 | Sodium alendronate for system suitability | 1 | 5 mg | 1 | 1564 | Yes | +5°C ± 3°C | ||
S0695000 | Sodium amidotrizoate | 1 | 125 mg | 1 | 1150 | Yes | +5°C ± 3°C | ||
Y0001669 | Sodium aminosalicylate dihydrate | 1 | 10 mg | 1 | 1993 | Yes | +5°C ± 3°C | ||
Y0000300 | Sodium aminosalicylate dihydrate - reference spectrum | 1 | n/a | 1 | |||||
Y0000039 | Sodium ascorbate | 1 | 50 mg | 1 | 1791 | Yes | +5°C ± 3°C | ||
S0700000 | Sodium calcium edetate | 1 | 100 mg | 1 | 0231 | Yes | +5°C ± 3°C | ||
S0710000 | Sodium cetostearyl sulfate | 1 | 100 mg | 1 | 0847 | Yes | +5°C ± 3°C | ||
S0750000 | Sodium cromoglicate | 2 | 10 mg | 1 | 0562 | Yes | +5°C ± 3°C | ||
Y0001300 | Sodium cromoglicate for system suitability | 1 | 20 mg | 1 | 0562 | Yes | +5°C ± 3°C | ||
S0760000 | Sodium cyclamate | 2 | 100 mg | 1 | 0774 | Yes | +5°C ± 3°C | ||
Y0001410 | Sodium fusidate | 1 | 10 mg | 1 | 0848 | Yes | +5°C ± 3°C | ||
S0780000 | Sodium hyaluronate BRP | 2 | 300 mg | 1 | 0912 | Yes | +5°C ± 3°C | ||
S0781000 | Sodium hyaluronate - reference spectrum | 1 | n/a | 1 | 1472 | ||||
Y0001468 | Sodium iodohippurate | 1 | 15 mg | 1 | 2352 | Yes | +5°C ± 3°C | ||
Y0000620 | Sodium laurilsulfate | 1 | 40 mg | 1 | 0802 | Yes | +5°C ± 3°C | ||
Y0001772 | Sodium lauroylsarcosinate | 1 | 550 mg | 1 | 2542 | Yes | +5°C ± 3°C | ||
Y0000808 | Sodium phenylbutyrate | 1 | 5 mg | 1 | 2183 | Yes | +5°C ± 3°C | ||
Y0000809 | Sodium phenylbutyrate impurity C | 1 | 10 mg | 1 | 4-cyclohexylbutanoic acid | 2183 | Yes | +5°C ± 3°C | |
S0785000 | Sodium picosulfate | 2 | 50 mg | 1 | 1031 | Yes | +5°C ± 3°C | ||
Y0000210 | Sodium polystyrene sulfonate - reference spectrum | 1 | n/a | 1 | 1909 | ||||
Y0000268 | Sodium propionate - reference spectrum | 1 | n/a | 1 | 2041 | ||||
S0800000 | Sodium salicylate | 1 | 100 mg | 1 | 0413 | Yes | +5°C ± 3°C | ||
S0808000 | Sodium stearyl fumarate | 1 | 50 mg | 1 | 1567 | Yes | +5°C ± 3°C | ||
S0808060 | Sodium stearyl maleate | 2 | 10 mg | 1 | 1567 | Yes | +5°C ± 3°C | ||
S0900000 | Sodium taurocholate BRP | 2 | 10000 mg | 1 | 0350 | Yes | +5°C ± 3°C | ||
S0930000 | Sodium valproate | 5 | 50 mg | 1 | 0678 | Yes | +5°C ± 3°C | ||
Y0001743 | Solifenacin for system suitability | 1 | 2.52 mg | 1 | 2779 | Yes | +5°C ± 3°C | ||
Y0001763 | Solifenacin succinate | 1 | 5 mg | 1 | 2779 | Yes | +5°C ± 3°C | ||
S0945000 | Somatostatin | 6 | 2.09 mg | 1 | See leaflet | 0949 | Yes | -20°C ± 5°C | |
S0947000 | Somatropin | 3 | 55 mg | 1 | See leaflet | 0950, 0951,0952, 2370 | Yes | -20°C ± 5°C | |
Y0000711 | Somatropin/desamidosomatropin resolution mixture | 1 | 33 mg | 1 | See leaflet | 0950,0951,0 952 | Yes | -20°C ± 5°C | |
S0950000 | Sorbic acid | 2 | 10 mg | 1 | 0592 | Yes | +5°C ± 3°C | ||
Y0000385 | 1,4-Sorbitan | 2 | 50 mg | 1 | See leaflet CÿHŒœO— | 2048 | Yes | +5°C ± 3°C | |
S1000000 | Sorbitol | 4 | 1250 mg | 1 | See leaflet | 0435,0436,0 437, 1235,1236,1 337, 1381,1531,2 048 | Yes | +5°C ± 3°C | |
Y0000114 | Sotalol hydrochloride | 1 | 25 mg | 1 | 2004 | Yes | +5°C ± 3°C | ||
Y0000115 | Sotalol impurity B | 2 | 20 mg | 1 | N-[4-[[(1-methylethyl)amino]acetyl]phenyl]methanesulfonamide | 2004 | Yes | +5°C ± 3°C | |
Y0001011 | Spanish sage oil for peak identification | 2 | 250 mg | 1 | 1849 | Yes | +5°C ± 3°C | ||
Y0000549 | Spectinomycin for system suitability | 1 | 20 mg | 1 | 1152, 1658 | Yes | -20°C ± 5°C | ||
Y0000597 | Spectinomycin hydrochloride | 2 | 100 mg | 1 | See leaflet | 1152, 1658 | Yes | -20°C ± 5°C | |
Y0000655 | Spectinomycin sulfate tetrahydrate | 1 | 10 mg | 1 | 1658 | Yes | -20°C ± 5°C | ||
Y0001126 | Spike lavender oil | 1 | 400 µl | 1 | 2419 | Yes | +5°C ± 3°C | ||
S1100000 | Spiramycin | 6 | 200 mg | 1 | See leaflet ; Batch 5 is valid until 21 October 2016 | 0179,0293,1 982,20702 | Yes | -20°C ± 5°C | |
Y0000381 | Spirapril hydrochloride monohydrate | 1 | 60 mg | 1 | See leaflet CœœH–ŒClNœO—Sœ | 1766 | Yes | +5°C ± 3°C | |
Y0000332 | Spirapril for system suitability | 1 | 15 mg | 1 | 1766 | Yes | +5°C ± 3°C | ||
S1200000 | Spironolactone | 4 | 160 mg | 1 | See leaflet; Spironolactone CRS 2 is suitable for monograph 01/2008:0688 only. | 0688 | Yes | +5°C ± 3°C | |
Y0001295 | Spironolactone for system suitability | 2 | 2.057 mg | 1 | 0688 | Yes | +5°C ± 3°C | ||
Y0000185 | Squalane | 1 | 250 µl | 1 | See leaflet C–ÐHÿœ | 1630 | Yes | +5°C ± 3°C | |
Y0001050 | St. John's wort dry extract | 2 | 500 mg | 1 | See leaflet | 1874 | Yes | -20°C ± 5°C | |
S1250000 | Stanozolol | 2 | 50 mg | 1 | 1568 | Yes | +5°C ± 3°C | ||
S1250010 | Stanozolol impurity A | 1 | 10 mg | 1 | 17β-hydroxy-17-methyl-5α-androstan-3-one (mestanolone) | 1568 | Yes | +5°C ± 3°C | |
Y0001420 | Stanozolol impurity B | 1 | 10 mg | 1 | 17β-hydroxy-2-(hydroxymethylene)-17-methyl-5α-androstan-3-one (oxymetholone) | 1568 | Yes | +5°C ± 3°C | |
S1300000 | Starch BRP | 4 | 50000 mg | 1 | 0350 | Yes | +5°C ± 3°C | ||
Y0000408 | Stavudine | 1 | 100 mg | 1 | see leaflet | 2130 | Yes | +5°C ± 3°C | |
Y0001683 | Stavudine impurity I | 1 | 5 mg | 1 | 1-(5-O-benzoyl-2,3-dideoxy-β-d-glycero-pent-2-enofuranosyl)-5- methylpyrimidine-2,4(1H,3H)-dione | 2130 | Yes | +5°C ± 3°C | |
Y0000421 | Stavudine for system suitability | 1 | 10 mg | 1 | 2130 | Yes | +5°C ± 3°C | ||
New | S1340000 | Stearic acid | 4 | 100 mg | 1 | Plastic additive 19 ; Batch 3 is valid until 30 November 2017 | 0229,0882,1 474, 1663, 2058, 30103, 30105, | Yes | +5°C ± 3°C |
S1350000 | Stearyl alcohol | 2 | 250 mg | 1 | See leaflet CŒ‡H–‡O | 0702,0753,0 801, 0802,0847,0 969, 1123,1340,1 411 | Yes | +5°C ± 3°C | |
Y0000868 | Streptokinase for system suitability | 1 | 30 µl | 1 | 0356 | Yes | -20°C ± 5°C | ||
S1400000 | Streptomycin sulfate | 4 | 100 mg | 1 | See leaflet | 0032,0033,0 053, 0485,20702 | Yes | -20°C ± 5°C | |
Y0001195 | Strychnine | 1 | 40 mg | 1 | see leaflet | 2513.2514 | Yes | +5°C ± 3°C | |
Y0001324 | Sucralfate | 1 | 10 mg | 1 | 1796 | Yes | +5°C ± 3°C | ||
Y0001344 | Sucralose | 1 | 550 mg | 1 | See leaflet CŒœHŒ„Cl–O‡ | 2368 | Yes | +5°C ± 3°C | |
Y0001342 | Sucralose impurity B | 3 | 0.5 mg | 1 | 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl 6-chloro-6-deoxy-α-D-glucopyranoside (1',6,6'-trichloro- 1',6,6'-trideoxysucrose) ; Batch 2 is valid until 30 April 2017 | 2368 | Yes | +5°C ± 3°C | |
S1600000 | Sucrose | 1 | 100 mg | 1 | 0204,1570,2 318, 2319 | Yes | +5°C ± 3°C | ||
S1608100 | * - reference spectrum | 1 | n/a | 1 | 1569 | ||||
S1609000 | * citrate - reference spectrum | 1 | n/a | 1 | 1269 | ||||
Y0000528 | Sulbactam | 2 | 150 mg | 1 | See leaflet | 2209, 2211, 2212 | Yes | -20°C ± 5°C | |
Y0000529 | Sulbactam sodium | 1 | 10 mg | 1 | See leaflet | 2209 | Yes | +5°C ± 3°C | |
Y0000550 | Sulbactam for peak identification | 1 | 20 mg | 1 | 2209 | Yes | +5°C ± 3°C | ||
S1700000 | Sulfacetamide sodium | 1 | 50 mg | 1 | 0107.0295 | Yes | +5°C ± 3°C | ||
S1800000 | Sulfadiazine | 1 | 100 mg | 1 | 0294 | Yes | +5°C ± 3°C | ||
Y0001480 | Sulfadiazine for identification of impurity F | 1 | 15 mg | 1 | 0294 | Yes | +5°C ± 3°C | ||
Y0001469 | Sulfadiazine impurity A | 1 | 20 mg | 1 | pyrimidin-2-amine | 0294 | Yes | +5°C ± 3°C | |
Y0001677 | Sulfadimethoxine | 1 | 60 mg | 1 | see leaflet | 2741, 2745 | Yes | +5°C ± 3°C | |
Y0001679 | Sulfadimethoxine for peak identification | 1 | 10 mg | 1 | 2741, 2745 | Yes | +5°C ± 3°C | ||
S1900000 | Sulfadimidine | 1 | 100 mg | 1 | 0295 | Yes | +5°C ± 3°C | ||
Y0001495 | Sulfadimidine for peak identification | 1 | 50 mg | 1 | 0295 | Yes | +5°C ± 3°C | ||
S1950000 | Sulfadoxine | 2 | 50 mg | 1 | 0740 | Yes | +5°C ± 3°C | ||
S1975000 | Sulfafurazole | 1 | 100 mg | 1 | 0741 | Yes | +5°C ± 3°C | ||
S1975600 | Sulfaguanidine | 2 | 60 mg | 1 | 0295.1476 | Yes | +5°C ± 3°C | ||
S2000000 | Sulfamerazine | 1 | 100 mg | 1 | 0358.1571 | Yes | +5°C ± 3°C | ||
S2050000 | Sulfamethizole | 1 | 100 mg | 1 | 0637 | Yes | +5°C ± 3°C | ||
S2100000 | Sulfamethoxazole | 1 | 50 mg | 1 | 0108 | Yes | +5°C ± 3°C | ||
Y0000412 | Sulfamethoxazole impurity A | 1 | 5 mg | 1 | N-[4-[(5-methylisoxazol-3-yl)sulfamoyl]phenyl]acetamide | 0108 | Yes | +5°C ± 3°C | |
Y0000413 | Sulfamethoxazole impurity F | 3 | 5 mg | 1 | 4-amino-N-(3-methylisoxazol-5-yl)benzenesulfonamide | 0108 | Yes | +5°C ± 3°C | |
S2150000 | Sulfamethoxypyridazine | 1 | 50 mg | 1 | 0638 | Yes | +5°C ± 3°C | ||
S2151000 | Sulfanilamide | 2 | 100 mg | 1 | 1571 | Yes | +5°C ± 3°C | ||
S2159100 | Sulfapyridine | 1 | 20 mg | 1 | 0863 | Yes | +5°C ± 3°C | ||
S2155000 | Sulfasalazine | 4 | 250 mg | 2 | See leaflet CŒ‡HŒ÷N÷O—S | 0863.1457 | Yes | +5°C ± 3°C | |
S2155010 | Sulfasalazine derivative for resolution | 1 | 20 mg | 1 | 2-hydroxy-5-[[4-[[(6-methylpyridin-2-yl)amino]-sulfonyl]phenyl]azo]benzoic acid | 0863 | Yes | +5°C ± 3°C | |
S2158000 | Sulfathiazole | 2 | 100 mg | 1 | Batch 1 is valid until 31 July 2016 | 0742 | Yes | +5°C ± 3°C | |
S2159000 | Sulfinpyrazone | 1 | 30 mg | 1 | 0790 | Yes | +5°C ± 3°C | ||
S2159010 | Sulfinpyrazone impurity A | 3 | 20 mg | 1 | 1,2-diphenyl-4-[2-(phenylsulfonyl)ethyl]pyrazolidine-3,5-dione | 0790 | Yes | +5°C ± 3°C | |
S2159015 | Sulfinpyrazone impurity B | 3 | 20 mg | 1 | 1,2-diphenyl-4-[2-(phenylsulfanyl)ethyl]pyrazolidine-3,5-dione | 0790 | Yes | +5°C ± 3°C | |
Y0001238 | Sulfinpyrazone for system suitability | 1 | 0.5 mg | 1 | 0790 | Yes | +5°C ± 3°C | ||
S2180000 | Sulindac | 3 | 50 mg | 1 | See leaflet CœÐHŒŸFO–S; Contains 0.3% m/m of E-isomer | 0864 | Yes | +5°C ± 3°C | |
S2190000 | Sulpiride | 4 | 100 mg | 1 | 1045.1348 | Yes | +5°C ± 3°C | ||
S2191000 | Sulpiride impurity A | 4 | 20 mg | 1 | [(2RS)-1-ethylpyrrolidin-2-yl]methanamine | 1045.1490 | Yes | +5°C ± 3°C | |
S2192000 | Sulpiride impurity B | 3 | 10 mg | 1 | methyl 2-methoxy-5-sulfamoylbenzoate | 1045 | Yes | +5°C ± 3°C | |
Y0000530 | Sultamicillin | 1 | 10 mg | 1 | 2211 | Yes | +5°C ± 3°C | ||
Y0000532 | Sultamicillin for peak identification | 1 | 10 mg | 1 | 2211 | Yes | +5°C ± 3°C | ||
Y0000531 | Sultamicillin tosilate | 3 | 200 mg | 1 | See leaflet | 2211.2212 | Yes | +5°C ± 3°C | |
Y0000022 | Sumatriptan succinate | 1 | 50 mg | 1 | See leaflet CŒ‡HœŸN–OÿS | 1573 | Yes | -20°C ± 5°C | |
Y0000026 | Sumatriptan impurity mixture | 8 | 3 mg | 1 | 1573 | Yes | -20°C ± 5°C | ||
Y0000027 | Sumatriptan for system suitability | 6 | 10 mg | 1 | Batch 5 is valid until 30 June 2017 | 1573 | Yes | -20°C ± 5°C | |
S2200000 | Suxamethonium chloride | 1 | 1000 mg | 1 | 0248 | Yes | +5°C ± 3°C | ||
Y0001778 | Rabeprazole for system suitability | 1 | 15 mg | 1 | 2331.2868 | Yes | +5°C ± 3°C | ||
S2400000 | Suxibuzone | 1 | 50 mg | 1 | 1574 | Yes | +5°C ± 3°C | ||
S2400004 | Suxibuzone impurity B | 1 | 10 mg | 1 | (4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl ethyl butanedioate | 1574 | Yes | +5°C ± 3°C | |
S2400006 | Suxibuzone impurity C | 1 | 10 mg | 1 | 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-1,2-dihydro-4H-pyrazole-3,5-dione | 1574 | Yes | +5°C ± 3°C | |
S5000001 | Swine erysipelas bacteria, serotyp 1 (for vaccines - vet. use) BRP | 1 | 1 mg | 1 | See leaflet | See leaflet, 0064 | Yes | +5°C ± 3°C | |
S5000002 | Swine erysipelas bacteria, serotyp 2 (for vaccines - vet. use) BRP | 1 | 1 mg | 1 | See leaflet | See leaflet, 0064 | Yes | +5°C ± 3°C | |
Y0001854 | Tacalcitol monohydrate | 1 | 15 mg | 1 | see leaflet CœŸH÷÷O–,HœO | 2272 | Yes | -20°C ± 5°C | |
Y0001610 | Tacalcitol for system suitability | 1 | 0.025 mg | 1 | 2272 | Yes | -20°C ± 5°C | ||
Y0001824 | Tacalcitol impurity A | 1 | 0.001 mg | 1 | (5E,7E)-(24R)-9,10-secocholesta-5,7,10(19)-triene-1α,3β,24-triol (trans- tacalcitol) | 2272 | Yes | -20°C ± 5°C | |
New | Y0001933 | Tacrolimus for system suitability | 1 | 10 mg | 1 | 2244 | Yes | +5°C ± 3°C | |
Y0001910 | Tacalcitol monohydrate - reference spectrum | 1 | 1 | 1 | 2272 | ||||
Y0001417 | Tadalafil | 2 | 200 mg | 1 | see leaflet | 2606 | Yes | +5°C ± 3°C | |
T0010000 | Talampicillin hydrochloride | 1 | 50 mg | 1 | 0808.0852 | Yes | +5°C ± 3°C | ||
T0014000 | Tamoxifen citrate | 2 | 80 mg | 1 | 1046 | Yes | +5°C ± 3°C | ||
T0015000 | Tamoxifen citrate for performance test | 3 | 10 mg | 1 | 1046 | Yes | +5°C ± 3°C | ||
Y0000650 | Tamsulosin hydrochloride | 1 | 10 mg | 1 | 2131 | Yes | +5°C ± 3°C | ||
Y0000651 | Tamsulosin impurity D | 2 | 10 mg | 1 | 2-methoxy-5-[(2R)-2-[[2-(2-methoxyphenoxy)ethyl]amino]propyl] benzenesulfonamide | 2131 | Yes | +5°C ± 3°C | |
Y0000652 | Tamsulosin impurity H | 2 | 10 mg | 1 | (2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan-2-amine | 2131 | Yes | +5°C ± 3°C | |
Y0000653 | Tamsulosin racemate | 2 | 15 mg | 1 | 2131 | Yes | +5°C ± 3°C | ||
Y0001560 | Tanshinone IIa | 1 | 15 mg | 1 | See leaflet CŒ„HŒ‡O– | 2663 | Yes | +5°C ± 3°C | |
Y0001840 | Taxifolin | 1 | 15 mg | 1 | See leaflet CŒ—HŒœOŸ | 2726 | Yes | -20°C ± 5°C | |
Y0001102 | Teicoplanin | 2 | 50 mg | 1 | see leaflet | 2358 | Yes | -20°C ± 5°C | |
Y0001047 | Teicoplanin for identification | 1 | 40 mg | 1 | 2358 | Yes | -20°C ± 5°C | ||
Y0000648 | misartan | 1 | 30 mg | 1 | 2154 | Yes | +5°C ± 3°C | ||
Y0000649 | misartan for peak identification | 3 | 10 mg | 1 | Batch 2 is valid until 31 August 2016 | 2154 | Yes | +5°C ± 3°C | |
Y0001003 | misartan for system suitability | 4 | 0.26 mg | 1 | 2154 | Yes | +5°C ± 3°C | ||
T0040000 | Temazepam - * psy | 1 | 50 mg | 1 | 0954 | Yes | +5°C ± 3°C | ||
Y0000344 | Temazepam impurity C | 1 | 5 mg | 1 | (3RS)-7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4- benzodiazepin-3-yl acetate | 0954 | Yes | +5°C ± 3°C | |
Y0000345 | Temazepam impurity D | 1 | 5 mg | 1 | (3RS)-7-chloro-3-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4- benzodiazepin-2-one | 0954 | Yes | +5°C ± 3°C | |
Y0000346 | Temazepam impurity F | 2 | 10 mg | 1 | (5RS)-7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3- dione | 0954 | Yes | +5°C ± 3°C | |
Y0000347 | Temazepam impurity G | 1 | 5 mg | 1 | (5RS)-7-chloro-1,4-dimethyl-5-phenyl-4,5-dihydro-1H-1,4- benzodiazepine-2,3-dione | 0954 | Yes | +5°C ± 3°C | |
Y0001827 | Temozolomide | 1 | 70 mg | 1 | See leaflet CÿHÿNÿOœ | 2780 | Yes | +5°C ± 3°C | |
T0040800 | Tenoxicam | 2 | 100 mg | 1 | 1156 | Yes | +5°C ± 3°C | ||
Y0001114 | Tenoxicam impurity mixture | 1 | 0.0042 mg | 1 | 1156 | Yes | +5°C ± 3°C | ||
Y0000621 | Terazosin hydrochloride dihydrate | 1 | 40 mg | 1 | 2021 | Yes | +5°C ± 3°C | ||
Y0000622 | Terazosin impurity A | 1 | 10 mg | 1 | 2-chloro-6,7-dimethoxyquinazolin-4-amine | 2021 | Yes | +5°C ± 3°C | |
Y0000665 | Terazosin impurity E | 1 | 10 mg | 1 | 2,2'-(piperazine-1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine) | 2021 | Yes | +5°C ± 3°C | |
Y0000623 | Terazosin impurity L | 1 | 10 mg | 1 | 1-(furan-2-ylcarbonyl)piperazine | 2021 | Yes | +5°C ± 3°C | |
Y0000624 | Terazosin impurity N | 1 | 10 mg | 1 | See leaflet C„HŒÿNœOœ; 1-[[(2RS)-tetrahydrofuran-2-yl]carbonyl]piperazine | 2021 | Yes | +5°C ± 3°C | |
Y0000666 | Terazosin for system suitability | 1 | 0.5 mg | 1 | 2021 | Yes | +5°C ± 3°C | ||
Y0000535 | Terbinafine hydrochloride | 1 | 10 mg | 1 | 1734 | Yes | +5°C ± 3°C | ||
Y0001143 | Terbinafine for system suitability | 2 | 10 mg | 1 | 1734 | Yes | +5°C ± 3°C | ||
T0050000 | Terbutaline sulfate | 2 | 100 mg | 1 | 0690, 2451 | Yes | +5°C ± 3°C | ||
T0050015 | Terbutaline impurity C | 4 | 15 mg | 1 | 1-(3,5-dihydroxyphenyl)-2-[(1,1-dimethylethyl)amino]ethanone ; Batch 3 is valid until 30 November 2016 | 0690 | Yes | +5°C ± 3°C | |
T0060000 | Terconazole | 2 | 250 mg | 1 | 1270 | Yes | +5°C ± 3°C | ||
T0071000 | Terfenadine | 1 | 100 mg | 1 | 0955 | Yes | +5°C ± 3°C | ||
T0080000 | Terfenadine impurity A | 2 | 20 mg | 1 | 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(hydroxydiphenylmethyl) piperidin-1-yl] butan-1-one | 0955 | Yes | +5°C ± 3°C | |
Y0001895 | Teriparatide for system suitability | 1 | 1.3 mg | 1 | 2829 | Yes | -20°C ± 5°C | ||
New | Y0001898 | Terlipressin for NMR identification | 1 | 2.9 mg | 1 | 2646 | Yes | -20°C ± 5°C | |
New | Y0001899 | Terlipressin impurity mixture | 1 | 0.03 mg | 1 | 2646 | Yes | -20°C ± 5°C | |
T0100000 | Testosterone | 3 | 30 mg | 1 | 1373, 1048 | Yes | +5°C ± 3°C | ||
Y0000342 | Testosterone for impurity D identification | 2 | 20 mg | 1 | 1373 | Yes | +5°C ± 3°C | ||
Y0000343 | Testosterone for system suitability | 3 | 20 mg | 1 | 1373 | Yes | +5°C ± 3°C | ||
T0210000 | Testosterone caproate | 1 | 50 mg | 1 | 1048 | Yes | +5°C ± 3°C | ||
T0240000 | Testosterone decanoate | 2 | 50 mg | 1 | See leaflet Cœ„H÷ÿO– | 1048, 1736 | Yes | -20°C ± 5°C | |
Y0000696 | Testosterone decanoate for system suitability | 1 | 0.4 mg | 1 | 1736 | Yes | -20°C ± 5°C | ||
T0250000 | Testosterone enantate | 2 | 40 mg | 1 | Batch 1 is valid until 31 October 2016 | 1048 | Yes | -20°C ± 5°C | |
Y0001313 | Testosterone enantate impurity H | 1 | 10 mg | 1 | androst-5-ene-3β,17β-diyl diheptanoate | 1048 | Yes | -20°C ± 5°C | |
Y0001312 | Testosterone enantate for peak identification | 1 | 10 mg | 1 | 1048 | Yes | -20°C ± 5°C | ||
Y0001317 | Testosterone enantate for system suitability | 1 | 2 mg | 1 | 1048 | Yes | -20°C ± 5°C | ||
T0260000 | Testosterone isocaproate | 2 | 50 mg | 1 | See leaflet Cœ—H–‡O– | 1048.1737 | Yes | +5°C ± 3°C | |
Y0000716 | Testosterone isocaproate for system suitability | 1 | 5 mg | 1 | 1737 | Yes | +5°C ± 3°C | ||
T0300000 | Testosterone propionate | 2 | 60 mg | 1 | See leaflet CœœH–œO– | 0297 | Yes | +5°C ± 3°C | |
New | Y0001409 | Testosterone propionate for system suitability | 2 | 10 mg | 1 | Batch 1 is valid until 30 September 2017 | 0297 | Yes | +5°C ± 3°C |
T0400000 | Tetanus vaccine (adsorbed) | 3 | 30 mg | 1 | See leaflet | See leaflet, 20708 | Yes | -20°C ± 5°C | |
T0500000 | Tetracaine hydrochloride | 1 | 100 mg | 1 | 0057 | Yes | +5°C ± 3°C | ||
Y0001002 | Tetracaine for system suitability | 1 | 2 mg | 1 | 0057 | Yes | +5°C ± 3°C | ||
T0550000 | Tetracosactide | 3 | 20.4 mg | 2 | See leaflet CŒ–ÿHœŒÐN÷ÐO–ŒS | 0644 | Yes | -20°C ± 5°C | |
T0600000 | Tetracycline hydrochloride | 3 | 100 mg | 1 | See leaflet CœœHœ—ClNœO‡ | 0173, 0210,0211,1 654 | Yes | +5°C ± 3°C | |
Y0001165 | Tetrandrine | 1 | 20 mg | 1 | See leaflet C–‡H÷œNœOÿ | 2478 | Yes | +5°C ± 3°C | |
New | Y0001087 | Tetra-O-acetyl-mannose triflate | 2 | 80 mg | 1 | See leaflet CŒ—HŒ„F–OŒœS ; Batch 1 is valid until 30 November 2017 | 2294 | Yes | -20°C ± 5°C |
Y0000015 | Tetrazepam - reference spectrum | 1 | n/a | 1 | 1738 | ||||
Y0000008 | Tetrazepam impurity C | 1 | 20 mg | 1 | 7-chloro-5-cyclohexyl-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one | 1738 | Yes | +5°C ± 3°C | |
Y0000460 | Tetryzoline hydrochloride | 1 | 10 mg | 1 | 2101 | Yes | +5°C ± 3°C | ||
Y0000723 | Thebaine - * narc | 1 | 15 mg | 1 | see leaflet | 0777,1839,1 840,1841 | Yes | +5°C ± 3°C | |
T0700000 | Theobromine | 2 | 25 mg | 1 | 0298 | Yes | +5°C ± 3°C | ||
T0800000 | Theophylline | 1 | 100 mg | 1 | 0300.0301 | Yes | +5°C ± 3°C | ||
Y0000294 | Theophylline - reference spectrum | 1 | n/a | 1 | 0299.0302 | ||||
Y0000336 | Thiamazole | 1 | 125 mg | 1 | 0884.1706 | Yes | +5°C ± 3°C | ||
Y0000372 | Thiamazole impurity A | 1 | 15 mg | 1 | 2,2-dimethoxy-N-methylethanamine | 1706 | Yes | +5°C ± 3°C | |
Y0000373 | Thiamazole impurity C | 4 | 20 mg | 1 | 1-methyl-2-(methylsulfanyl)-1H-imidazole ; Batch 2 is valid until 30 November 2016 Batch 3 is valid until 31 March 2017 | 1706 | Yes | +5°C ± 3°C | |
Y0000467 | Thiamine hydrochloride | 2 | 10 mg | 1 | 0303 | Yes | +5°C ± 3°C | ||
Y0001749 | Thiamine for system suitability | 1 | 0.5 mg | 1 | 0303.0531 | Yes | +5°C ± 3°C | ||
Y0001758 | Thiamine nitrate | 1 | 15 mg | 1 | 0531 | Yes | +5°C ± 3°C | ||
T1100000 | Thiamphenicol | 1 | 125 mg | 1 | 0109 | Yes | +5°C ± 3°C | ||
Y0001789 | Thiocolchicoside hydrate | 1 | 60 mg | 1 | See leaflet CœŸH––NOŒÐS | 2814.2896 | Yes | +5°C ± 3°C | |
Y0001790 | Thiocolchicoside crystallised from ethanol | 1 | 10 mg | 1 | 2896 | Yes | +5°C ± 3°C | ||
Y0001791 | Thiocolchicoside for system suitability | 1 | 10 mg | 1 | 2814.2896 | Yes | +5°C ± 3°C | ||
Y0000546 | Thioctic acid | 2 | 110 mg | 1 | See leaflet | 1648 | Yes | +5°C ± 3°C | |
Y0000545 | Thioctic acid containing impurity B | 2 | 25 mg | 1 | 1648 | Yes | +5°C ± 3°C | ||
Y0000592 | Thioctic acid for system suitability | 2 | 15 mg | 1 | Batch 1 is valid until 30 June 2016 | 1648 | Yes | +5°C ± 3°C | |
Y0000109 | Thiomersal | 1 | 30 mg | 1 | 1625 | Yes | +5°C ± 3°C | ||
T1200000 | Thiopental | 1 | 500 mg | 1 | 0212 | Yes | +5°C ± 3°C | ||
New | Y0001478 | Thiopental for system suitability | 2 | 10 mg | 1 | Batch 1 is valid until 31 December 2017 | 0212 | Yes | +5°C ± 3°C |
Y0000704 | Thioridazine | 1 | 10 mg | 1 | 2005 | Yes | +5°C ± 3°C | ||
T1300000 | Thioridazine hydrochloride | 1 | 100 mg | 1 | 0586 | Yes | +5°C ± 3°C | ||
Y0000541 | Thioridazine for system suitability | 1 | 0.21 mg | 1 | 0586, 2005 | Yes | +5°C ± 3°C | ||
T1305100 | Thioxanthene | 3 | 20 mg | 1 | 1347 | Yes | +5°C ± 3°C | ||
T1305000 | Thioxanthone | 2 | 10 mg | 1 | 1347 | Yes | +5°C ± 3°C | ||
T1340000 | Threonine | 1 | 50 mg | 1 | 1049 | Yes | +5°C ± 3°C | ||
T1350000 | Thymol | 2 | 50 mg | 1 | 0791 | Yes | +5°C ± 3°C | ||
T1410000 | Tiabendazole | 1 | 50 mg | 1 | 0866 | Yes | +5°C ± 3°C | ||
Y0000379 | Tiamulin - reference spectrum | 1 | n/a | 1 | 1660 | ||||
Y0000333 | Tiamulin hydrogen fumarate | 2 | 500 mg | 1 | See leaflet C–œH—ŒNO‡S | 1659.1660 | Yes | +5°C ± 3°C | |
Y0000414 | Tiamulin for peak identification | 2 | 10 mg | 1 | 1659 | Yes | +5°C ± 3°C | ||
Y0000151 | Tianeptine sodium - reference spectrum | 1 | n/a | 1 | 2022 | ||||
Y0000153 | Tianeptine impurity A | 1 | 30 mg | 1 | ethyl 7-bromoheptanoate | 2022 | Yes | +5°C ± 3°C | |
Y0000152 | Tianeptine for system suitability | 1 | 30 mg | 1 | 2022 | Yes | +5°C ± 3°C | ||
T1405000 | Tiapride hydrochloride | 1 | 60 mg | 1 | 1575 | Yes | +5°C ± 3°C | ||
T1405050 | Tiapride N-oxide | 1 | 20 mg | 1 | 1575 | Yes | +5°C ± 3°C | ||
T1410900 | Tiaprofenic acid | 1 | 50 mg | 1 | 1157 | Yes | +5°C ± 3°C | ||
T1410910 | Tiaprofenic acid impurity C | 1 | 20 mg | 1 | (2RS)-2-(5-benzoylthiophen-3-yl)propanoic acid | 1157 | Yes | +5°C ± 3°C | |
Y0000748 | Tibolone - reference spectrum | 1 | n/a | 1 | 1739 | ||||
Y0000668 | Tibolone for system suitability | 1 | 10 mg | 1 | 1739 | Yes | +5°C ± 3°C | ||
Y0000465 | Ticarcillin monosodium | 3 | 250 mg | 1 | see leaflet ; Batch 2 is valid until 8 February 2017 | 0956 | Yes | -20°C ± 5°C | |
T1420010 | Ticarcillin impurity A | 2 | 50 mg | 1 | See leaflet; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(thiophen-3-yl)acetyl]- amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid (decarboxyticarcillin) | 0956 | Yes | +5°C ± 3°C | |
T1423000 | Ticlopidine hydrochloride | 3 | 50 mg | 1 | 1050 | Yes | +5°C ± 3°C | ||
T1423025 | Ticlopidine impurity F | 3 | 15 mg | 1 | 6-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine ; Batch 2 is valid until 31 August 2016 | 1050 | Yes | +5°C ± 3°C | |
Y0000325 | Tilidine hydrochloride hemihydrate - reference spectrum | 1 | n/a | 1 | 1767 | ||||
Y0000644 | (R)-timolol | 2 | 20 mg | 1 | 0572 | Yes | +5°C ± 3°C | ||
T1450000 | Timolol maleate | 3 | 100 mg | 1 | 0572 | Yes | +5°C ± 3°C | ||
Y0001690 | Timolol impurity F | 1 | 10 mg | 1 | 4-(4-chloro-1,2,5-thiadiazol-3-yl)morpholine | 0572 | Yes | +5°C ± 3°C | |
Y0001270 | Timolol for system suitability | 2 | 5.045 mg | 1 | 0572 | Yes | +5°C ± 3°C | ||
T1470000 | Tinidazole | 1 | 100 mg | 1 | 1051 | +5°C ± 3°C | |||
Y0000899 | Tinidazole impurity A | 1 | 15 mg | 1 | 2-methyl-5-nitro-1H-imidazole | 1051 | Yes | +5°C ± 3°C | |
T1471000 | Tinidazole impurity B | 4 | 20 mg | 1 | 1-[2-(ethylsulphonyl)ethyl]-2-methyl-4-nitro-1H-imidazole | 1051 | Yes | +5°C ± 3°C | |
T1490000 | Tinzaparin sodium | 1 | 250 mg | 1 | 1271 | Yes | +5°C ± 3°C | ||
Y0000292 | Tioconazole - reference spectrum | 1 | n/a | 1 | 2074 | ||||
Y0000282 | Tioconazole for system suitability | 1 | 50 mg | 1 | 2074 | Yes | +5°C ± 3°C | ||
Y0001188 | Tiotropium bromide monohydrate | 1 | 10 mg | 1 | 2420 | Yes | +5°C ± 3°C | ||
Y0001216 | Tiotropium impurity F | 3 | 15 mg | 1 | dithiophen-2-ylmethanone ; Batch 2 is valid until 30 September 2017 | 2420 | Yes | +5°C ± 3°C | |
Y0001189 | Tiotropium for system suitability | 2 | 10 mg | 1 | 2420 | Yes | +5°C ± 3°C | ||
New | Y0001929 | Tiotropium for system suitability 1 | 1 | 10 mg | 1 | 2420 | Yes | +5°C ± 3°C | |
Y0001179 | Tiotropium impurity mixture | 2 | 0.08 mg | 1 | 2420 | Yes | +5°C ± 3°C | ||
Y0001700 | Tizanidine hydrochloride | 1 | 100 mg | 1 | See leaflet C„H„ClœN—S | 2578 | Yes | +5°C ± 3°C | |
Y0001698 | Tizanidine impurity B | 1 | 10 mg | 1 | N-(5-chloro-2,1,3-benzothiadiazol-4-yl)thiourea | 2578 | Yes | +5°C ± 3°C | |
T1500000 | Tobramycin | 4 | 49 mg | 1 | See leaflet CŒ‡H–ŸN—O„; Suitable for LC assay only | 0645 | Yes | +5°C ± 3°C | |
Y0001210 | Tobramycin for identification | 1 | 250 mg | 1 | Suitable for identification tests only | 0645 | Yes | +5°C ± 3°C | |
New | T1550000 | alpha-Tocopherol | 8 | 1.5 mL | 1 | See leaflet Cœ„H—ÐOœ ; Vitamin E ; Batch 7 is valid until 8 October 2016 | 0692.1256 | Yes | +5°C ± 3°C |
T1600000 | alpha-Tocopheryl acetate | 9 | 500 mg | 1 | See leaflet C–ŒH—œO– | 0439,0691,1 257 | Yes | +5°C ± 3°C | |
Y0000383 | All-rac-alpha-tocopherol for peak identification | 3 | 50 mg | 1 | 0692 | Yes | +5°C ± 3°C | ||
Y0000384 | All-rac-alpha-tocopheryl acetate for peak identification | 2 | 30 mg | 1 | 0439 | Yes | +5°C ± 3°C | ||
T1610000 | RRR-alpha-Tocopheryl hydrogen succinate | 1 | 150 mg | 1 | See leaflet C––H—÷O— | 1258.1259 | Yes | +5°C ± 3°C | |
T1700000 | Tolbutamide | 1 | 100 mg | 1 | 0304 | Yes | +5°C ± 3°C | ||
Y0000154 | Tolfenamic acid | 1 | 100 mg | 1 | 2039 | Yes | +5°C ± 3°C | ||
T1707000 | Tolnaftate | 1 | 60 mg | 1 | 1158 | Yes | +5°C ± 3°C | ||
Y0001123 | Tolnaftate for system suitability | 1 | 10 mg | 1 | 1158 | Yes | +5°C ± 3°C | ||
Y0001696 | Tolterodine tartrate | 1 | 5 mg | 1 | 2781 | Yes | +5°C ± 3°C | ||
Y0001699 | Tolterodine impurity E | 1 | 5 mg | 1 | 4-methyl-2-[(1RS)-3-[(1-methylethyl)amino]-1-phenylpropyl]phenol | 2781 | Yes | +5°C ± 3°C | |
Y0001697 | Tolterodine for system suitability | 1 | 5 mg | 1 | 2781 | Yes | +5°C ± 3°C | ||
Y0000461 | Torasemide anhydrous | 1 | 10 mg | 1 | 2132 | Yes | +5°C ± 3°C | ||
Y0001366 | Torasemide impurity E | 2 | 0.0006 mg | 1 | ethyl [[4-[(3-methylphenyl)amino]pyridin-3-yl]sulfonyl]carbamate ; Batch 1 is valid until 31 August 2017 | 2132 | Yes | +5°C ± 3°C | |
Y0000462 | Torasemide for system suitability | 2 | 5 mg | 1 | 2132 | Yes | +5°C ± 3°C | ||
Y0000155 | Tramadol hydrochloride | 3 | 75 mg | 1 | 1681 | Yes | +5°C ± 3°C | ||
Y0000156 | Tramadol impurity A | 4 | 25 mg | 1 | (1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol | 1681 | Yes | +5°C ± 3°C | |
Y0000157 | Tramadol impurity E | 4 | 15 mg | 1 | (2RS)-2-[(dimethylamino)methyl]cyclohexanone ; Batch 3 is valid until 31 January 2017 | 1681 | Yes | +5°C ± 3°C | |
Y0000072 | Tramazoline hydrochloride monohydrate | 1 | 20 mg | 1 | 1597 | Yes | +5°C ± 3°C | ||
Y0000065 | Tramazoline impurity A | 2 | 15 mg | 1 | N-(naphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine | 1597 | Yes | +5°C ± 3°C | |
Y0000066 | Tramazoline impurity B | 2 | 15 mg | 1 | See leaflet; Mixture of 1-acetyl-N-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5- dihydro-1H-imidazol-2-amine and 1-[(EZ)-1-[(5,6,7,8- tetrahydronaphthalen-1-yl)imino]ethyl]imidazolidin-2-one ; Batch 1 is valid | 1597 | Yes | +5°C ± 3°C | |
Y0000501 | Trandolapril | 1 | 10 mg | 1 | 2245 | Yes | +5°C ± 3°C | ||
Y0000495 | Trandolapril impurity C | 1 | 10 mg | 1 | (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino] propanoyl]octahydro-1H-indole-2-carboxylic acid (hexahydrotrandolapril) | 2245 | Yes | +5°C ± 3°C | |
Y0000496 | Trandolapril impurity D | 1 | 10 mg | 1 | ethyl (2S)-2-[(3S,5aS,9aR,10aS)-3-methyl-1,4-dioxodecahydropyrazi,2- a]indol-2(1H)-yl]-4-phenylbutanoate (trandolapril diketopiperazine) | 2245 | Yes | +5°C ± 3°C | |
T1810000 | Tranexamic acid | 5 | 50 mg | 1 | 0875 | Yes | +5°C ± 3°C | ||
T1820000 | Trapidil | 1 | 50 mg | 1 | 1576 | Yes | +5°C ± 3°C | ||
T1820002 | Trapidil impurity A | 1 | 20 mg | 1 | 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol | 1576 | Yes | +5°C ± 3°C | |
T1820004 | Trapidil impurity B | 1 | 20 mg | 1 | 1,2,4-triazol-3-amine | 1576 | Yes | +5°C ± 3°C | |
Y0001172 | Trehalose dihydrate | 1 | 250 mg | 1 | See leaflet CŒœHœœOŒŒ,2HœO | 2297 | Yes | +5°C ± 3°C | |
T1850000 | Tretinoin | 2 | 50 mg | 1 | 0693,1019,1 385 | Yes | +5°C ± 3°C | ||
G0400010 | Triacetin - reference spectrum | 1 | n/a | 1 | 1106 | ||||
T1899990 | Triamcinolone | 2 | 150 mg | 1 | 1376 | Yes | +5°C ± 3°C | ||
Y0000050 | Triamcinolone impurity C | 1 | 10 mg | 1 | 9-fluoro-11β,16α,17,21-tetrahydroxypregn-4-ene-3,20-dione (pretriamcinolone) | 1376 | Yes | +5°C ± 3°C | |
T1900000 | Triamcinolone acetonide | 6 | 150 mg | 1 | See leaflet Cœ÷H–ŒFOÿ | 0533,0867,1 075 | Yes | +5°C ± 3°C | |
Y0001459 | Triamcinolone acetonide for system suitability | 1 | 10 mg | 1 | 0533 | Yes | +5°C ± 3°C | ||
T1950000 | Triamcinolone hexacetonide | 3 | 100 mg | 1 | See leaflet C–ÐH÷ŒFOŸ ; Batch 2 is valid until 31 December 2016 | 0533.0867 | Yes | +5°C ± 3°C | |
Y0000837 | Triamterene | 1 | 10 mg | 1 | 0058 | Yes | +5°C ± 3°C | ||
Y0000870 | Triamterene impurity B | 1 | 0.5 mg | 1 | 2,7-diamino-6-phenylpteridin-4-ol | 0058 | Yes | +5°C ± 3°C | |
T1975000 | Triazolam - * psy | 1 | 10 mg | 1 | 1065 | Yes | +5°C ± 3°C | ||
Y0000165 | Tribenoside | 3 | 150 mg | 1 | See leaflet | 1740 | Yes | -20°C ± 5°C | |
Y0000166 | Tribenoside impurity A | 4 | 70 mg | 1 | See leaflet C–ÐH–÷Oÿ; 3,5,6-tri-O-benzyl-1,2-O-(1-methylethylidene)-α-d- glucofuranose | 1740 | Yes | -20°C ± 5°C | |
Y0001628 | Tribenoside impurity D | 1 | 35 mg | 1 | Benzyl ether | 1740 | +5°C ± 3°C | ||
Y0001055 | Tributyl acetylcitrate | 2 | 1 mL | 1 | 1770 | Yes | +5°C ± 3°C | ||
Y0000799 | Tributyl acetylcitrate for peak identification | 1 | 25 mg | 1 | 1770 | Yes | +5°C ± 3°C | ||
T1977990 | Tricaprin | 2 | 150 mg | 1 | Batch 1 is valid until 31 May 2017 | 1410 | Yes | -20°C ± 5°C | |
T1977995 | Tricaproin | 1 | 40 mg | 1 | 1410 | Yes | -20°C ± 5°C | ||
T1978000 | Tricaprylin | 1 | 225 mg | 1 | 1410 | Yes | -20°C ± 5°C | ||
Y0000111 | Trichloroacetic acid - reference spectrum | 1 | n/a | 1 | 1967 | ||||
T1985000 | Trichlorotrifluoroethane | 1 | 2.5 ml | 1 | 0393 | Yes | +5°C ± 3°C | ||
Y0001737 | Triclabendazole | 1 | 10 mg | 1 | 2609 | Yes | +5°C ± 3°C | ||
Y0001723 | Triclabendazole for system suitability | 1 | 0.012 mg | 1 | 2609 | Yes | +5°C ± 3°C | ||
T1986000 | Triethyl citrate - reference spectrum | 1 | n/a | 1 | 1479 | ||||
T2000000 | Trifluoperazine hydrochloride | 1 | 100 mg | 1 | 0059 | Yes | +5°C ± 3°C | ||
T2005000 | Triflusal | 1 | 50 mg | 1 | 1377 | Yes | +5°C ± 3°C | ||
T2005010 | Triflusal impurity B | 1 | 15 mg | 1 | 2-hydroxy-4-(trifluoromethyl)benzoic acid (4-(trifluoromethyl)salicylic acid) | 1377 | Yes | +5°C ± 3°C | |
Y0000720 | Triglycerol diisostearate | 1 | 200 mg | 1 | 2032 | Yes | +5°C ± 3°C | ||
Y0000108 | Trihexyphenidyl hydrochloride | 1 | 100 mg | 1 | 1626 | Yes | +5°C ± 3°C | ||
Y0000068 | Trihexyphenidyl impurity A | 1 | 20 mg | 1 | 1-phenyl-3-(piperidin-1-yl)propan-1-one | 1626 | Yes | +5°C ± 3°C | |
T2009000 | Trilaurin | 3 | 1250 mg | 1 | 1410 | Yes | -20°C ± 5°C | ||
Y0001319 | Trimebutine maleate | 1 | 10 mg | 1 | 2182 | Yes | +5°C ± 3°C | ||
Y0001260 | Trimebutine for system suitability | 2 | 1.02 mg | 1 | 2182 | Yes | +5°C ± 3°C | ||
Y0000092 | Trimetazidine dihydrochloride - reference spectrum | 1 | n/a | 1 | 1741 | ||||
Y0000093 | Trimetazidine for system suitability | 3 | 50 mg | 1 | 1741 | Yes | +5°C ± 3°C | ||
T2100000 | Trimethadione | 1 | 250 mg | 1 | See leaflet CÿH„NO– | 0440 | Yes | +5°C ± 3°C | |
T2200000 | Trimethoprim | 1 | 50 mg | 1 | 0060 | Yes | +5°C ± 3°C | ||
T2200010 | Trimethoprim impurity B | 5 | 15 mg | 1 | (2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone | 0060 | Yes | +5°C ± 3°C | |
Y0000684 | Trimethoprim for system suitability | 4 | 0.00075 mg | 1 | Batch 3 is valid until 30 November 2016 | 0060 | Yes | +5°C ± 3°C | |
Y0001497 | 3-trimethylsilyl-1-propanesulfonic acid sodium salt | 2 | 120 mg | 1 | See leaflet CÿHŒ—O–SSi,Na | 2645, 2165 | Yes | +5°C ± 3°C | |
T2450000 | Trimethyltetradecylammonium bromide | 2 | 200 mg | 1 | 0378 | Yes | +5°C ± 3°C | ||
T2500000 | Trimipramine maleate | 1 | 100 mg | 1 | 0534 | Yes | +5°C ± 3°C | ||
Y0000759 | Trimipramine for peak identification | 1 | 0.51 mg | 1 | 0534 | Yes | +5°C ± 3°C | ||
T2500100 | Trimyristin | 2 | 500 mg | 1 | 1410 | Yes | -20°C ± 5°C | ||
Y0000279 | Tri-n-butyl phosphate | 1 | 300 µl | 1 | 1682 | Yes | +5°C ± 3°C | ||
New | Y0001113 | Triolein | 2 | 30 mg | 1 | See leaflet C—ŸHŒÐ÷Oÿ | 2454 | Yes | -20°C ± 5°C |
T2501200 | Tristearin | 1 | 100 mg | 1 | 1410 | Yes | -20°C ± 5°C | ||
T2545000 | Trolamine | 3 | 2250 mg | 1 | 1577 | Yes | +5°C ± 3°C | ||
Y0001184 | Trolamine impurity A | 2 | 250 mg | 1 | 2-aminoethanol (ethanolamine) ; Batch 1 is valid until 30 June 2016 | 1577 | Yes | +5°C ± 3°C | |
Y0001183 | Trolamine impurity B | 3 | 1.5 mL | 1 | 2,2′-iminodiethanol (diethanolamine) ; Batch 1 is valid until 31 August 2016 | 1577 | Yes | +5°C ± 3°C | |
T2550000 | Trometamol | 4 | 100 mg | 1 | Batch 3 is valid until 31 January 2017 | 1053 | Yes | +5°C ± 3°C | |
T2580000 | Tropicamide | 2 | 50 mg | 1 | 1159.1197 | Yes | +5°C ± 3°C | ||
Y0001247 | Tropicamide impurity C | 1 | 10 mg | 1 | (2RS)-3-hydroxy-2-phenylpropanoic acid (tropic acid) | 1159 | Yes | +5°C ± 3°C | |
Y0001248 | Tropicamide impurity D (Phenylacetic acid - * Drug Precursor) | 1 | 10 mg | 1 | Phenylacetic acid | 1159 | Yes | +5°C ± 3°C | |
Y0001316 | Tropicamide for peak identification | 1 | 10 mg | 1 | 1159 | Yes | +5°C ± 3°C | ||
T2580300 | Tropine | 1 | 50 mg | 1 | 1308, 2102 | Yes | +5°C ± 3°C | ||
Y0000616 | Tropisetron hydrochloride | 1 | 40 mg | 1 | 2102 | Yes | +5°C ± 3°C | ||
Y0000618 | Tropisetron impurity B | 1 | 10 mg | 1 | 1H-indole-3-carboxylic acid | 2102 | Yes | +5°C ± 3°C | |
Y0000429 | Trospium chloride | 1 | 10 mg | 1 | 1798 | Yes | +5°C ± 3°C | ||
Y0000432 | Trospium impurity A | 1 | 20 mg | 1 | hydroxydiphenylacetic acid (benzilic acid) | 1798 | Yes | +5°C ± 3°C | |
Y0000431 | Trospium impurity B | 2 | 20 mg | 1 | (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl hydroxydiphenylacetate | 1798 | Yes | +5°C ± 3°C | |
Y0000430 | Trospium impurity C | 3 | 5 mg | 1 | (1R,3R,5S)-3-hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium] | 1798 | Yes | +5°C ± 3°C | |
Y0000497 | Troxerutin | 1 | 30 mg | 1 | 2133 | Yes | +5°C ± 3°C | ||
T2600000 | Trypsin BRP | 2 | 100 mg | 1 | See leaflet | 0476,0579,0 580, 0694 | Yes | +5°C ± 3°C | |
T2610000 | Tryptophan | 2 | 100 mg | 1 | See leaflet | 1272, 2290 | Yes | +5°C ± 3°C | |
T2880000 | Tylosin | 2 | 150 mg | 1 | see leaflet | 1273,1274,1 661, 20702 | Yes | +5°C ± 3°C | |
T2880100 | Tylosin D | 2 | 5 mg | 1 | 1273,1274,1 661 | Yes | +5°C ± 3°C | ||
T2880200 | Tylosin tartrate - reference spectrum | 1 | n/a | 1 | 1274 | ||||
Y0000498 | Tylosin phosphate for peak identification | 1 | 10 mg | 1 | 1273,1274,1 661 | Yes | +5°C ± 3°C | ||
T2900000 | Tyrosine | 2 | 50 mg | 1 | 1161, 1384 | Yes | +5°C ± 3°C | ||
T3000000 | Tyrothricin | 2 | 20 mg | 1 | 0907.1662 | Yes | +5°C ± 3°C | ||
U0020000 | Ubidecarenone | 3 | 70 mg | 1 | See leaflet C—„H„ÐO÷ ; Batch 2 is valid until 30 June 2016 | 1578 | Yes | +5°C ± 3°C | |
U0020008 | Ubidecarenone impurity D | 2 | 5 mg | 1 | 5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31,35- nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]benzene-1,4- dione (ubiquinone-9) | 1578 | Yes | +5°C ± 3°C | |
Y0001861 | Uncaria stem with hooks dry extract for system suitabilit | 1 | 10 mg | 1 | 2729 | Yes | -20°C ± 5°C | ||
U0020001 | Ubidecarenone for system suitability | 3 | 1 mg | 1 | 1578 | Yes | +5°C ± 3°C | ||
U0100000 | Uracil arabinoside | 2 | 60 mg | 1 | 0760 | Yes | +5°C ± 3°C | ||
U0600000 | Urea | 2 | 100 mg | 1 | 0743 | Yes | +5°C ± 3°C | ||
U0800000 | Ursodeoxycholic acid | 3 | 100 mg | 1 | Batch 2 is valid until 30 June 2017 | 1189.1275 | Yes | +5°C ± 3°C | |
Y0001163 | Ursodeoxycholic acid for system suitability | 3 | 1.26 mg | 1 | Batch 2 is valid until 31 October 2016 | 1275 | Yes | +5°C ± 3°C | |
Y0001523 | Ursolic acid | 1 | 25 mg | 1 | See leaflet C–ÐH÷‡O– | 2439 | Yes | +5°C ± 3°C | |
Y0000834 | Valaciclovir hydrochloride (anhydrous) | 1 | 100 mg | 1 | See leaflet CŒ–HœŒNÿO÷Cl | 1768.2751 | Yes | +5°C ± 3°C | |
Y0001096 | Valaciclovir impurity D | 1 | 10 mg | 1 | 2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl N-ethyl-l-valinate | 1768 | Yes | +5°C ± 3°C | |
Y0001097 | Valaciclovir impurity E | 1 | 10 mg | 1 | 2-[(2-amino-6-oxo-1,6 dihydro-9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy) carbonyl]-L-valinate | 1768 | Yes | +5°C ± 3°C | |
Y0001098 | Valaciclovir impurity F para-toluenesulfonate | 1 | 12 mg | 1 | 2-hydroxyethyl L-valinate | 1768 | Yes | +5°C ± 3°C | |
Y0001099 | Valaciclovir impurity G | 1 | 10 mg | 1 | N,N-dimethylpyridin-4-amine | 1768.2751 | Yes | +5°C ± 3°C | |
Y0001662 | Valaciclovir impurity P | 1 | 5 mg | 1 | 2,2′-[methylenebis[imino(6-oxo-1,6-dihydro-9H-purine-9,2-diyl) methyleneoxy]]diethyl di(l-valinate) | 2751 | Yes | -20°C ± 5°C | |
Y0001655 | Valaciclovir impurity S | 1 | 15 mg | 1 | 2751 | Yes | +5°C ± 3°C | ||
Y0001225 | Valaciclovir for system suitability | 1 | 10 mg | 1 | 1768.2751 | Yes | +5°C ± 3°C | ||
Y0000583 | Valerian dry extract | 3 | 400 mg | 1 | See leaflet | 0453,1898,1 899,2400,25 | Yes | -20°C ± 5°C | |
V0030000 | Valine | 1 | 50 mg | 1 | 0796 | Yes | +5°C ± 3°C | ||
Y0000584 | Valnemulin hydrochloride | 1 | 10 mg | 1 | 2137 | Yes | +5°C ± 3°C | ||
Y0000586 | Valnemulin impurity E | 1 | 10 mg | 1 | (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1- oxodecahydro-3a,9-propano-3aH-cyclopenta[8]annulen-8-yl 2-hydroxyacetate (pleuromulin) | 2137 | Yes | +5°C ± 3°C | |
Y0000585 | Valnemulin for peak identification | 1 | 10.25 mg | 1 | 2137 | Yes | +5°C ± 3°C | ||
Y0000533 | Valnemulin hydrogen tartrate | 1 | 120 mg | 1 | See leaflet C–—H—‡NœOŒŒS | 2137 | Yes | +5°C ± 3°C | |
V0033000 | Valproic acid | 3 | 100 mg | 1 | 1378 | Yes | +5°C ± 3°C | ||
Y0001422 | Valproic acid for system suitability | 3 | 10 mg | 1 | Batch 2 is valid until 30 November 2016 | 0678.1378 | Yes | +5°C ± 3°C | |
Y0001132 | Valsartan | 1 | 15 mg | 1 | 2423 | Yes | +5°C ± 3°C | ||
Y0001131 | Valsartan for peak identification | 2 | 10 mg | 1 | 2423 | Yes | +5°C ± 3°C | ||
Y0001145 | Valsartan for system suitability | 2 | 0.202 mg | 1 | 2423 | Yes | +5°C ± 3°C | ||
V0045000 | Vancomycin hydrochloride | 3 | 100 mg | 1 | See leaflet | 1058.20702 | Yes | -20°C ± 5°C | |
V0050000 | Vanillin | 2 | 100 mg | 1 | Batch 1 is valid until 30 November 2016 | 0747 | Yes | +5°C ± 3°C | |
Y0001648 | Vardenafil for system suitability | 1 | 10 mg | 1 | 2782 | Yes | +5°C ± 3°C | ||
Y0001647 | Vardenafil hydrochloride | 1 | 120 mg | 1 | See leaflet | 2782 | Yes | +5°C ± 3°C | |
Y0001198 | Varicella vaccine ( live) | 1 | 420 mg | 1 | See leaflet | 0648, 2442 | Yes | -20°C ± 5°C | |
Y0000561 | Vecuronium bromide | 1 | 10 mg | 1 | 1769 | Yes | +5°C ± 3°C | ||
Y0001862 | Vecuronium for system suitability system suitability CRS | 1 | 15 mg | 1 | 1769 | Yes | +5°C ± 3°C | ||
Y0001093 | Vedaprofen | 1 | 5 mg | 1 | 2248 | Yes | +5°C ± 3°C | ||
Y0001118 | Vedaprofen impurity mixture | 1 | 0.006 mg | 1 | 2248 | Yes | +5°C ± 3°C | ||
Y0000587 | Venlaine hydrochloride | 2 | 50 mg | 1 | 2119 | Yes | +5°C ± 3°C | ||
Y0000588 | Venlaine for system suitability | 3 | 1.002 mg | 1 | 2119 | Yes | +5°C ± 3°C | ||
V0100000 | Verapamil hydrochloride | 1 | 100 mg | 1 | 0573 | Yes | +5°C ± 3°C | ||
V0100018 | Verapamil impurity I | 3 | 5 mg | 1 | (2RS)-2-(3,4-dimethoxyphenyl)-2-[2-[[2-(3,4-dimethoxy-phenyl)ethyl] (methyl)amino]ethyl]-3-methylbutanenitrile | 0573 | Yes | +5°C ± 3°C | |
V0100026 | Verapamil impurity M | 2 | 10 mg | 1 | 5,5'-[[2-(3,4-dimethoxyphenyl)ethyl]imino]bis[2-(3,4-dimethoxyphenyl)-2-(1- methylethyl)pentanenitrile] | 0573 | Yes | +5°C ± 3°C | |
Y0000661 | Verbenalin | 1 | 11 mg | 1 | See leaflet CŒŸHœ÷OŒÐ | 1854 | Yes | +5°C ± 3°C | |
V0180000 | VERO cells | 1 | 1 ml | 2 | Cell lines (kidney, african green monkey, Cercopithecus aethiops) titration of live measles, mumps and rubella vaccines | 0213,0538,1 057 | Yes | Liquid nitrogen | |
Y0001400 | Vigabatrin | 1 | 10 mg | 1 | 2305 | Yes | +5°C ± 3°C | ||
Y0001401 | Vigabatrin impurity A | 1 | 25 mg | 1 | See leaflet CÿH„NO; (5RS)-5-ethenylpyrrolidin-2-one | 2305 | Yes | -20°C ± 5°C | |
Y0001402 | Vigabatrin impurity B | 1 | 20 mg | 1 | (2E)-2-(2-aminoethyl)but-2-enoic acid | 2305 | Yes | +5°C ± 3°C | |
Y0001404 | Vigabatrin impurity D | 1 | 50 mg | 1 | 4-aminobutanoic acid | 2305 | Yes | +5°C ± 3°C | |
Y0001403 | Vigabatrin impurity E | 1 | 10 mg | 1 | 2-[(2RS)-2-aminobut-3-enyl]propanedioic acid | 2305 | Yes | +5°C ± 3°C | |
V0300000 | Vinblastine sulfate | 4 | 5.01 mg | 1 | See leaflet C÷ÿHÿÐN÷OŒ–S | 0748.0749 | Yes | -80°C ± 10°C | |
V0305000 | Vinblastine sulfate - reference spectrum | 1 | n/a | 1 | 0748 | ||||
V0400000 | Vincristine sulfate | 5 | 4.96 mg | 1 | see leaflet | 0748.0749 | Yes | -80°C ± 10°C | |
V0405000 | Vincristine sulfate - reference spectrum | 1 | n/a | 1 | 0749 | ||||
V0500000 | Vindesine sulfate | 3 | 5 mg | 1 | See leaflet C÷–H—ŸN—OŒŒS | 1276 | Yes | -80°C ± 10°C | |
V0500010 | Vindesine sulfate - reference spectrum | 1 | n/a | 1 | 1276 | ||||
Y0000463 | Vinorelbine tartrate | 3 | 50 mg | 1 | 2107 | Yes | -80°C ± 10°C | ||
Y0000464 | Vinorelbine impurity B | 4 | 7 mg | 1 | methyl (3aR,4R,5S,5aR,10bR,13aR)-3a-ethyl-9-[(6R,8S)-4-ethyl-8- (methoxycarbonyl)1,3,6,7,8,9-hexahydro-2,6-methano-2H-azacyclodecino [4,3-b]indol-8-yl]-4,5-dihydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a- octahydro-1Hindolizino[8,1-cd]carbazole-5-carboxylate | 2107 | Yes | -80°C ± 10°C | |
Y0000589 | Vinpocetine | 1 | 10 mg | 1 | 2139 | Yes | +5°C ± 3°C | ||
Y0000590 | Vinpocetine impurity A | 2 | 15 mg | 1 | ethyl (12S,13aS,13bS)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b- octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12- carboxylate (ethyl vincaminate) ; Batch 1 is valid until 31 January 2017 | 2139 | Yes | +5°C ± 3°C | |
Y0000591 | Vinpocetine impurity B | 2 | 10 mg | 1 | methyl (13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1- de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine) ; Batch 1 is valid until 31 January 2017 | 2139 | Yes | +5°C ± 3°C | |
Y0000790 | Vinpocetine impurity C | 2 | 15 mg | 1 | ethyl (13aS,13bS)-13a-ethyl-10-methoxy-2,3,5,6,13a,13b-hexahydro-1H- indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (methoxyvinpocetine) | 2139 | Yes | +5°C ± 3°C | |
Y0000760 | Vinpocetine impurity D | 2 | 10 mg | 1 | ethyl (12RS,13aRS,13bRS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H- indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine) ; Batch 1 is valid until 28 February 2017 | 2139 | Yes | +5°C ± 3°C | |
Y0000793 | Vinyl acetate | 1 | 200 mg | 1 | 2152.2523 | Yes | +5°C ± 3°C | ||
Y0001395 | Voriconazole | 2 | 120 mg | 1 | See leaflet CŒÿHŒ÷F–N—O | 2576 | Yes | +5°C ± 3°C | |
Y0001396 | Voriconazole impurity B | 2 | 10 mg | 1 | (2RS,3SR)-2-(2,4-difluorophenyl)-3-pyrimidin-4-yl-1-(1H-1,2,4-triazol-1-yl) butan-2-ol ; Batch 1 is valid until 31 December 2016 | 2576 | Yes | +5°C ± 3°C | |
Y0001398 | Voriconazole impurity D | 2 | 10 mg | 1 | (2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4- triazol-1-yl)butan-2-ol (voriconazole enantiomer) | 2576 | Yes | +5°C ± 3°C | |
Y0001397 | Voriconazole impurity E | 1 | 50 mg | 1 | [(1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid ((+-)-camphorsulfonic acid) | 2576 | Yes | +5°C ± 3°C | |
W0100000 | Warfarin sodium | 2 | 10 mg | 1 | 0698 | Yes | +5°C ± 3°C | ||
Y0000778 | Warfarin sodium clathrate | 1 | 10 mg | 1 | 0699 | Yes | +5°C ± 3°C | ||
Y0001599 | Wedelolactone | 1 | 15 mg | 1 | See leaflet | 2564 | Yes | -20°C ± 5°C | |
X0075000 | Xylazine hydrochloride | 1 | 125 mg | 1 | 1481 | Yes | +5°C ± 3°C | ||
Y0000158 | Xylazine impurity C | 3 | 50 mg | 1 | 2,6-dimethylphenyl isothiocyanate ; Batch 2 is valid until 28 February 2017 | 1481 | Yes | +5°C ± 3°C | |
Y0001224 | Xylazine impurity mixture | 1 | 0.02 mg | 1 | 1481 | Yes | +5°C ± 3°C | ||
X0080000 | Xylitol | 2 | 500 mg | 1 | See leaflet | 1381 | Yes | +5°C ± 3°C | |
X0100000 | Xylometazoline hydrochloride | 3 | 100 mg | 1 | 0972.1162 | Yes | +5°C ± 3°C | ||
X0101000 | Xylometazoline impurity A | 3 | 15 mg | 1 | N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]acetamide ; Batch 2 is valid until 30 June 2017 | 1162 | Yes | +5°C ± 3°C | |
X0200000 | Xylose | 1 | 100 mg | 1 | 1278 | Yes | +5°C ± 3°C | ||
Y0000656 | Yohimbine hydrochloride | 1 | 20 mg | 1 | See leaflet CœŒHœŸClNœO– | 2172 | Yes | +5°C ± 3°C | |
Y0001715 | Zanamivir hydrate | 1 | 5 mg | 1 | 2611 | Yes | +5°C ± 3°C | ||
Y0001703 | Zanamivir impurity F | 1 | 10 mg | 1 | see leaflet C÷HŸClN÷; 1H-pyrazole-1-carboximidamide | 2611 | Yes | +5°C ± 3°C | |
Y0001702 | Zanamivir for assay | 1 | 50 mg | 1 | see leaflet CŒœHœÐN÷OŸ | 2611 | Yes | +5°C ± 3°C | |
Y0001708 | Zanamivir for system suitability | 1 | 10 mg | 1 | 2611 | Yes | +5°C ± 3°C | ||
Z1900000 | Zidovudine | 3 | 60 mg | 1 | see leaflet | 1059 | Yes | +5°C ± 3°C | |
Z1904000 | Zidovudine impurity B | 3 | 5 mg | 1 | 1-(3-chloro-2,3-dideoxy-β-d-erythro-pentofuranosyl)-5-methylpyrimidine-2,4 (1H,3H)-dione | 1059 | Yes | +5°C ± 3°C | |
Y0001654 | Zidovudine impurity D | 1 | 15 mg | 1 | Triphenylmethanol | 1059 | Yes | +5°C ± 3°C | |
Y0001641 | Zidovudine for system suitability | 1 | 10 mg | 1 | 1059 | Yes | +5°C ± 3°C | ||
Y0001807 | Pregabalin impurity B | 1 | 5 mg | 1 | (3R)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin enantiomer) | 2777 | Yes | +5°C ± 3°C | |
Z2000000 | Zinc acexamate | 1 | 50 mg | 1 | 1279 | Yes | +5°C ± 3°C | ||
Z2000010 | Zinc acexamate impurity A | 1 | 50 mg | 1 | 6-[[6-(acetylamino)hexanoyl]amino]hexanoic acid | 1279 | Yes | +5°C ± 3°C | |
Y0001286 | Ziprasidone hydrochloride monohydrate | 1 | 100 mg | 1 | see leaflet CœŒHœœClœN÷OS | 2421.2649 | Yes | +5°C ± 3°C | |
Y0001626 | Ziprasidone mesilate trihydrate | 1 | 30 mg | 1 | 2649 | Yes | +5°C ± 3°C | ||
Y0001272 | Ziprasidone for system suitability 1 | 1 | 10 mg | 1 | 2421, 2649 | Yes | +5°C ± 3°C | ||
Y0001241 | Ziprasidone for system suitability 2 | 1 | 0.465 mg | 1 | 2421, 2649 | Yes | +5°C ± 3°C | ||
Z2500000 | Zolpidem tartrate - * psy | 3 | 200 mg | 1 | 1280 | Yes | +5°C ± 3°C | ||
Z2500010 | Zolpidem impurity A | 4 | 10 mg | 1 | N,N-dimethyl-2-[7-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl] acetamide | 1280 | Yes | +5°C ± 3°C | |
Z3000000 | Zopiclone -* psy | 2 | 40 mg | 1 | 1060 | Yes | +5°C ± 3°C | ||
Y0001822 | Zopiclone Impurity B | 1 | 10 mg | 1 | (7RS)-6-(5-chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-b] pyrazin-5-one | 1060 | Yes | +5°C ± 3°C | |
Z3001000 | Zopiclone oxide | 3 | 20 mg | 1 | 1060 | Yes | +5°C ± 3°C | ||
Y0000062 | Zuclopenthixol decanoate - reference spectrum | 1 | n/a | 1 | 1707 | ||||
Y0000083 | Zuclopenthixol impurity B | 1 | 10 mg | 1 | 2-chloro-9H-thioxanthen-9-one | 1707 | Yes | +5°C ± 3°C | |
Y0000534 | Zuclopenthixol for system suitability | 1 | 0.26 mg | 1 | 1707 | Yes | +5°C ± 3°C | ||
New | Y0001925 | Betamethasone dipropionate for system suitability A | 1 | 10 mg | 1 | 0809 | Yes | +5°C ± 3°C | |
Y0001843 | Triamcinolone Hexacetonide for system suitability | 1 | 10 mg | 1 | 0867 | Yes | +5°C ± 3°C |
產(chǎn)品咨詢
聯(lián)系我們
上海宸喬生物科技有限公司 公司地址:上海市阿克蘇路1187號516室 技術(shù)支持:化工儀器網(wǎng)掃一掃 更多精彩
微信公眾號
網(wǎng)站二維碼